0000827871-21-000029.txt : 20211109 0000827871-21-000029.hdr.sgml : 20211109 20211109162213 ACCESSION NUMBER: 0000827871-21-000029 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211109 DATE AS OF CHANGE: 20211109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EAGLE PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000827871 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36306 FILM NUMBER: 211392535 BUSINESS ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 BUSINESS PHONE: 201-326-5300 MAIL ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 FORMER COMPANY: FORMER CONFORMED NAME: EAGLE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19880120 10-Q 1 egrx-20210930.htm 10-Q egrx-20210930
000082787112/312021Q3falsehttp://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent0.500008278712021-01-012021-09-30xbrli:shares00008278712021-11-02iso4217:USD00008278712021-09-3000008278712020-12-31iso4217:USDxbrli:shares0000827871us-gaap:ProductMember2021-07-012021-09-300000827871us-gaap:ProductMember2020-07-012020-09-300000827871us-gaap:ProductMember2021-01-012021-09-300000827871us-gaap:ProductMember2020-01-012020-09-300000827871us-gaap:RoyaltyMember2021-07-012021-09-300000827871us-gaap:RoyaltyMember2020-07-012020-09-300000827871us-gaap:RoyaltyMember2021-01-012021-09-300000827871us-gaap:RoyaltyMember2020-01-012020-09-300000827871us-gaap:LicenseMember2021-07-012021-09-300000827871us-gaap:LicenseMember2020-07-012020-09-300000827871us-gaap:LicenseMember2021-01-012021-09-300000827871us-gaap:LicenseMember2020-01-012020-09-3000008278712021-07-012021-09-3000008278712020-07-012020-09-3000008278712020-01-012020-09-300000827871us-gaap:CommonStockMember2021-06-300000827871us-gaap:AdditionalPaidInCapitalMember2021-06-300000827871us-gaap:TreasuryStockMember2021-06-300000827871us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000827871us-gaap:RetainedEarningsMember2021-06-3000008278712021-06-300000827871us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000827871us-gaap:CommonStockMember2021-07-012021-09-300000827871us-gaap:TreasuryStockMember2021-07-012021-09-300000827871us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000827871us-gaap:RetainedEarningsMember2021-07-012021-09-300000827871us-gaap:CommonStockMember2021-09-300000827871us-gaap:AdditionalPaidInCapitalMember2021-09-300000827871us-gaap:TreasuryStockMember2021-09-300000827871us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000827871us-gaap:RetainedEarningsMember2021-09-300000827871us-gaap:CommonStockMember2020-12-310000827871us-gaap:AdditionalPaidInCapitalMember2020-12-310000827871us-gaap:TreasuryStockMember2020-12-310000827871us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000827871us-gaap:RetainedEarningsMember2020-12-310000827871us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300000827871us-gaap:CommonStockMember2021-01-012021-09-300000827871us-gaap:TreasuryStockMember2021-01-012021-09-300000827871us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000827871us-gaap:RetainedEarningsMember2021-01-012021-09-300000827871us-gaap:CommonStockMember2020-06-300000827871us-gaap:AdditionalPaidInCapitalMember2020-06-300000827871us-gaap:TreasuryStockMember2020-06-300000827871us-gaap:RetainedEarningsMember2020-06-3000008278712020-06-300000827871us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000827871us-gaap:CommonStockMember2020-07-012020-09-300000827871us-gaap:TreasuryStockMember2020-07-012020-09-300000827871us-gaap:RetainedEarningsMember2020-07-012020-09-300000827871us-gaap:CommonStockMember2020-09-300000827871us-gaap:AdditionalPaidInCapitalMember2020-09-300000827871us-gaap:TreasuryStockMember2020-09-300000827871us-gaap:RetainedEarningsMember2020-09-3000008278712020-09-300000827871us-gaap:CommonStockMember2019-12-310000827871us-gaap:AdditionalPaidInCapitalMember2019-12-310000827871us-gaap:TreasuryStockMember2019-12-310000827871us-gaap:RetainedEarningsMember2019-12-3100008278712019-12-310000827871us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300000827871us-gaap:CommonStockMember2020-01-012020-09-300000827871us-gaap:TreasuryStockMember2020-01-012020-09-300000827871us-gaap:RetainedEarningsMember2020-01-012020-09-30egrx:product0000827871us-gaap:FairValueInputsLevel1Member2021-09-300000827871us-gaap:FairValueInputsLevel2Member2021-09-300000827871us-gaap:FairValueInputsLevel3Member2021-09-300000827871us-gaap:FairValueInputsLevel1Member2020-12-310000827871us-gaap:FairValueInputsLevel2Member2020-12-310000827871us-gaap:FairValueInputsLevel3Member2020-12-31xbrli:pure0000827871us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberegrx:CephalonInc.Member2021-07-012021-09-300000827871us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberegrx:CephalonInc.Member2020-07-012020-09-300000827871us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberegrx:CephalonInc.Member2021-01-012021-09-300000827871us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberegrx:CephalonInc.Member2020-01-012020-09-300000827871us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberegrx:OtherCustomersMember2021-07-012021-09-300000827871us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberegrx:OtherCustomersMember2020-07-012020-09-300000827871us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberegrx:OtherCustomersMember2021-01-012021-09-300000827871us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberegrx:OtherCustomersMember2020-01-012020-09-300000827871us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300000827871us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300000827871us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300000827871us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300000827871us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberegrx:CephalonInc.Member2021-01-012021-09-300000827871us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberegrx:CephalonInc.Member2020-01-012020-12-310000827871us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberegrx:OtherCustomersMember2021-01-012021-09-300000827871us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberegrx:OtherCustomersMember2020-01-012020-12-310000827871us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300000827871us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310000827871egrx:BendekaMember2021-01-012021-09-300000827871us-gaap:EmployeeStockOptionMember2021-07-012021-09-300000827871us-gaap:EmployeeStockOptionMember2020-07-012020-09-300000827871us-gaap:EmployeeStockOptionMember2021-01-012021-09-300000827871us-gaap:EmployeeStockOptionMember2020-01-012020-09-300000827871us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300000827871us-gaap:RestrictedStockUnitsRSUMember2020-07-012020-09-300000827871us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300000827871us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300000827871us-gaap:FurnitureAndFixturesMember2021-09-300000827871us-gaap:FurnitureAndFixturesMember2020-12-310000827871us-gaap:FurnitureAndFixturesMember2021-01-012021-09-300000827871us-gaap:OfficeEquipmentMember2021-09-300000827871us-gaap:OfficeEquipmentMember2020-12-310000827871us-gaap:OfficeEquipmentMember2021-01-012021-09-300000827871us-gaap:EquipmentMember2021-09-300000827871us-gaap:EquipmentMember2020-12-310000827871us-gaap:EquipmentMember2021-01-012021-09-300000827871us-gaap:LeaseholdImprovementsMember2021-09-300000827871us-gaap:LeaseholdImprovementsMember2020-12-310000827871us-gaap:LeaseholdImprovementsMember2021-01-012021-09-3000008278712020-01-012020-12-310000827871egrx:RoyaltyBuyBackAgreementMember2021-01-012021-09-300000827871egrx:RoyaltyBuyBackAgreementMember2021-09-300000827871us-gaap:DevelopedTechnologyRightsMember2021-01-012021-09-300000827871us-gaap:DevelopedTechnologyRightsMember2021-09-300000827871egrx:RoyaltyBuyBackAgreementMember2020-01-012020-12-310000827871egrx:RoyaltyBuyBackAgreementMember2020-12-310000827871us-gaap:DevelopedTechnologyRightsMember2020-01-012020-12-310000827871us-gaap:DevelopedTechnologyRightsMember2020-12-310000827871egrx:March2020PlanMember2020-03-170000827871egrx:October2018PlanMember2018-10-312020-03-170000827871egrx:March2020PlanMember2020-09-230000827871egrx:March2020PlanMember2020-09-240000827871egrx:March2020PlanMember2020-09-242020-09-240000827871egrx:March2020PlanMember2020-01-012020-12-310000827871egrx:AcceleratedShareRepurchaseMember2016-08-012021-06-300000827871us-gaap:PerformanceSharesMember2021-01-012021-03-310000827871egrx:SPBiotechnologyMemberus-gaap:PerformanceSharesMember2021-01-012021-03-310000827871egrx:MilestonePerformanceBasedStockUnitsMember2021-01-012021-03-310000827871egrx:MilestonePerformanceBasedStockUnitsMembersrt:MinimumMember2021-01-012021-03-310000827871egrx:MilestonePerformanceBasedStockUnitsMembersrt:MaximumMember2021-01-012021-03-31egrx:milestone0000827871us-gaap:RestrictedStockUnitsRSUMember2019-12-310000827871us-gaap:PerformanceSharesMember2019-12-310000827871us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300000827871us-gaap:PerformanceSharesMember2020-01-012020-09-300000827871us-gaap:RestrictedStockUnitsRSUMember2020-09-300000827871us-gaap:PerformanceSharesMember2020-09-300000827871us-gaap:RestrictedStockUnitsRSUMember2020-12-310000827871us-gaap:PerformanceSharesMember2020-12-310000827871us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300000827871us-gaap:PerformanceSharesMember2021-01-012021-09-300000827871us-gaap:RestrictedStockUnitsRSUMember2021-09-300000827871us-gaap:PerformanceSharesMember2021-09-300000827871us-gaap:EmployeeStockOptionMember2021-07-012021-09-300000827871us-gaap:EmployeeStockOptionMember2020-07-012020-09-300000827871us-gaap:EmployeeStockOptionMember2021-01-012021-09-300000827871us-gaap:EmployeeStockOptionMember2020-01-012020-09-300000827871us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300000827871us-gaap:RestrictedStockUnitsRSUMember2020-07-012020-09-300000827871us-gaap:PerformanceSharesMember2021-07-012021-09-300000827871us-gaap:PerformanceSharesMember2020-07-012020-09-300000827871us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000827871us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-07-012020-09-300000827871us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000827871us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-09-300000827871us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000827871us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300000827871us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000827871us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300000827871egrx:SecondAmendedAndRestatedCreditAgreementMemberus-gaap:LineOfCreditMember2019-11-082019-11-080000827871us-gaap:RevolvingCreditFacilityMemberegrx:SecondAmendedAndRestatedCreditAgreementMember2019-11-080000827871us-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMemberegrx:SecondAmendedAndRestatedCreditAgreementMember2019-11-082019-11-080000827871us-gaap:LondonInterbankOfferedRateLIBORMemberegrx:SecondAmendedAndRestatedCreditAgreementMembersrt:MaximumMember2019-11-082019-11-080000827871egrx:SecondAmendedAndRestatedCreditAgreementMemberegrx:AdjustedLondonInterbankOfferedRateLIBORMember2019-11-082019-11-080000827871srt:MinimumMemberegrx:SecondAmendedAndRestatedCreditAgreementMemberus-gaap:PrimeRateMember2019-11-082019-11-080000827871egrx:SecondAmendedAndRestatedCreditAgreementMemberus-gaap:PrimeRateMembersrt:MaximumMember2019-11-082019-11-080000827871srt:MinimumMemberegrx:SecondAmendedAndRestatedCreditAgreementMember2019-11-082019-11-080000827871egrx:SecondAmendedAndRestatedCreditAgreementMembersrt:MaximumMember2019-11-082019-11-080000827871egrx:SecondAmendedAndRestatedCreditAgreementMemberegrx:NewYorkFederalReserveBankNYFRBMember2019-11-082019-11-08egrx:jurisdictionegrx:patent0000827871egrx:ParPharmaceuticalIncEtAlVEaglePharmaceuticalsIncVasopressinMemberus-gaap:PendingLitigationMember2019-12-202019-12-200000827871egrx:CombioxinMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-08-310000827871egrx:AOPOrphanPharmaceuticalsGmbHMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-09-300000827871egrx:AOPOrphanPharmaceuticalsGmbHMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-08-310000827871egrx:TymeMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2020-01-070000827871egrx:TymeMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-07-012021-09-300000827871egrx:TymeMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2020-07-012020-09-300000827871egrx:TymeMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-01-012021-09-300000827871egrx:TymeMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2020-01-012020-09-300000827871us-gaap:ConvertibleDebtSecuritiesMember2021-03-310000827871us-gaap:ConvertibleDebtSecuritiesMember2021-01-012021-03-310000827871us-gaap:ConvertibleDebtSecuritiesMember2021-01-012021-09-300000827871us-gaap:ConvertibleDebtSecuritiesMember2021-09-300000827871us-gaap:ConvertibleDebtSecuritiesMember2021-06-300000827871us-gaap:ConvertibleDebtSecuritiesMember2021-07-012021-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
OR 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to ____________
Commission File Number 001-36306
 
Eagle Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware283420-8179278
(State or Other Jurisdiction of
Incorporation or Organization)
(Primary Standard Industrial
Classification Code Number)
(I.R.S. Employer
Identification Number)
50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ 07677
(201) 326-5300
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common stock, $0.001 par value per shareEGRXThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes     No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes     No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer 
Non-accelerated filerSmaller reporting company
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes    No  
The number of shares outstanding of the registrant’s common stock as of November 2, 2021: 12,913,879 shares.



CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q, or this Quarterly Report, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “project,” “continue,” “potential,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, statements about:

the impact of the ongoing coronavirus 2019, or COVID-19, pandemic on our business and operations, results of operations and financial performance including: disruption in the sales of our marketed products; delays, interruptions or other adverse effects to clinical trials and patient enrollment; delays in regulatory review; manufacturing and supply chain interruptions; and the adverse effects on healthcare systems and disruption of the global economy overall;
the potential benefits and commercial potential of rapidly infused bendamustine RTD, or Bendeka, Ryanodex® (dantrolene sodium), and bendamustine ready-to-dilute, or RTD, 500ml solution, or Belrapzo for approved indications and any expanded uses;
sales of our products in various markets worldwide, pricing for our products, level of insurance coverage and reimbursement for our products, timing regarding development and regulatory approvals for our products or for additional indications or in additional territories;
future expansion of our commercial organization and transition to third-parties in certain jurisdictions to perform sales, marketing and distribution functions;
the number and timing of potential product launches, development initiatives or new indications for the Company’s product candidates, and the commercial potential of additional indications for our products;
the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development program;
our ability to obtain and maintain regulatory approval of our products and product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product;
our plans to research, develop and commercialize our products and product candidates and our ability to successfully commercialize our products and product candidates;
our ability to attract collaborators with development, regulatory and commercialization expertise;
the size and growth potential of the markets for our products and product candidates, and our ability to serve those markets;
the diversion of healthcare resources away from the conduct of clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals and doctor offices serving as locations for administration of our products, including Bendeka and hospital staff supporting the conduct of such administration;
the interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others in connection with the ongoing COVID-19 pandemic;
the rate and degree of market acceptance of our products;
our ability to significantly grow our commercial sales and marketing organization, whether alone or with potential future collaborators;
the performance of our strategic partners and success of our current strategic partnerships and the timing and results of these partners’ preclinical studies and clinical trials, including the Company’s collaborations with its licensing partners SymBio, Combioxin SA and AOP Orphan Pharmaceuticals GmbH;
regulatory developments in the United States and foreign countries;
the performance of our third-party suppliers and manufacturers;
the success of competing drugs that are or become available;
the retention of key scientific or management personnel;
our ability to obtain additional funding for our operations;
our ability to obtain, maintain, protect and enhance intellectual property rights and proprietary technologies and operate our business without infringing the intellectual property rights and proprietary technology of third parties;
our ability to prevent or minimize the effects of Paragraph IV patent litigation;
our expectations regarding anticipated future costs, operating expenses and capital requirements;
our expectations regarding our clinical trial, development plan and litigation matters for vasopressin; and
•    our expectations regarding our submission of formal protocols for clinical study on fulvestrant (EA-114).







Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties, assumptions and other factors described under the “Risk Factors” section and elsewhere in this Quarterly Report, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

In addition, statements such as “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements as predictions of future events. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

This Quarterly Report also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.


NOTE REGARDING COMPANY REFERENCES

References to the “Company,” “Eagle Pharmaceuticals,” “Eagle,” “we,” “us” or “our” mean Eagle Pharmaceuticals, Inc., a Delaware corporation, together with its subsidiaries, references to “Eagle Biologics” mean Eagle Biologics, Inc. and references to “Eagle Research Lab” means Eagle Research Lab Limited.


NOTE REGARDING TRADEMARKS

All trademarks, trade names and service marks appearing in this Quarterly Report are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this Quarterly Report may appear without the ® or TM symbols.








TABLE OF CONTENTS
Page
Part I - Financial Information (unaudited)
Item 1.Condensed Consolidated Financial Statements
Item 2.
Item 3.
Item 4.
Part II - Other Information
Item 1.
Item 1A.
Risk Factors
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.





PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

EAGLE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands, except share amounts)

September 30, 2021December 31, 2020
ASSETS
Current assets:
Cash and cash equivalents$99,741 $103,155 
Accounts receivable, net45,335 50,678 
Inventories9,315 8,075 
Prepaid expenses and other current assets17,303 4,157 
Total current assets171,694 166,065 
Property and equipment, net1,775 2,077 
Intangible assets, net10,799 12,917 
Goodwill 39,743 39,743 
Deferred tax asset, net 17,713 15,180 
Other assets14,537 17,208 
Total assets$256,261 $253,190 
LIABILITIES AND STOCKHOLDERS' EQUITY 
Current liabilities: 
Accounts payable$12,717 $6,268 
Accrued expenses and other liabilities27,714 23,817 
Current portion of long-term debt8,000 8,000 
Total current liabilities48,431 38,085 
Other long-term liabilities3,048 3,959 
Long-term debt, less current portion19,489 25,135 
Total liabilities70,968 67,179 
Commitments and Contingencies
Stockholders' equity:
Preferred stock, 1,500,000 shares authorized and no shares issued or outstanding as of September 30, 2021 and December 31, 2020
  
Common stock, $0.001 par value; 50,000,000 shares authorized; 16,886,123 and 16,739,203 shares issued as of September 30, 2021 and December 31, 2020, respectively
17 17 
Additional paid in capital320,566 305,403 
Accumulated other comprehensive loss(882) 
Retained earnings 82,058 84,489 
Treasury stock, at cost, 3,941,541 and 3,682,176 shares as of September 30, 2021 and December 31, 2020, respectively
(216,466)(203,898)
Total stockholders' equity185,293 186,011 
Total liabilities and stockholders' equity$256,261 $253,190 
See accompanying notes to condensed consolidated financial statements (unaudited).
1


EAGLE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except share and per share amounts)

 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2021202020212020
Revenue:  
Product sales, net$12,124 $17,317 $48,865 $49,387 
Royalty revenue27,729 27,611 80,361 83,499 
License and other revenue 5,000  5,000 
Total revenue39,853 49,928 129,226 137,886 
Operating expenses: 
Cost of product sales 5,486 8,726 21,835 23,804 
Cost of royalty revenue2,773 3,260 8,036 9,120 
Research and development23,289 4,828 47,488 21,390 
Selling, general and administrative18,482 17,697 54,997 60,411 
Total operating expenses50,030 34,511 132,356 114,725 
(Loss) income from operations(10,177)15,417 (3,130)23,161 
Interest income197 46 395 542 
Interest expense(396)(489)(1,240)(2,164)
Other expense(2,284)(6,049)(1,797)(10,249)
Total other expense, net(2,483)(6,492)(2,642)(11,871)
(Loss) income before income tax benefit (provision)(12,660)8,925 (5,772)11,290 
Income tax benefit (provision)7,038 (1,866)3,341 (7,358)
Net (loss) income $(5,622)$7,059 $(2,431)$3,932 
(Loss) earnings per share attributable to common stockholders:
Basic $(0.43)$0.52 $(0.19)$0.29 
Diluted $(0.43)$0.51 $(0.19)$0.28 
Weighted average number of common shares outstanding:
Basic 13,077,298 13,531,372 13,103,203 13,620,981 
Diluted 13,077,298 13,786,803 13,103,203 13,917,800 
See accompanying notes to condensed consolidated financial statements (unaudited).

2


EAGLE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)
(In thousands)


Three Months Ended
September 30,
Nine Months Ended
September 30,
2021202020212020
Net (loss) income$(5,622)$7,059 $(2,431)$3,932 
Other comprehensive income (loss), net of tax:
Unrealized gain (loss) for convertible promissory note
22  (882) 
Total other comprehensive income (loss)22  (882) 
Comprehensive (loss) income $(5,600)$7,059 $(3,313)$3,932 


3


EAGLE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)
(In thousands)
Common StockAdditional
Paid-In Capital
Treasury StockAccumulated Other Comprehensive (Loss) IncomeRetained EarningsTotal
Stockholders'
Equity
Number of
Shares
Amount
Balance at June 30, 202116,880 $17 $316,249 $(208,195)$(904)$87,680 $194,847 
Stock-based compensation expense— — 4,084 — — — 4,084 
Issuance of common stock upon exercise of stock option grants6 — 233 — — — 233 
Common stock repurchases— — — (8,271)— — (8,271)
Other comprehensive income— — — — 22 — 22 
Net (loss)— — — — — (5,622)(5,622)
Balance at September 30, 202116,886 $17 $320,566 $(216,466)$(882)$82,058 $185,293 
Common StockAdditional
Paid-In Capital
Treasury StockAccumulated Other Comprehensive LossRetained EarningsTotal
Stockholders'
Equity
Number of
Shares
Amount
Balance as of December 31, 202016,739 $17 $305,403 $(203,898)$ $84,489 $186,011 
Stock-based compensation expense— — 14,873 — — — 14,873 
Issuance of common stock upon exercise of stock option grants84 — 1,841 — — — 1,841 
Issuance of common stock related to vesting of restricted stock units63 — (1,551)— — — (1,551)
Common stock repurchases— — — (12,568)— — (12,568)
Other comprehensive loss— — — — (882)— (882)
Net (loss)— — — — — (2,431)(2,431)
Balance as of September 30, 202116,886 $17 $320,566 $(216,466)$(882)$82,058 $185,293 

4


Common StockAdditional
Paid-In Capital
Treasury StockRetained EarningsTotal
Stockholders'
Equity
Number of
Shares
Amount
Balance at June 30, 202016,622 $17 $291,434 $(176,860)$69,373 $183,964 
Stock-based compensation expense— — 4,722 — — 4,722 
Issuance of common stock upon exercise of stock option grants3 — 42 — — 42 
Payment of employee withholding tax upon vesting of stock-based awards— — — — — — 
Issuance of common stock related to vesting of restricted stock units— — — — — — 
Common stock repurchases— — — (23,000)— (23,000)
Net income— — — — 7,059 7,059 
Balance at September 30, 202016,625 $17 $296,198 $(199,860)$76,432 $172,787 
 Common StockAdditional
Paid-In Capital
Treasury Stock Retained EarningsTotal
Stockholders'
Equity
 Number of
Shares
Amount
Balance at December 31, 201916,538 $17 $278,518 $(171,861)$72,500 $179,174 
Stock-based compensation expense— — 18,435 — — 18,435 
Issuance of common stock upon exercise of stock option grants42 — 555 — — 555 
Payment of employee withholding tax upon vesting of stock-based awards— — (1,310)— — (1,310)
Issuance of common stock related to vesting of restricted stock units45 — — — — — 
Common stock repurchases— — — (27,999)— (27,999)
Net income— — — — 3,932 3,932 
Balance at September 30, 202016,625 $17 $296,198 $(199,860)$76,432 $172,787 

See accompanying notes to unaudited condensed consolidated financial statements.
5


EAGLE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands)
 Nine Months Ended September 30,
 20212020
Cash flows from operating activities:  
Net (loss) income $(2,431)$3,932 
Adjustments to reconcile net (loss) income to net cash provided by operating activities:  
Deferred income taxes(2,533)(1,671)
Depreciation expense575 656 
Noncash operating lease expense related to right-of-use assets768 980 
Amortization expense of intangible assets2,118 1,999 
Fair value adjustments on equity investment 1,900 7,700 
Stock-based compensation expense14,873 18,435 
Convertible promissory note related credit losses150  
Amortization of debt issuance costs 354 301 
   Fair value adjustments related to derivative instrument (254)2,549 
Accretion of discount on convertible promissory note(102) 
Changes in operating assets and liabilities which provided (used) cash: 
Accounts receivable5,343 (4,195)
Inventories(1,240)(20)
Prepaid expenses and other current assets(8,821)(2,774)
Accounts payable6,449 7,606 
Accrued expenses and other liabilities3,897 (3,916)
Other assets and other long-term liabilities, net(908)(1,845)
Net cash provided by operating activities20,138 29,737 
Cash flows from investing activities:  
Purchase of equity investment security  (17,500)
Purchase of property and equipment(274)(577)
Purchase of convertible promissory note(5,000) 
Net cash used in investing activities(5,274)(18,077)
Cash flows from financing activities:  
Proceeds from common stock option exercises 1,841 555 
Employee withholding taxes related to stock-based awards(1,551)(1,310)
Proceeds from existing revolving credit facility  110,000 
Repayment of existing revolving credit facility (110,000)
Payment of debt (6,000)(3,000)
Repurchases of common stock (12,568)(27,999)
Net cash used in financing activities(18,278)(31,754)
Net decrease in cash and cash equivalents(3,414)(20,094)
Cash and cash equivalents at beginning of period103,155 109,775 
Cash and cash equivalents at end of period$99,741 $89,681 
Supplemental disclosures of cash flow information: 
Cash paid during the period for:  
Income taxes, net$6,303 $3,036 
Interest 917 1,878 
Right-of-use asset obtained in exchange for lease obligation - lease amendment 842 
See accompanying notes to condensed consolidated financial statements (unaudited).
6


EAGLE PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(In thousands, except share and per share amounts)

1. Basis of Presentation and Other Company Information
The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting quarterly information. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2020 was derived from audited financial statements, but certain information and footnote disclosures normally included in our annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results for the year ending December 31, 2021 or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 5, 2021.
We are an integrated pharmaceutical company focused on finding ways to help medicines do more for patients. We and our collaborators have the capabilities to take a molecule from preclinical research through regulatory approval and into the marketplace, including development, manufacturing and commercialization. Our business model applies our scientific expertise, proprietary research-based insights and marketplace proficiency to identify challenging-to-treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. By focusing on patients' unmet needs, we strive to provide healthcare professionals with urgently needed treatment solutions that are designed to improve patient care and outcomes and create near- and long-term value for our stakeholders, including patients and healthcare providers and our employees, marketing partners, collaborators and investors. Our science-based business model has a proven track record with U.S. Food and Drug Administration ("FDA") approval and commercial launches of three products: Ryanodex® (dantrolene sodium) ("Ryanodex"), bendamustine ready-to-dilute ("RTD") 500ml solution ("Belrapzo"), and rapidly infused bendamustine RTD ("Bendeka"). We market our products through marketing partners and/or our internal direct sales force. We market Ryanodex and Belrapzo, and Teva Pharmaceutical Industries Ltd. ("Teva") markets Bendeka through its subsidiary Cephalon, Inc. SymBio Pharmaceuticals Limited, or SymBio, markets Treakisym, a RTD product, in Japan. Reflecting further expansion of our oncology portfolio, in February 2020, we received final FDA approval for Pemfexy, a branded alternative to Alimta for metastatic non-squamous non-small cell lung cancer and malignant pleural mesothelioma.
With several pipeline projects underway and the potential for up to five product launches over the next several years, we believe we have many growth opportunities ahead. We believe that each of our pipeline projects currently has the potential to enter the market as a first-in-class, first-to-file, first-to-market or best-in-class product. In particular, we are applying our expertise to conduct novel research regarding the potential for Ryanodex to address conditions including Alzheimer’s disease, traumatic brain injury/concussion, nerve agent exposure and acute radiation syndrome. In addition, our clinical development program includes a strategic partnership with Tyme Technologies, Inc., or Tyme, for Tyme’s product candidate for the treatment of patients with pancreatic or other advanced cancers, SM-88, as well as investigations of compounds such as EA-114 (our fulvestrant product candidate) for patients with HR-positive advanced breast cancer. Other products in development include Vasopressin, our first-to-file Abbreviated New Drug Application, or ANDA, that references Endo International plc’s Vasostrict indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines; and EA-111, a new chemical entity and next-generation ryanodine receptor antagonist, in an intramuscular formulation that that would allow for easier and more rapid administration in emergency situations (military and civilian).

2. Summary of Significant Accounting Policies
Significant Accounting Policies
Our significant accounting policies are described in the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 and the notes thereto filed with the SEC on March 5, 2021. Since the date
7

of those consolidated financial statements, there have been no material changes to our significant accounting policies other than as listed below.
Significant Risks and Uncertainties
In response to the ongoing COVID-19 pandemic, we have taken and continue to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on our business, such as remote working policies, facilitating management’s periodic communication to address employee and business concerns and providing frequent updates to our Board of Directors (“Board”). During the second quarter of 2021, we implemented a plan to reopen our office to allow employees to return to the office, with a focus on employee safety and optimal work environment. Our management continues to monitor and evaluate such plans as the pandemic continues to evolve. We anticipate that the COVID-19 pandemic may also have an impact on the clinical development timelines for certain of our clinical programs. We also anticipate that the COVID-19 pandemic may have an impact on our supply chain. The COVID-19 pandemic and associated lockdowns have resulted in a decrease in healthcare utilization broadly and specifically lead to a continuing reduction in the utilization of physician-administered oncology products including Belrapzo and Bendeka. In addition, the COVID-19 pandemic has delayed the timing of certain litigation, including the litigation with Par (as defined below) with respect to Vasopressin, and we anticipate that such delays will continue for the duration of the pandemic. The extent to which the COVID-19 pandemic will continue to impact our business, clinical development and regulatory efforts, supply chain and sales efforts, corporate development objectives and the value of, and market for, our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and other risks and uncertainties associated with the pandemic have impacted our operations and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

In addition, we are subject to other challenges and risks specific to our business and our ability to execute on our business plan and strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with research and development operations, including, without limitation, risks and uncertainties associated with: delays or problems in obtaining clinical supply; obtaining regulatory approval of product candidates; loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing intellectual property rights; and the challenges of complying with applicable regulatory requirements. In addition, as the ongoing COVID-19 pandemic affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.
Use of Estimates
These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. Our critical accounting policies are those that are both most important to our financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. We anticipate that the COVID-19 pandemic will continue to disrupt our supply chain and marketing and sales efforts for certain of our products, including Bendeka, although it is not currently expected that any disruption would be significant. As of the date of issuance of these financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying value of our assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates, and any such differences may be material to our financial statements.
Reclassifications
Certain reclassifications have been made to prior year amounts to conform with the current year presentation, including for amounts related to accounts receivable, net and prepaid expenses and other current assets. None of the amounts pertaining to the reclassifications were significant.
8

Cash and Cash Equivalents
We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.
We, at times, maintain balances with financial institutions in excess of the Federal Deposit Insurance Corporation (“FDIC”) limit.
Fair Value Measurements

U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
Level 1: Quoted prices in active markets for identical assets or liabilities.
Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The fair value of interest-bearing cash, cash equivalents, accounts receivable and accounts payable approximate fair value due to their life being short term in nature, and are classified as Level 1 for all periods presented.
Financial assets and liabilities measured and recognized at fair value are as follows:
September 30, 2021
TotalLevel 1Level 2Level 3
Assets:
Money market funds$95,255 $95,255 $ $ 
Convertible promissory note3,795   3,795 
Embedded derivative asset in convertible promissory note530   530 
Investment in Tyme10,300 10,300   
Total financial assets$109,880 $105,555 $ $4,325 
December 31, 2020
TotalLevel 1Level 2Level 3
Assets:
Money market funds$79,682 $79,682 $ $ 
Investment in Tyme12,200 12,200   
Total financial assets$91,882 $91,882 $ $ 

9

We recognize transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months or nine months ended September 30, 2021 and 2020, respectively.

Our investment in the convertible promissory note and the embedded derivative are classified as Level 3. We analyzed and accessed the embedded derivative feature contained in the convertible promissory note agreement. We used a probability factor to value the embedded derivative asset based on management's best estimate, including the principal and estimated accrued interest among other contractual terms. The convertible promissory note is accounted for as available for sale. The convertible promissory note is reported at fair value with unrealized gains and losses included in Accumulated other comprehensive income (loss). Refer to Note 13, Convertible Promissory Note for further details.

Our investment in restricted shares of common stock of Tyme Technologies, Inc.are classified as Level 1. Refer to Note 12, License and Collaboration Agreements for further details.

The fair value of debt is classified as Level 2 for the periods presented and approximates its book value due to the variable interest rate.
Intangible Assets
We review the recoverability of our finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, we assess the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, we measure the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets. The Company determined that no indicators of impairment of finite-lived intangible assets or long-lived assets existed as of September 30, 2021.
Goodwill
Goodwill represents the excess of purchase price over the fair value of net assets acquired in the Eagle Biologics acquisition. Goodwill is not amortized, but is evaluated for impairment on an annual basis, in the fourth quarter, or more frequently if events or changes in circumstances indicate that the reporting unit’s goodwill is less than its carrying amount. We did not identify any impairment to goodwill during the periods presented.
Concentration of Major Customers and Vendors
We are dependent on our commercial partner, Teva, who markets and sells Bendeka. Our customer for Bendeka is our commercial and licensing partner; therefore, our future revenues are highly dependent on the related exclusive license and distribution arrangement.
The total revenues and accounts receivables broken down by major customers as a percentage of the total are as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2021202020212020
Total revenues
Teva - See Revenue Recognition
69 %74 %66 %72 %
Other31 %26 %34 %28 %
100 %100 %100 %100 %
10

September 30, December 31,
20212020
Accounts receivable
Teva - See Revenue Recognition
63 %58 %
Other37 %42 %
100 %100 %

Inventories
Inventories are recorded at the lower of cost and net realizable value, with cost determined on a first-in first-out basis. We periodically review the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, we will record a write-down to lower of cost and net realizable value in the period that the decline in value is first recognized.
Research and Development Expense
Costs for research and development are charged to expense as incurred and include; employee-related expenses including salaries, benefits, travel and stock-based compensation expense for research and development personnel; expenses incurred under agreements with contract research organizations, contract manufacturing organizations and service providers that assist in conducting clinical and preclinical studies; costs associated with preclinical activities and development activities, costs associated with regulatory operations; and depreciation expense for assets used in research and development activities.
Costs for certain development activities, such as in licensing intellectual property related to new projects, clinical studies, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid expenses or accrued expenses as deemed appropriate. Recoveries of previously recognized research and development expenses from third parties are recorded as a reduction to research and development expense in the period it becomes realizable.
Advertising and Marketing
Advertising and marketing costs are expensed as incurred. Advertising and marketing costs were $0.5 million and $0.3 million for the three months ended September 30, 2021 and 2020, respectively, and $1.3 million and $2.2 million for the nine months ended September 30, 2021 and 2020, respectively.
Income Taxes
We account for income taxes using the liability method in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), 740 - Income Taxes (“ASC 740”). Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax bases of assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income (loss) in the period that the rate changes. A valuation allowance is required when it is “more likely than not” that all or a portion of deferred tax assets will not be realized. ASC 740 also prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that a company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. We recognize any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
Revenue Recognition
Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for
11

arrangements that an entity determines are within the scope of ASC 606 - Revenue from Contracts with Customers (“ASC 606”), we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determines those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Receivables from our product sales have payment terms ranging from 30 to 75 days with select extended terms to wholesalers on initial purchases of product launch quantities. Our receivables from royalty revenue are due 45 days from the end of the quarter.
Product revenue - We recognize net revenue on sales to our commercial partners and to end users. In each instance, revenue is generally recognized when the customer obtains control of our product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.
Revenue on sales to commercial partners relates to Bendeka and Treakisym. Sales to our commercial partners are presented gross because we are primarily responsible for fulfilling the promise to provide the product, and are responsible to ensure that the product is produced in accordance with the related supply agreement and we bear risk of loss while the inventory is in-transit to the commercial partner.
Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services to a customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing the expected value method to which we expect to be entitled. As such, revenue on sales to customers for Belrapzo and Ryanodex are recorded net of chargebacks, rebates, returns, prompt pay discounts, wholesaler fees and other deductions. Our products are contracted with a limited number of oncology distributors and hospital buying groups with narrow differences in ultimate realized contract prices used to estimate our chargeback and rebate reserves. We have a product return policy on some of our products that allows the customer to return pharmaceutical products within a specified period of time both prior to and subsequent to the product’s expiration date. Our estimate of the provision for returns is analyzed quarterly and is based upon many factors, including historical experience of actual returns and analysis of the level of inventory in the distribution channel, if any. We have terms on sales of Ryanodex by which we do not accept returns. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration are made using the expected value method and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available. We believe that the estimates we have established are reasonable based upon current facts and circumstances. Applying different judgments to the same facts and circumstances could result in the estimated amounts to vary.
Components of Gross-to-Net (GTN) Estimates
Chargebacks: Chargebacks are discounts that occur when certain contracted customers, including group purchasing organizations (“GPOs”), public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase from our distributors. Our distributors purchase product from us at invoice price, then resell the product to certain contracted customers on the basis of prices negotiated between us and the providers. The difference between the distributors’ purchase price and the typically lower certain contracted customers’ purchase price is refunded to the distributors through a chargeback credit. We record estimates for these chargebacks at the time of sale as deductions from gross revenues, with corresponding adjustments to our accounts receivable reserves and allowances.
The provision for chargebacks is the most significant provision in the context of our gross-to-net adjustments in the determination of net revenue. Chargebacks are estimated based on payer mix and contracted price, adjusted for current period assumptions.

Commercial and Medicaid Rebates: We contract with government agencies or collectively, third-party payors, so that Belrapzo and Ryanodex will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. We estimate the rebates we will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a
12

reduction of product revenue and the establishment of a current liability. The current liability is included in accrued expenses and other current liabilities on the consolidated balance sheets. We estimate the rebates that we will provide to third-party payors based upon (i) our contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payer mix, and (iv) information obtained from our distributors.
The information that we also consider when establishing our rebate reserves are purchases by customers, projected annual sales for customers, actual rebates payments made, processing time lags, and for indirect rebates, the level of inventory in the distribution channel that will be subject to indirect rebates. We do not provide incentives designed to increase shipments to our customers that we believe would result in out-of-the-ordinary course of business inventory for them. We regularly review and monitor estimated or actual customer inventory information at our largest distributors for our key products to ascertain whether customer inventories are in excess of ordinary course of business levels.

Product Returns: Our distributors have the right to return unopened unprescribed Belrapzo during certain time periods around the period beginning prior to the labeled expiration date and ending after the labeled expiration date. We estimate future product returns on sales of Belrapzo based on: (i) data provided to us by our distributors (including weekly reporting of distributors’ sales and inventory held by distributors that provided us with visibility into the distribution channel in order to determine what quantities were sold to retail pharmacies and other providers), (ii) information provided to us from retail pharmacies, (iii) data provided to us by a third-party data provider which collects and publishes prescription data, and other third parties, (iv) historical industry information regarding return rates for similar pharmaceutical products, (v) the estimated remaining shelf life of Belrapzo previously shipped and currently being shipped to distributors and (vi) contractual agreements intended to limit the amount of inventory maintained by our distributors. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Our provision for product returns based on the factors noted above generally encompass a time range from 12 to 48 months after revenue is recognized. Additionally, we consider other factors when estimating our current period return provision, including levels of inventory in the distribution channel, significant market changes that may impact future expected returns, and actual product returns, and may record additional provisions for specific returns that it believes are not covered by the historical rates. Our commercial returns policy and terms with certain customers also states that certain products are sold as non-returnable.

Wholesaler fees and other incentives: We generally provide invoice discounts on Belrapzo and Ryanodex sales to our distributors for prompt payment and fees for distribution services, such as fees for certain data that distributors provide to us. The payment terms for sales to distributors generally include a 2% discount for prompt payment which is generally defined in invoice terms as a range from 30 to 70 days, while the fees for distribution services are based on contractual rates agreed with the respective distributors. Based on historical data, we expect our distributors to earn these discounts and fees, and deducts the full amount of these discounts and fees from our gross product revenues and accounts receivable at the time such revenues are recognized.

Other GTN considerations
We may at our discretion provide price adjustments due to various competitive factors. There are circumstances under which we may not provide price adjustments to certain customers as a matter of business strategy, and consequently may lose future sales volume to competitors and risk a greater level of product returns.

As detailed above, we have the experience and access to relevant information that we believe are necessary to reasonably estimate the amounts of such deductions from gross revenues. Some of the assumptions we use for certain of these estimates are based on information received from third parties, such as wholesale customer inventories and market data, or other market factors beyond our control. The estimates that are most critical to the establishment of these reserves, and therefore, would have the largest impact if these estimates were not accurate, are estimates related to contract sales volumes, average contract pricing, customer inventories and return volumes. We regularly review the information related to these estimates and adjust our reserves accordingly, if and when actual experience differs from previous estimates. With the exception of the product returns allowance, the ending balances of accounts receivable reserves and allowances generally are processed during a two-month to four-month period.
13


Royalty Revenue — We recognize revenue from license arrangements with our commercial partners' net sales of products. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner’s products occurs. Our commercial partners are obligated to report their net product sales and the resulting royalty due to us within 25 days for Bendeka. Based on historical product sales, royalty receipts and other relevant information, we accrue royalty revenue each quarter and subsequently determine a true-up when we receive royalty reports from our commercial partners. Historically, these true-up adjustments have been immaterial.
License and other revenue — We analyze each element of our licensing agreements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer.
If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. We determine standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, we estimate the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.
We recognize sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, we determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, we assess each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of these future events, we will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event.
When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, we do not assess whether a significant financing component exists if the period between when we perform our obligations under the contract and when the customer pays is one year or less. None of our contracts contained a significant financing component as of September 30, 2021.
Stock-Based Compensation
We account for stock-based compensation using the fair value provisions of ASC 718, Compensation - Stock Compensation that requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock-based payments including stock options and restricted stock. This topic requires companies to estimate the fair value of the stock-based awards on the date of grant for options issued to employees and directors and record expense over the employees' service periods, which are generally the vesting period of the equity awards.
We account for stock-based compensation by measuring and recognizing compensation expense for all stock-based payments made to employees and directors based on estimated grant date fair values. The straight-line method is used to allocate compensation cost to reporting periods over each optionee's requisite service period, which is generally the vesting period. The fair value of our stock option awards to employees and directors is estimated using the Black-Scholes valuation model and a Monte Carlo simulation model is used to estimate the fair value for market condition share units. These models require the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, historical forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate is determined with the implied yield currently available for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options. The fair value of restricted stock units ("RSUs") granted are estimated based on the trading price of our common stock on the date of grant. The fair value of performance condition performance-based stock units ("PSUs") granted are also estimated based on the trading price of our common stock on the date of grant and adjusted for the probability of achievement of the performance conditions. Forfeitures are estimated for all stock-based awards.
14

Earnings Per Share
Basic earnings per common share is computed using the weighted average number of shares outstanding during the period. Diluted earnings per share is computed in a manner similar to the basic earnings per share, except that the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of warrants, options, convertible debt and other such convertible instruments. Diluted earnings per share contemplate a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share.
The anti-dilutive common share equivalents outstanding for the three and nine months ended September 30, 2021 and 2020 were as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2021202020212020
Stock options2,446,657 3,156,166 2,777,995 2,905,021 
Restricted stock units
 205,891 123,600 225,177 
Total2,446,657 3,362,057 2,901,595 3,130,198 

The following table sets forth the computation for basic and diluted net (loss) earnings per share for the three and nine months ended September 30, 2021 and 2020:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2021202020212020
Numerator
Numerator for basic and diluted (loss) earnings per share-net (loss) earnings $(5,622)$7,059 $(2,431)$3,932 
Denominator
Basic weighted average common shares outstanding 13,077,298 13,531,372 13,103,203 13,620,981 
Dilutive effect of stock awards — 255,431 — 296,819 
Diluted weighted average common shares outstanding 13,077,298 13,786,803 13,103,203 13,917,800 
Basic net (loss) earnings per share
Basic net (loss) earnings per share $(0.43)$0.52 $(0.19)$0.29 
Diluted net (loss) earnings per share
Diluted net (loss) earnings per share $(0.43)$0.51 $(0.19)$0.28 

All potentially dilutive items were excluded from the diluted share calculation for the three months and nine months ended September 30, 2021 because their effect would have been anti-dilutive, as the Company was in a loss position.

Recent Accounting Pronouncements
Recent Accounting Pronouncements - Not Yet Adopted
In March 2020, the FASB issued Update 2020-04 Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting to provide temporary optional guidance to ease the potential burden in accounting for
15

reference rate reform. The amendments in Update 2020-04 are elective and apply to all entities that have contracts, hedging relationships, and other transactions that reference LIBOR, formerly known as the London Interbank Offered Rate,
or another reference rate expected to be discontinued due to reference rate reform. The new guidance provides optional expedients, including; (1) Simplify accounting analyses under current GAAP for contract modifications, such as modifications of contracts within the scope of Topic 470, Debt, that will be accounted for by prospectively adjusting the effective interest rate, as if any modification was not substantial. That is, the original contract and the new contract shall be accounted for as if they were not substantially different from one another; (2) Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue; (3) Allow a one-time election to sell or transfer debt securities classified as held to maturity before January 1, 2020 that reference a rate affected by reference rate reform. The amendments are effective for all entities from the beginning of an interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The adoption of ASU 2020-4 is not expected to have a material impact on our financial position or results of operations.

3. Property and Equipment, net
Property and equipment consisted of the following:
 September 30, 2021December 31, 2020Estimated Useful Life (years)
Furniture and fixtures$1,476 $1,476 7
Office equipment1,077 1,152 3
Equipment3,834 3,485 7
Leasehold improvements1,155 1,155 2
 7,542 7,268  
Less accumulated depreciation(5,767)(5,191)
Property and equipment, net$1,775 $2,077  

Depreciation expense related to property and equipment amounted to $197 and $196 for the three months ended September 30, 2021 and 2020, respectively, and $575 and $656 for the nine months ended September 30, 2021 and 2020, respectively.

4. Inventories
Inventories consist of the following:
September 30, December 31,
20212020
Raw materials$6,006 $3,515 
Work in process 1,309 2,589 
Finished products2,000 1,971 
Total inventories$9,315 $8,075 

16

5. Balance Sheet Accounts
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
September 30, December 31,
20212020
Prepaid income taxes$5,898 $ 
Prepaid FDA user fee and advances to clinical research organization1,478 1,262 
Prepaid insurance468 191 
Advances to commercial manufacturers734 660 
Receivable from commercial partner
1,746 439 
Convertible promissory note, net4,551  
All other2,428 1,605 
Total prepaid expenses and other current assets$17,303 $4,157 

Accrued Expenses
Accrued expenses consist of the following:
September 30, December 31,
20212020
Accrued sales reserves$3,046 $4,966 
Royalties payable to commercial partners4,879 5,996 
Accrued salary and other compensation 5,255 4,686 
Accrued professional fees2,552 2,370 
Accrued research & development8,528 2,724 
Current portion of lease liability1,199 1,123 
Accrued other 2,255 1,952 
Total accrued expenses$27,714 $23,817 

Leases
We lease office space in Woodcliff Lake, New Jersey for our principal office under an amended lease agreement through June 2025. We also lease a lab space in Cambridge, Massachusetts under a lease agreement through April 2024. Both of our leases are classified as operating leases and have remaining lease terms of approximately 3.3 years. The principal office and the lab space leases include renewal options to extend the lease for up to 5 years. Furthermore, we have not elected the practical expedient to separate lease and non-lease components for all classes of underlying assets.
17

The table below summarizes our total lease costs included in the condensed consolidated financial statements, as well as other required quantitative disclosures (in thousands):

September 30, 2021December 31, 2020
Cash paid for amounts included in the measurement of lease liabilities
     Operating cash flows for operating leases$1,040 $1,323 
Right-of-use assets obtained in exchange for new operating lease liabilities$ $855 
Weighted-average remaining lease term - operating leases 3.3 years4.1 years
Weighted-average discount rate - operating leases 6.0 %6.0 %

Balance Sheet Classification as of September 30:
Current lease liabilities (included with Accrued Expenses and other liabilities)$1,199 
Long-term lease liabilities (included with Other long-term liabilities)3,048 
Total lease liabilities$4,247 



6. Intangible Assets, Net
The gross carrying amounts and net book value of our intangible assets are as follows:
September 30, 2021
Useful Life (In Years)Gross Carrying AmountAccumulated AmortizationNet Book Value
Ryanodex intangible (i)
20$15,000 $(4,404)$10,596 
Developed technology58,100 (7,897)203 
Total$23,100 $(12,301)$10,799 
December 31, 2020
Useful Life (In Years)Gross Carrying AmountAccumulated AmortizationNet Book Value
Ryanodex intangible (i)
2015,000 (3,500)11,500 
Developed technology58,100 (6,683)1,417 
Total$23,100 $(10,183)$12,917 
(i) Represents a one-time payment made to reduce the royalties payable to a third party on Ryanodex net sales.
Amortization expense was $706 and $667 for the three months ended September 30, 2021 and 2020, respectively and $2,118 and $1,999 for the nine months ended September 30, 2021 and 2020, respectively.
Estimated Amortization Expense for Intangible Assets
Based on definite-lived intangible assets recorded as of September 30, 2021, and assuming that the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses are estimated as follows:
18

Estimated Amortization Expense
Year Ending December 31,
2021 (remainder)504 
20221,369 
20231,570 
20241,898 
20251,520 
Thereafter3,938 
Total estimated amortization expense$10,799 

7. Common Stock and Stock-Based Compensation
Common Stock
Share Repurchase Program

On March 17, 2020, we announced that our Board approved a new share repurchase program, or the Share Repurchase Program, providing for the repurchase of up to an aggregate of $160 million of our outstanding common stock. The Share Repurchase Program replaced our then existing share repurchase program, or the Previous Share Repurchase Program, which was announced on October 30, 2018 and was terminated in connection with the Board’s approval of the Share Repurchase Program. At termination, we had repurchased approximately $68 million of our outstanding common stock under the Previous Share Repurchase Program.

Under the Share Repurchase Program, we are authorized to repurchase shares through open market purchases, privately-negotiated transactions, accelerated share repurchases or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans and under Rule 10b-18 of the Exchange Act. The repurchases have no time limit and may be suspended or discontinued completely at any time. The specific timing and amount of repurchases will vary based on available capital resources and other financial and operational performance, market conditions, securities law limitations, and other factors. The repurchases will be made using our cash resources.

On September 23, 2020, our Board of Directors approved a $25 million accelerated share repurchase (“ASR”) transaction with JPMorgan Chase Bank, National Association (“JP Morgan”) as part of our existing $160 million share repurchase program. The specific number of shares to be repurchased pursuant to the ASR is based on the average of the daily volume weighted average share prices of our common stock, less a discount, during the term of the ASR program. Under the terms of our agreement with JP Morgan, we paid $25 million to JP Morgan on September 24, 2020, and received 550,623 shares, representing the notional amount of the ASR, based on the average of the daily volume weighted average share prices of our common stock, less a discount, during the term of the ASR, which was $45.40. The ASR was completed in the fourth quarter of 2020. We determined the ASR contained a forward contract and therefore we recorded fair value adjustments on the accelerated share repurchase agreement in the amount of $3 million which was a loss recorded in Other expense on our consolidated statements of operations in the year ended December 31, 2020.

As of September 30, 2021, we had repurchased an aggregate of 3,941,541 shares of common stock for an aggregate of $219.5 million pursuant to our share repurchase programs in effect since August 2016.

Stock-Based Compensation
In November 2013, our Board of Directors approved the 2014 Equity Incentive Plan (the "2014 Plan") which became effective on February 11, 2014. The 2014 Plan provides for the awards of incentive stock options, non-qualified stock options, restricted stock, restricted stock units and other stock-based awards. Awards generally vest equally over a period of four years from grant
19

date. Vesting may be accelerated under a change in control of the Company or in the event of death or disability to the recipient. In the event of termination, any unvested shares or options are forfeited.

During the first quarter of 2018, we introduced a new long-term incentive program with the objective to better align the stock-based awards granted to management with our focus on improving total shareholder return over the long-term. The stock-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and PSUs. PSUs are comprised of awards: i) that would have vested upon achievement of certain share price appreciation conditions or ii) that would have vested upon achievement of certain milestone events. These PSUs expired in the first quarter of 2021.

During the first quarter of 2021, 97,750 market condition PSUs expired. We also granted 99,500 market condition PSUs based on our total shareholder return ("TSR") relative to the TSR of each member of the S&P Biotechnology Select Industry Index (the defined peer group) with a weighted-average grant date fair value of $71.09 per respective PSU. The fair value of PSUs granted to employees was estimated using a Monte Carlo simulation model. Inputs used in the calculation include a risk-free interest rate of 0.18%, an expected volatility of 44%, contractual term of 3 years, and no expected dividend yield.

During the first quarter of 2021, we also granted 59,500 performance based (milestones) PSUs with grant date fair value of $49.32 using our closing stock price on the date of the grant. These PSUs will vest (if earned) from 0% to 200% of target number granted based on the achievement of one or more of three milestones related to i) regulatory approval of Fulvestrant ("EA-114"), ii) sales of Pemfexy and; iii) sales of Vasopressin, respectively. The contractual term of these awards is 3 years. We estimated 0% probability of achievement for the year-to-date period of 2021.

A summary of stock option, RSU and PSU activity under the 2014 Plan during the nine months ended September 30, 2021 and 2020 is presented below:
 Stock OptionsRSUsPSUs
Outstanding at December 31, 20193,096,161 251,215 116,181 
Granted662,700 231,450  
Options exercised/RSUs vested/PSUs vested(41,951)(67,970) 
Forfeited or expired(185,615)(53,824)(11,431)
Outstanding at September 30, 20203,531,295 360,871 104,750 
Outstanding at December 31, 20203,331,890 328,396 97,750 
Granted109,000 106,600 159,000 
Options exercised/RSUs vested/PSUs vested(100,477)(94,273) 
Forfeited or expired(308,815)(46,941)(97,750)
Outstanding at September 30, 20213,031,598 293,782 159,000 
20


Stock Options
The fair value of stock options granted to employees, directors, and consultants were estimated using the following assumptions:
Three Months Ended
September 30,
Nine Months Ended 
 September 30,
2021202020212020
Risk-free interest rate
0.82% - 0.93%
0.37% - 0.41%
0.51% - 1.12%
0.37% - 1.65%
Volatility54.92%55.42%56.07%54.98%
Expected term (in years)6.08 years6.07 years5.68 years6.03 years
Expected dividend yield0.0%0.0%0.0%0.0%

RSUs
Each vested time-based RSU represents the right of a holder to receive one share of our common stock. The fair value of each RSU granted was estimated based on the trading price of our common stock on the date of grant.
PSUs
The fair value of market condition PSUs granted to employees was estimated using a Monte Carlo simulation model. Inputs used in the calculation are described above.

The fair value of performance condition PSUs granted to employees was estimated based on the trading price of our common stock on the date of grant adjusted for probability of achievement of the performance conditions as described above.

We did not recognize any expense for performance based PSUs granted to employees based on our estimated probability of achievement as described above.

We recognized stock-based compensation in our condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 as follows:
Three Months Ended September 30, Nine Months Ended September 30,
2021202020212020
Stock options $2,515 $3,685 $8,393 $12,831 
RSUs1,046 928 4,051 4,115 
PSUs523 109 2,429 1,489 
Stock-based compensation expense $4,084 $4,722 $14,873 $18,435 
Selling, general and administrative$3,443 $5,236 $12,696 $16,365 
Research and development641 (514)2,177 2,070 
Stock-based compensation expense$4,084 $4,722 $14,873 $18,435 

21


8. Commitments
Our future material contractual obligations as of September 30, 2021, included the following:
ObligationsTotal202120222023202420252026Beyond
Operating leases (1)$4,680 $351 $1,423 $1,455 $1,038 $413 $ $ 
Credit facility (2)28,000 2,000 26,000      
Purchase obligations (3)53,176 53,176       
Total obligations $85,856 $55,527 $27,423 $1,455 $1,038 $413 $ $ 

(1) We lease our corporate office location. The term of our existing lease expires on June 30, 2025. We also lease our lab space under a lease agreement that expires on October 31, 2023. Rental expense for the operating leases was $325 and $276, for the three months ended September 30, 2021 and 2020, respectively. Rental expense for the operating leases was $976 and $910 for the nine months ended September 30, 2021 and 2020. The remaining future lease payments under the operating leases are $4.7 million as of September 30, 2021.
(2) Refer to Note 9, “Debt” for further information regarding our Credit Agreement.
(3) As of September 30, 2021, we had purchase obligations in the amount of $53.2 million which represents the contractual commitments under contract manufacturing and supply agreements with suppliers. The obligations under the supply agreements are primarily for finished product, inventory, and research and development.

9. Debt
On November 8, 2019, we entered into the Second Amended and Restated Credit Agreement (the “Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”) and the lenders party thereto. The terms and amounts borrowed under the Credit Agreement includes a drawn term loan of $40 million and an undrawn revolving credit facility of $110 million. The schedule of principal payments for the new term loan facility was extended to November 8, 2022.
We classified the current portion of long-term debt of $8 million on the condensed consolidated balance sheet as of September 30, 2021. Per the terms of the Credit Agreement, the Company is limited in its ability to pay dividends. As of September 30 2021, we were in compliance with each of the senior secured net leverage ratio; total net leverage ratio; and fixed charge coverage ratio covenants.
The term loan facility bears interest at the Adjusted LIBOR (equal to (a) the LIBOR for such Interest Period multiplied by (b) the Statutory Reserve Rate as established by Board of Governors of the Federal Reserve System of the United States of America) for the interest period in effect for such borrowing plus the applicable rate as described below. The Agent and us may amend the Credit Agreement to replace the LIBOR with a Benchmark Replacement, described below.

Loans under the Credit Agreement bear interest at a rate equal to either (a) the LIBOR rate, plus an applicable margin ranging from 2.25% to 3.0% per annum, based upon the total net leverage ratio (as defined in the Credit Agreement), or (b) the Benchmark Replacement which is defined as the greatest of the prime lending rate, or the NYFRB Rate (the rate for a federal funds transaction) in effect on such day plus ½ of 1% or the Adjusted LIBO Rate for a one month Interest Period on such day plus 1% plus an applicable margin ranging from 1.25% to 2.0% per annum, based upon the total net leverage ratio. 
We are required to pay a commitment fee on the unused portion of the new revolving credit facility in the Credit Agreement at a rate ranging from 0.35% to 0.45% per annum based upon the total net leverage ratio.

As of September 30, 2021, we had $0.5 million of unamortized deferred debt issuance costs as part of long-term debt in its condensed consolidated balance sheets.

22

Debt Maturities As of September 30, 2021
     2021 (remainder)$2,000 
     202226,000 
Total$28,000 

10. Income Taxes
Three Months Ended September 30, Nine Months Ended September 30,
2021202020212020
Income tax benefit (provision)$7,038 $(1,866)$3,341 $(7,358)
Effective tax rate 56 %21 %58 %65 %

For interim periods, we recognize an income tax provision based on our estimated annual effective tax rate expected for the entire year plus the effects of certain discrete items occurring in the quarter. The interim annual estimated effective tax rate is based on the statutory tax rates then in effect, as adjusted for changes in estimated permanent differences, and certain discrete items whose tax effect, when material, is recognized in the interim period in which they occur.
The effective tax rate for the three and nine months ended September 30, 2021, reflects an interim tax benefit resulting from our research and development expense of acquired licenses and credits for research and development activity, partially offset by impact of certain non-deductible executive compensation and expired stock compensation. We review the realizability of our deferred tax assets on a quarterly basis, or whenever events or changes in circumstances indicate that a review is required. In determining the requirement for a valuation allowance, the historical and projected financial results of the legal entity or consolidated group recording the net deferred tax asset are considered, along with any other positive or negative evidence. Since future financial results, including the fair value adjustment on our investment in Tyme may differ from previous estimates, periodic adjustments to our valuation allowances may be necessary.
Deferred income tax assets as of September 30, 2021 consisted of temporary differences primarily related to stock-based compensation and research and development tax credit carryforwards, partially offset by temporary differences related to intangible assets.
We file income tax returns in the U.S. federal jurisdiction and several states. Given that we have incurred tax losses in most years since our inception, all of our tax years are effectively open to examination. We are currently under audit by three State tax jurisdictions. We had no amount recorded for any unrecognized tax benefits as of September 30, 2021. We regularly evaluate our tax positions for additional unrecognized tax benefits and associated interest and penalties, if applicable. There are many factors that are considered when evaluating these tax positions including: interpretation of tax laws, recent tax litigation on a position, past audit or examination history, and subjective estimates and assumptions. We reflect interest and penalties attributable to income taxes, to the extent they arise, as a component of income tax provision or benefit.

11. Legal Proceedings
In addition to the below legal proceedings, from time to time, we may be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters, or matters discussed below, will not have a material adverse effect on our business nor have we recorded any loss in connection with these matters because we believe that loss is neither probable nor estimable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Commercial Litigation
Cipla v. Eagle
On April 16, 2020, Cipla Limited (“Cipla”) filed a request for arbitration against Eagle with the London Court of International Arbitration. The request alleges that Eagle’s refusal to take delivery of several batches of Argatroban finished drug product
23

constitutes a breach of the parties’ December 14, 2012 supply agreement. Eagle believes that the allegations against it are without merit and is vigorously defending itself in the Arbitration, which was scheduled for June 2021, has been rescheduled for April 2022.

Patent Litigation
Eagle Pharmaceuticals, Inc., et al. v. Slayback Pharma Limited Liability Company; Eagle Pharmaceuticals, Inc., et al. v. Apotex Inc. and Apotex Corp.; Eagle Pharmaceuticals, Inc., et al. v. Fresenius Kabi USA, LLC; Eagle Pharmaceuticals, Inc., et al. v. Mylan Laboratories Limited; Eagle Pharmaceuticals, Inc. et al. v. Hospira, Inc; Eagle Pharmaceuticals, Inc. et al. v. Lupin, Ltd. and Lupin Pharmaceuticals, Inc.; Teva Pharmaceuticals Int’l GmbH et al v. Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., and Eugia Pharma Specialities Ltd.; Teva Pharmaceuticals Int’l GmbH et al v. Accord Healthcare Inc., Accord Healthcare Ltd., and Intas Pharmaceuticals Ltd.; Teva Pharmaceuticals Int’l GmbH et al v. Dr. Reddy’s Laboratories, Ltd., and Dr. Reddy’s Laboratories, Inc. - (Bendeka®)

Bendeka, which contains bendamustine hydrochloride, is an alkylating drug that is indicated for the treatment of patients with chronic lymphocytic leukemia, as well as for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Slayback Pharma Limited Liability Company (“Slayback”), Apotex Inc. and Apotex Corp. (“Apotex”), Fresenius Kabi USA, LLC (“Fresenius”), Mylan Laboratories Limited (“Mylan”), Lupin, Ltd. and Lupin Pharmaceuticals, Inc. (“Lupin”), and Aurobindo Pharma, Ltd, Aurobindo Pharma USA, Inc., and Eugia Pharma Specialities Ltd (“Aurobindo”) have filed Abbreviated New Drug Applications (“ANDA’s”) referencing Bendeka® that include challenges to one or more of the Bendeka® Orange Book-listed patents. Hospira, Inc. (“Hospira”) filed a 505(b)(2) NDA.

We, Cephalon, Inc. and/or Teva Pharmaceuticals International GMBH (together the “Patentees”), filed separate suits against Slayback, Apotex, Fresenius, Mylan, Hospira, Lupin, and Aurobindo in the United States District Court for the District of Delaware on August 16, 2017 (Slayback (“Slayback I”)), August 18, 2017 (Apotex), August 24, 2017 (Fresenius), December 12, 2017 (Mylan), January 19, 2018 (Slayback (“Slayback II”)), July 19, 2018 (Hospira), and July 2, 2019 (Lupin) and May 11, 2020 (Aurobindo). In these Complaints, the Patentees allege infringement of the challenged patents, namely U.S. Patent Nos. 8,791,270 and 9,572,887 against Slayback (Slayback I and Slayback II), and of U.S. Patent Nos. 8,609,707, 8,791,270, 9,000,021, 9,034,908, 9,144,568, 9,265,831, 9,572,796, 9,572,797, 9,572,887, 9,579,384, 9,597,397, 9,597,398, 9,597,399 against Fresenius, Apotex, and Mylan, and of U.S. Patent Nos. 9,572,887, 10,010,533, 9,034,908, 9,144,568, 9,597,397, 9,597,398, 9,597,399, 9,000,021, 9,579,384 against Hospira, and of U.S. Patent Nos. 8,609,707, 9,000,021, 9,034,908, 9,144,568, 9,265,831, 9,572,796, 9,572,797, 9,572,887, 9,579,384, 9,597,397, 9,597,398, 9,597,399, 10,010,533, and 10,052,385 against Lupin and of U.S. Patent Nos. 8,609,707, 9,265,831, 9,572,796, 9,572,797, 9,034,908, 9,144,568, 9,572,887, 9,597,397, 9,597,398, 9,597,399, 9,000,021, 9,579,384, 10,010,533, and 10,052,385 against Aurobindo. The parties stipulated to dismiss without prejudice U.S. Patent No. 8,791,270 as to Apotex, Fresenius and Mylan on July 24, 2018, August 2, 2018, and August 3, 2018, respectively. Slayback, Apotex, Fresenius, and Mylan answered their Complaints and some filed various counterclaims on September 29, 2017 (Slayback I), February 12, 2018 (Slayback II), November 27, 2017, September 15, 2017, and February 14, 2018, respectively. The Patentees answered the Slayback I, Slayback II, Fresenius, and Apotex counterclaims on October 20, 2017, March 5, 2018, October 6, 2017, and December 18, 2017, respectively. On October 15, 2018, the Patentees filed a suit against Fresenius and Mylan in the United States District Court for the District of Delaware, alleging patent infringement of U.S. Patent Nos. 10,010,533 and 10,052,385. The Slayback I, Slayback II, Apotex, Fresenius and Mylan cases have been consolidated for all purposes (the “Consolidated Bendeka Litigation”), and a bench trial in these cases was held September 9-19, 2019. On April 27, 2020, the district court held that the asserted patents are valid and infringed by Slayback, Apotex, Fresenius and Mylan. On July 6, 2020, the district court entered a final judgment reflecting this decision, stating that pursuant to 35 U.S.C. § 271(e)(4)(A), the FDA shall not approve Apotex’s, Fresenius’s, Mylan’s, or Slayback’s ANDA products on a date which is earlier than January 28, 2031, and enjoining Apotex, Fresenius, Mylan, and Slayback from commercially manufacturing, using, offering to sell, or selling within the US or importing into the US, their ANDA products before that date. On August 4, 2020, Apotex, Fresenius, and Mylan appealed this final judgment, and filed their opening briefs on November 4, 2020. Plaintiffs’ responsive appeal brief was filed on February 12, 2021. Defendants’ reply briefs were filed April 5, 2021. On August 2, 2021, Fresenius’s appeal was dismissed pursuant to a settlement agreement reached with Patentees. Oral argument for the remaining defendants occurred on August 3, 2021. On August 13, 2021, the appeals court affirmed the trial court’s decision. The mandate was issued on October 22, 2021.

24

Hospira filed a motion to dismiss, which was fully briefed on November 16, 2018. On December 16, 2019, the United States District Court for the District of Delaware denied Hospira’s motion to dismiss with respect to U.S. Patent No. 9,572,887 and granted that motion with respect to the remaining patents. On December 15, 2020, the Court held a claim construction hearing, ruling in our favor on all claim terms. Fact discovery closed on April 1, 2021. Expert discovery is ongoing. Trial has been rescheduled for April 25, 2022. The case remains pending.

On March 10, 2020, the parties filed a stipulation and order of dismissal without prejudice as to Lupin, which the Court entered March 11, 2020.

Aurobindo answered the Complaint on July 20, 2020. The parties exchanged initial disclosures on December 11, 2020. Plaintiffs provided their infringement contentions on March 12, 2021. On October 20, 2021 the Court entered a stipulation of dismissal based on a settlement between the parties.

Patentees filed suit against Dr. Reddy’s Laboratories on May 13, 2021. Patentees have asserted U.S. Patent Nos. 8,609,707, 9,265,831, 9,572,796, 9,572,797, 9,034,908, 9,144,568, 9,572,887, 9,597,397, 9,597,398, 9,597,399, 9,000,021, 9,579,384, 10,010,533, and 10,052,385. Dr. Reddy’s answer was filed August 16, 2021. Scheduling for the case is ongoing.

Patentees filed suit against Accord Healthcare on June 29, 2021. Patentees have asserted U.S. Patent Nos. 8,609,707, 9,265,831, 9,572,796, 9,572,797, 9,034,908, 9,144,568, 9,572,887, 9,597,397, 9,597,398, 9,597,399, 9,000,021, 9,579,384, 10,010,533, and 10,052,385. Accord has answered the complaint.

Eagle Pharmaceuticals, Inc. v. Slayback Pharma Limited Liability Company
Slayback filed an ANDA referencing Eagle's Belrapzo NDA. Slayback’s ANDA includes challenges to one or more of the Belrapzo Orange Book-listed patents. On September 20, 2018, the Company filed a suit against Slayback in the United States District Court for the District of Delaware, alleging patent infringement of U.S. Patent Nos. 8,609,707, 9,265,831, 9,572,796, 9,572,797 and 10,010,533. On October 10, 2018, Slayback answered the Complaint and filed various counterclaims. On October 31, 2018, the Company answered Slayback’s counterclaims. Pursuant to a stipulation between the parties, Slayback is bound by any final judgment entered in the Consolidated Bendeka Litigation. This case is currently stayed.

Eagle Pharmaceuticals, Inc. v. Slayback Pharma Limited Liability Company, Apotex, Inc. and Apotex Corp.
Both Slayback and Apotex filed NDAs referencing Eagle’s Belrapzo NDA. On August 31, 2021, the Company filed suit against Slayback and Apotex in the United States District Court for the District of Delaware, alleging infringement of U.S. Patent No. 11,103,483. On September 22, 2021, both Slayback and Apotex filed their Answers. Scheduling for the case is ongoing.

Par Pharmaceutical, Inc. et al. v. Eagle Pharmaceuticals, Inc. (Vasopressin)
On May 31, 2018, Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC (together, “Par”) filed suit against the Company in the United States District Court for the District of Delaware. Par alleged patent infringement based on the filing of the Company’s ANDA seeking approval to manufacture and sell the Company’s vasopressin product. The Company’s vasopressin product, if approved by FDA, will be an alternative to Vasostrict, which is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. The Company answered the complaint on August 6, 2018, and filed an amended answer and counterclaims on October 30, 2019. The court issued a Markman ruling on July 1, 2019. On December 20, 2019, Par dismissed with prejudice claims of three of the patents asserted against Eagle, and the Court entered an Order reflecting that dismissal on December 27, 2019. Mediation took place on March 3, 2020. On April 17, 2020, we submitted a letter requesting leave to file a motion for summary judgment of non-infringement. Par’s responsive letter was submitted on May 8, 2020. On May 18, 2020, the court said it would hear non-infringement arguments at trial and not through summary judgment. Fact discovery ended in October 2019, and expert discovery ended in February 2020. Due to the COVID-19 pandemic, the trial, which was scheduled to begin May 18, 2020, was rescheduled to and occurred on July 7-9, 2021. Post-trial briefing was submitted on July 28, 2021. The Court issued an opinion on August 31, 2021 and entered a final judgment of non-infringement in favor of Eagle on September 16, 2021. Par filed a Notice of Appeal of the final judgment on September 22, 2021, and the appeal was docketed with the United States Court of Appeals for the Federal Circuit on September 23, 2021. The 30-month stay of FDA approval expired on October 17, 2020. This suit is pending.

25

On December 7, 2020, Par filed a separate suit against us in the United States District Court for the District of New Jersey, asserting patent infringement of U.S. Patent No. 10,844,435, based on the filing of our ANDA seeking approval to manufacture and sell our vasopressin product. Eagle moved to dismiss Par’s complaint on March 2, 2021. On March 22, 2021, Par amended its complaint to additionally assert U.S. Patent No. 10,920,278, and on April 5, 2021, Eagle moved to dismiss Par’s amended complaint. This suit is pending.

12. License and Collaboration Agreements

License agreement with Combioxin

In August 2021, we entered into a license agreement with Combioxin, SA under which the Company was granted exclusive, worldwide development and commercialization rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. The Company will be solely responsible for the development, regulatory, manufacturing and commercialization activities of CAL02. Combioxin will assist the Company in transitioning the manufacturing and supply of CAL02 to the Company.

Under the terms of the agreement, we paid $10 million as upfront license consideration that was expensed immediately as research and development and is reflected within the operating activities of the condensed consolidated statements of cash flows. The Company may pay to Combioxin up to $105 million upon achievement of certain development, regulatory and sales based milestone payments plus royalty payments at royalty rates ranging in low double digit percentages on the net sales of all products sold, subject to certain adjustments as provided in the agreement. The Company is also obligated to make certain payments based upon amounts received by sublicensees under the agreement.

License agreement with AOP Orphan

In August 2021, we entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH (“AOP Orphan”), a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, landiolol in the United States. Landiolol, a leading hospital emergency use product, is currently approved in Europe for the treatment of non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias. We will support the submission of a new drug application (“NDA”) by AOP Orphan to the FDA seeking approval for landiolol for the short term reduction of ventricular rate in patients with supraventricular tachycardia (“SVT”), including atrial fibrillation and atrial flutter.

Under the terms of the agreement, we accrued a $5 million upfront license consideration that was expensed immediately as research and development and is reflected within the operating activities of the condensed consolidated statements of cash flows. The Company may pay to AOP Orphan up to $25 million upon achievement of certain regulatory milestone payments plus profit share payments, subject to certain adjustments as provided in the agreement. We also entered into a supply agreement at the same time as the licensing agreement.

Collaboration with Tyme
On January 7, 2020, Tyme and we announced a strategic collaboration to advance SM-88, an oral product candidate for the treatment of patients with cancer. SM-88 is an investigational agent in two Phase II studies, one for pancreatic cancer and another for prostate cancer.
Under the terms of a related co-promotion agreement, we would be responsible for 25% of the promotional sales effort of SM-88 and would receive 15% royalty on the net revenues of SM-88 in the United States. Tyme is responsible for clinical development, regulatory approval, commercial strategy, marketing, reimbursement and manufacturing of SM-88. Tyme retains the remaining 85% of net U.S. revenues and reserves the right to repurchase our U.S. co-promotion right for $200.0 million.

26

Our equity investment in Tyme is included in Other assets on our condensed consolidated balance sheet. For the three months ended September 30, 2021 and 2020, the fair value adjustments for the equity investment was a loss of $2.3 million and $3.5 million, respectively. For the nine months ended September 30, 2021 and 2020, the fair value adjustments for the equity investment was a loss of $1.9 million and a loss of $7.7 million, respectively. These adjustments were recorded in Other (expense) income on our condensed consolidated statements of operations.

13. Convertible Promissory Note

During the first quarter of 2021, we invested $5 million in a convertible promissory note ("the note") of a privately held clinical-stage biotechnology company (the "issuer"). The note bears an 8% annual interest rate and has an 18-month term. The issuer is not required to make any principal or interest payments until the end of the term. The note, along with any accrued interest, may automatically convert into equity securities of the issuer under either a financing event or a change in control event as defined in the convertible promissory note agreement. The issuer's product development efforts could encounter technical or other difficulties that could increase their development costs more than expected. The issuer will likely require additional capital prior to obtaining certain regulatory approval or to be able to repay the convertible promissory note with accrued interest at the end of the term.

The following table summarizes the amounts recorded and activity during the nine months ended September 30, 2021;
InitialFair Value Adjustments to the noteAccretion of DiscountEstimated Credit LossInterest IncomeFair Value Adjustment to Embedded DerivativeSeptember 30, 2021
Fair value of the note$5,000 $(882)$— $— $— $— $4,118 
Discount on the note(276)— 102 — — — (174)
Estimated Credit Loss — — (150)— — (150)
Convertible Promissory Note, net$4,724 $(882)$102 $(150)$— $— $3,794 
Embedded Derivative$276 $— $— $— $— $254 $530 
Interest Receivable$ $— $— $— $227 $— $227 
Total in Other Current Assets$5,000 $(882)$102 $(150)$227 $254 $4,551 

27

The following table summarizes the activity during the three months ended September 30, 2021;
June 30, 2021Fair Value Adjustments to the noteAccretion of DiscountEstimated Credit LossInterest IncomeFair Value Adjustment to Embedded DerivativeSeptember 30, 2021
Fair value of the note$4,096 $22 $— $— $— $— $4,118 
Discount on the note(220)— 46 — — — (174)
Estimated Credit Loss(100)— — (50)— — (150)
Convertible Promissory Note, net$3,776 $22 $46 $(50)$— $— $3,794 
Embedded Derivative$464 $— $— $— $— $66 $530 
Interest Receivable$125 $— $— $— $102 $— $227 
Total in Other Current Assets$4,365 $22 $46 $(50)$102 $66 $4,551 
28



Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following information should be read in conjunction with our unaudited consolidated financial statements and the notes thereto included in this Quarterly Report on Form 10-Q, or the Quarterly Report, and the audited financial information and the notes thereto included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission, or the SEC, on March 5, 2021, or our Annual Report. This discussion and analysis contains forward-looking statements that involve significant risks and uncertainties. Our actual results, performance or experience could differ materially from what is indicated by any forward-looking statement due to various important factors, risks and uncertainties, including, but not limited to, those set forth under “Risk Factors” included elsewhere in this Quarterly Report. Such factors may be amplified by the COVID-19 pandemic and its current or its potential impact on our business and the global economy. Unless otherwise indicated or required by context, references throughout to “Eagle,” the “Company,” “we,” “our,” or “us” refer to financial information and transactions of Eagle Pharmaceuticals, Inc.


29


Overview
We are an integrated pharmaceutical company focused on finding ways to help medicines do more for patients. Along with our collaborators, we have the capabilities to take a molecule from preclinical research through regulatory approval and into the marketplace, including development, manufacturing and commercialization of our products and product candidates. Our business model applies our scientific expertise, proprietary research-based insights and marketplace proficiency to identify challenging-to-treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. By focusing on patients’ unmet needs, we strive to provide healthcare professionals with urgently needed treatment solutions that are designed to improve patient care and outcomes and create near- and long-term value for our stakeholders, including patients and healthcare providers and our employees, marketing partners, collaborators and stockholders.
Our science-based business model has a proven track record with the U.S. Food and Drug Administration, or FDA, approval and commercial launches of three products: Ryanodex, Belrapzo and Bendeka. We market our products through marketing partners and/or our internal direct sales force. We market Ryanodex and Belrapzo, and Teva markets Bendeka through its subsidiary, Cephalon, Inc. SymBio Pharmaceuticals Limited, or SymBio, markets Treakisym, a RTD product, in Japan. Reflecting further expansion of our oncology portfolio, in February 2020, we received final FDA approval for Pemfexy, a branded alternative to Alimta for metastatic non-squamous non-small cell lung cancer and malignant pleural mesothelioma. We expect to launch Pemfexy in early 2022.
With several pipeline projects underway and the potential for up to five product launches over the next several years, we believe we have many growth opportunities ahead. We believe that each of our pipeline projects currently has the potential to enter the market as a first-in-class, first-to-file, first-to-market or best-in-class product. In particular, we are applying our expertise to conduct novel research regarding the potential for Ryanodex to address conditions including Alzheimer’s disease, traumatic brain injury/concussion, nerve agent exposure and acute radiation syndrome. In addition, our clinical development program includes a strategic partnership with Tyme Technologies, Inc., or Tyme, for Tyme’s product candidate for the treatment of patients with pancreatic or other advanced cancers, SM-88, as well as investigations of compounds such as EA-114 (our fulvestrant product candidate) for patients with HR-positive advanced breast cancer. Other products in development include Vasopressin, our first-to-file Abbreviated New Drug Application, or ANDA, that references Endo International plc’s Vasostrict indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines; and EA-111, a new chemical entity and next-generation ryanodine receptor antagonist, in an intramuscular formulation that that would allow for easier and more rapid administration in emergency situations (military and civilian).

Recent Developments
Vasopressin - Patent litigation
On February 2, 2021, we also announced that our ongoing patent suit with Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC, or together, Par, was rescheduled to July 7, 2021. The trial took place on July 7-9, 2021, and post-trial briefing was submitted on July 28, 2021. On August 31, 2021, we announced the U.S. District Court for the District of Delaware held that Eagle's proposed vasopressin product does not infringe any of the patents Par asserted against the Company. We are confident that our ANDA will be approved in a reasonable timeframe.

Combioxin License Agreement

In August 2021, we entered into a license agreement with Combioxin, SA under which the Company was granted exclusive, worldwide development and commercialization rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. The Company will be solely responsible for the development, regulatory, manufacturing and commercialization activities of CAL02. Combioxin will assist the Company in transitioning the manufacturing and supply of CAL02 to the Company.

Under the terms of the agreement, we paid $10 million as upfront license consideration that was expensed immediately as research and development. The Company may pay to Combioxin up to $105 million upon achievement of certain development, regulatory and sales based milestone payments plus royalty payments at royalty rates ranging in low double digit percentages on the net sales of all products sold, subject to certain adjustments as provided in the agreement. The Company is also obligated to make certain payments based upon amounts received by sublicensees under the agreement.

We and Combioxin will establish a joint development committee to review and discuss the overall strategy for the development and regulatory activities of CAL02, oversee the activities under the license agreement, including with respect to clinical trials and manufacturing activities, and perform such other functions as expressly set forth in the license agreement or allocated to it by the parties.


30



AOP License Agreement

In August 2021, we entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH (“AOP Orphan”), a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, landiolol in the United States. Landiolol, a leading hospital emergency use product, is currently approved in Europe for the treatment of non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias. We will support the submission of a NDA by AOP Orphan to the FDA seeking approval for landiolol for the short term reduction of ventricular rate in patients with SVT, including atrial fibrillation and atrial flutter. We anticipate the filing of such NDA in the first half of 2022, with an expected ten-month review, based on feedback from the FDA provided during AOP Orphan’s Type C meeting with the FDA. We will be responsible for the U.S. commercialization of the product upon approval. Landiolol, which has not previously been marketed in the U.S., is covered by several patents, and we anticipate five years of new chemical entity exclusivity. Landiolol is already commercially available in Japan and several European markets. The licensing agreement is subject to regulatory clearance. We also entered into a supply agreement at the same time as the licensing agreement.
We accrued $5 million as upfront license consideration, and we may pay up to $25 million upon achievement of certain regulatory milestone payments plus profit share payments, subject to certain adjustments as provided in the license agreement.

Vasopressin - FDA

On February 2, 2021, we announced that the U.S. Food and Drug Administration, or FDA, issued a complete response letter, or CRL, for our ANDA for vasopressin. We completed the last study required by the FDA for vasopressin during the first quarter of 2021, and we submitted our response to the CRL on June 15, 2021. The FDA has assigned a Generic Drug User Fee Amendments / Act, or GDUFA, date of December 15, 2021, and we expect a commercial launch prior to year-end. Importantly, we have completed an extensive amount of developmental work and continue to do so for our first-to-file polypeptide, where brand sales of the product are over $700 million annually. In its communication with us, the FDA restated that it has prioritized our ANDA, and that the ANDA has also been flagged as a COVID-19 priority by FDA. We believe we have fully responded to the questions raised. Based on similar studies previously run on our vasopressin product, we expect the results will be satisfactory. In addition, we expect we will have a 180 day period of exclusivity for vasopressin.

Treakisym (bendamustine) Ready-to-Dilute and Rapid Infusion Formulation

On April 30, 2021, we announced that Treakisym ready-to-dilute, or RTD, (bendamustine hydrochloride 120 mg/m2) liquid formulation was approved for a new indication in combination with rituximab, or BR therapy, as treatment for relapsed or refractory diffuse large B-cell lymphoma, or r/r DLBCL, by the Pharmaceuticals and Medical Devices Agency in Japan.

On May 10, 2021, we announced that an application for Treakisym rapid infusion, or RI, (50ml) liquid formulation was filed with the PMDA in Japan. The application is based on the results of clinical studies investigating the safety and pharmacokinetics of Treakisym RTD administered by 10-minute intravenous infusion.

Pursuant to our license agreement with SymBio, SymBio may develop and commercialize our bendamustine hydrochloride ready-to-dilute injection product and rapid infusion injection product in Japan. SymBio currently markets in Japan Treakisym, a RTD bendamustine hydrochloride indicated for CLL, relapsed or refractory low-grade NHL, mantle cell lymphoma, or MCL, and as a first line treatment of low-grade NHL and MCL. Under the license agreement, SymBio may develop and market certain other bendamustine hydrochloride products in Japan for limited indications. As part of the agreement, SymBio assumed responsibility for securing regulatory approval of the Treakisym RTD and RI products using the licensed technology in Japan.

COVID-19 Business Update
In response to the ongoing COVID-19 pandemic, we have taken and continue to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on our business, such as remote working policies, facilitating management’s daily communication to address employee and business concerns and providing frequent updates to the Board. During the second quarter of 2021, we implemented a plan to reopen our office to allow employees to return to the office, with a focus on employee safety and optimal work environment. Our management continues to monitor and evaluate such plans as the pandemic continues to evolve. We anticipate that the COVID-19 pandemic may have an impact on the clinical development timeline for EA-114. We anticipate that the COVID-19 pandemic will continue to delay our supply chain and marketing and sales efforts for certain of its products, including Bendeka, although it is not currently expected that any disruption would be material. The COVID-19 pandemic and associated lockdowns have resulted in a decrease in healthcare utilization broadly and specifically lead to a continuing reduction in the utilization of physician-administered oncology products including Belrapzo and Bendeka. In addition, the COVID-19 pandemic has delayed the timing of ongoing litigation, including the litigation with Par Pharmaceutical, Inc. and its affiliated entities with respect to Vasopressin, and we anticipate that such delays will continue for the duration of the pandemic. While we have experienced variable financial impacts to date, the ongoing COVID-19
31


pandemic, including the global economic slowdown, government measures taken in response thereto, the overall disruption of global healthcare systems and other risks and uncertainties associated with the pandemic, could materially adversely affect our business, financial condition, results of operations and growth prospects. We continue to closely monitor the COVID-19 pandemic as we evaluate and evolve our business plans and response strategy. The impact of the COVID-19 pandemic on our business and financial condition is more fully described below in Trends and Uncertainties.

Financial Operations Overview

Revenue

Our revenue consists of product sales, royalty revenue and license and other revenue.
Product Sales. Through September 30, 2021, we have recognized revenues from product sales including Bendeka, Treakisym, Ryanodex and Belrapzo. Sales of Bendeka were made to our commercial partner, Teva, and are typically made at little or no profit for resale. Sales of Treakisym were made to Symbio pursuant to a supply agreement with Symbio. Ryanodex and Belrapzo were sold directly to wholesalers, hospitals and surgery centers through a third-party logistics partner.
We typically enter into agreements with group purchasing organizations acting on behalf of their hospital members, in connection with the hospitals’ purchases of our direct commercial products. Based on these agreements, most of our hospital customers have contracted prices for products and volume-based rebates on product purchases. These amounts are estimated and recorded at the time of sale. In the case of discounted pricing, we typically provide a chargeback, representing the difference between the price invoiced to the wholesaler and the customer contract price.
Royalty Revenue. We recognize revenue from royalties based on a percentage of Teva’s net sales of Bendeka and Symbio’s net sales of Treakisym, net of discounts, returns and allowances incurred by our commercial partners. Royalty revenue is recognized as earned in accordance with contract terms when it can be reasonably estimated and collectability is reasonably assured.
License and Other Revenue. Our revenues may either be in the form of the recognition of deferred revenues upon milestone achievement for which cash has already been received or recognition of revenue upon milestone achievement the payment for which is reasonably assured to be received in the future.
The primary factors that determine our revenues derived from Bendeka are:
the level of orders submitted by our commercial partner, Teva;
the rate at which Teva can convert the current market to Bendeka;
the level of institutional demand for Bendeka;
unit sales prices charged by Teva, net of any sales reserves; and
the level of orders submitted by wholesalers, hospitals and surgery centers.
The primary factors that may determine our revenues derived from Ryanodex, Belrapzo and our future products are:
the effectiveness of our sales force;
the level of orders submitted by wholesalers, hospitals and surgery centers;
the level of institutional demand for our products; and
unit sales prices, net of any sales reserves.

Cost of Revenues
Cost of revenue consists of the costs associated with producing our products for our commercial partners. In particular, our cost of revenue includes production costs of our products paid to a contract manufacturing organization coupled with shipping and customs charges, cost of royalty and the amortization of intangible assets. Cost of revenue may also include the effects of product recalls, if applicable.

Research and Development
Costs for research and development are charged to expenses as incurred and include: employee-related expenses including salaries, benefits, travel and stock-based compensation expense for research and development personnel; expenses incurred under agreements with contract research organizations, contract manufacturing organizations and service providers that assist in conducting clinical and preclinical studies; costs associated with preclinical activities and development activities; costs associated with regulatory operations; and depreciation expense for assets used in research and development activities.
Costs for certain development activities, such as clinical studies, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to the
32


Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid expenses or accrued expenses as deemed appropriate. Recoveries of previously recognized research and development expenses from third parties are recorded as a reduction to research and development expense in the period it becomes realizable.

Selling, General and Administrative
Selling, general and administrative costs consist of employee-related costs including salaries, benefits and other related costs, stock-based compensation for executive, finance, sales and operations personnel. Selling, general and administrative expenses also include facility and related costs, professional fees for legal, consulting, tax and accounting services, insurance, selling, marketing, market research, advisory board and key opinion leaders, depreciation and general corporate expenses.

Income Taxes
We account for income taxes using the liability method in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740, “Income Taxes,” or ASC 740.  Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax bases of assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled.  Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income (loss) in the period that the rate changes.  A valuation allowance is required when it is “more likely than not” that all or a portion of deferred tax assets will not be realized. ASC 740 also prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that it has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction.  We recognize any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
The provision for income taxes was based on the applicable federal and state tax rates for those periods. The effective tax rate for the nine months ended September 30, 2021 reflects certain non-deductible executive compensation and expired stock compensation, partially offset by credits for research and development activity and excess tax deduction we can realize for our stock based awards. The effective tax rate for the nine months ended September 30, 2020 reflects the impact of a valuation allowance established and adjusted for the fair value adjustments on our investment in Tyme, certain non-deductible executive compensation and changes in state filing positions, partially offset by credits for research and development activity.

.

Results of Operations
Comparison of Three Months Ended September 30, 2021 and 2020
Revenues
Three Months Ended
September 30,
(Decrease)
Increase
20212020
(in thousands)
Product sales, net$12,124 $17,317 $(5,193)
Royalty revenue27,729 27,611 118 
License and other revenue— 5,000 (5,000)
Total revenue$39,853 $49,928 $(10,075)

Our product sales decreased $5.2 million during the three months ended September 30, 2021 as compared to the three months ended September 30, 2020. The decrease was attributable to lower product sales for Belrapzo and Bendeka of $3.8 million and $3.3 million, respectively, which were primarily due to volume decreases, partially offset by $1.6 million in product sales of Treakisym, following the launch of Treakisym in Japan by Symbio in the first quarter of 2021.

Our royalty revenue increased $0.1 million during the three months ended September 30, 2021 as compared to the three months ended September 30, 2020. The increase was primarily as a result of $1.2 million royalty revenue from Treakisym, offset by $1.1 million decrease in royalty revenue from Bendeka.

33


We earned a $5.0 million milestone payment during the three months ended September 30, 2020 when SymBio received regulatory approval for Treakisym RTD bendamustine formulation from the Pharmaceuticals and Medical Devices Agency in Japan.

Cost of revenue
Three Months Ended
September 30,
Decrease
20212020
(in thousands)
Cost of product sales $5,486 $8,726 $(3,240)
Cost of royalty revenue 2,773 3,260 (487)
Total cost of revenue $8,259 $11,986 $(3,727)

Our cost of product sales decreased $3.2 million during the three months ended September 30, 2021 as compared to the three months ended September 30, 2020. This was primarily attributable to a decrease of $3.6 million in Bendeka cost of revenue resulting from lower product unit sales, coupled with a decrease of $1.2 million in Belrapzo cost of revenue resulting from lower product unit sales. These decreases were partially offset by an increase of $1.5 million in Treakisym cost of revenue resulting from product unit sales, following the launch of Treakisym RTD in Japan by Symbio in the first quarter of 2021.

Our cost of royalty revenue decreased by $487 thousand during the three months ended September 30, 2021 as compared to the three months ended September 30, 2020. This was primarily attributable to costs related to the royalty revenue for Belrapzo and Bendeka of $0.5 million and $0.1 million, respectively. These decreases were partially offset by an increase in costs as a result of royalties related to Treakisym of $0.1 million.

Research and development
The table below details the Company’s research and development expenses by significant project for the periods presented.
 Three Months Ended September 30,Increase /(Decrease)
 2021 2020
(in thousands)
Fulvestrant “EGL-5385-C-1701” $729 $474 $255 
Vasopressin 2,086 1,298 788 
CAL02 / Combioxin10,000 — 10,000 
Landilol / AOP5,000 — 5,000 
Pemfexy
1,386 288 1,098 
All other projects 602 904 (302)
Salary and other personnel related costs3,486 1,864 1,622 
Research and development $23,289 $4,828 $18,461 

Our research and development expenses increased $18.5 million in the three months ended September 30, 2021 as compared to the three months ended September 30, 2020. The increase primarily resulted from a $10.0 million upfront payment related to our license agreement with Combioxin, a $5.0 million upfront payment related our licensing agreement with AOP Orphan, a $0.8 million increase in development cost for the Vasopressin project, a $1.1 million increase related to Pemfexy and a $1.2 million increase in stock compensation, included with Salary and other personnel related costs.
34



Selling, general and administrative
Three Months Ended
September 30,

Increase
20212020
(in thousands)
Selling, general and administrative $18,482 $17,697 $785 

Our selling, general and administrative expenses increased $0.8 million for the three months ended September 30, 2021 as compared to the three months ended September 30, 2020. This increase is primarily related to an increase in external legal costs partially offset by a decrease in stock compensation expense.

Other expense, net
Three Months Ended
September 30,
Increase / (Decrease)
20212020
(in thousands)
Interest income$197 $46 $151 
Interest expense(396)(489)(93)
Other expense(2,284)(6,049)3,765 
Total other expense, net$(2,483)$(6,492)$4,009 

Our interest income slightly increased $151 thousand for the three months ended September 30, 2021 as compared to the three months ended September 30, 2020. This increase is primarily due to accrued interest recorded on the convertible promissory note agreement entered into in the first quarter of 2021.

Our interest expense decreased $0.1 million for the three months ended September 30, 2021 as compared to the three months ended September 30, 2020. This decrease is primarily due to lower borrowings from our revolving credit facility during the three months ended September 30, 2021.

Our other (expense) income was a net expense of $2.3 million for the three months ended September 30, 2021 as compared to a net expense of $6.0 million the three months ended September 30, 2020. The $2.3 million related to fair value adjustments on our equity investment in Tyme during the three months ended September 30, 2021. The $6.0 million primarily related to fair value adjustments on the Company’s equity investment in Tyme in the amount of $3.5 million and the related fair value adjustments related to the final settlement of the $25.0 million accelerated share repurchase, or ASR, transaction with JPMorgan Chase Bank, National Association, or JP Morgan, as part of our existing $160 million share repurchase program. We determined the ASR contained a forward contract and therefore we recorded fair value adjustments on unsettled accelerated share repurchase agreement in the amount of $2.5 million in the three months ended September 30, 2020.

Income tax benefit (provision)
Three Months Ended September 30,
20212020
(in thousands)
Benefit (provision) for income taxes$7,038 $(1,866)
Effective tax rate 56 %21 %

The effective tax rate for the three months ended September 30, 2021, reflects an interim tax benefit resulting from our research and development expense of acquired licenses and credits for research and development activity, partially offset by impact of certain non-deductible executive compensation and expired stock compensation. The effective tax rate for the three months ended September 30, 2020 reflects the impact of a valuation allowance established and adjusted for the fair value adjustments on our investment in Tyme, certain non-deductible executive compensation partially offset by credits for research and development activity.
35



Comparison of Nine Months Ended September 30, 2021 and 2020
Revenues
Nine Months Ended September 30,(Decrease)
20212020
(in thousands)
Product sales, net$48,865 $49,387 $(522)
Royalty revenue80,361 83,499 (3,138)
License and other revenue— 5,000 (5,000)
Total revenue$129,226 $137,886 $(8,660)

Our product sales decreased $0.5 million in the nine months ended September 30, 2021 as compared to the nine months ended September 30, 2020 primarily driven by decreases in product sales of Ryanodex of $1.2 million and Bendeka of $3.9 million primarily due to a decrease in unit volume. These decreases were partially offset by $3.9 million in product sales of Treakisym, following the launch of Treakisym RTD in Japan by Symbio in the first quarter of 2021, coupled with an increase in product sales of $0.9 million of Belrapzo primarily due to unit volume.

Our royalty revenue decreased $3.1 million in the nine months ended September 30, 2021 as compared to the nine months ended September 30, 2020, primarily as a result of lower royalties on Teva's sales of Bendeka of $5.0 million, which were partially offset by new royalties on Symbio's sales of Treakisym of $2.2 million.

Cost of revenue

Nine Months Ended September 30,(Decrease)
20212020
(in thousands)
Cost of product sales$21,835 $23,804 $(1,969)
Cost of royalty revenue8,036 9,120 (1,084)
Total cost of revenue$29,871 $32,924 $(3,053)

Our cost of product sales decreased $2.0 million in the nine months ended September 30, 2021 as compared to the nine months ended September 30, 2020, primarily as a result of decreased cost of product sales of Ryanodex of $1.7 million and of Bendeka of $4.9 million, each related to lower unit sales. These decreases were partially offset by an increase of $3.9 million in Treakisym cost of product sales resulting from product unit sales, following the launch of Treakisym RTD in Japan by Symbio in the first quarter of 2021 coupled with an increase for Argatroban of $0.4 million related end of product life costs.

Our cost of royalty revenue decreased $1.1 million in the nine months ended September 30, 2021 as compared to the nine months ended September 30, 2020, primarily as a result of a decrease in royalty revenue on Teva’s sales of Bendeka coupled with lower cost of royalty associated with Belrapzo and the ending of royalties related to Argatroban.

36


Research and development

Nine Months Ended September 30,Increase / (Decrease)
20212020
(in thousands)
Fulvestrant “EGL-5385-C-1701”$5,207 $4,633 $574 
Vasopressin7,297 2,440 4,857 
Ryanodex related projects3,625 2,325 1,300 
CAL02 / Combioxin10,000 — 10,000 
Landilol / AOP5,000 — 5,000 
Pemfexy
2,502 340 2,162 
All other projects2,475 1,810 665 
Salary and other personnel related costs11,382 9,842 1,540 
Research and development$47,488 $21,390 $26,098 

Our research and development expenses increased $26.1 million in the nine months ended September 30, 2021 as compared to the nine months ended September 30, 2020. The increase primarily resulted from a $10.0 million upfront payment related to our license agreement with Combioxin, a $5.0 million upfront payment related our licensing agreement with AOP Orphan, a $4.9 million increase in development cost for the Vasopressin project, a $2.2 million increase related to Pemfexy, coupled with a net increase in our Ryanodex related projects of $1.3 million and a $1.5 million total increase in salaries, bonuses, and severance, included with Salary and other personnel related costs.

Selling, general and administrative
Nine Months Ended September 30,(Decrease)
20212020
(in thousands)
Selling, general and administrative$54,997 $60,411 $(5,414)

Our selling, general and administrative expenses decreased $5.4 million in the nine months ended September 30, 2021 as compared to the nine months ended September 30, 2020. The decrease is primarily related to lower stock compensation expense of $3.7 million, the non-recurrence of $2.5 million of costs related to the collaboration with Tyme in 2020, coupled with decreased spend on marketing consultants of $1.1 million, partially offset by increased expense related to ongoing litigation matters of $2.4 million.

Other expense, net
Nine Months Ended September 30,(Decrease) / Increase
20212020
(in thousands)
Interest income$395 $542 $(147)
Interest expense(1,240)(2,164)(924)
Other expense(1,797)(10,249)8,452 
Total other expense, net$(2,642)$(11,871)$9,229 

Our interest income decreased $0.1 million in the nine months ended September 30, 2021 as compared to the nine months ended September 30, 2020. This decrease is primarily due to lower interest rates associated with money market funds as compared to the nine months ended September 30, 2020.

37


Our interest expense decreased $0.9 million in the nine months ended September 30, 2021 as compared to the nine months ended September 30, 2020. This decrease is primarily due to lower borrowings from our revolving credit facility during the 2021 year to date period.

Our other (expense) income was an expense amount of $1.8 million for the nine months ended September 30, 2021 as compared to an expense amount of $10.2 million for the nine months ended September 30, 2020. The $1.8 million expense amount for the nine months ended September 30, 2021 primarily resulted from fair value adjustments on equity investment in Tyme during the nine months ended September 30, 2021. The $10.2 million expense amount for the nine months ended September 30, 2020 related to fair value adjustments on equity investment in Tyme in the amount of $7.7 million and the related fair value adjustments related to the final settlement of the $25.0 million ASR transaction with JPMorgan. We determined the ASR contained a forward contract and therefore we recorded fair value adjustments on unsettled accelerated share repurchase agreement in the amount of $2.5 million in the nine months ended September 30, 2020.

Income tax benefit (provision)
Nine Months Ended September 30,
20212020
(in thousands)
Benefit (Provision) for income taxes$3,341 $(7,358)
Effective tax rate58 %65 %

The effective tax rate for the nine months ended September 30, 2021, reflects an interim tax benefit resulting from our research and development expense of acquired licenses and credits for research and development activity, partially offset by impact of certain non-deductible executive compensation and expired stock compensation. The effective tax rate for the nine months ended September 30, 2020 reflects the impact of a valuation allowance established and adjusted for the fair value adjustments on our investment in Tyme, certain non-deductible executive compensation, non-deductible nature of the fair value adjustment on the unsettled ASR agreement and changes in state filing positions, partially offset by credits for research and development activity.

Liquidity and Capital Resources

Our primary uses of cash are to fund working capital requirements, product development costs and operating expenses. Cash and cash equivalents were $99.7 million and $89.7 million as of September 30, 2021 and September 30, 2020, respectively.

For the nine months ended September 30, 2021, we realized a net loss of $2.4 million. As of September 30, 2021, our working capital surplus was $123.3 million. For the nine months ended September 30, 2020, we realized net income of $3.9 million.
We believe that future cash flows from operations will be sufficient to fund our currently anticipated working capital requirements for at least the next 12 months.
The COVID-19 pandemic has disrupted and continues to disrupt the U.S. healthcare system, global economies and global capital markets. There remain significant uncertainties surrounding the full extent and duration of the impact of the COVID-19 pandemic on our business and operations. We have experienced variable financial impacts to date, as a result of the COVID-19 pandemic and the ongoing pandemic could have a material adverse impact on our financial condition and results of operations in the future, including our ability to obtain financing when and if needed. The impact of COVID-19 on our business and financial condition is more fully described below in Trends and Uncertainties.

Operating Activities:

Net cash provided by operating activities for the nine months ended September 30, 2021 was $20.1 million. Net loss for the period was $2.4 million offset by the net of non-cash adjustments of approximately $17.8 million from deferred income taxes, depreciation expense, amortization expense of right-of-use assets, amortization expense of intangible assets, fair value adjustments on equity investment, stock-based compensation expense, amortization of debt issuance costs and other items. Net changes in working capital increased cash from operating activities by approximately $4.7 million, due to changes in working capital accounts. The total amount of accounts receivable at September 30, 2021 was approximately $45.3 million, which included $17.4 million related to product sales and $27.9 million related to royalty revenue. Receivables from our product sales have payment terms ranging from 30 to 70 days with select extended terms to wholesalers on initial purchases of product launch quantities. Our receivables from royalty revenue are due 45 days from the end of the quarter.
38



Investing Activities:

Net cash used by investing activities for the nine months ended September 30, 2021 was $5.3 million, as a result of $5.0 million of investment to purchase a convertible promissory note and we spent $0.3 million for purchases of property and equipment.

Financing Activities:

Net cash used by financing activities for the nine months ended September 30, 2021 was $18.3 million, as a result of $6 million of principal payments for debt required by our Second Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent and the lenders party thereto, or the Credit Agreement, $12.6 million in payments related to the repurchases of our common stock, $1.6 million of payments associated with employee withholding tax upon vesting of stock-based awards, partially offset by $1.8 million of proceeds from common stock exercises of employee stock options.

Trends and Uncertainties
Impact of the COVID-19 Pandemic
The COVID-19 pandemic has resulted in authorities implementing aggressive actions. Government authorities in the United States have recommended or imposed various social distancing, quarantine, and isolation measures on large portions of the population, and similar measures have also been taken in many other countries around the world. While many of these
governmental restrictions have begun to be lifted, the timing and extent to which such orders and restrictions will be removed
remains uncertain. Both the COVID-19 pandemic and the containment and mitigation efforts related to the pandemic have had a serious adverse impact on the U.S. economy and the economies of other countries around the world, the severity and duration of which are uncertain. There is no guarantee that prior or new restrictions will not be reinstated in response to the continued spread of COVID-19.

During the nine months ended September 30, 2021, we have experienced a variable impact on our business and financial condition due to the COVID-19 pandemic, which impacts include a decrease in revenue from sales of Belrapzo resulting, in part, from a decrease in inventory stocking and utilization rates, as well as a decrease in research and development expenses partially resulting from preclinical program delays. We also incurred an insignificant amount of incremental administrative costs related to the COVID-19 pandemic. The COVID-19 pandemic, including containment and mitigation measures, has impacted, and is expected to continue to impact, our business and operations in a number of ways, including:
Day-to-Day Operations: Since mid-March 2020, certain of our employees, including customer-facing employees, had been primarily working remotely. The duration and extent of these restrictions are anticipated to be eased in the short term. During the second quarter of 2021, we developed and implemented plans to resume in-person work practices while adhering to relevant health authority guidance. We expect to incur additional expenses in 2021 related to the impact of the COVID-19 pandemic on our operations, including updates to our facilities to align with safety protocols.
Manufacturing and Supply Chain: We are working closely with our commercial partners and third-party manufacturers to mitigate potential disruptions as a result of the COVID-19 pandemic by continuing to monitor the supply and availability of Bendeka, Ryanodex and Belrapzo for the patients who rely on these products. We anticipate that the COVID-19 pandemic will continue to delay our supply chain and marketing and sales efforts for certain of our products, including Bendeka, although it is not currently expected that any disruption would be material. If the COVID-19 pandemic continues to persist for an extended period of time and impacts essential distribution systems such as FedEx and postal delivery, we could experience future disruptions to our supply chain and operations, and associated delays in the manufacturing and our clinical supply, which would adversely impact our development activities.
Marketing and Sale of Products: In addition to the impact on our product revenues resulting in a decrease in sales from Belrapzo, driven, in part, by the COVID-19 pandemic, we have also observed a reduction in the number of Bendeka patients visiting infusion centers, hospitals and clinics for intravenous administration of Bendeka due to interruptions in healthcare services, and the patients’ inability to visit administration sites as well as desire to avoid contact with infected individuals. In addition, our sales and marketing teams have been working remotely and our virtual initiatives with respect to marketing and supporting the sale and administration of our products have not been as effective as our in-person sales and marketing activities.
Liquidity and Capital Resources: We believe that future cash flows from operations will be sufficient to fund our currently anticipated working capital requirements for the next 12 months. While the COVID-19 pandemic has not had, and we do not expect it to have, a material adverse effect on our liquidity, the situation continues to rapidly evolve and has already resulted in a significant disruption of global financial markets. If the disruption persists or deepens, we could experience an inability to access additional capital when and if needed. If we are unable to obtain funding, we
39


could be forced to delay, reduce or eliminate distribution of our commercialized products, product portfolio expansion or some or all of our research and development programs, which would adversely affect our business prospects. We expect to be able to obtain future funding under the terms of the Credit Agreement, for general corporate purposes and any strategic acquisitions.
Regulatory Activities: We may experience further delays in the timing of NDA review and/or our interactions with FDA due to, for example, absenteeism by governmental employees, inability to conduct planned physical inspections related to regulatory approval, or the diversion of FDA’s efforts and attention to approval of other therapeutics or other activities related to the COVID-19 pandemic, which could further delay approval decisions with respect to regulatory submissions or obtain new product approvals.
Clinical Development Timelines: The clinical trial timelines for certain of our product candidates have been delayed given difficulties with limited patient enrollment resulting from the impact of the COVID-19 pandemic, and we expect that our clinical trial timelines will continue to be impacted for the duration of the pandemic.

There are significant uncertainties surrounding the extent and duration of the impact of the COVID-19 pandemic on our business and operations. We continue to evaluate the impact of the COVID-19 pandemic on our operating results and financial condition. The COVID-19 pandemic has had a variable impact on our results of operations during the nine months ended September 30, 2021 and, it could have a material adverse impact on our financial condition and results of operations in the future.

Contractual Obligations
Other than as set forth below, there have been no material changes to our contractual and commercial obligations during the nine months ended September 30, 2021, as compared to the obligations disclosed in our Annual Report.
Our future material contractual obligations included the following as of September 30, 2021 (in thousands):
ObligationsTotal202120222023202420252026Beyond
Operating leases (1)$4,680 $351 $1,423 $1,455 $1,038 $413 $— $— 
Credit facility (2)28,000 2,000 26,000 — — — — — 
Purchase obligations (3)53,176 53,176 — — — — — — 
Total obligations $85,856 $55,527 $27,423 $1,455 $1,038 $413 $— $— 
(1) We lease our corporate office location. On August 8, 2019, we amended the lease for our corporate office location in order to rent additional office space and extend the term of our existing lease to June 30, 2025. We also lease lab space under a lease agreement that expires on April 1, 2024.
(2) Refer to Note 9 Debt for details of our Credit Agreement.
(3) As of September 30, 2021, we had purchase obligations in the amount of $53.2 million which represents the contractual commitments under contract manufacturing and supply agreements with suppliers. The obligation under the supply agreement is primarily for finished product, inventory, and research and development.

Critical Accounting Policies

Our significant accounting policies are disclosed in “Note 2. Summary of Significant Accounting Policies” in our audited financial statements for the year ended December 31, 2020 included in our Annual Report. Since the date of such financial statements, there have been no changes to our significant accounting policies other than those described in Note 2 of the notes to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report.

Recent Accounting Pronouncements

Recent Accounting Pronouncements - Not Yet Adopted
In March 2020, the FASB issued Update 2020-04 Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting to provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The amendments in Update 2020-04 are elective and apply to all entities that have contracts, hedging relationships, and other transactions that reference LIBOR, formerly known as the London Interbank Offered Rate, or another reference rate expected to be discontinued due to reference rate reform. The new guidance provides optional expedients, including; (1) Simplify accounting analyses under current GAAP for contract modifications, such as modifications of contracts within the scope of Topic 470, Debt, that will be accounted for by prospectively adjusting the effective interest rate, as if any
40


modification was not substantial. That is, the original contract and the new contract shall be accounted for as if they were not substantially different from one another; (2) Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue; (3) Allow a one-time election to sell or transfer debt securities classified as held to maturity before January 1, 2020 that reference a rate affected by reference rate reform. The amendments are effective for all entities from the beginning of an interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The adoption of ASU 2020-4 is not expected to have a material impact on the Company's financial position or results of operations.
Recently Adopted Accounting Pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses which requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. This standard is effective for fiscal years beginning after December 15, 2019 and the Company adopted the standard effective January 1, 2020. The adoption of ASU 2016-13 had no material impact on the Company's financial position and results of operations.

Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.

Impact of Inflation
While it is difficult to accurately measure the impact of inflation due to the imprecise nature of the estimates required, we believe the effects of inflation, if any, on our results of operations and financial condition have been immaterial.
41



Item 3. Quantitative and Qualitative Disclosures About Market Risk
During the nine months ended September 30, 2021, there were no material changes to our market risk disclosures as set forth in Part II, Item 7A “Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report, except as discussed below.
We are monitoring the ongoing impacts of the COVID-19 pandemic on our business. While the full extent of the economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact on the global financial markets may reduce our ability to access capital, which could negatively impact our long-term liquidity.

Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the “Exchange Act”, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Based on their evaluation at September 30, 2021, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended September 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
42


PART II-OTHER INFORMATION

Item 1. Legal Proceedings
The disclosures under Note 11. Legal Proceedings in the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report are incorporated into this Part II, Item 1 by reference.


Item 1A. Risk Factors
An investment in our securities involves a high degree of risk. Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. Except for the updated risk factor set forth immediately below, our risk factors have not changed materially from those described in “Part I, Item 1A. Risk Factors” of our Annual Report.

Current and future legislation and regulations may increase the difficulty and cost for us to commercialize our product candidates and affect the prices we may obtain for our products.
The United States and some foreign jurisdictions are considering, or have enacted, a number of legislative and regulatory proposals to change the health care system in ways that could affect our ability to sell our products and our product candidates profitably, once they are approved for sale. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in health care systems with the stated goals of containing health care costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.
By way of example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care Education and Reconciliation Act, or collectively, the ACA, was passed, which significantly changed health care financing by both governmental and private insurers. There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, the Tax Cuts and Jobs Act of 2017, or Tax Act, included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. On June 17, 2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Thus, the ACA will remain in effect in its current form. Moreover, prior to the United States Supreme Court ruling, on January 28, 2021, the current U.S. President issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the current Presidential administration will impact the ACA and our business. We cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.
In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals for spending reductions to Congress. The Joint Select Committee on Deficit Reduction did not achieve its targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation's automatic reductions to several government programs. These reductions include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. However, COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2021. Additionally, in January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.
Further, under the Drug Supply Chain Security Act signed into law on November 27, 2013, certain drug manufacturers will be subject to product identification, tracing and verification requirements, among others, that are designed to improve the detection and removal of counterfeit, stolen, contaminated or otherwise potentially harmful drugs from the U.S. drug supply chain. These requirements will be phased in over several years and compliance with this law will likely increase the costs of the manufacture and distribution of drug products, which could have an adverse effect on our financial condition.
Additionally, there has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and adopted federal and state
43


legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, the former U.S. Presidential administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, in May 2019, the Centers for Medicare & Medicaid Services, or CMS, issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning on January 1, 2020. The final rule codified a CMS policy change that was effective January 1, 2019. In a final rule issued by CMS on December 31, 2020, CMS established a broader definition for a “line extension” drug such that the line extension of the initial brand name listed drug would not need to be an oral solid dosage form. This final rule, may impact the rebate amounts associated with our products and negatively affect the commercial success of our products. Additionally, on December 2, 2020, CMS published changes to the Medicare Physician Fee Schedule for Calendar Year 2021 that also may adversely impact the coverage and reimbursement of our products. Under the changes, CMS will assign certain 505(b)(2) drug products to existing multiple source drug codes because, according to CMS, some drug products approved under the 505(b)(2) pathway share similar labeling and uses with generic drugs that are assigned to multiple source drug codes. CMS noted that this change is consistent with efforts to “curb drug prices” and encourages competition among products that are described by one billing code and share similar labeling. On July 24, 2020 and September 13, 2020, the former U.S. Presidential administration announced several executive orders related to prescription drug pricing that attempted to implement several of the administration’s proposals. As a result, the FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the current administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing the former President’s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the Most Favored Nation model, on August 10, 2021, CMS published a proposed rule that seeks to rescind the Most Favored Nation Model interim final rule. In July 2021, the Biden administration released an executive order, “Promoting Competition in the American Economy,” with multiple provisions aimed at prescription drugs. In response to Biden’s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of the budget reconciliation process. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. The full impact of these laws, as well as other new laws and reform measures that may be proposed and adopted in the future remains uncertain, but may result in additional reductions in Medicare and other health care funding, or higher production costs which could have a material adverse effect on our customers and, accordingly, our financial operations.



Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

Share Repurchase Program

On March 17, 2020, we announced that our Board approved a new share repurchase program, or the Share Repurchase Program, providing for the repurchase of up to an aggregate of $160 million of the Company’s outstanding common stock. The Share Repurchase Program replaced the Previous Share Repurchase Program, which was announced on October 30, 2018 and was terminated in connection with the Board’s approval of the Share Repurchase Program. At termination, we had repurchased approximately $68 million of our outstanding common stock under the Previous Share Repurchase Program.

Under the Share Repurchase Program, we are authorized to repurchase shares through open market purchases, privately-negotiated transactions, accelerated share repurchases or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans and under Rule 10b-18 of the Securities Exchange Act of 1934, as amended. The
44


repurchases have no time limit and may be suspended or discontinued completely at any time. The specific timing and amount of repurchases will vary based on available capital resources and other financial and operational performance, market conditions, securities law limitations, and other factors. The repurchases will be made using our cash resources.

We made the following purchases of our equity securities during the period covered by this Quarterly Report on Form 10-Q.
PeriodTotal Number of Shares Purchased (1)Average Price Paid per ShareTotal Number of Shares Purchased as Part Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares that May Yet Be Purchased Under the Programs
(dollars in thousands)
July 1, 2021 to July 31, 2021— N/A— 120,691 
August 1, 2021 to August 31, 2021— N/A— 120,691 
September 1, 2021 to September 30, 2021158,680 $52.12 158,680 113,316 
Total158,680 158,680 

(1) All shares repurchased by us during the three months ended September 30, 2021 were repurchased pursuant to the Share Repurchase Program, described above.

Item 3. Defaults Upon Senior Securities
None.

Item 4. Mine Safety Disclosures
Not applicable.

Item 5. Other Information
None.



Item 6.    Exhibits

45


EXHIBIT INDEX
Exhibit
Number
Description of Exhibit
3.1
3.2
10.1+(1)
10.2+(1)
31.1(1)
31.2(1)
32.1
**
101.INSXBRL Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

(1) Filed herewith.

+ Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

**The certifications attached as Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Eagle Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date hereof), irrespective of any general incorporation language contained in such filing.




46

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized
 
  EAGLE PHARMACEUTICALS, INC.
DATED: November 9, 2021 By:
/s/ Scott Tarriff
 
   Scott Tarriff
   
(On behalf of the Registrant and as Chief Executive Officer as Principal Executive Officer)
DATED: November 9, 2021 By:
/s/ Brian J. Cahill
 
   Brian J. Cahill
   Chief Financial Officer
(Principal Accounting Officer and Principal Financial Officer)

47
EX-10.1 2 exhibit101redacted.htm EX-10.1 Document
Exhibit 10.1


[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.


CONFIDENTIAL
Execution Copy












LICENSE AGREEMENT

BETWEEN

EAGLE PHARMACEUTICALS, INC.

AND

COMBIOXIN SA



259471316 v2




259471316 v2



LICENSE AGREEMENT
THIS LICENSE AGREEMENT (“Agreement”) dated as of August 19, 2021 (“Effective Date”), is entered into between Eagle Pharmaceuticals, Inc., a Delaware corporation having offices at 50 Tice Boulevard, Suite 315, Woodcliff Lake, New Jersey, United States (“Eagle”) and Combioxin SA, a Swiss corporation having offices at Route de la Corniche 5, 1066 Epalinges, Switzerland (“Combioxin”).
BACKGROUND
A.    Eagle is a specialty pharmaceutical company focused on developing and commercializing drugs;
B.     Combioxin is a biotechnology company dedicated to the development of drugs for severe bacterial and viral infections;
C.     Combioxin has developed that certain liposome product known as CAL02 and controls certain related Patents and know-how;
D.    Eagle desires to obtain from Combioxin and Combioxin desires to grant to Eagle an exclusive license with respect to the development, and manufacture and commercialization of the Licensed Products (as defined below), all on the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:
ARTICLE I
DEFINITIONS
I.1Affiliate” of a Party means any Person that, directly or indirectly, controls, is controlled by, or is under common control with such Party, as the case may be. As used in this Section 1.1, the word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such Person, whether by the ownership of more than fifty percent (50%) of the voting share capital in such Person, or by contract or otherwise.
I.2Anti-Corruption Laws” shall mean the U.S. Foreign Corrupt Practices Act (15 U.S.C. §§78dd-1, et. seq.), as amended, the Organization for Economic Co-operation and Development (OECD) Convention on combating bribery of foreign public officials in international business transactions, and any other applicable anti-corruption laws.
I.3Applicable Law” means the applicable provisions of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidances, ordinances, judgments, decrees, directives, injunctions, orders, permits of or from any court, arbitrator, Regulatory Authority, Governmental Authority or authority having jurisdiction
1
259471316 v2



over or related to the subject item, including the FD&C Act, GCP, GLP, GMP, Anti-Corruption Laws and Export Control Laws.
I.4Change of Control” means, with respect to a Party: (a) the sale of all or substantially all of its assets or all of its assets relating to the Licensed Products; (b) a merger, reorganization or consolidation involving such Party in which the holders of the voting securities of such Party outstanding immediately prior thereto cease to beneficially own at least fifty percent (50%) of the combined voting power of the surviving entity, directly or indirectly, immediately after such merger, reorganization or consolidation; or (c) a transaction in which an entity or individual, or group of entities and/or individuals acting in concert, acquires more than fifty percent (50%) of the voting equity securities of such Party.
I.5Clinical Studies” means any human clinical study or clinical trial of a Licensed Product.
I.6CMC Data means analytical and quality control data, stability data, batch records, and other data or information relating to chemistry, manufacturing and control of Licensed Products, including that which is filed or required to be filed to obtain authorization to conduct Clinical Studies or to obtain or maintain Regulatory Approval for a Licensed Product.
I.7Combination Product” means: (a) a pharmaceutical product that consists of a Licensed Product and at least one other pharmaceutically active ingredient that is not a Licensed Product in a fixed dose combination; or (b) any combination of a Licensed Product and another pharmaceutical product that [***]. The other pharmaceutically active ingredient(s) in clause (a) and the other pharmaceutical product(s) in clause (b) are each referred to as the “Other Product(s)”.
I.8Commercialization” means any and all activities related to pre-marketing, launching, marketing, promotion (including advertising and detailing), labeling, bidding and listing, pricing and reimbursement, distribution, storage, handling, offering for sale, selling, having sold, importing, having imported, exporting, having exported, distributing, having distributed, providing customer service and support, conducting medical affairs, conducting post-marketing safety surveillance and reporting of or otherwise commercializing or exploiting Licensed Products. “Commercialize” and “Commercializing” have the correlative meanings.
I.9Commercially Reasonable Efforts” means, with respect to the efforts to be expended by Eagle in connection with a particular activity or objective to be conducted under this Agreement, that level of efforts that [***] would normally use, in the exercise of its prudent scientific and business judgment, for the development and/or commercialization of a comparable pharmaceutical product for a similar patient population at a similar stage of its development or commercialization, taking into account all relevant scientific, commercial, business and other factors, including issues of safety and efficacy, expected and approved product labeling, expected and actual cost and time to develop, expected and actual profitability, expected and actual return on investment, expected and actual competitiveness of Third Party alternative products (including generic products) in the marketplace, the nature and extent of expected and actual market exclusivity (including Patent coverage and regulatory exclusivity), the expected likelihood of marketing
2
259471316 v2



approval, the expected and actual pricing and level of reimbursement, and the expected and actual amounts of marketing and promotional expenditures required. [***]
I.10Control” (including any variations such as “Controlled” and “Controlling”), in the context of intellectual property rights, material, data and/or other information or subject matter, means the possession by a Person or its Affiliate of the ability (whether by ownership or license, other than pursuant to a license granted to such Person by a Party to this Agreement) to grant the applicable access to, or a license or sublicense under this Agreement, without violating the terms of any agreement or other arrangement with any Third Party existing as of the Effective Date or at such later time as such Party or its Affiliate first acquired rights to such subject matter.
I.11Cover” means, with respect to a claim of a Patent and a Licensed Product, that such claim would be infringed, absent a license, by the manufacture, use, offer for sale, sale or importation of such Licensed Product (considering claims of patent applications to be issued as then pending).
I.12Data” means any and all data, information and materials relating to a Licensed Product, including manufacturing data (including without limitation, CMC Data), research data, pharmacology data, preclinical data, clinical data (including patient samples and associated annotations), master clinical trial records and databases, safety databases, and all Regulatory Filings and/or other regulatory documentation, information and submissions pertaining to, or made in association with an IND, Marketing Approval Application, or Regulatory Approval, for a Licensed Product, in each case to the extent Controlled by Combioxin as of the Effective Date or during the term of this Agreement.
I.13Development” or “Develop” means all activities that relate to the development of Licensed Products or to (a) obtaining, maintaining or expanding Regulatory Approval of a Licensed Product, or (b) developing the ability to manufacture clinical and commercial quantities of a Licensed Product. This includes: [***].
I.14EMA” means the European Medicines Agency or any successor entity.
I.15Europe” means the European Economic Area, Switzerland and the United Kingdom.
I.16Export Control Laws” shall mean: (a) all applicable U.S. laws and regulations relating to sanctions and embargoes imposed by U.S. Department of Treasury’s Office of Foreign Assets Control (or its successor office or other body having substantially the same function); (b) all applicable U.S. export control laws, including the Arms Export Controls Act (22 U.S.C. Ch. 39), the International Emergency Economic Powers Act (50 U.S.C. §§ 1701 et seq.), the Trading With the Enemy Act (50 U.S.C. app. §§ 1 et seq.), the Export Administration Act of 1979 (50 U.S.C. app. §§ 2401 et seq.), International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986, and all rules, regulations and executive orders relating to any of the foregoing, including but not limited to the International Traffic in Arms Regulations (22 C.F.R. §§ 120 et seq.), the Export Administration Regulations (15 C.F.R. §§ 730 et. seq.), and the regulations administered by the Office of Foreign Assets Controls of the United States Department of the Treasury; and (c) all export
3
259471316 v2



controls imposed on any Licensed Product by any country or organization or nation within the jurisdiction of which either party operates or does business.
I.17FD&C Act” means the U.S. Federal Food, Drug and Cosmetic Act, as amended.
I.18FDA” means the U.S. Food and Drug Administration, or any successor entity thereto performing similar functions.
I.19Field” means any and all indications and uses.
I.20First Commercial Sale” means, on a country-by-country basis, the first commercial transfer or disposition for monetary value of a Licensed Product in a country in the Territory for use or consumption by a Third Party end user, in each case, after all Regulatory Approvals [***] have been obtained for such country and where such disposition or transfer results in a recordable Net Sale in accordance with Eagle’s, or its Affiliate’s or Sublicensee’s, applicable accounting practices (consistently applied).
I.21Generic Product” means, with respect to a particular Licensed Product and a particular country, any pharmaceutical product that: (a) [***].
I.22Good Clinical Practice” or “GCP” means the then-current standards, practices and procedures promulgated or endorsed by the FDA as set forth in the guidelines entitled “Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,” including related regulatory requirements imposed by the FDA and comparable regulatory standards, practices and procedures promulgated by the EMA or other Regulatory Authority applicable to the Territory, as they may be updated from time to time, including applicable quality guidelines promulgated under the ICH.
I.23Good Laboratory Practice” or “GLP” means the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, and comparable regulatory standards promulgated by the EMA or other Regulatory Authority applicable to the Territory, as they may be updated from time to time, including applicable quality guidelines promulgated under the ICH.
I.24Good Manufacturing Practices” or “GMP” means the then-current Good Manufacturing Practices required by the FDA, as set forth in the FD&C Act and the regulations promulgated thereunder, for the manufacture and testing of pharmaceutical materials, and comparable laws and regulations applicable to the manufacture and testing of pharmaceutical materials promulgated by other Regulatory Authorities, as they may be updated from time to time.
I.25Governmental Authority” means any multi-national, federal, state, local, municipal, provincial or other governmental authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, counsel, court or other tribunal).
I.26ICH” means International Conference on Harmonisation.
4
259471316 v2



I.27IND” means an Investigational New Drug application, as defined in the U.S. Federal Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or the equivalent application to the equivalent agency in any other regulatory jurisdiction, the filing of which is necessary to Initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction, in each case with respect to a Licensed Product for use within the Field.
I.28Information” means any data, results, technology, business or financial information or information of any type whatsoever, in any tangible or intangible form, including know-how, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications, formulations, formulae, software, algorithms, marketing reports, expertise, technology, test data (including pharmacological, biological and chemical, biochemical, clinical test data and data resulting from non-clinical studies), CMC information, stability data and other study data and procedures.
I.29Initiation” means, with respect to any Clinical Study, the first dosing of the first human subject in such Clinical Study. “Initiate” and “Initiated” have correlative meanings.
I.30Joint Development Committee” or “JDC” means the committee formed by the Parties as described in Section 3.1.
I.31Licensed Know-How” means all Information that both (a) is owned or Controlled by Combioxin or any of its Affiliates [***] and (b) is necessary or reasonably useful in the Development, Manufacture, Commercialization and other exploitation of a Licensed Product (including the Data and all tangible embodiments thereof).
I.32Licensed Patent Rights” means any Patents owned or Controlled by Combioxin or any of its Affiliates as of the Effective Date or at any time during the Term of the Agreement that Cover the Development, Manufacture, Commercialization, and other exploitation of a Licensed Product. A list of Licensed Patent Rights as of the Effective Date is set forth on Exhibit 1.32 (the “Program Patent Rights”).
I.33Licensed Product(s)” means Combioxin’s engineered liposome products, including its product referred to as “CAL02” as further described in Exhibit 1.33, [***].
I.34Licensed Intellectual Property” means Licensed Patent Rights and Licensed Know-How.
I.35Manufacture” and “Manufacturing” means all activities related to the synthesis, making, production, processing, purifying, formulating, filling, finishing, packaging, labeling, shipping, and holding of the any Licensed Product or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial production and analytic development, product characterization, stability testing, quality assurance, and quality control.
I.36Manufacturing Process” means all information pertaining to the Manufacture of a Licensed Product, as applicable, including without limitation the manufacturing methods, test
5
259471316 v2



methods, specifications, materials, and other procedures, directions and controls associated with the Manufacture and testing of such Licensed Product, as applicable.
I.37Marketing Approval Application” (or “MAA”) means application to the appropriate Regulatory Authority for approval to market a Licensed Product in any particular jurisdiction, including an NDA in the U.S.
I.38NDA” means a New Drug Application, as defined in the FD&C Act, as amended, and applicable regulations promulgated thereunder by the FDA.
I.39Net Sales” means, with respect to any Licensed Product, the gross amounts invoiced by Eagle and its Affiliates and Sublicensees for sales of such Licensed Product in the Field to Third Parties, less the following deductions as accrued:
(a)[***];
(b)[***];
(c)[***];
(d)[***];
(e)[***];
(f)[***];
(g)[***]; and
(h)[***].
Notwithstanding the foregoing, amounts received or invoiced by Eagle or its Affiliates or Sublicensees for the sale of Licensed Products among Eagle and its Affiliates and Sublicensees shall not be included in the computation of Net Sales hereunder. Net Sales shall be accounted for in accordance with the selling party’s standard practices in the relevant country in the Territory.
[***], either Party may submit the matter to dispute resolution pursuant to Section 13.1.
I.40Party” means Combioxin or Eagle, individually; and “Parties” means Combioxin and Eagle, collectively.
I.41Patent(s)” means all patents and patent applications (including provisional applications), including all divisionals, continuations, substitutions, continuations-in-part, re-examinations, re-issues, additions, renewals, extensions, confirmations, registrations, any other pre- or post-grant forms of any of the foregoing, any confirmation patent or registration patent or patent of addition, utility models, patent term extensions, and supplemental protection certificates or requests for continued examinations, foreign counterparts, and the like of any of the foregoing.
6
259471316 v2



I.42Person” means any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, Governmental Authority or agency, or any other entity not specifically listed herein.
I.43Phase 2 Clinical Study” means a human clinical trial of a Licensed Product, the principal purpose of which is to evaluate the effectiveness and/or safety of such Licensed Product in the target patient population, as described in 21 C.F.R. § 312.21(b), as amended from time to time, or the corresponding foreign regulations, and which trial is intended to be the final clinical trial before the initiation of a Pivotal Clinical Trial and to establish the dosing for such Pivotal Clinical Trial. A “Phase 2/3 Clinical Study” shall be deemed to be a Phase 2 Clinical Study with respect to the portion of that clinical trial that is regarded as its Phase 2 component, in accordance with the applicable protocol.
I.44Phase 3 Clinical Study” means a human clinical trial of a Licensed Product, the principal purpose of which is to establish safety and efficacy in patients with the disease being studied and that would satisfy the requirements under 21 C.F.R. §312.21(c) for the U.S., as amended from time to time, or the corresponding foreign regulations for a comparable filing with a comparable Regulatory Authority. A “Phase 2/3 Clinical Study” shall be deemed to be a Phase 3 Clinical Study with respect to the portion of that clinical trial that is regarded as its Phase 3 component, in accordance with the applicable protocol.
I.45Pivotal Clinical Trial” means a pivotal human clinical trial of a Licensed Product (whether or not denominated a “Phase 3” clinical trial under applicable regulations) with a defined dose or a set of defined doses of such Licensed Product designed to ascertain efficacy and safety of such Licensed Product for the purpose of enabling the preparation and submission of an MAA to the competent Regulatory Authorities in a country of the Territory, as further defined in 21 C.F.R. § 312.21(c) for the U.S., as amended from time to time, or the corresponding foreign regulations.
I.46Pricing and Reimbursement Approval” means, with respect to any country or jurisdiction in the Territory in which Governmental Authorities determine the pricing at which a Licensed Product will be reimbursed, the approval, agreement, determination or decision by the applicable Governmental Authorities establishing the pricing and reimbursement status for such Licensed Product.
I.47Regulatory Approval” means all approvals, licenses, registrations or authorizations of any governmental entity that are necessary for the manufacturing, use, storage, import, transport and sale of Licensed Products in a regulatory jurisdiction, including in each case, Pricing and Reimbursement Approval.
I.48Regulatory Authority” means any national (e.g., the FDA) or, supra-national (e.g., the EC or the EMA), or other governmental entity in any jurisdiction of the world involved in the granting of Regulatory Approval for pharmaceutical products.
I.49Regulatory Filing” means all approvals, licenses, registrations, submissions and authorizations made to or received from a Regulatory Authority in a jurisdiction necessary for or in connection with the development, manufacture and/or commercialization of a pharmaceutical product, including any INDs, Marketing Approval Applications and Regulatory Approvals. As used
7
259471316 v2



herein, “Regulatory Filing” also includes all correspondence with Regulatory Authorities (and their agents) regarding Licensed Products, including all submissions, meeting minutes, reports and other items exchanged between or under authority from Combioxin or its licensors with respect to a Licensed Product, or the Development, Manufacture, Commercialization or exploitation thereof.
I.50Senior Executives” means the [***] of Combioxin and the [***] of Eagle.
I.51SOFR” means the secured overnight financing rate published for by the Federal Reserve Bank of New York, as the administrator of the benchmark (or a successor administrator) on the Federal Reserve Bank of New York’s website, as at the date on which the respective obligation to pay interest under this Agreement arises, and re-fixed for each day thereafter for as long as that obligation remains out-standing. In no event, however, shall the SOFR, for the purposes of this Agreement, be lower than 0.00%. In the absence of a SOFR at the relevant time as provided by this Agreement, the term SOFR shall mean the successor product to the secured overnight financing rate published for by the Federal Reserve Bank of New York for deposits in United States Dollars [***].
I.52Sublicensee” means a Third Party that has been granted a right to sell, market, distribute and/or promote Licensed Products in the Territory pursuant to Section 2.2 and Section 2.3; provided that as used herein, “Sublicensee” shall not be deemed to include any distributor, wholesaler or reseller of a Licensed Product who is not responsible for marketing or promotion of such Licensed Product.
I.53Sublicensee Payments” means all (i) cash upfront payments, (ii) royalty payments, and (iii) milestone payments that are paid to Eagle by any Sublicensee to the extent in consideration for the grant of a sublicense of Eagle’s rights under this Agreement, but excluding the following payments:
(a)[***];
(b)[***];
(c)[***]; and
(d)[***].
I.54Terminated Country” means any country for which this Agreement has been terminated in accordance with ARTICLE IX.
I.55Territory” means worldwide.
I.56Third Party” means any Person other than other than a Party or an Affiliate of a Party.
I.57Upstream Agreement” means that certain License Agreement between the [***].
I.58US” means the United States of America, including all possessions and territories thereof.
8
259471316 v2



I.59U.S. Dollars” means the legal currency of the United States of America.
I.60Valid Claim” means a claim of an issued, unexpired patent within the Licensed Patent Rights that has not been revoked, disclaimed, abandoned or held invalid or unenforceable by a court or other body of competent jurisdiction in an unappealed or unappealable decision.
I.61Additional Definitions. Each of the following terms shall have the meaning described in the corresponding section of this Agreement indicated below:

Term
Section Defined
Existing Supplies
Section 2.4(c)
Milestone A
Section 4.3(a)(i)
Milestone B
Section 4.3(a)(ii)
Commercialization Plan
Section 4.3(a)(ii)
Development Milestone Payment
Section 5.2(a)
Development Milestone Event
Section 5.2(a)
Total Net Sales
Section 5.3(a)
Sales Milestone Payment
Section 5.3(a)
Sales Milestone Event
Section 5.3(a)
Royalty Term
Section 5.4(b)
Third Party Payments
Section 5.4(c)(i)
Royalty Report
Section 5.4(d)
Material Underpayment
Section 6.5(b)
Receiving Party
Section 7.1
Disclosing Party
Section 7.1
Confidential Information
Section 7.1
Representatives
Section 7.1
Prior CDA
Section 7.8
9
259471316 v2



Enforcement Action
Section 8.3(a)(i)
Infringement Actions
Section 8.4
Term
Section 9.1
Combioxin Indemnitees
Section 12.1
Liabilities
Section 12.1
Third Party Claim
Section 12.1
Eagle Indemnitees
Section 12.2
Indemnitor
Section 12.3
Indemnitee
Section 12.3
Dispute
Section 13.1
ICC
Section 13.2
Acquisition
Section 14.9


ARTICLE II
GRANT OF LICENSE
II.1License to Eagle. Subject to the terms and conditions of this Agreement, Combioxin hereby grants to Eagle an exclusive (even as to Combioxin and its Affiliates) license, with the right to grant and authorize sublicenses as provided in Section 2.2 and Section 2.3, to the Licensed Intellectual Property and to the Licensed Products, including to Develop, Manufacture, have Manufactured, register, Commercialize, market, distribute, import and otherwise exploit the Licensed Products in the Field in the Territory.
II.2Sublicensing. Eagle shall have the right to grant and authorize sublicenses (through multiple tiers) under the rights granted to Eagle under Section 2.1 to one or more of its Affiliates, Sublicensees or other Third Parties.
II.3Disclosure and termination. Eagle shall cause each Sublicensee to comply with the applicable terms and conditions of this Agreement. The grant of any such sublicense shall not relieve Eagle of its liabilities and obligations under this Agreement, except to the extent they are discharged or performed by such Sublicensee. Any such permitted sublicenses shall be consistent with and expressly made subject to the terms and conditions of this Agreement. A copy of any sublicense agreement [***] by Eagle shall be provided to Combioxin within [***] its execution.
10
259471316 v2



In the event of termination of this Agreement, in whole or in part, Combioxin shall have the right to determine, in is sole discretion, for each sublicense, whether [***]. Combioxin shall inform Eagle and each Sublicensee of Combioxin’s decision within [***] of the effective date of termination of this Agreement.
II.4Transfer of Licensed Know-How.
(a)Initial Transfer. Promptly following the Effective Date and in any event no later than [***] thereafter, Combioxin shall, and shall use diligent efforts to cause any Affiliates or contractors to, transfer to Eagle, subject to reimbursement by Eagle of Combioxin’s out-of-pocket costs, with complete and accurate copies of all Licensed Know-How in existence as of the Effective Date, in accordance with the technology transfer plan as set forth on Exhibit 2.4; provided that if, despite exercising diligent efforts to do so, Combioxin is unable to transfer (or have transferred) all of the Licensed Know-How to Eagle within such [***] period, Combioxin shall continue to exercise diligent efforts to complete such transfer of Licensed Know-How to Eagle as soon as thereafter reasonably practicable.
(b)Upon Eagle’s written request after the Effective Date, a transfer of the global safety database available compiled by Combioxin until then from Combioxin to Eagle will be completed within [***]. Other than with respect to such transfer of the global safety database (to the extent required and available), Combioxin shall have no ongoing pharmacovigilance obligations, and Eagle shall assume all pharmacovigilance activities and obligations for the Licensed Products as of the Effective Date.
(c)Existing Supplies. In addition, to the extent Eagle requests, Combioxin shall, and shall use diligent efforts to cause any Affiliates and contractors to, transfer to Eagle (or Eagle’s designee) all existing quantities of the CAL02, including all intermediates, works in progress, batch and stability samples, and other materials owned or controlled by Combioxin or its Affiliates for use in manufacturing or testing the Licensed Products (collectively, “Existing Supplies”), [***]. Prior to Eagle’s request for such transfer, Combioxin shall, and shall [***] cause any contractors to, hold and maintain (under proper storage conditions necessary to maintain compliance with GMP) such Existing Supplies for the benefit and cost of Eagle until Eagle requests such transfer (up to a maximum of [***] after the Effective Date).
(d)Ongoing Transfer. Without limiting Section 2.4(a), if from time to time during the term of this Agreement, Eagle learns or believes that a particular item of Licensed Know-How and/or Existing Supplies has not been provided to Eagle, then upon request by Eagle, Combioxin shall, and shall use diligent efforts to cause any Affiliate or contractors, to promptly transfer to Eagle all such Licensed Know-How and/or Existing Supplies that has not previously been provided to Eagle hereunder, [***].
(e)Cooperation. The Parties will cooperate and reasonably agree upon formats and procedures to facilitate the orderly and efficient exchange of the Licensed Know-How and/or Existing Supplies in accordance with this Section 2.4. Without limiting the foregoing, Combioxin shall provide all such Licensed Know-How items [***]. It is understood all Licensed Know-How shall be made available to Eagle [***]. Upon request by Eagle, Combioxin shall, and shall [***]
11
259471316 v2



cause any Affiliates or contractors to, reasonably cooperate with and assist Eagle as may be necessary or desirable in order to allow Eagle to understand the Licensed Know-How and/or Existing Supplies and to utilize the Licensed Know-How and/or Existing Supplies for the purposes contemplated in this Agreement.
II.5Upstream Agreement.
(a)Payments. All amounts payable to [***] under the Upstream Agreement shall be the responsibility of Combioxin.
(b)Combioxin Covenants. During the Term, Combioxin hereby covenants to Eagle and agrees as follows:
(i)Combioxin shall maintain the Upstream Agreement in full force and effect and not terminate the Upstream Agreement, except with Eagle’s prior written consent;
(ii)Combioxin shall not assign or otherwise transfer its rights, title or interest in the Upstream Agreement to any Third Party;
(iii)Combioxin shall not amend the Upstream Agreement or waive any obligation of [***] under the Upstream Agreement in any manner, except with Eagle’s prior written consent;
(iv)Combioxin shall not take any action or omit to take any action that would result (including through the passage of time) in a default or breach of the Upstream Agreement; and
(v)Combioxin shall promptly notify Eagle in writing of the receipt or delivery of any notice of default or notice of termination under, or any termination or amendment of, the Upstream Agreement.
(c)Breach. Upon notification of a breach of the Upstream Agreement, Eagle shall have the right to step in to remedy the breach on Combioxin’s behalf. Upon termination of the Upstream Agreement for a breach by Combioxin, Eagle shall have the right to receive, subject to [***] consent, a direct license from [***] with respect to the Licensed Intellectual Property under the terms and conditions set forth in the Upstream Agreement, as such are available and as such terms and conditions apply to Eagle.
II.6No Other Rights. Except for the rights and licenses expressly granted in this Agreement, each Party retains all rights under its intellectual property, and neither Party shall be deemed by estoppel or implication to have granted the other Party any license or other right to any intellectual property of such Party.
ARTICLE III
GOVERNANCE
III.1Joint Development Committee.
12
259471316 v2



(a)Formation and Role. Promptly, and in any event within [***] after the Effective Date, the Parties shall establish a joint development committee to oversee Eagle’s Development activities in connection with the Licensed Products.
(b)Members. Each Party shall initially appoint up to [***] to the JDC, each of whom [***]. The JDC may change its size from time to time by mutual consent of its members, and each Party may replace its representatives at any time upon written notice to the other Party. The JDC elects a chairperson among its members.
(c)Meetings. For the first [***] following the Effective Date, the JDC shall meet [***]. Following [***] of the Effective Date, the JDC shall meet [***] thereafter. Meetings of the JDC may be held in person, by audio or video teleconference, as determined by the Parties. Each Party shall be responsible for all of its own expenses of participating in the JDC. The JDC shall continue to exist until the First Commercial Sale of a Licensed Product in the US or Europe. The chairperson shall be responsible for calling meeting on [***] prior written notice. Each Party shall make proposals for agenda items and shall provide all appropriate information with respect to such proposed item at least [***] in advance of the meeting. The chairperson shall prepare and circulate for review and approval of the Parties minutes of each meeting within [***] from the meeting. The Parties shall agree on the minutes of each meeting promptly, but in no event later than the next meeting of the JDC.
(d)A quorum of the JDC shall exist whenever there is present at a meeting at least [***] appointed by each Party. If the quorum is met, the JDC shall take action by consensus of the representatives present at a meeting, or by a written resolution signed by at least [***] appointed by each Party.
(e)Duties. The JDC shall be responsible for:
(i)reviewing the strategy of Development and Regulatory Approval for Licensed Product in the Territory;
(ii)reviewing the activities [***] proposed to be conducted by or on behalf of Licensee in the Territory;
(iii)[***];
(iv)[***];
(v)[***]; and
(vi)undertaking or approving such other matters as are specifically assigned to the JDC in this Agreement.
(f)Limitation of JDC Authority; Information Sharing. The JDC shall be a non-voting body and is intended as an operational and informational sharing committee that discusses Eagle's Development activities and strategies to reach the Milestones A and B defined in this Agreement as well as successful Commercialization of the Licensed Product. The JDC may
13
259471316 v2



suggest actions to both Parties to reach the aforementioned aims under this Agreement, and, where necessary, suggest amendments to this Agreement or any of its Exhibits. However, the JDC shall not have the power to make decisions under this Agreement and, for clarity, the JDC shall not have the authority to: (a) modify or amend the terms and conditions of this Agreement; (b) waive or determine either Party’s compliance with the terms and conditions of under this Agreement; or (c) decide any such issue in a manner that would conflict with the express terms and conditions of this Agreement.
ARTICLE IV
DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES
IV.1Development Responsibility. From and after the Effective Date for the Term of this Agreement, Eagle will have the exclusive right to conduct, and be solely responsible for all aspects of, the Development of Licensed Products including Manufacturing the Licensed Products, setting the regulatory strategy for seeking Regulatory Approvals for Licensed Products in the Field in the Territory, and seeking and obtaining Regulatory Approvals. As between the Parties, Eagle shall bear all of its costs and expenses incurred in connection with such Development activities.
IV.2Regulatory Responsibility. Eagle shall prepare and own all Regulatory Filings (including all INDs, NDAs, MAAs and Regulatory Approvals) for each Licensed Product in the Field in the Territory. Combioxin shall not submit any Regulatory Filings for Licensed Products in the Territory without the prior written consent of Eagle. Except as expressly requested by Eagle in writing, Combioxin shall not communicate with respect to the Licensed Products with any Regulatory Authority, unless so required to comply with Applicable Laws, in which case Combioxin shall promptly notify Eagle of such requirement under Applicable Laws, shall submit any proposed communication to Eagle for prior approval or, if not practicable or legally permitted, shall provide Eagle with a copy or summary thereof as soon as reasonably practicable thereafter.
IV.3Development Diligence. Eagle, directly and/or through its Affiliates or Sublicensees, shall use Commercially Reasonable Efforts to Develop the Licensed Products in the Field in the Territory.
(a)Diligence Milestones. Eagle, directly and/or through its Affiliates or Sublicensees, shall adhere to the following Development milestones:
(i)Milestone A: [***].
(ii)Milestone B: [***].
IV.4Development Reports. At least [***] prior to the regularly scheduled JDC meetings, Eagle will provide to Combioxin a written update summarizing the material Development activities conducted by Eagle during the period since the last JDC meeting, and anticipated to be conducted by Eagle in the following [***] period, with respect to the Development of Licensed Products in the Territory, including any material interactions with Regulatory Authorities. Upon reasonable request from time to time, Eagle will use good faith efforts to apprise Combioxin of material events with respect to the Development of Licensed Products, as mutually agreed at the time.
14
259471316 v2



IV.5Transition of Development and Regulatory Activities. Combioxin shall cooperate fully and use diligent efforts to effect a prompt, smooth and orderly transition of all Development and regulatory activities with respect to the Licensed Products to Eagle or its designee, as reasonably requested by Eagle, including the assignment of all Regulatory Filings for the Licensed Products in the Territory existing as of the Effective Date. To the extent reasonably requested by Eagle, Combioxin shall fully assist and cooperate with Eagle in connection with Eagle’s preparation of filings, reports, responding to questions and other communications with Regulatory Authorities to the extent the same pertain to activities conducted by or on behalf of Combioxin or its licensors with respect to any Licensed Product prior to the Effective Date. For clarity, [***].
IV.6Manufacturing. Eagle directly and/or through its Affiliates and/or one or more Third Parties, including a designated contract manufacturer, shall have the sole and exclusive right and responsibility, at its cost, for Manufacturing Licensed Products for clinical and commercial use in the Territory. Combioxin shall cooperate fully and use diligent efforts to effect a prompt, smooth and orderly transition of the Manufacture and supply of Licensed Products to Eagle or its designee, including the following:
(a)Arrangements with Prior CMO and Contractors: Upon Eagle’s request, Combioxin shall (i) provide contact information for any manufacturer(s) or supplier(s) used by or on behalf of Combioxin with respect to the Licensed Products, and (ii) upon request by Eagle, fully cooperate and use diligent efforts [***] with respect to or in support of the Manufacture and supply of the Licensed Product(s), for use in the Development or Commercialization activities hereunder. Without limiting the foregoing Combioxin shall provide all necessary authorizations to permit the manufacturers and suppliers to use any Licensed Know-How in such entity’s possession, including the Manufacturing Process, for the benefit of Eagle.
(b)Manufacturing Process Transfer: Promptly following the Effective Date and in any event no later than [***] thereafter, Combioxin shall, [***], promptly disclose to Eagle or its designee, such Licensed Know-How as is reasonably necessary or useful for the Manufacture of Licensed Products, including the manufacturing portions of any existing Regulatory Filings, in each case to the extent not previously provided to Eagle in accordance with the manufacturing technology transfer plan set forth on Exhibit 2.4.
(c)Transition Costs. Combioxin shall provide all such assistance without charge, provided that in the event that a Licensed Product is being Manufactured for Combioxin by a Third Party and Eagle requests the technical assistance of such Third Party manufacturer in connection with such transfer, or the assistance of such Third Party manufacturer is necessary to effectuate such transfer, Eagle agrees to reimburse Combioxin for all amounts paid to such Third Party for such technical assistance rendered to Eagle under this Section 4.6. [***].
IV.7Assignment of Agreements. Promptly following the Effective Date, Combioxin shall assign to Eagle those agreements with Third Parties listed on Exhibit 4.7.
IV.8Commercialization. As between the Parties and for the Term of this Agreement, Eagle shall have the exclusive right to conduct, and be solely responsible for all aspects of, the Commercialization of Licensed Products in the Field in the Territory, including: [***] As between
15
259471316 v2



the Parties, Eagle shall bear all of its costs and expenses incurred in connection with such Commercialization activities.
IV.9Commercial Diligence. Eagle shall use Commercially Reasonable Efforts to Commercialize each Licensed Product for which it has obtained Regulatory Approval in the Territory. Eagle shall, and shall cause its Affiliates and Sublicensees to, comply with all Applicable Law and GMP with respect to the Commercialization and Manufacturing of the Licensed Products.
IV.10Product Trademarks. As between the Parties, Eagle shall have the sole and exclusive right to determine and own the trademarks to be used with respect to the Commercialization of the Licensed Products in the Field in the Territory, which branding may vary by country and Licensed Product. Eagle may, directly or through one or more Affiliates or Third Parties, register, maintain, enforce and defend such trademarks in the Territory, where and how it determines appropriate.
IV.11Subcontracting. Eagle may subcontract with a Third Party to perform any or all of its obligations hereunder, provided that no such permitted subcontracting shall relieve Eagle of any liability or obligation hereunder.
ARTICLE V
PAYMENTS
V.1Upfront Payment. Eagle shall pay to Combioxin a one-time, non-refundable, non-creditable upfront payment of ten million U.S. dollars ($10,000,000) within [***] following the Effective Date in accordance with the payment provisions of ARTICLE VI.
V.2Development Milestone Payments.
(a)Development Milestone Payments. Eagle shall pay to Combioxin the one-time milestone payments set forth below following the first achievement by Eagle, and/or any of its Affiliates or Sublicensees, of the corresponding milestone events defined below with respect to the first Licensed Product to achieve such event (each, a “Development Milestone Payment” and “Development Milestone Event,” respectively). The Development Milestone Payments shall be payable in accordance with the payment provisions in ARTICLE VI and following receipt of the relevant invoice from Combioxin as further described in Section 5.2(c).
No.
Development Milestone Event
Payment
1[***]
[***]
2[***]
[***]
      Total
[***]
(b)One-Time Payments. Each Development Milestone Payment is payable one time only, regardless of the number of times the corresponding event is achieved by a Licensed
16
259471316 v2



Product and regardless of the number of Licensed Products to achieve such Development Milestone Event. Accordingly, in no event shall the aggregate amount to be paid to Combioxin pursuant to this Section 5.2 exceed [***] with respect to the achievement of all Development Milestone Events for all Licensed Products.
(c)Reports and Payments. Eagle shall notify Combioxin in writing within [***] after the achievement of each Development Milestone Event set out in Section 5.2(a) by Eagle, or any of its Affiliates, and in the case of Sublicensees, within [***] after such Development Milestone Event is achieved by such Sublicensee. Based on this notice, Combioxin shall then issue and send to Eagle the invoice for the appropriate Development Milestone Payment, which shall be paid by Eagle within [***] of receipt of such invoice.
V.3Sales Milestone Payments.
(a)Sales Milestone Payments. Eagle shall pay to Combioxin the one-time sales milestone payments set out below when cumulative Net Sales of all Licensed Products (combined) in the Territory since the First Commercial Sale (“Total Net Sales”) reach the respective thresholds (each, a “Sales Milestone Payment” and a “Sales Milestone Event,” respectively), in accordance with this Section 5.3 and the payment provisions in ARTICLE VI and following receipt of the relevant invoice from Combioxin as further described in Section 5.3(c).
No.
Sales Milestone Event
Payment
1Total Net Sales equals [***]
[***]
2Total Net Sales equals [***]
[***]
3Total Net Sales equals [***]
[***]
Total
[***]
(b)One-Time Payments. Each of the foregoing Sales Milestone Payments shall be paid no more than once. In no event shall the aggregate amount to be paid to Combioxin pursuant to this Section 5.3 exceed [***].
(c)Reports and Payments. Eagle shall notify Combioxin in writing within [***] after the achievement of each Sales Milestone Event set out in Section 5.3(a). Based on this notice, Combioxin shall then issue and send to Eagle the invoice for the appropriate Sales Milestone Payment, which shall be paid by Eagle within [***] of receipt of such invoice.
V.4Royalty Payments.
(a)Base Royalties. Subject to the terms and conditions of this Agreement, in consideration for the rights and licenses granted under this Agreement, Eagle shall pay to Combioxin the following royalties on Net Sales of Licensed Products by Eagle and its Affiliates (but not Sublicensees), in accordance with this Section 5.4 and the payment provisions in ARTICLE VI, equal to the following percentages of such Net Sales:
17
259471316 v2



Total Net Sales of Licensed Product by Eagle and its Affiliates (but not Sublicensees)
Royalty Rate
Total Net Sales of Licensed Products equal to or less than [***]
[***]
Total Net Sales of Licensed Products greater than [***] but equal to or less than [***]
[***]
Total Net Sales of Licensed Products greater than [***] but equal to or less than [***]
[***]
Total Net Sales of Licensed Products greater than [***]
[***]
(b)Royalty Term. Eagle’s obligation to pay royalties under this Section 5.4 shall continue with respect to sales of Licensed Products on a country-by-country and Licensed Product-by-Licensed Product basis until the date which is the later of: (a) expiration of the last to expire Valid Claim of a Program Patent Right Covering the Licensed Product in the country for which such Licensed Product is sold; or (b) [***] after the First Commercial Sale of the first Licensed Product in such country (“Royalty Term”). After the expiration of the applicable Royalty Term with respect to a Licensed Product in a country, no further royalties shall be due with respect to such Licensed Product in such country and the licenses and rights granted by Combioxin to Eagle under this Agreement with respect to such Licensed Product in such country will become fully paid-up, royalty-free, perpetual and irrevocable (except as otherwise expressly set forth in Section 5.5).
(c)Royalty Adjustments.
(i)Third Party Payments. If Eagle, its Affiliate or Sublicensee becomes obligated to make payment to a Third Party [***] (“Third Party Payments”), Eagle may [***] of the amount payable to each such Third Party from the amounts payable to Combioxin under this ARTICLE V; provided that such deduction shall not reduce the amounts so payable to Combioxin to [***] of the amount that would otherwise be due hereunder. Eagle may carry forward to subsequent calendar quarters any deductions that it was not able to deduct as a result of the foregoing proviso. For the avoidance of doubt, if Eagle elects to develop or use a Third Party intellectual property right solely for the Manufacture, use or sale of an Other Product that is part of a Combination Product, then no royalty adjustment shall be applied pursuant to this Section 5.4(c)(i).
(ii)Valid Claim Coverage. If the Licensed Product is not Covered by a Valid Claim of a Licensed Patent Right in the country for which such Licensed Product is sold, the royalty payable by Eagle with respect to such Licensed Product in such country shall be reduced [***] of the amount otherwise payable pursuant to this Section 5.4. Notwithstanding the foregoing, the reduction in this Section 5.4(c)(ii) shall not apply with respect to a Licensed Product in a calendar quarter in a particular country if a reduction is made under Section 5.4(c)(iii) below for such Licensed Product in such quarter in such country.
18
259471316 v2



(iii)Generic Products. If, in any country in the Territory during the Royalty Term for a Licensed Product, Generic Products to such Licensed Product are sold by any Third Party that is not a Sublicensee, and the aggregated (all package sizes) sales turnover of the Licensed Product in such country (measured in unit sales) is [***] of the aggregated sales volume of such Licensed Product for the [***] immediately prior to the launch of the Generic Product in such country, then the then-applicable royalty rates (i.e., as set forth in Section 5.4(a) and as such royalties may have been further reduced pursuant to Section 5.4(c)) for such calendar quarter for Licensed Product sold in such country will be reduced [***] of the royalty rates then applicable. If, in any country in the Territory during the Royalty Term for a Licensed Product, Generic Products to such Licensed Product are sold by any Third Party that is not a Sublicensee, and the aggregated (all package sizes) sales turnover of the License Product in such country (measured in unit sales) is [***] of the aggregated sales volume of such Licensed Product for the [***] immediately prior to the launch of the Generic Product in such country, then the then-applicable royalty rates (i.e., as set forth in Section 5.4(a) and as such royalties may have been further reduced pursuant to Section 5.4(c)) for such calendar quarter for Licensed Product sold in such country will be reduced [***] of the royalty rates then applicable. All such determinations of unit sales shall be based upon a mutually acceptable calculation method using market share data provided by a reputable and mutually agreed upon provider, [***].
(iv)One Royalty. No more than one royalty payment shall be due under this Agreement with respect to a sale of a particular Licensed Product (e.g., even if such Licensed Product is Covered by multiple Valid Claims or multiple Licensed Patent Rights).
(d)Royalty Reports. Commencing with the calendar quarter in which the First Commercial Sale of a Licensed Product occurs in the Territory or Eagle first receives a Sublicensee Payment, Eagle shall deliver to Combioxin a report (each, a “Royalty Report”) setting out the following details as reasonably necessary to calculate the payments due under this Section 5.4:
(i)[***];
(ii)[***];
(iii)[***];
(iv)[***]; and
(v)[***].
Royalty Reports shall be due [***] following the end of each such calendar quarter during the term of this Agreement. Promptly following the delivery of the applicable Royalty Report, Combioxin will invoice Eagle for the royalties due to Combioxin under Section 5.4 above with respect to the Net Sales in the Territory in such calendar quarter and the share of Sublicensee Payments due to Combioxin under Section 5.5 below with respect to such calendar quarter. Eagle shall pay such amounts to Combioxin within [***] following Eagle’s receipt of such invoice.
V.5Sublicensees.
19
259471316 v2



(a)Sales by Sublicensees. Eagle shall pay to Combioxin [***] of all Sublicensee Payments. Notwithstanding the foregoing, regardless of the actual royalty rate set forth in the applicable sublicense agreement with a Sublicensee, Combioxin’s share of any Sublicensee Payments that constitute a royalty on Net Sales of a Licensed Product shall not be less than [***] or greater than [***] of the Net Sales of such Sublicensee of such Licensed Product. For example, [***].
(b)Termination of Royalty-Based Sublicensee Payments. Notwithstanding the forgoing Section 5.5(a), on a country-by-country and Licensed Product-by-Licensed Product basis, in the event that Combioxin does not owe a royalty payment to the [***] pursuant to Section 3.1(b) of the Upstream Agreement with respect to a particular Licensed Product in a particular country, then the minimum royalty rate set forth in Section 5.5(a) shall no longer apply.
ARTICLE VI
PAYMENTS; BOOKS AND RECORDS
VI.1Payment Method; Currency Conversion. All amounts specified in this Agreement are in U.S. Dollars, and all cash payments under this Agreement shall be paid in U.S. Dollars. As applicable, Net Sales and any royalty reductions incurred in other currencies will be translated into U.S. Dollars in the manner used by Eagle from time to time in the preparation of its audited financial statements for external reporting purposes. All payments under this Agreement will be paid in U.S. Dollars by wire transfer to an account designated by Combioxin (which account Combioxin may update from time to time in writing, subject to Eagle’s reasonable confirmation). If at any time legal restrictions prevent the prompt remittance of any royalties or other amounts with respect to any country where Licensed Products are sold, Eagle shall have the right, at its option, to make such payments by depositing, or causing to be deposited, the amount of such payments in local currency to Combioxin’s account in a bank or other depository designated by Combioxin in such country.
VI.2Withholding Taxes. Notwithstanding any other provision of this Agreement, Eagle shall be entitled to deduct and withhold from any payments such amounts as it is required to deduct and withhold pursuant to any tax laws of any jurisdiction or any regulation of any taxing authority thereof. To the extent such amounts are deducted, withheld and paid by or on behalf of Eagle to the appropriate taxing authority, such amounts shall be treated for all purposes of this Agreement as having been paid to Combioxin. Eagle shall provide Combioxin with official receipts issued by the appropriate governmental agency to Eagle. Each Party shall provide to the other Party such assistance as may be reasonably requested in connection with any application to qualify for the benefit of a reduced rate of withholding taxation, under the terms of any income tax treaty between the United States and other jurisdictions, in particular under the terms of the existing tax treaty between the United States and Switzerland.
If Eagle assigns this Agreement as per Section 14.8 or moves its business operations out of the US, or if Eagle is acquired by a company outside the US, then any negative withholding taxes consequences shall be fully and solely be compensated by Eagle.
VI.3Late Payments. In the event that any undisputed amount payable by Eagle to Combioxin hereunder is not made when due, such outstanding payment shall accrue interest, to the
20
259471316 v2



extent permitted by Applicable Law, at an annual rate of [***], computed from the date such payment was due until the date Eagle makes the payment.
VI.4Records. Eagle and its Affiliates shall keep complete and accurate books of account and records in reasonably sufficient detail to enable the amounts payable under this Agreement to be determined. Such books and records shall be kept at the principal place of business of Eagle, its Affiliate or Sublicensee, as the case may be, for at least [***] following the end of the calendar year to which such books and records pertain.
VI.5Audits.
(a)Audit Rights. Upon at least [***] prior written notice from Combioxin, Eagle shall permit, and shall require its Affiliates and use reasonable efforts to require its Sublicensees, to permit, an independent certified public accounting firm of nationally recognized standing, selected by Combioxin and reasonably acceptable to Eagle, to have access during normal business hours to such books of account and records of Eagle, and its Affiliates and Sublicensees, at such Person’s principal place of business, as may be reasonably necessary to verify the accuracy of the reports provided by Eagle pursuant to Section 5.4(d). Such audits may not (i) be conducted for any calendar year ending more than [***] prior to the date of such request, (ii) be conducted more than [***] in any calendar year or (iii) [***].
(b)Audit Results. Combioxin shall require the independent accountant to provide to Eagle an audit report containing its conclusions regarding any audit, and specifying whether the amounts paid were correct or, if incorrect, the amount of any underpayment or overpayment. The independent accountant shall provide to Eagle a preliminary copy of its audit report and shall discuss with Eagle any issues or discrepancies that Eagle identifies, prior to submission to Combioxin. If such audit establishes that additional royalties and/or Sales Milestones Payments are properly owed to Combioxin in accordance with this Agreement during the period covered by any audit pursuant to Section 6.5(a), Eagle shall remit to Combioxin within [***] of the date on which Combioxin delivers to Eagle an invoice for such amounts: (i) the amount of such additional royalties and/or Development Milestone Payments or Sales Milestone Payments; and (ii) interest on such amount which shall be calculated pursuant to Section 6.3. In the event such audit establishes that amounts were overpaid by Eagle during such period, the amount of such overpayment shall be credited to Eagles next payments and Combioxin will include such amount in the next invoice issued in accordance with this Agreement. The fees charged by the independent accountant in connection with any audit pursuant to this Section 6.5 shall be paid by Combioxin; provided, however, that if a discrepancy in favor of Combioxin of more than [***] of the payments due hereunder for the period being audited (a “Material Underpayment”) is established, then Eagle shall pay the reasonable fees and expenses charged by such accounting firm in connection with such audit.
(c)Confidential Financial Information; Other Matters. Combioxin shall treat all financial information subject to review under this ARTICLE VI as the Confidential Information of Eagle in accordance with Section 7.1. Any such auditor appointed by Combioxin shall enter into a confidentiality agreement with Eagle and shall not disclose or use Eagle’s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the financial reports
21
259471316 v2



furnished by Eagle or the amount of payments due by Eagle to Combioxin under this Agreement. If Eagle is unable to obtain from any Sublicensee a right for Combioxin to audit the books of account and records of such Sublicensee, Eagle shall obtain the right to inspect and audit such Sublicensee’s books and records for itself and shall exercise such audit rights on behalf and at the expense of Combioxin upon Combioxin’s written request and disclose the results of any such audit to Combioxin in accordance with Section 6.5(b). Combioxin shall be responsible for the costs incurred by Eagle with respect to such audit and inspection, provided that if such audit establishes a Material Underpayment, Eagle shall reimburse Combioxin for the costs so paid by Combioxin to Eagle with respect to such audit.
ARTICLE VII
CONFIDENTIALITY
VII.1Confidential Information. Except to the extent expressly authorized by this Agreement, each Party agrees that, during the term of this Agreement, and for [***] thereafter, such Party (the “Receiving Party”) shall keep confidential, and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement or in the exercise of rights granted to it hereunder, any information furnished to it by or on behalf of the other Party (the “Disclosing Party”) pursuant to this Agreement that is marked or otherwise identified as confidential or proprietary at the time of disclosure or is disclosed in such a manner or is of such a nature that a reasonable person would understand such information to be confidential or proprietary, independent of whether such information was shared in writing, orally, electronically or any other form tangible or intangible form (collectively, “Confidential Information”). The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to prevent unauthorized access, use and disclosure of the Disclosing Party’s Confidential Information and to ensure that its, and its Affiliates’, employees, agents, consultants, other representatives (“Representatives”) do not disclose, except as otherwise expressly permitted under this Agreement, or make any unauthorized use of, the Disclosing Party’s Confidential Information. The Receiving Party shall promptly notify the Disclosing Party upon discovery of any unauthorized use or unauthorized disclosure of the Disclosing Party’s Confidential Information. For purposes of this Agreement, the terms of this Agreement and the Licensed Know-How (to the extent such Licensed Know-How is related to the Licensed Products) shall be deemed the Confidential Information of both Eagle and Combioxin.
VII.2Exceptions. Confidential Information of a Disclosing Party shall not include any information to the extent that such information (which the Receiving Party can prove by competent written evidence): (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement, generally known or available to the public; (b) is lawfully known by the Receiving Party or any of its Affiliates (to the extent such Receiving Party or Affiliate has the right to use and disclose such information) at the time of receiving such information from the Disclosing Party; (c) is hereafter furnished to the Receiving Party or any of its Affiliates by a Third Party who has a legal right to make such disclosure and who did not obtain such information directly or indirectly from the Receiving Party (to the extent such Receiving Party or Affiliate has the right to use and disclose such information); or (d) is independently discovered or developed by the Receiving Party or any of its Affiliates, without the use of or reference to Confidential Information of the Disclosing Party.
22
259471316 v2



VII.3Authorized Disclosure. Notwithstanding the provisions of Section 7.1, the Receiving Party may disclose Confidential Information of the Disclosing Party as expressly permitted by this Agreement, or if and to the extent such disclosure is reasonably necessary in the following instances:
(a)In the case of either Party as the Receiving Party:
(i)enforcing such Party’s rights or performing its obligations under this Agreement;
(ii)prosecuting or defending litigation as permitted by this Agreement;
(iii)such disclosure is reasonably necessary to its employees, agents, consultants, contractors, licensees or Sublicensees on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement; provided that in each case, the disclosees are bound by obligations of confidentiality and non-use consistent with those contained in this Agreement;
(iv)such disclosure is necessary to comply with Applicable Laws, including regulations promulgated by applicable security exchanges, court order, administrative subpoena or order; provided in the event the Receiving Party is required to make a disclosure of the Disclosing Party’s Confidential Information pursuant to this subparagraph 7.3(a)(iii), it will, except where legally prohibited, (i) give reasonable advance notice to the Disclosing Party of such disclosure, (ii) use efforts to secure confidential treatment of such information at least as diligent as the Receiving Party would use to protect its own confidential information, and (iii) in the case of disclosures under this subparagraph 7.3(a), cooperate with any efforts by the Disclosing Party, at the Disclosing Party’s request and expense, to prevent or limit disclosure of such Confidential Information; or
(v)disclosure to Third Parties in connection with due diligence or similar investigations, and disclosure to any bona fide potential or actual investor, acquiror or merger partner for the sole purpose of evaluating an actual or potential investment, acquisition or merger; provided that in connection with such disclosure, such Party shall inform each disclosee of the confidential nature of such Confidential Information and ensure that any such Third Party agrees to be bound by obligations of confidentiality and non-use similar to those contained in this Agreement.
(b)In the case of Eagle as the Receiving Party:
(i)[***];
(ii)[***]; and
(iii)[***].
(c)In the case of Combioxin as the Receiving Party in case of a termination of this Agreement and return of any Licensed Know-How, Licensed Product and Licensed Patent
23
259471316 v2



Rights to Combioxin in accordance with Section 10.3, Section 10.4 and Section 10.5 that includes Eagle Confidential Information:
(i)[***];
(ii)[***]; and
(iii)[***].
(d)Each Party shall be responsible for any breaches of confidentiality by any of its Affiliates, subcontractors, Representatives, advisors and Third Parties to whom it discloses Confidential Information pursuant to Section 7.3.
VII.4Confidential Disclosure of Terms. The Parties agree that the terms of this Agreement are the Confidential Information of both Parties that a Party shall not disclose to any Third Party without the prior written consent of the other Party hereto, except as permitted under Section 7.2 or 7.3 above, and notwithstanding the foregoing, each Party may disclose the existence and/or terms of this Agreement to [***] on a reasonable need to know basis, in each case under circumstances that reasonably protect the confidentiality thereof.
VII.5Publications. As between the Parties, from and after the Effective Date until termination, Eagle shall have the sole and exclusive right to publish and present the results of any Development activities with respect to Licensed Products and may further publish and disclose the results of any Clinical Study and other Data included in the Licensed Know-How.
VII.6Use of Name. Except as expressly provided herein, neither Party shall mention or otherwise use the name, logo, or trademark of the other Party or any of its Affiliates (or any abbreviation or adaptation thereof) in any public communication without the prior written consent of the other Party. The restrictions imposed by this Section 7.6 shall not prohibit either Party from making any disclosure identifying the other Party that, in the opinion of the Disclosing Party’s counsel, is required by Applicable Law; provided such Party shall submit the proposed disclosure identifying the other Party in writing to the other Party as far in advance as reasonably practicable so as to provide a reasonable opportunity to comment thereon.
VII.7Press Releases.
(a)The Parties have mutually approved a joint press release attached hereto as Exhibit 7.7 with respect to this Agreement to be published on the Effective Date or immediately thereafter. Each Party agrees not to issue any other press release or other public statement, whether oral or written, disclosing the terms hereof or any of the activities conducted hereunder without the prior written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed), except as permitted under Section 7.3(a) above. Notwithstanding the foregoing, after release of a press release in accordance with this Section 7.7(a), either Party may disclose to Third Parties the information contained in such press release without further consent.
24
259471316 v2



(b)For clarity, Eagle shall have the right to issue subsequent press releases or other public statements pertaining to the activities conducted hereunder. For avoidance of doubt, Eagle shall have the right to publicly disclose without Combioxin’s prior written consent: [***].
(c)Eagle shall have the right to hold an investors’ day following the issue of the joint press release and to discuss matters pertaining to this Agreement during that investors’ day, provided that Eagle shall comply with its confidentiality obligations hereunder in relation to that investors’ day.
VII.8Prior Non-Disclosure Agreements. This Agreement supersedes the Confidentiality and Nondisclosure Agreement between Eagle and Combioxin effective as of [***] (“Prior CDA”) regarding the subject matter of this Agreement. All information exchanged between the Parties under the Prior CDA shall be deemed to have been disclosed under this Agreement on a going-forward basis and shall be subject to the terms of this ARTICLE VII as of the Effective Date.
VII.9Trade Secrets. Eagle acknowledges that Combioxin may transfer trade secrets to Eagle in connection with this Agreement. Combioxin shall take all steps reasonably necessary to maintain such information as a trade secret for an indefinite period, notwithstanding Section 7.3. Such trade secrets may only be used by Eagle as expressly set forth in this Agreement.
ARTICLE VIII
PATENT PROSECUTION AND ENFORCEMENT
VIII.1Ownership of Inventions. Inventorship of inventions shall be determined in accordance with the rules of inventorship under U.S. patent laws. As between the Parties, Eagle (or its Affiliate) shall solely own all inventions made solely by Eagle personnel, and Combioxin (or its Affiliate) shall solely own all inventions made solely by personnel of Combioxin. The Parties (or their respective Affiliates) shall jointly own all inventions made jointly by personnel of both Eagle and Combioxin; provided that, subject to the rights and licenses granted under and the restrictions set forth in this Agreement, [***].
VIII.2Patent Prosecution and Maintenance.
(a)Eagle Prosecution and Maintenance. As between the Parties, Eagle shall, at its expense, have the first right, but not the obligation, to file, maintain and prosecute (particularly with respect to any Patent dispute) the Licensed Patent Rights throughout the Territory, including conducting any interferences, inter parte reviews, reexaminations, reissues, opposition, and other similar proceedings relating thereto. [***], Eagle shall keep Combioxin reasonably informed of progress with regard to the prosecution and maintenance of Licensed Patent Rights as set forth in this Section 8.2(a). Combioxin shall have the right to consult and review all material Patent filings in advance of any deadline, submission to or action with any patent office. Eagle shall furnish to Combioxin copies of all relevant drafts and documents of such material Licensed Patent Rights as reasonably as practicable in advance of such consultation for Combioxin’s review. Eagle shall provide to Combioxin copies of all patent office submissions and patent office correspondence relevant to such Licensed Patent Rights within [***] following submission or receipt thereof by Eagle. Eagle shall consider in good faith any reasonable and timely comments provided by Combioxin in connection with the prosecution and maintenance of such Licensed Patents Rights. At
25
259471316 v2



Eagle’s request, Combioxin shall reasonably cooperate with Eagle in the prosecution and maintenance of such Licensed Patent Rights. If Eagle desires to abandon or cease prosecution or maintenance of any such Licensed Patent Right in any country in the Territory in its entirety, Eagle shall provide written notice to Combioxin of such intention promptly after Eagle makes such determination, but in no event later than [***] prior to any final deadline that must be met in order to avoid such abandonment, and Combioxin shall have the right, but not the obligation, to assume responsibility for prosecution and maintenance of such Licensed Patent Right at its sole cost and expense. If Combioxin assumes responsibility for the prosecution and maintenance of any such Licensed Patent Rights, Combioxin shall similarly (i) consult with Eagle as to the prosecution and maintenance of such Licensed Patents Rights in the Territory reasonably prior to any deadline, submission to or action with any patent office, (ii) furnish to Eagle copies of all relevant drafts and documents reasonably in advance of such consultation, (iii) provide to Eagle copies of all patent office submissions and correspondence relevant to such Licensed Patent Rights within a reasonable amount of time following submission or receipt thereof by Combioxin, (iv) consider in good faith any reasonable and timely comments provided by Eagle in connection with the prosecution and maintenance of such Licensed Patent Rights, and (v) Eagle shall have the right to veto claim amendments and prosecution arguments to the extent such amendments or arguments are reasonably likely to result in a negative impact on Eagle’s prosecution and maintenance of other Patents that claim a License Product. Combioxin shall provide Eagle with an updated Exhibit 1.32 on [***] basis or more frequently upon Eagle’s reasonable request.
(b)Patent Term Extensions. Eagle shall have the sole right to obtain patent term extensions, supplementary protection certificates, and equivalents thereof with respect to any Licensed Product in the Field in the Territory, including with respect to any Licensed Patent Right in any country in the Territory, and Combioxin shall reasonably cooperate with Eagle in connection therewith.
VIII.3Enforcement.
(a)Enforcement Actions.
(i)In the event that either Party becomes aware of any patent nullity, invalidity or unenforceability actions, any declaratory judgment actions, or any actual or threatened infringement of any Licensed Patent Right, including any claims arising under the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417), as amended, or its equivalent in a country other than the United States, that Party shall promptly notify the other Party in writing. Eagle (itself or through a designee) shall have the first right, but not the obligation, to initiate proceedings or take other action it believes appropriate, at its own expense, to enforce or defend the Licensed Patent Rights with respect to any such activities involving or applicable to a Licensed Product (each, an “Enforcement Action”). If Eagle does not initiate proceedings within [***] from the date of Combioxin’s request that Eagle initiate such proceedings, (or in the event that written notice is received under any statute expediting litigation (e.g. Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417)) or any foreign counterparts of such law, within thirty (30) days of the date of such notice) or resolve the dispute, then Combioxin shall be entitled, but shall not be obliged, to initiate infringement proceedings or take other action it believes appropriate against such Third Party at its own expense.
26
259471316 v2



(ii)The Party conducting such Enforcement Action under this Section 8.3(a) shall have full control over its conduct, including settlement thereof; provided, however, that the Party conducting such Enforcement Action may not settle any such Enforcement Action, or make any admissions or assert any position in such Enforcement Action, in a manner that would materially adversely affect the validity of a Licensed Patent Right, without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed. If one Party brings any suit, action or proceeding under this Section 8.3(a), the other Party agrees to be joined as party plaintiff if reasonably necessary to prosecute the suit, action or proceeding and to give the first Party authority to file, prosecute and control the suit, action or proceeding; provided, however, that such other Party shall in any case have the right to be represented by its own counsel at its cost and expense. In any event, the Parties shall assist one another and cooperate in any such litigation at the other’s reasonable request.
(iii)The Party initiating the Enforcement Action under Section 8.3(a) shall assume and pay all costs and expenses incurred by it with respect to such Enforcement Action, including fees and expenses of counsel selected by it.
(b)Recovery. Combioxin and Eagle shall each recover their respective actual out-of-pocket expenses (including attorneys’ fees), or equitable proportions thereof, associated with any Enforcement Action against infringers undertaken pursuant to Section 8.3(a) from any resulting amount received by award of a court of competent jurisdiction. Any excess amount of such a recovery shall (i) be retained [***]; or (ii) otherwise retained by [***].
VIII.4Third Party Infringement Claims. If the production, sale, importation, or use of any Licensed Product in any country of the Territory pursuant to this Agreement results in a claim, suit or proceeding alleging patent or other intellectual property infringement against Combioxin or Eagle (or their respective Affiliates, or Sublicensees) (collectively, “Infringement Actions”), such Party shall promptly notify the other Party hereto in writing. Eagle shall have the right to direct and control the defense thereof, at its own expense (subject to Combioxin’s indemnification obligations set forth in Section 12.2) with counsel of its choice. Eagle shall keep Combioxin reasonably informed of all material developments in connection with any such Infringement Action. Eagle may treat any out-of-pocket costs incurred in connection with such Infringement Action, including reasonable attorneys’ fees, damages and other liabilities that are part of any final judgment, and any amounts paid by Eagle in a settlement of the Infringement Action as Third Party Payments under Section 5.4(c)(i) above.
ARTICLE IX
TERM AND TERMINATION
IX.1Term. This Agreement shall commence on the Effective Date and, unless terminated earlier pursuant to Section 9.2, Section 9.3, Section 9.4 or Section 9.5, shall continue in full force and effect until the expiration of the last to expire Royalty Term (“Term”).
IX.2Termination for Material Breach. If either Party materially breaches this Agreement at any time, the non-breaching Party shall have the right to terminate this Agreement by written notice to the breaching Party, if such material breach is not cured within [***] after written
27
259471316 v2



notice is given by the non-breaching Party to the breaching Party specifying the breach, subject to Section 13.2 below. Notwithstanding the foregoing, to the extent any material breach is limited to a particular country, then the non-breach Party shall only have the right to terminate this Agreement with respect to such country.
IX.3Termination for Bankruptcy. Either Party shall have the right to terminate this Agreement upon written notice to the other Party: (a) if such other Party is declared insolvent or bankrupt by a court of competent jurisdiction; (b) if a voluntary or involuntary petition in bankruptcy is filed in any court of competent jurisdiction against such other Party and such petition is not dismissed within [***] after filing; (c) if such other Party shall make or execute an assignment of substantially all of its assets for the benefit of creditors; or (d) substantially all of the assets of such other Party are seized or attached and not released within [***] thereafter.
IX.4Termination by Eagle. Eagle shall have the right to terminate this Agreement, in its entirety or on a country-by-country basis or Licensed Product-by-Licensed Product basis, for convenience, without cause, and for any or no reason prior to the First Commercial Sale of the first Licensed Product on not less than ninety (90) days’ prior written notice to Combioxin, and thereafter, on not less than one hundred and eighty (180) days’ prior written notice to Combioxin.
IX.5Termination by Combioxin. Combioxin shall have the right to terminate this Agreement in its entirety or on a country-by-country basis, for cause in case of:
(a)failure to achieve the Development Milestone A with prior written notice of [***]; and
(b)failure to achieve Development Milestone B, [***] prior written notice.
ARTICLE X
EFFECT OF TERMINATION
X.1Accrued Obligations. The expiration or termination of this Agreement for any reason shall not release either Party from any liability which, at the time of such expiration or termination, has already accrued to the other Party prior to such expiration or termination, nor will any termination of this Agreement preclude either Party from pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with respect to any breach of this Agreement that occurred prior to such expiration or termination.
X.2Return of Confidential Information. Within [***] after the Effective Date of any such termination, each Party shall promptly return to the other Party, or delete or destroy, all Confidential Information of the other Party; provided that (i) each Party may retain copies of the Confidential Information of the other Party to the extent necessary to perform its obligations or exercise its rights that survive expiration or termination of this Agreement; (ii) each Party may retain one copy of the Confidential Information of the other Party [***]. Upon any termination of this Agreement by either Party under Section 9.2 or 9.3, by Eagle under Section 9.4, or by Combioxin under Section 9.5, Confidential Information comprising Licensed Know-How shall cease to be Confidential Information of Eagle, and thereafter shall be Confidential Information solely of Combioxin.
28
259471316 v2



X.3Cease of use. Upon termination, independent of its cause, Eagle shall immediately cease to use the Licensed Know-How, Licensed Product and Licensed Patent Rights except where such further use is necessary to ensure patient safety until such safety obligations are assumed by Combioxin.
X.4Reversion of Rights. All rights and licenses granted to Eagle under this Agreement shall terminate and revert to Combioxin, provided that if this Agreement is only terminated with respect to one or more countries, only the rights and licenses with respect to such country or countries shall terminate and revert to Combioxin.
X.5Consequences of Termination. In the event this Agreement is not terminated in its entirety, but rather is terminated on a country-by-country basis or Licensed Product-by-Licensed Product basis, then, notwithstanding anything to the contrary in this Section 10.5, the consequences of termination described herein shall only apply to such terminated country or terminated Licensed Product, and this Agreement shall remain in full force and effect with respect to all countries other than such terminated country or terminated Licensed Product, as applicable. In the event of a termination of this Agreement prior to the end of the Term,
(a)[***];
(b)[***];
(c)[***];
(d)[***];
(e)[***];
(f)[***];
(g)[***]; and
(h)[***].
X.6Survival. Upon the expiration or termination of this Agreement, all rights and obligations of the Parties under this Agreement shall terminate except that [***] shall survive expiration or any termination of this Agreement.
ARTICLE XI
REPRESENTATIONS, WARRANTIES AND COVENANTS
XI.1Representations, Warranties and Covenants of Combioxin. Combioxin represents, warrants and covenants to Eagle that, as of the Effective Date:
(a)Combioxin is a corporation duly organized, validly existing and is in good standing under the laws of Switzerland, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its
29
259471316 v2



properties requires such qualification and failure to have such would prevent Combioxin from performing its obligations under this Agreement;
(b)this Agreement is a legal and valid obligation binding upon Combioxin and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by Combioxin have been duly authorized by all necessary corporate action and do not and will not: (i) violate any law, rule, regulation, order, writ, judgment, decree, determination or award of any court, governmental body or administrative or other agency having jurisdiction over Combioxin; nor (ii) conflict with, or constitute a default under, any agreement, instrument or understanding, oral or written, to which Combioxin is a party or by which it is bound;
(c)Combioxin is the sole owner or otherwise has sufficient legal title and/or beneficial title or ownership or license with respect to the Licensed Patent Rights and the Licensed Know-How and has the full right and authority to grant the rights and licenses with respect to the Licensed Patent Rights and Licensed Know-How, without limitation or restriction;
(d)Combioxin hereby covenants that it shall not, during the Term, without the prior written approval of Eagle, (i) amend any provision of the Upstream Agreement that would adversely impact Eagle’s rights under this Agreement, or (ii) assign (except an assignment to a party to which this Agreement has been assigned as permitted under Section 14.8 or to any Affiliate), in whole or in part, the Upstream Agreement in any manner that would adversely impact Eagle’s rights under this Agreement, in each case, without the prior written consent of Eagle;
(e)Combioxin has provided Eagle with a true and correct copy (as of the Effective Date) of the Upstream Agreement in effect as of the Effective Date. Combioxin and its Affiliates are not in breach of the Upstream Agreement and the [***] has not threatened to terminate or otherwise allege any breach under the Upstream Agreement;
(f)The Licensed Know-How includes, to Combioxin’s knowledge, all proprietary aspects of the Manufacturing Process and CMC Data, and is sufficient for Eagle, its designees and Sublicensees to Manufacture the Licensed Products, in the same manner has they have been Manufactured prior to the Effective Date;
(g)Exhibit 1.32 sets forth a true and complete list of all Patents owned by Combioxin or its Affiliates as of the Effective Date that Cover the Licensed Products, and Combioxin has the full right and authority to grant to Eagle the right to make, use, sell, offer to sell, import, sublicense and otherwise exploit worldwide, all of the Patents described in Exhibit 1.32, and to prosecute and enforce such Patents in accordance with ARTICLE VIII above;
(h)Exhibit 4.7 sets forth all contracts entered into by Combioxin or its Affiliate prior to the Effective Date that could, to Combioxin’s knowledge, pertain to Licensed Products, Licensed Patent Rights or Licensed Know-How after the Effective Date.
(i)Combioxin has not previously granted and will not grant any right, license or interest in or to a Licensed Product, Licensed Know-How and/or Licensed Patent Rights, or any portion thereof, that is in conflict with, limits or derogates from the rights or licenses granted to Eagle under this Agreement;
30
259471316 v2



(j)the Licensed Patent Rights and the Licensed Know-How are free and clear of all liens, claims, security interests or other encumbrances of any kind and during the term of this Agreement, Combioxin shall not permit the Licensed Patent Rights or the Licensed Know-How to become encumbered by any liens, claims, security interests or other encumbrances that could diminish Eagle’s rights or licenses with respect to any Patent or other subject matter;
(k)to Combioxin’s knowledge, there are no actual, pending, alleged or threatened actions, suits, claims, interference or governmental investigations involving a Licensed Product, the Licensed Patent Rights or the Licensed Know-How by or against Combioxin, or any of its Affiliates or other licensees;
(l)all necessary consents, approvals and authorizations of all Regulatory Authorities, other Governmental Authorities and other persons or entities required to be obtained by Combioxin in order to enter into this Agreement have been obtained for the Licensed Product at its current stage of development;
(m)to Combioxin’s knowledge, the practice of the Licensed Patent Rights or the Licensed Know-How and the making, using, selling, offering for sale and importing of any Licensed Product does not infringe, violate or misappropriate the intellectual property rights of any Third Party;
(n)Combioxin has not received notice from a Third Party claiming that the practice of the Licensed Patent Rights or the Licensed Know-How or the making, using, selling, offering for sale and importing of a Licensed Product infringes, violates or misappropriates the intellectual property rights of any Third Party;
(o)Combioxin has not knowingly withheld any Licensed Know-How that is reasonably relevant for Eagle’s conduct of activities under this Agreement and, to Combioxin’s knowledge, all Licensed Know-How provided to Eagle is free from any material inaccuracies;
(p)Combioxin has disclosed to Eagle all information relating to the safety and efficacy of the Licensed Product known to it or its Affiliates;
(q)to Combioxin’s knowledge, there is no actual, pending, alleged or threatened infringement by a Third Party of any of the Licensed Patent Rights or the Licensed Know-How;
(r)Combioxin has complied with all Applicable Laws in all material respects, including any disclosure requirements, in connection with the filing, prosecution and maintenance of the Licensed Patent Rights and, to Combioxin’s knowledge, none of the issued Licensed Patent Rights are invalid or unenforceable;
(s)the Licensed Patent Rights and Licensed Know-How are not subject to any funding agreement with any government or Governmental Authority;
(t)Combioxin has [***];
(u)Combioxin has [***];
31
259471316 v2



(v)[***];
(w)to Combioxin’s knowledge, none of the materials and documents provided to Eagle in the course of Eagle’s due diligence preceding execution of this Agreement contained any untrue statement of material fact; and
(x)all Licensed Products Manufactured and delivered by or under the authority of Combioxin to Eagle pursuant to Section 2.4 of this Agreement, and that are identified as being “GMP” in Exhibit 2.4, were Manufactured and are as of the Effective Date in compliance with all Applicable Laws, GMP and any other applicable manufacturing standards.
XI.2Representations and Warranties of Eagle. Eagle represents and warrants to Combioxin that, as of the Effective Date:
(a)Eagle is a corporation duly organized, validly existing and is in good standing under the laws of the State of Delaware, U.S.A., is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and failure to have such would prevent Eagle from performing its obligations under this Agreement;
(b)this Agreement is a legal and valid obligation binding upon Eagle and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by Eagle have been duly authorized by all necessary corporate action and do not and will not: (i) violate any law, rule, regulation, order, writ, judgment, decree, determination or award of any court, governmental body or administrative or other agency having jurisdiction over Eagle; nor (ii) conflict with, or constitute a default under, any agreement, instrument or understanding, oral or written, to which Eagle is a party or by which it is bound;
(c)all necessary consents, approvals and authorizations of all Regulatory Authorities, other Governmental Authorities and other persons or entities required to be obtained by Eagle in order to enter into this Agreement have been obtained;
(d)Eagle is not under any obligation, contractual or otherwise, to any Person that conflicts with the terms of this Agreement;
(e)Eagle and its Affiliates have never been, are not currently, and will not knowingly use in any capacity, in connection with the obligations to be performed under this Agreement, any Person who is or was, debarred under 21 U.S.C. §335a (a) or (b) or an equivalent Applicable Law.
XI.3Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
32
259471316 v2



ARTICLE XII
INDEMNIFICATION; RECALLS
XII.1Indemnification of Combioxin. Eagle shall indemnify and hold harmless each of Combioxin, its Affiliates, and the directors, officers, shareholders and employees of such entities and the successors and assigns of any of the foregoing (the “Combioxin Indemnitees”), from and against any and all liabilities, damages, penalties, fines, costs, expenses (including, reasonable attorneys’ fees and other expenses of litigation) (“Liabilities”) incurred by any Combioxin Indemnitee as a result of any claims, actions, suits or proceedings brought by a Third Party (a “Third Party Claim”) against a Combioxin Indemnitee, arising from, or occurring as a result of: (a) the Development, Manufacture or Commercialization of any Licensed Product by Eagle, its Affiliates or Sublicensees; (b) any breach of any representations or warranties by Eagle in ARTICLE XI above; and (c) any breach by Eagle or failure by Eagle to perform an agreement assigned to Eagle pursuant to Section 4.7, to the extent such breach or failure first arose after the date of such assignment; except to the extent such Third Party Claims fall within the scope of Combioxin’s indemnification obligations set forth in Section 12.2 below or result from the fault of a Combioxin Indemnitee.
XII.2Indemnification of Eagle. Combioxin shall indemnify and hold harmless each of Eagle, its Affiliates and Sublicensees and the directors, officers and employees of Eagle, its Affiliates and Sublicensees and the successors and assigns of any of the foregoing (the “Eagle Indemnitees”), from and against any and all Liabilities incurred by any Eagle Indemnitee as a result of any Third Party Claims against an Eagle Indemnitee, arising from, or occurring as a result of (a) the Development, Manufacture or Commercialization of any Licensed Product by Combioxin, its Affiliates or (sub)licensees prior to the Effective Date; (b) any breach of any representations, warranties or covenants by Combioxin in ARTICLE XI above, (c) any breach by Combioxin of the Upstream Agreement, and (d) any breach of or failure to perform an agreement assigned to Eagle pursuant to Section 4.7 above, to the extent such breach or failure occurred prior to such assignment; except to the extent such Third Party Claims fall within the scope of Eagle’s indemnification obligations set forth in Section 12.1 above or result from the fault of an Eagle Indemnitee.
XII.3Procedure. A Party that intends to claim indemnification under this ARTICLE XII (the “Indemnitee”) shall promptly notify the other Party (the “Indemnitor”) in writing of any Third Party Claim, in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense and/or settlement thereof, except as set forth in Section 8.4. The indemnity arrangement in this Section 12.3 shall not apply to amounts paid in settlement of any action with respect to a Third Party Claim, if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Third Party Claim, if prejudicial to its ability to defend such action, shall relieve such Indemnitor of any liability to the Indemnitee under this Section 12.3, but the omission to so deliver written notice to the Indemnitor shall not relieve the Indemnitor of any liability that it may have to any Indemnitee otherwise than under this Section 12.3. The Indemnitee under this Section 12.3 shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Third Party Claim covered by this indemnification.
33
259471316 v2



XII.4Recalls. For the Term of this Agreement, Eagle shall solely be responsible for the handling any recalls, claims relating to recalls of or serious adverse events in relation to any Licensed Product that arises in the process of Development and Commercialization.
XII.5Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 12.5 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 12.1 OR 12.2, AND THE FOREGOING LIMITATIONS SHALL NOT APPLY WITH RESPECT TO DAMAGES RESULTING FROM A PARTY’S WILLFUL MISCONDUCT OR GROSS NEGLIGENCE OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE VII.
ARTICLE XIII
DISPUTE RESOLUTION
XIII.1Referral to Senior Executives. The Parties recognize that disputes as to certain matters relating to this Agreement may from time to time arise during the term of this Agreement (each, including any dispute arising with respect to the existence, object, interpretation, performance, enforcement, termination, invalidity or arbitrability of this Agreement, a “Dispute”). If any such Dispute cannot be resolved by good faith negotiations, such Dispute shall be referred, by written notice from either Party to the other, to the Senior Executives for resolution. The Senior Executives or their respective designees (with similar authority to resolve such Dispute) shall negotiate in good faith to resolve such Dispute through discussions promptly following such written notice. If the Senior Executives cannot resolve the Dispute within [***] of such written notice[***] then, the provisions of Section 13.2 shall apply.
XIII.2Arbitration. Any Dispute that is not resolved pursuant to Section 13.1 shall be finally settled in accordance with the [***]. The seat of arbitration shall be [***]. The language of the arbitration shall be English. The Parties agree that decision and/or award rendered by the arbitrator shall be the sole, exclusive and binding remedy between them regarding any Dispute presented to the arbitrator. Any decision and/or award of the arbitrator may be entered in any court of competent jurisdiction for judicial recognition of the decision and an order of enforcement. The arbitration proceedings and the decision of the arbitrator shall be deemed the Confidential Information of both Parties subject to ARTICLE VII above.
XIII.3General Terms of Arbitration.
(a)Interim Relief. Notwithstanding anything in Section 13.2 to the contrary, each Party shall have the right to apply to any court of competent jurisdiction for a temporary restraining order, preliminary injunction or other similar interim or conservatory relief, as necessary to protect the rights or property of such Party, pending the selection of the arbitrator or pending the arbitrator’s determination of the merits of any Dispute. Nothing in the preceding sentence shall be
34
259471316 v2



interpreted as limiting the powers of the arbitrator with respect to any Dispute subject to arbitration under this Agreement.
(b)Jury Waiver. EACH PARTY, TO THE EXTENT PERMITTED BY LAW, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES AND AGREES TO ARBITRATE AS SET FORTH IN SECTION 13.2 (ARBITRATION). THIS WAIVER APPLIES TO ANY ACTION OR LEGAL PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE.
ARTICLE XIVGENERAL PROVISIONS
XIV.1Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from events beyond the reasonable control of and which were reasonably unforeseeable at the time of the execution of this Agreement by the non-performing Party, including but not limited to fire, flood, earthquake, hurricane, embargo, shortage, epidemic, pandemic, quarantine, war, act of war (whether war be declared or not), terrorist act, insurrection, riot, civil commotion, strike, lockout or other labor disturbance (whether involving the workforce of the non-performing Party or of any other Person) or act, omission or delay in acting by any Governmental Authority, including due to a clinical hold pursuant to 21 C.F.R. §312.42, as amended (and any equivalent in any jurisdiction outside the United States). The non-performing Party shall notify the other Party of such force majeure by giving written notice to the other Party stating the nature of the event, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than necessary to resolve such force majeure event and the non-performing Party shall use diligent efforts to remedy its inability to perform.
XIV.2Governing Law. This Agreement and all questions regarding its validity or interpretation, or the breach or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of [***], without reference to conflict of law principles. The Parties hereby agree that the provisions of the United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement and are strictly excluded.
XIV.3Waiver of Breach. The failure of either Party at any time or times to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another condition or term.
XIV.4Modification. No amendment or modification of any provision of this Agreement shall be effective unless in writing signed by both Parties hereto. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by both Parties hereto.
XIV.5Severability. In the event any provision of this Agreement should be held invalid, illegal, or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and
35
259471316 v2



enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Agreement shall remain in full force and effect in such jurisdiction. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction.
XIV.6Entire Agreement; Amendments. This Agreement (including the Exhibits attached hereto) constitutes the complete, final and entire agreement between the Parties relating to the subject matter hereof and supersede all prior and contemporaneous agreements, representations and/or understandings, including the Prior CDA. The foregoing shall not be interpreted as a waiver of any remedies available to either Party as a result of any breach, prior to the Effective Date, by the other Party of its obligations under the Prior CDA. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party.
XIV.7Notices. Unless otherwise agreed by the Parties or specified in this Agreement, all communications between the Parties relating to, and all written documentation to be prepared and provided under, this Agreement shall be in the English language. Any notice between the Parties required or permitted under this Agreement shall be in writing in the English language, and (a) delivered personally, (b) sent by air mail or express courier service providing evidence of receipt, postage pre-paid where applicable, or (c) by electronic transmission (complete transmission confirmed and a copy promptly sent by another permissible method of providing notice described in paragraph (a) or (b) above), to the following addresses of the Parties (or such other address for a Party as may be specified by like notice):
To Combioxin:

Combioxin SA.
Route de la Corniche 5
1066 Epalinges
Switzerland Attention: [***]
To Eagle:

Eagle Pharmaceuticals, Inc.
50 Tice Blvd, Suite 315
Woodcliff Lake, NJ 07677
Attention: General Counsel
Electronic mail: [***]
With a copy to:

VISCHER AG
[***]
Aeschenvorstadt 4
4051 Basel
Switzerland
Attn: Christian Wyss
Electronic mail: cwyss@vischer.com
With a copy to:

Cooley LLP
One Freedom Square
Reston Town Center
11951 Freedom Drive
Reston, Virginia 20190-5656
Attn: Kenneth J. Krisko
Electronic mail: KKrisko@cooley.com
Any notice required or permitted to be given concerning this Agreement shall be effective upon receipt by the Party to whom it is addressed.
36
259471316 v2



XIV.8Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other, except that each Party may assign purely financial rights arising out of this Agreement and that each Party may make such an assignment or transfer without the other Party’s consent to its Affiliates or to a Third Party successor to substantially all of the business of such Party, whether in a merger, sale of stock, sale of assets or other transaction. With respect to an assignment to an Affiliate, such Party shall remain responsible for the performance by its Affiliate of the rights and obligations hereunder. Combioxin shall not assign or otherwise transfer to any Affiliate or any Third Party any ownership interest in or to any Licensed Know-How or Licensed Patent Rights, without Eagle’s prior written consent. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Subject to the foregoing, this Agreement shall inure to the benefit of each Party, its successors and permitted assigns. Any purported assignment of this Agreement in contravention of this Section 14.8 shall be null and void.
XIV.9Effect of Acquisition. Notwithstanding any other provision of this Agreement, in the event of the Acquisition of Combioxin, no intellectual property, compounds, products or other subject matter owned or controlled by the acquiring entity or any of its affiliates prior to such Acquisition, or developed or acquired by such acquiring entity after such acquisition, shall be included as Licensed Patent Rights, Licensed Know-How or Licensed Products hereunder, so long as (a) such intellectual property, compounds, products and other subject matter were developed without use of the Licensed Know-How and without practicing Licensed Patent Rights; and (b) such acquiring entity segregates the personnel and activities of Combioxin and its Affiliates (as determined immediately prior to such Acquisition) from any other programs of such acquiring entity and its affiliates directed to the Development or Commercialization of liposome products. “Acquisition” means: (a) a merger involving Combioxin, in which the shareholders of Combioxin immediately prior to such merger cease to control (as defined in Section 1.1) Combioxin after such merger; (b) a sale of all or substantially all of the business or assets of a Combioxin to an acquiring entity; or (c) a sale of a controlling (as defined in Section 1.1) interest of Combioxin to an acquiring entity.
XIV.10No Partnership or Joint Venture. Nothing in this Agreement is intended, or shall be deemed, to establish a joint venture or partnership between Eagle and Combioxin. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, or to bind the other Party to any contract, agreement or undertaking with any Third Party.
XIV.11Interpretation. The captions to the several Articles and Sections of this Agreement are not a part of this Agreement, but are included for convenience of reference and shall not affect its meaning or interpretation. In this Agreement: (a) the word “including” shall be deemed to be followed by the phrase “without limitation” or like expression; (b) the singular shall include the plural and vice versa; and (c) masculine, feminine and neuter pronouns and expressions shall be interchangeable. Each accounting term used herein that is not specifically defined herein shall have the meaning given to it under generally accepted cost accounting principles, but only to the extent consistent with its usage and the other definitions in this Agreement. This Agreement has been prepared jointly by the Parties and shall not be strictly construed against either Party. Ambiguities,
37
259471316 v2



if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.
XIV.12Performance by Affiliates. Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party’s Affiliate.
XIV.13Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.
XIV.14Counterparts; Other Matters. This Agreement and any amendment thereto may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Signatures to this Agreement or any amendment thereto delivered by facsimile or in electronic form (such as an electronic file which contains a scan of the wet ink signature or signed by a (qualified or non-qualified) electronic signature, such as DocuSign, AdobeSign, or a similar tool will be deemed to be binding as originals. This Agreement is established in the English language. Any translation in another language shall be deemed for convenience only and shall never prevail over the original English version.
[Remainder of this page intentionally blank.]
38
259471316 v2


CONFIDENTIAL
Execution Copy
IN WITNESS WHEREOF, the Parties have executed this License Agreement as of the Effective Date.

COMBIOXIN SA
BY: _/s/ Samareh Azeredo da Silveira Lajaunias
NAME: Samareh Azeredo da Silveira Lajaunias
TITLE: Managing Director_________________

BY: /s/ Frédéric Lajaunias_____________
NAME: Frédéric Lajaunias_____________
TITLE: Managing Director_____________

EAGLE PHARMACEUTICALS, INC.
BY: /s/ Michael S. Moran______________
NAME: Michael S. Moran_____________
TITLE: Executive Vice President, Head of Sales, Business Development & Gov’t Sales

259471316 v2




EXHIBIT 1.32
[***]




259471316 v2



EXHIBIT 1.33
[***]

259471316 v2



EXHIBIT 2.4
[***]


259471316 v2



EXHIBIT 4.7

[***]








259471316 v2



EXHIBIT 7.7
Press Release


[***]

[***] For Immediate Release
Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia


-- CAL02 neutralizes toxic virulence effectors (“VE”) produced by bacteria; VEs play a decisive role in the development of long-term, severe and fatal pneumonia complications --

-- Results of first-in-human1 clinical trial published in The Lancet Infectious Diseases, where accompanying comments characterized CAL02 as “One step closer to precision medicine for infectious diseases,” describing “this study a medical breakthrough” --

-- Potential to address significant unmet need in the treatment of severe pneumonia, which accounts for 2.4 million deaths per year globally --

-- Eagle anticipates ten years of regulatory exclusivity --

-- Eagle to host CAL02 Investor Event on September 9, 2021 --


WOODCLIFF LAKE, NJ—[***] 2021—Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a worldwide licensing agreement with Combioxin SA (“Combioxin”), a clinical-stage biotechnology company based in Epalinges, Switzerland, for the commercial rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs.

259471316 v2



Under the Agreement, Eagle will be solely responsible for further clinical development of CAL02, and will make an upfront payment, followed by additional payments upon achievement of development milestones, regulatory approval and based upon commercial sales. Eagle expects to invest $35 million to achieve interim results. These interim results are expected the first half of 2023.

CAL02 is designed to be an add-on therapy to antibiotics to neutralize virulence effectors. CAL02 consists of liposomes that capture and neutralize bacterial toxins produced by a broad range of Gram-positive and Gram-negative bacteria. Bacterial toxins play a critical role in severe, complicated, and resistant infections. They are known to dysregulate inflammation, cause organ damage and impede immune defense. Unlike traditional antibacterial drugs, CAL02 does not target bacteria directly.

The first-in-human clinical trial results show a favorable safety profile when administered in combination with standard antibiotics to patients with severe community-acquired bacterial pneumonia (“CABP”) hospitalized in the intensive care unit (“ICU”). Furthermore, as compared to patients under placebo, patients who were treated with CAL02 presented a faster clinical improvement, including a significantly faster resolution of organ dysfunctions (as per Sequential Organ Failure Assessment score).

“We are thrilled to be part of this potentially groundbreaking advancement in the treatment of severe bacterial pneumonia. Despite the widespread availability of antibiotic drugs today, pneumonia is still the leading cause of infectious mortality in the world. CAL02’s ability to neutralize virulence effectors could fill a significant medical gap by offering physicians a new treatment that has the potential to dramatically improve patient outcomes. We believe that CAL02 could change the standard of care for patients and have a broad therapeutic impact, especially in critical situations. This deal, along with the recent AOP Pharmaceuticals transaction, broadens our pipeline and provides opportunities for continued leadership in the hospital acute care space,” stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.

“We are thrilled to partner with Eagle Pharmaceuticals, which has shown tremendous commitment to bringing innovative solutions in the hospital acute care space. This transaction represents a significant milestone in the development of CAL02 and we believe that it will bring about a true transformation in the treatment of severely infected patients around the world,” said Dr. Samareh Azeredo da Silveira Lajaunias, Managing Director of Combioxin SA.

“Pneumonia remains one of the deadliest infectious diseases in the world. In addition to the associated morbidity and mortality, severe pneumonia represents a major economic burden due to how it prolongs hospitalization. Targeting virulence effectors, CAL02 addresses the fundamental damage of severe community-acquired pneumonia. In its first in-human clinical trial, a randomized, double-blind, placebo-controlled study, CAL02 was shown to be as safe as placebo and resulted in
259471316 v2



significantly fewer ICU days. CAL02 has the potential to transform the care for severe pneumonia,” said Professor of Medicine Andrew Shorr, Georgetown University.

Clinical Status and Regulatory Path Forward

Preclinical data were published in Nature Biotechnology, followed by numerous peer-reviewed articles. The results of the first-in-human clinical trial (randomized, double-blind, placebo-controlled, multi-center), which was carried out in ICU patients with severe CABP, were published in The Lancet Infectious Diseases, in May 2019, and the study was described as a “medical breakthrough”.

The clinical development plan has been discussed with the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency (“EMA”). FDA and EMA each indicated no requirement of further dose finding for Phase 2b, and that empiric use of CAL02 could be added to the standard of care antibacterial drug therapy prior to pathogen identification given its mechanism of action.

“CAL02 could represent a true paradigm shift in terms of the treatment cascade for bacterial pneumonia patients. With an estimated 350,000 patients requiring treatment in the ICU in the U.S. in 2020, CAL02 could provide a significant opportunity to improve patient outcomes and save lives,” stated Judith Ng-Cashin, MD, Chief Medical Officer of Eagle Pharmaceuticals.

The Company plans to advance the clinical program and initiate a robust Phase 2b/3 study in the first half of 2022. CAL02 is an acute care drug, and therefore the Company expects a fast turnaround to receive individual patient results. Interim results are expected in the second quarter of 2023.

Eagle anticipates ten years of regulatory exclusivity, including five years as a New Chemical Entity and five years as a qualified infectious disease product (“QIDP”) under the Generating Antibiotic Incentives Now (“GAIN”) Act. Eagle believes that CAL02 could be eligible for fast track and breakthrough therapy designations. In addition, Eagle believes a CAL02 new drug application for the treatment of severe CABP may qualify for priority review. The Company expects to build a meaningful patent portfolio for to this asset.

259471316 v2



Large Unmet Medical Need

Complications associated with CABP represent a significant unmet medical need. CAL02 has the potential to transform the standard of care for patients with CABP, which accounts for an estimated 2.4 million deaths per year globally. In the United States, about one million adults seek hospital care for pneumonia every year, and 50,000 die from this disease. Older patients with chronic illnesses are at the greatest risk for severe infection, complications and mortality. For children, pneumonia is the most common reason for hospitalization, and it is the world’s leading cause of death among children under the age of five. Pneumonia is also the most common cause of sepsis and septic shock, responsible for 50% of all episodes, and can result in admission to the ICU. Hospital-acquired pneumonia has a higher mortality rate than any other hospital-acquired infection.

Pneumonia places a huge burden on the U.S. healthcare system and is among the top ten costly conditions seen during inpatient hospitalizations. Despite the availability of antibiotics, the death rate from pneumonia in the U.S. has seen little improvement in the past half century.

Conference Call

Eagle management will host a CAL02 Investor Event as follow:

Date
Thursday, September 9, 2021
Time8:30 A.M. EDT
Toll free (U.S.)INSERT
InternationalINSERT
Webcast (live and replay)
www.eagleus.com, under the “Investor + News” section

A replay of the conference call will be available for one week after the call's completion by dialing 888-562-2815 (US) or 402-220-7352 (International) and entering conference call ID INSERT. The webcast will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines
259471316 v2



that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

About CAL02

CAL02 is an investigational innovative anti-infective drug that acts as a trap for bacterial virulence effectors (toxins) which contribute to infection-related complications, sepsis, septic shock and death. CAL02 consists of liposomes engineered to clear away the virulence effectors produced by the most relevant bacteria seen in severe pneumonia. CAL02 is poised to play a key role in the fight against anti-microbial resistance, since its action is complementary to that of antibiotics and does not appear to give rise to drug resistance. Because of its safety profile, its breadth of activity and the fact that it is not conducive to the emergence of any new resistance, CAL02 could be administered empirically, as soon as patients with a suspected or confirmed pneumonia show signs of severity. Clinical results to date underscore the potential of CAL02 to transform the standard of care and to dramatically reduce the time and the cost of care for millions of critically ill patients.

About Combioxin

Combioxin SA is a Swiss-based clinical-stage biotechnology company founded in 2015. The company is committed to the development of disruptive treatments for severe infections. Combioxin is a recipient of the Swiss FIT SEED program and is a spin-off of LASCCO SA, a company that propels academic discovery-stage inventions into life science ventures. Additional information is available on Combioxin’s website at www.combioxin.com.


Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities law. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “may,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,”
259471316 v2



“near future,” “belief,” “guidance,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements concerning the licensing agreement between the Company and Combioxin and the timing and ability to obtain regulatory approval of CAL02; statements regarding the collaboration between the Company and Combioxin, including statements about CAL02’s ability to address unmet need in patients with severe pneumonia and its other anticipated benefits and expected duration of regulatory exclusivity for CAL02, if approved; CAL02’s potential acceptance by clinicians; the timing, progress and results of additional trials of CAL02 and the ability of such trial results to support regulatory filings and approvals; anticipated actions by FDA, EMA and other regulatory agencies; the Company’s ability to support the commercial launch of CAL02, if approved; anticipated future payments, including upfront and milestone payments, from the Company to Combioxin; the anticipated market opportunity for CAL02; and the ability of the product candidates in the Company’s pipeline to deliver value to stockholders. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the impacts of the ongoing COVID-19 pandemic, including interruptions or other adverse effects on clinical trials and delays in regulatory review or further disruption or delay of any pending or future litigation; delay in or failure to obtain regulatory approval of the Company's product candidates, including CAL02, and successful compliance with FDA, EMA and other governmental regulations applicable to product approvals; whether the Company will successfully implement its development plan for its product candidates, including CAL02; the inability to recognize the anticipated benefits of the collaboration between the Company and Combioxin; whether the Company can successfully collaborate with its partners and market and commercialize its product candidates; the outcome of litigation involving any of its products or that may have an impact on any of its products; possible safety and efficacy concerns; risks that preliminary results from clinical trials are not necessarily predictive of future clinical trial results; the strength and enforceability of the Company’s intellectual property rights or the rights of third parties; the risks inherent in drug development and in conducting clinical trials; and those risks and uncertainties identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (the “SEC”) on March 5, 2021, as updated by the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2021 and June 30, 2021, filed with the SEC on May 10, 2021 and August 9, 2021, respectively, and its other subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Relations for Eagle Pharmaceuticals, Inc.:
Lisa M. Wilson    
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
259471316 v2




Media Relations for Eagle Pharmaceuticals, Inc.:
Faith Pomeroy-Ward
T: 817-807-8044
E: faith@fpwservices.com



259471316 v2

EX-10.2 3 ex102eagle-aoplicenseagree.htm EX-10.2 Document
Exhibit 10.2


[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.



CONFIDENTIAL
LICENSE AGREEMENT

BETWEEN

AOP ORPHAN PHARMACEUTICALS GmbH

AND

EAGLE PHARMACEUTICALS, INC.









LICENSE AGREEMENT
THIS LICENSE AGREEMENT (this “Agreement”) dated as of August 6, 2021 (the “Execution Date”), is entered into between AOP Orphan Pharmaceuticals GmbH, an Austrian company having offices at Leopold-Ungar-Platz 2, 1190 Vienna, Austria (“AOP”) and Eagle Pharmaceuticals, Inc., a Delaware corporation having offices at 50 Tice Boulevard, Suite 315, Woodcliff Lake, New Jersey, United States (“Eagle”).
BACKGROUND
A.    Eagle is a specialty pharmaceutical company focused on developing and commercializing drugs.
B.    AOP is a pharmaceutical company dedicated to the development of therapy options for patients with rare diseases, including therapies containing landiolol, a short acting superselective beta-1 adrenergic blocker that aims at the reduction of ventricular rate;
C.    Eagle desires to obtain from AOP and AOP desires to grant to Eagle an exclusive license with respect to the development and commercialization of the Licensed Product (as defined below) in the Eagle Territory (as defined below), all on the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:
Article I
DEFINITIONS
I.1Administrative Fees” means the portion of administrative fees, not to exceed [***], accrued during the relevant time period to group purchasing organizations, pharmaceutical benefit managers, Medicare Prescription Drug Plans, Medicaid, or the like (including similar plans and programs outside the United States) relating to such Licensed Product.
I.2Affiliate” of a Party means any Person that, directly or indirectly, controls, is controlled by, or is under common control with such Party, as the case may be. As used in this Section 1.1, the word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such Person, whether by the ownership of more than fifty percent (50%) of the voting share capital in such Person, or by contract or otherwise.
I.3Allowable Expenses” means, with respect to a given period, the following expenses to the extent specifically identifiable and directly allocable to Eagle’s and its Affiliates’ activities in relation to exploitation of the Licensed Product in the Eagle Territory pursuant to this Agreement, incurred by or on behalf of Eagle, its Affiliates, or Sublicensees, in each case in accordance with Eagle’s, its Affiliates’ or Sublicensee’s accounting practices (consistently applied): [***].
I.4ANDA” means an Abbreviated New Drug Application, as defined in the FD&C Act, as amended, and applicable regulations promulgated thereunder by the FDA.
I.5Anti-Corruption Laws” shall mean the U.S. Foreign Corrupt Practices Act (15 U.S.C. §§78dd-1, et. seq.), as amended, the Organization for Economic Co-operation and Development (OECD)
Page 1
259471241 v2



Convention on combating bribery of foreign public officials in international business transactions, and any other applicable anti-corruption laws.
I.6AOP Background Know-How” means any and all Know-How that (a) is Controlled by AOP or any of its Affiliates (i) as of the Effective Date, or (ii) during the Term as a result of performing activities outside the scope of this Agreement, and (b) is necessary or reasonably useful for the Development, Manufacture or Commercialization of Licensed Products and other activities under this Agreement for the Territory.
I.7AOP Background Patents” means any and all Patents that (a) are Controlled by AOP or any of its Affiliates as of the Effective Date or during the Term and (b) Cover AOP Background Know-How.
I.8AOP Competitor” means any Third Party competitor of AOP [***].
I.9AOP Indemnitees” has the meaning given to this term in Section 13.1.
I.10AOP Non-Product-Specific Collaboration Know-How” means any and all Non-Product-Specific Collaboration Know-How that is made or conceived by or on behalf of AOP or its Affiliates, solely, jointly with Eagle or its Affiliates, or jointly with a Third Party.
I.11AOP Non-Product-Specific Collaboration Patents” means any and all Collaboration Patents that cover AOP Non-Product-Specific Collaboration Know-How.
I.12AOP Territory” means all countries in the world other than the Eagle Territory.
I.13AOP Trademark” means each of the trademarks [***] owned by AOP and all registrations thereof [***], as well as future trademarks and trademark registrations owned by AOP [***] and intended to be used in connection with the Commercialization of the Licensed Product [***].
I.14API” has the meaning given to the term in the Supply Agreement.
I.15Applicable Laws” means the applicable provisions of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidances, ordinances, judgments, decrees, directives, injunctions, orders, permits of or from any court, arbitrator, Regulatory Authority, Governmental Authority or authority having jurisdiction over or related to the subject item, including the FD&C Act, GCP, GLP, GMP, and Anti-Corruption Laws, as well as all applicable data protection and privacy laws, rules and regulations, including the United States Department of Health and Human Services privacy rules under the Health Insurance Portability and Accountability Act, as amended, and the Health Information Technology for Economic and Clinical Health Act and the EU General Data Protection Regulation 2016/679 of the European Parliament and of the Counsel of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC, along with other country-level data protection laws, as may be applicable.
I.16Clinical Studies” means any human clinical study or clinical trial of a Licensed Product.
I.17CMC Data” means analytical and quality control data, stability data, batch records, and other data or information relating to chemistry, manufacturing and control of Licensed Products, including that which is filed or required to be filed to obtain authorization to conduct Clinical Studies or to obtain or maintain Regulatory Approval for a Licensed Product.
Page 2
259471241 v2



I.18Collaboration Know-How” means any and all Know-How that is made or conceived by or on behalf of either Party, solely, jointly with the other Party or its Affiliates, or jointly with a Third Party, in performing activities under this Agreement.
I.19Collaboration Patents” means any and all patents that cover Collaboration Know-How.
I.20Commercialization” means any and all activities related to pre-marketing, launching, marketing, promotion (including advertising and detailing), labeling, bidding and listing, pricing and reimbursement, distribution, storage, handling, offering for sale, selling, having sold, distributing, having distributed, providing customer service and support, conducting medical affairs, conducting post-marketing safety surveillance and reporting of or otherwise commercializing or exploiting Licensed Products. “Commercialize” and “Commercializing” have the correlative meanings.
I.21Commercially Reasonable Efforts” means, with respect to the efforts to be expended by Eagle in connection with a particular activity or objective to be conducted under this Agreement, that level of efforts that [***], taking into account all relevant scientific, commercial, business and other factors, including issues of safety and efficacy, expected and approved product labeling, expected and actual cost and time to develop, expected and actual profitability, expected and actual return on investment, expected and actual competitiveness of Third Party alternative products (including generic products) in the marketplace, the nature and extent of expected and actual market exclusivity (including Patent coverage and regulatory exclusivity), the expected likelihood of marketing approval, the expected and actual pricing and level of reimbursement, and the expected and actual amounts of marketing and promotional expenditures required. [***]
I.22Competitive Change of Control Over Eagle” shall mean, with respect to Eagle, any of the following events: [***].
I.23Competing Product” means a pharmaceutical product that is (i) [***] and (ii) [***].
I.24Control” (including any variations such as “Controlled” and “Controlling”) of intellectual property rights, intangible material, Data and/or other information or subject matter, means the possession by a Person or its Affiliate of the ability (whether by ownership or license, other than pursuant to this Agreement) to grant the applicable access to, or a license or sublicense under this Agreement on, said intellectual property rights, intangible material, Data and/or other information or subject matter, without violating (i) Applicable Law or (ii) the terms of any agreement or other arrangement with any Third Party existing as of the Effective Date or at such later time as such Party or its Affiliate first acquired rights to such subject matter.
I.25[***]:
(a)[***];
(b)[***], or
(c)[***].
I.26Cover” means, with respect to a claim of a Patent and a Licensed Product, that such claim would be infringed, absent a license, by the Manufacture, use, Development, or Commercialization of such Licensed Product (considering claims of patent applications to be issued as then pending).
I.27Data” means any and all data, information and materials relating to a Licensed Product, including manufacturing data (including without limitation, CMC Data), research data, pharmacology
Page 3
259471241 v2



data, preclinical data, clinical data (including patient samples and associated annotations), master clinical trial records and databases, safety databases, and all Regulatory Filings or other regulatory documentation, information and submissions pertaining to, or made in association with an IND, Marketing Approval Application, or Regulatory Approval, for a Licensed Product, in each case to the extent Controlled by AOP or Eagle as of the Effective Date or during the Term.
I.28Development” or “Develop” means all activities that relate to (a) the development of Licensed Products, or (b) obtaining, maintaining or expanding Regulatory Approval of a Licensed Product, including [***]. “Develop” has a correlative meaning.
I.29Development Milestone Event” has the meaning set forth in Section 6.2.
I.30Development Milestone Payment” has the meaning set forth in Section 6.2.
I.31Dispute” has the meaning given to this term in Section 14.1.
I.32[***].
I.33Eagle Background Know-How” means any and all Know-How that (a) is Controlled by Eagle or any of its Affiliates (i) as of the Effective Date, or (ii) during the Term as a result of performing activities outside the scope of this Agreement and (b) is necessary for AOP’s performance under this Agreement.
I.34Eagle Background Patents” means any and all Patents that (a) are Controlled by Eagle or any of its Affiliates as of the Execution Date or during the Term and (b) Cover Eagle Background Know-How.
I.35Eagle Indemnitees” has the meaning given to this term in Section 13.2.
I.36Eagle Non-Product-Specific Collaboration Know-How” means any and all Non-Product-Specific Collaboration Know-How that is made or conceived solely by Eagle or its Affiliates, or jointly by Eagle or its Affiliates with a Third Party.
I.37Eagle Non-Product-Specific Collaboration Patents” means any and all Collaboration Patents that cover Eagle Non-Product-Specific Collaboration Know-How.
I.38Eagle Territory” means the United States of America, including all possessions and territories thereof.
I.39Effective Date” has the meaning set forth in Section 10.2.
I.40EMA” means the European Medicines Agency or any successor entity.
I.41Enforcement Action” has the meaning set forth in Section 9.8.
I.42EU” means the European Economic Area, Switzerland and the United Kingdom.
I.43Existing Licensed Product” means the pharmaceutical product containing landiolol in a [***], as further described in Exhibit 1.43.
I.44FD&C Act” means the U.S. Federal Food, Drug and Cosmetic Act, as amended.
Page 4
259471241 v2



I.45FDA” means the U.S. Food and Drug Administration, or any successor entity thereto performing similar functions.
I.46Field” means any and all indications and uses of the Licensed Product.
I.47Finance Liaison” means a Party’s appointed representative who shall act as such Party’s point of contact in order to coordinate and manage the reporting of Net Sales, Net Profit, Net Loss and Allowable Expenses. Each Party can change its Finance Liaison at any time during the Term, and shall notify the other Party of its new Finance Liaison as soon as reasonably practicable.
I.48First Commercial Sale” means the first [***], in each case, after all Regulatory Approvals necessary for the lawful exercise of said transfer or disposition have been obtained in the Eagle Territory and [***].
I.49Good Clinical Practice” or “GCP” means the then-current standards, practices and procedures promulgated or endorsed by the FDA as set forth in the guidelines entitled “Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,” including related regulatory requirements imposed by the FDA and comparable regulatory standards, practices and procedures promulgated by the EMA or other Regulatory Authority, as they may be updated from time to time, including applicable quality guidelines promulgated under the ICH.
I.50Good Laboratory Practice” or “GLP” means the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, and comparable regulatory standards promulgated by the EMA or other Regulatory Authority, as they may be updated from time to time, including applicable quality guidelines promulgated under the ICH.
I.51Good Manufacturing Practices” or “GMP” means the then-current Good Manufacturing Practices required by the FDA, as set forth in the FD&C Act and the regulations promulgated thereunder, for the manufacture and testing of pharmaceutical materials, and comparable laws and regulations applicable to the manufacture and testing of pharmaceutical materials promulgated by other Regulatory Authorities, as they may be updated from time to time.
I.52Governmental Authority” means any multi-national, federal, state, local, municipal, provincial or other governmental authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, counsel, court or other tribunal).
I.53Guaranteed Minimum Profit Share Payments” has the meaning set forth in Section 6.4.
I.54HSR Act” means Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended from time to time, and the rules and regulations promulgated thereunder, or any successor statute, rules and regulations promulgated thereunder.
I.55HSR Filing” has the meaning set forth in Section 10.1.
I.56ICH” means International Conference on Harmonisation.
I.57IND” means an Investigational New Drug application, as defined in the U.S. Federal Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or the equivalent application to the equivalent agency in any other regulatory jurisdiction, the filing of which is necessary to Initiate or
Page 5
259471241 v2



conduct clinical testing of a pharmaceutical product in humans in such jurisdiction, in each case with respect to a Licensed Product for use within the Field.
I.58Indemnitee” has the meaning given to this term in Section 13.3.
I.59Indemnitor” has the meaning given to this term in Section 13.3.
I.60Infringement Actions” has the meaning set forth in Section 9.9
I.61Know-How” means any and all commercial, technical, scientific, and other know-how and information, Data, results, inventions, methods, processes, trade secrets, techniques, technology, and other proprietary information, whether patentable or not, including discoveries, formulae, materials (including chemicals), biological materials, practices, test data (including pharmacological, toxicological, pre-clinical and clinical information and test data), analytical and quality control data (including drug stability data), manufacturing technology and data (including formulation data and CMC Data), and sales forecasts, data and descriptions; provided that Know-How does not include Patents.
I.62Joint Steering Committee” or “JSC” means the committee formed by the Parties as described in Section 3.1.
I.63Lead Indication” means the control of ventricular rate in patients with atrial fibrillation or atrial flutter (as such indication may be amended by the Parties following interactions with the FDA regarding such lead indication).
I.64Liabilities” has the meaning given to this term in Section 13.1.
I.65Licensed Intellectual Property” means Licensed Patent Rights and Licensed Know-How.
I.66Licensed Know-How” means all AOP Background Know-How, Product-Specific Collaboration Know-How, and AOP Non-Product-Specific Collaboration Know-How.
I.67Licensed Patent Right” means any and all Patents within the AOP Background Patents, the Product-Specific Collaboration Patents, or the AOP Non-Product-Specific Collaboration Patents. A list of AOP Background Patents as of the Effective Date is set forth on Exhibit 1.67.
I.68Licensed Product” means any pharmaceutical product containing landiolol [***]. “Licensed Products” shall have a correlative meaning.
I.69Manufacture” and “Manufacturing” means all activities related to (a) developing the ability to manufacture clinical and commercial quantities of a Licensed Product, and (b) the synthesis, making, production, processing, purifying, formulating, filling, finishing, packaging, labeling, shipping, importing, having imported, and holding of any Licensed Product or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial production and analytic development, product characterization, stability testing, quality assurance, and quality control.
I.70Market Exclusivity” means [***].
I.71Marketing Approval Application” (or “MAA”) means application to the appropriate Regulatory Authority for approval to market a Licensed Product in any particular jurisdiction, including an NDA in the U.S.
Page 6
259471241 v2



I.72NDA” means a New Drug Application, as defined in the FD&C Act, as amended, and applicable regulations promulgated thereunder by the FDA.
I.73Net Profit” and, with correlative meaning, “Net Losses”, means Net Sales less Allowable Expenses.
I.74Net Sales” means, with respect to any Licensed Product in a given period, the gross amounts invoiced by Eagle and its Affiliates and Sublicensees for sales of such Licensed Product in the Eagle Territory to Third Parties, less the following deductions as accrued in direct connection to the sale of a Licensed Product to a Third Party:
(a)[***];
(b)[***];
(c)[***];
(d)[***]; and
(e)[***].
Notwithstanding the foregoing, amounts [***] shall not be included in the computation of Net Sales hereunder.
I.75Non-Product-Specific Collaboration Know-How” means any and all Collaboration Know-How, except Product-Specific Collaboration Know-How, that is made or conceived by or on behalf of either Party, solely, jointly with the other Party or its Affiliates, or jointly with a Third Party, in performing activities under this Agreement.
I.76Non-Product-Specific Collaboration Patents” means any and all Collaboration Patents that cover Non-Product-Specific Collaboration Know-How.
I.77P&L Report” has the meaning given to this term by Section 6.3.
I.78Patent(s)” means all patents and patent applications (including provisional applications), including all divisionals, continuations, substitutions, continuations-in-part, re-examinations, re-issues, additions, renewals, extensions, confirmations, registrations, any other pre- or post-grant forms of any of the foregoing, any confirmation patent or registration patent or patent of addition, utility models, patent term extensions, and supplemental protection certificates or requests for continued examinations, foreign counterparts, and the like of any of the foregoing.
I.79Patent Challenge” means any direct or indirect dispute or challenge, or any assistance in the dispute or challenge, of the validity, patentability, scope, priority, construction, non-infringement, inventorship, ownership or enforceability of any Patent or any claim thereof, or opposition or assistance in the opposition of the grant of any Patents, in any legal or administrative proceedings, including in a court of law, before the United States Patent and Trademark Office or other agency or tribunal in any jurisdiction, or in arbitration including, without limitation, [***].
I.80Party” means AOP or Eagle, individually; and “Parties” means AOP and Eagle, collectively.
Page 7
259471241 v2



I.81Person” means any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, Governmental Authority or agency, or any other entity not specifically listed herein.
I.82Prior CDA” has the meaning given to this term by Section 8.8.
I.83Product-Specific Collaboration Know-How” means, with respect to a Licensed Product, (a) any Collaboration Know-How that describes or comprises solely the composition of matter, use, or method of Manufacture of such Licensed Product, but does not describe or comprise the composition of matter, use, or method of Manufacture of a different product, and (b) all clinical data generated in the Development of a Licensed Product in the Eagle Territory or in the AOP Territory.
I.84Product-Specific Collaboration Patent” means any Patent that Covers Product-Specific Collaboration Know-How.
I.85Regulatory Approval” means all approvals, licenses, registrations, designations, or authorizations of any governmental entity that are necessary for the manufacturing, use, storage, import, transport and sale of Licensed Products in a regulatory jurisdiction.
I.86Regulatory Authority” means any national (e.g., the FDA) or, supra-national (e.g., the EC or the EMA), or other governmental entity in any jurisdiction of the world involved in the granting of Regulatory Approval for pharmaceutical products.
I.87Regulatory Filing” means all approvals, licenses, registrations, submissions, designations, and authorizations made to or received from a Regulatory Authority in a jurisdiction necessary for or in connection with the development, manufacture and/or commercialization of a pharmaceutical product, including any INDs, Marketing Approval Applications and Regulatory Approvals. As used herein, “Regulatory Filing” also includes all correspondence with Regulatory Authorities (and their agents) regarding Licensed Products, including all submissions, meeting minutes, reports and other items exchanged between or under authority from AOP or its licensors with respect to a Licensed Product, or the Development, Manufacture, Commercialization or exploitation thereof.
I.88“[*** Licensed Product” means a Licensed Product in [***].
I.89Senior Executives” means the [***] of AOP and the [***] of Eagle.
I.90Sublicensee” means a Third Party that has been granted a right to Develop or Commercialize Licensed Products in the Eagle Territory pursuant to Section 2.3, provided that as used herein, “Sublicensee” shall not be deemed to include any distributor, wholesaler or reseller of a Licensed Product with regards to its distribution, wholesale or resale activity.
I.91Supply Agreement” means a separate agreement to be entered into between the Parties regarding the supply of Licensed Product from AOP or its Affiliates to Eagle or its Affiliates.
I.92Supply Failure” has the meaning given to the term in the Supply Agreement.
I.93Supply Price” has the meaning given to this term in Section 5.2.
I.94Supply Source Deficiency” has the meaning given to the term in the Supply Agreement.
I.95Term” has the meaning given to this term by Section 10.3.
Page 8
259471241 v2



I.96Third Party” means any Person other than a Party or an Affiliate of a Party.
I.97Third Party Claim” has the meaning given to this term in Section 13.1.
I.98Third Party Payments” has the meaning given to this term by Section 9.9.
I.99Valid Claim” means a claim of an issued, unexpired patent within the Licensed Patent Rights that has not been revoked, disclaimed, abandoned or held invalid or unenforceable by a court or other body of competent jurisdiction in an unappealed or unappealable decision.
Article II
GRANT OF LICENSE
II.1License to Eagle. Subject to the terms and conditions of this Agreement, AOP hereby grants to Eagle:
(a)an exclusive (even as to AOP) license under the Licensed Intellectual Property to Commercialize the Licensed Products in the Field in the Eagle Territory;
(b)an exclusive (except as to AOP and its Affiliates to the extent reasonably required or useful for AOP’s performance of its obligations and exercise of its rights pursuant to this Agreement) license under the Licensed Intellectual Property to Develop the Licensed Products in the Field in the Eagle Territory;
(c)only if and when a Supply Failure occurs, a non-exclusive, worldwide license under the Licensed Intellectual Property to Manufacture finished Licensed Products for use in the Field in the Eagle Territory; and
(d)a non-exclusive, perpetual, irrevocable, fully paid-up, royalty-free, sublicensable (through multiple tiers) worldwide license for any and all purposes under the AOP Non-Product-Specific Collaboration Know-How and the AOP Non-Product-Specific Collaboration Patents, to the extent that such AOP Non-Product-Specific Collaboration Know-How and AOP Non-Product-Specific Collaboration Patents were conceived, made or generated by Eagle or any of its Affiliates jointly with AOP or its Affiliates.
II.2AOP Trademark License to Eagle. Subject to the terms and conditions of this Agreement, AOP hereby grants to Eagle, an exclusive (even as to AOP) license to Commercialize the Licensed Products under an AOP Trademark in the Field in the Eagle Territory.
II.3Sublicensing. Eagle shall have the right to grant and authorize sublicenses (through multiple tiers) under the rights granted to Eagle under Sections 2.1 and 2.2 to one or more of its Affiliates and to Sublicensees. Such sublicenses may only be granted provided that: (1) each Sublicensee shall agree to be subject to the terms of this Agreement and the Supply Agreement, including [***], (2) no such sublicense shall prevent Eagle (directly or with and through its Sublicensees) to perform its obligations hereunder, (3) no such sublicense shall limit or impair AOP’s rights hereunder, and (4) Eagle shall remain responsible for its and its Affiliates and Sublicensees’ compliance with the terms and conditions set forth herein, including without limitation the obligation to make payments as and when due hereunder, and the obligation to keep records and make reports hereunder. Eagle shall provide AOP with a true, accurate and complete copy of each sublicense agreement with its Sublicensees [***], subject to Eagle’s right to redact any confidential or proprietary information of Eagle or the Sublicensee. Each sublicense granted to a Sublicensee by Eagle to any rights licensed to it hereunder shall terminate immediately upon the termination of the license from AOP to Eagle with respect to such rights as of the effective date of such
Page 9
259471241 v2



termination. Any Sublicensee engaging in Development is subject to AOP’s prior written approval, not to be unreasonably withheld, conditioned, or delayed.
II.4Transfer of Licensed Know-How
(a)Initial Transfer. [***] and in any event no later than [***] thereafter, AOP shall, and shall use diligent efforts to cause any Affiliates or Third Party contractors to, transfer to Eagle complete and accurate copies of all Licensed Know-How regarding the Licensed Product (other than Manufacturing Know-How) in existence as of the Effective Date; provided that if, despite exercising diligent efforts to do so, AOP is unable to transfer (or have transferred) all of the Licensed Know-How to Eagle within such [***] period, AOP shall [***].
(b)Ongoing Transfer and Access. Without limiting Section 2.4(a), if from time to time during the Term it becomes apparent that a particular item of Licensed Know-How should be provided to Eagle, then upon reasonable request by Eagle, AOP shall, [***].
(c)Cooperation. The Parties will cooperate in good faith and reasonably agree upon formats and procedures to facilitate the orderly and efficient exchange of the Licensed Know-How in accordance with this Section 2.4. Without limiting the foregoing, AOP shall provide all such items in electronic form to the extent the same exist in electronic form and shall provide copies and an opportunity to inspect (and copy) original versions for all other materials comprising such Licensed Know-How (including for example, original patient report forms). It is understood all Licensed Know-How shall be made available to Eagle [***]. Upon request by Eagle, AOP shall reasonably cooperate with and assist Eagle as may be necessary or desirable in order to allow Eagle to understand the Licensed Know-How and to utilize the Licensed Know-How for the purposes contemplated in this Agreement.
II.5No Other Rights. Except for the rights and licenses expressly granted in this Agreement, each Party retains all rights under its intellectual property, and neither Party shall be deemed by estoppel or implication to have granted the other Party any license or other right to any intellectual property of such Party.
Article III
GOVERNANCE
III.1Joint Steering Committee. [***] after the Effective Date, the Parties shall establish a joint steering committee (the “Joint Steering Committee” or the “JSC”) to oversee the Development activities [***] and serve as a forum for the coordination of the Development [***].
III.2JSC Members. Each Party shall initially appoint up to [***] to the JSC, each of whom [***]. The JSC may change its size from time to time by mutual consent of its members, and each Party may replace its representatives at any time upon written notice to the other Party. [***] not to be unreasonably withheld, conditioned or delayed.
III.3Meetings. For the first [***] following the Effective Date, the JSC shall meet [***]. Following the [***] of the Effective Date, the JSC shall meet [***] thereafter. Meetings of the JSC may be held in person, by audio or video teleconference, as determined by the Parties. Each Party shall be responsible for all of its own expenses of participating in the JSC.
III.4Specific Responsibilities of the JSC. The JSC shall oversee the performance of Development activities of the Licensed Product and shall, in particular:
(a)[***]; and
Page 10
259471241 v2



(b)[***]; and
(c)[***].
(d)[***].
III.5Decision-making. All JSC decisions shall be made [***]. If, after reasonable discussion and good faith consideration of each Party’s view, the JSC does not reach consensus on a matter within the responsibilities of the JSC, [***] provided that:
(a)[***];
(b)[***]; and
(c)[***].
III.6Limitation of JSC Authority. The JSC shall not have the authority to (a) modify or amend the terms and conditions of this Agreement, (b) waive or determine [***], or (c) decide [***]. For the sake of clarity, [***].
Article IV
DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES
IV.1Development Responsibility.
(a)From and after the Effective Date, and except as otherwise set forth in this Agreement, Eagle will have the exclusive (except as to AOP and its Affiliates to the extent required for AOP’s performance of its obligations and exercise of its rights pursuant to this Agreement) right to conduct the Development of Licensed Products in the Eagle Territory. From and after the Effective Date, and except as otherwise set forth in this Agreement, Eagle will have the right to set, in agreement with AOP, the regulatory strategy for Indications for the Licensed Products in the Eagle Territory and to seek and obtain Regulatory Approvals for Licensed Products in the Field in the Eagle Territory. Eagle shall, however, not initiate any Development activities in the Eagle Territory without AOP’s prior written consent, such consent not to be unreasonably withheld. Neither Eagle nor AOP shall conduct, or cause or support any of their respective Affiliates or sublicensees or any other Third Party to conduct, any [***] without notifying one another in writing about [***], provided, for clarity, that nothing in this Agreement shall [***]. Eagle shall not conduct, or cause or support any of its respective Affiliates or Sublicensees or any other Third Party to conduct, [***] in the AOP Territory.
(b)Neither Party anticipates that any Clinical Studies will be required to be conducted after the Effective Date in order to obtain Regulatory Approval of the Existing Licensed Product in the Lead Indication in the Eagle Territory, whereas the Parties acknowledge that the exact wording of the Regulatory Approval for the Licensed Product in the European Union may differ from the Regulatory Approval approved by the FDA in the Eagle Territory. However, [***]. AOP shall submit any such proposed Regulatory Filing and any proposed communication in relation to such Regulatory Filings and approvals to Eagle, and shall afford Eagle the opportunity to, at Eagle’s expense, participate in any meetings with Regulatory Authorities in the Eagle Territory relating to the Existing Licensed Product. For the avoidance of doubt, AOP shall be responsible for obtaining Regulatory Approval for the Existing Licensed Product in the Lead Indication.
(c)Except to the extent otherwise set forth in Section 4.1(b), Eagle shall prepare and own all Regulatory Filings (including all INDs, NDAs, and Regulatory Approvals) for each Licensed
Page 11
259471241 v2



Product in the Field in the Eagle Territory during the Term. For the avoidance of doubt, during the Term, Eagle shall be the holder of all Regulatory Approvals of the Licensed Products in the Territory.
(d)Except as set forth in Section 4.1(b), AOP shall not, without the prior written consent of Eagle, submit any Regulatory Filings for Licensed Products in the Eagle Territory or communicate with respect to the Licensed Products with any Regulatory Authority in the Eagle Territory, unless (i) so required to comply with Applicable Laws upon written advice of AOP counsel, in which case AOP shall promptly notify Eagle of such requirement under Applicable Laws, shall submit any proposed communication to Eagle for Eagle’s review and comment and discussion between the Parties or, if not practicable or legally permitted, shall provide Eagle with a copy or summary thereof as soon as reasonably practicable thereafter, or (ii) the Regulatory Filings or communication relate to AOP’s activities in the Eagle Territory, but such activities are exclusively aimed at obtaining Regulatory Approval or at Commercialization outside of the Eagle Territory.
(e)AOP shall be free to perform Development activities in the AOP Territory if [***]. For the sake of clarity, [***]. AOP shall be free to perform Development activities in the Eagle Territory if [***].
(f)Any benefits or proceeds gained [***].
IV.2Development Diligence. Following assignment to Eagle of the Regulatory Approval for the Existing Licensed Product in the Lead Indication in the Eagle Territory, Eagle shall use, and shall require its Affiliates or Sublicensees to use, Commercially Reasonable Efforts to Develop Licensed Products (including the Existing Licensed Product) in the Field in the Eagle Territory.
IV.3Development Reports. At the regularly scheduled JSC meetings, [***].
IV.4Transition of Development and Regulatory Activities. AOP shall reasonably cooperate with Eagle and use diligent efforts to effect a prompt, smooth and orderly transition to Eagle of Development and regulatory activities with respect to the Licensed Products that are, according to this Agreement, to be carried out by Eagle, as reasonably requested by Eagle. Upon receipt of the Regulatory Approval for the Existing Licensed Product in the Lead Indication in the Eagle Territory by the FDA, AOP shall assign said Regulatory Approval to Eagle together with all Regulatory Filings associated therewith. To the extent reasonably requested by Eagle, AOP shall [***].
IV.5Access to Data.
(a)As permitted by and in compliance with Applicable Laws (including applicable privacy laws) and other applicable contractual obligations, and solely to the extent such Data is reasonably necessary or useful for purposes of the Development and Commercialization of the Licensed Products in the Eagle Territory, Eagle will have access to, and the right to use, and AOP will provide to Eagle upon request, Data Controlled by AOP or its Affiliates and generated in connection with the Development of the Licensed Products outside the Eagle Territory and will have access to, and right to reference, all EU Regulatory Filings Controlled by AOP or its Affiliates and all relevant safety information for the Licensed Products. Following the Effective Date, AOP shall supply such Data that exists as of the Effective Date in a specific data-room for a period of [***] but shall not be obligated to maintain or regularly update the Data in the data-room.
(b)As permitted by and in compliance with Applicable Laws (including applicable privacy laws) and other applicable contractual obligations, AOP will have access to, and the right to use, Data Controlled by Eagle, its Affiliates, Sublicensees or Third Parties cooperating with Eagle, and
Page 12
259471241 v2



generated in connection with the Development of the Licensed Products in the Eagle Territory. Furthermore, AOP will have access to, and the right to reference, all Regulatory Filings Controlled by Eagle or its Affiliates in the Eagle Territory for the Licensed Products.
IV.6Commercialization. As between the Parties, Eagle shall have the exclusive right to conduct, and be solely responsible for all aspects of, the Commercialization of Licensed Products in the Field in the Eagle Territory, including (a) [***]. Eagle shall bear all costs and expenses incurred in connection with such Commercialization activities. Subject to Applicable Laws, [***] shall conduct and will require that its respective Affiliates or Sublicensees will not conduct and will not cause or support any other Third Party to conduct, [***].
IV.7Commercialization Diligence. Following assignment to Eagle of the Regulatory Approval for the Existing Licensed Product in the Lead Indication in the Eagle Territory, Eagle shall use Commercially Reasonable Efforts to Commercialize each Licensed Product for which Regulatory Approval has been obtained in the Eagle Territory. For each Licensed Product, Eagle shall provide to AOP [***], starting from [***], a report specifying Eagle’s Commercialization efforts for such Licensed Product in the [***]. If Eagle were to fail for [***] to perform reasonable Commercialization efforts (including but not limited to promoting and marketing the Licensed Product) in the Eagle Territory, other than for reasons outside of Eagle’s control, including any Force Majeure, [***], AOP shall have the right to terminate this Agreement pursuant to Section 10.4, after a discussion between the Parties on a remediation plan, such discussion not to exceed [***], if, Eagle failed to resume the applicable Commercialization efforts within [***].
IV.8Pharmacovigilance. Following the Effective Date, the Parties shall negotiate and agree in good faith on a pharmacovigilance agreement that sets forth mutually agreed terms and conditions for the receipt, investigation, recordation, communication, and exchange (as between the Parties) of adverse event reports, pregnancy reports, medical inquiries, and any other information concerning the safety of Licensed Products. The Parties shall use reasonable and good faith efforts to execute a definitive pharmacovigilance agreement not later than [***] after the Effective Date.
IV.9Restrictions. Each Party agrees that it will not, and will require that its Affiliates and (sub)licensees (including Sublicensees) will not, to the extent admissible under Applicable Laws, [***].
Article V
MANUFACTURING
V.1Manufacturing Responsibility. Except in case of a Supply Failure, AOP, directly or through its Affiliates or one or more Third Parties, including a designated contract manufacturer, shall have the sole and exclusive right and responsibility for having Licensed Products Manufactured for Development and Commercialization use in the Eagle Territory.
V.2Supply of Licensed Product
(a)During the Term, Eagle shall purchase from AOP, and AOP shall Manufacture and supply to Eagle, all of Eagle’s and its Affiliates’ and Sublicensees’ (and any of their successor entities’) requirements of Licensed Product for Development and Commercialization use in the Field in the Eagle Territory, subject to and in accordance with the terms and conditions of a Supply Agreement that will set forth the specific terms and conditions of the supply of Licensed Products for Development and Commercialization in the Eagle Territory and such other quality agreements as required to comply with Applicable Laws.
Page 13
259471241 v2



(b)The supply price for each unit of Licensed Product supplied by AOP to Eagle pursuant to the Supply Agreement for Development and Commercialization use in the Field in the Eagle Territory shall be [***] (“Supply Price”).
(c)For the sake of clarity, [***].
(d)The term of the Supply Agreement shall be the same as the Term and termination of this Agreement shall cause the termination of the Supply Agreement.
V.3Supply Source Deficiency. In the event of a Supply Source Deficiency, AOP shall use Commercially reasonable efforts to transfer the Licensed Know-How necessary or useful for the Manufacture of finished Products to the relevant Third Party contract manufacturers and provide to Eagle:
(a)[***], and
(b)[***];
(c)[***]; and
(d)[***].
V.4Supply Failure. In the event that a Supply Failure occurs regarding a Licensed Product, and for the duration of such Supply Failure, Eagle shall, at Eagle’s expense, have the right to enter into a direct supply agreement and quality agreement to have, under the supervision of the JSC, Manufactured the affected Licensed Product in finished form for use in the Eagle Territory through one or more Third Party contract manufacturers acceptable to both Parties (such acceptance not to be unreasonably withheld, conditioned or delayed), provided that AOP will supply API to Eagle or the relevant Third Party contract manufacturer for use in such manufacturing (mutatis mutandis according to Section 5.2) for as long as AOP is able to supply API to Eagle or to Eagle’s Third Party contract manufacturers. The Parties will cooperate in a transition of the Manufacturing sufficient to enable Eagle or another supplier to manufacture the Licensed Products for Development and Commercialization purposes in the Eagle Territory.
Article VI
PAYMENTS
VI.1Upfront Payment. Eagle shall pay to AOP an [***] upfront payment of five million U.S. Dollars ($5,000,000) within [***] following the Effective Date in accordance with the payment provisions of ARTICLE VII.
VI.2Development Milestone Payments
(a)Development Milestone Payments. Eagle shall pay to AOP the [***] milestone payments set forth below following the achievement by Eagle or any of its Affiliates or Sublicensees, of the corresponding milestone events defined below (each, a “Development Milestone Payment” and “Development Milestone Event,” respectively). The Development Milestone Payments shall be payable in accordance with the payment provisions in ARTICLE VII and following receipt of the relevant invoice from AOP as further described in Section 6.2(b).
Page 14
259471241 v2



No.Development Milestone EventPayment
1[***][***]
2[***][***]
3[***][***]

(b)Reports and Payments. Eagle shall notify AOP in writing within [***] after the achievement of each Development Milestone Event set out in Section 6.2(a) by Eagle, or any of its Affiliates, and in the case of Sublicensees, within [***] after such Development Milestone Event is achieved by such Sublicensee. Based on this notice, AOP shall then issue and send to Eagle the invoice for the appropriate Development Milestone Payment, which shall be paid by Eagle within [***] of receipt of such invoice.
VI.3Profit Share Payments
(a)Profit Share Percentage. During the Term of this Agreement, AOP will receive [***] of Net Profits from each calendar quarter resulting from the Commercialization of the Licensed Product in the Eagle Territory and Eagle will receive [***] of Net Profits from each calendar quarter resulting from the Commercialization of the Licensed Product in the Eagle Territory. [***].
(b)Calculation and Payment of Net Profit Share
(i)[***].
(ii)[***].
(iii)[***].
(iv)Reports and Payments. Starting from the First Commercial Sale of a Licensed Product in the Eagle Territory, within [***], Eagle will report to AOP in a written report in the form agreed by the Parties ([***]), in relation to the Commercialization of Licensed Product in the Eagle Territory in such calendar quarter, the Net Sales, Free Goods, the Allowable Expenses ([***]), as well as [***] (such report, the “P&L Report”). Without limiting the generality of the foregoing, Eagle shall require its Affiliates and Sublicensees to report their Net Sales and to provide such reports with respect thereto to Eagle. [***] in accordance with Section 6.3(a).
(v)Invoices will be issued and paid as follows: [***].
VI.4Guaranteed Minimum Profit Share Payments. From the [***] date of the First Commercial Sale of the Licensed Product, Eagle shall be required to make the annual Minimum Profit Share Payments for the Licensed Product as set forth in Exhibit 6.4 (the “Guaranteed Minimum Profit Share Payments”). Should Eagle fail to make the Minimum Profit Share Payments for [***], AOP shall have the right to convert the licenses granted to Eagle hereunder into non-exclusive licenses. Notwithstanding the foregoing, [***] AOP shall not be entitled to convert the exclusive licenses granted to Eagle into non-exclusive licenses.
VI.5Sample Calculation. A sample calculation for Net Sales, Net Profit and profit share payments (cf. Section 6.3) is attached hereto as Exhibit 6.5, provided, however, that such sample
Page 15
259471241 v2



calculation is for illustration purposes only and shall not be admissible in any dispute or otherwise influence the interpretation of this Agreement.
VI.6Royalties to Eagle
(a)With respect to Licensed Product that AOP, its Affiliates or (sub)licensees Commercialize in the AOP Territory, AOP shall pay [***], if and for as long as the following cumulative conditions are met: (i) [***] Valid Claim of a [***] covers such [***], (ii) the [***] was made or conceived [***], and (iii) such [***] provides [***].
(b)Royalties, if any, according to this Section 6.4 shall be payable on a calendar quarter basis and [***] in the appropriate form.
Article VII
PAYMENTS; BOOKS AND RECORDS
VII.1Payment Method; Currency Conversion. All amounts specified in this Agreement are in U.S. Dollars, and all cash payments under this Agreement shall be paid in U.S. Dollars. All payments under this Agreement will be paid in U.S. Dollars by wire transfer to an account designated, as applicable, by AOP (which account AOP may update from time to time in writing, subject to Eagle’s confirmation, such confirmation not be unreasonably withheld) or by Eagle (which account Eagle may update from time to time in writing, subject to AOP’s reasonable confirmation).
VII.2Withholding Taxes. The upfront, milestone, profit sharing, and royalty payments to be made under this Agreement shall be paid free and clear of any taxes, except for any withholding taxes required by Applicable Law. To the extent any withholding taxes are deducted, withheld and paid by or on behalf of a Party to the appropriate taxing authority, such amounts shall be treated for all purposes of this Agreement as having been paid to the other Party. The Parties shall provide each other with official receipts issued by the appropriate governmental agency to them. Each Party shall provide to the other Party such assistance as may be reasonably requested in connection with any application to qualify for the benefit of a reduced rate of withholding taxation, under the terms of any income tax treaty between the United States and other jurisdictions.
VII.3Late Payments. In the event that any amount payable by Eagle to AOP or by AOP to Eagle hereunder is not made when due, such outstanding payment shall accrue interest, to the extent permitted by Applicable Laws, at the [***], computed from the date such payment was due until the date the payment is made.
VII.4Records. Eagle and its Affiliates shall keep complete and accurate books of account and records in reasonably sufficient detail to enable the amounts payable under this Agreement to be determined. Such books and records shall be kept at the principal place of business of Eagle, its Affiliates or Sublicensees, as the case may be, for at least [***].
VII.5Audits
(a)Audit Rights
(i)Upon at least [***] prior written notice from AOP, Eagle shall permit, and shall require its Affiliates and, under the applicable sublicense agreement, its Sublicensees, to permit, an independent certified public accounting firm of nationally recognized standing, selected by AOP and reasonably acceptable to Eagle, to have access during normal business hours to such books of account and records of Eagle, and its Affiliates and Sublicensees, at their principal place of business, as may be
Page 16
259471241 v2



reasonably necessary to verify the accuracy of the reports to be provided by Eagle pursuant to this Agreement and the Supply Agreement. Such audits may not [***].
(ii)Upon at least [***] prior written notice from Eagle, AOP shall permit, and shall require its Affiliates, to permit, an independent certified public accounting firm of nationally recognized standing, selected by Eagle and reasonably acceptable to AOP, to have access during normal business hours to such books of account and records of AOP and its Affiliates, at their principal place of business, as may be reasonably necessary to verify the accuracy of the Supply Price’s calculation and reports to be provided to Eagle pursuant to Section 6.3. Such audits may not [***].
(b)Audit Results. The Parties shall require the independent accountant to provide to the auditing Party an audit report containing its conclusions regarding any audit, and specifying whether the amounts paid were correct or, if incorrect, the amount of any underpayment or overpayment. [***] If such audit establishes any underpayment, the applicable Party shall remit or reimburse to the other Party, within [***] of the date on which the applicable party delivers to the other Party an invoice for the amount of the applicable underpayment, (i) the amount of such underpayment and (ii) interest on the amount of such underpayment, with such interest being calculated pursuant to Section 7.3. In the event such audit establishes that amounts were overpaid, the amount of such overpayment shall be refunded to the applicable Party within [***] of the date on which the applicable party delivers to the other Party an invoice for the amount of the applicable overpayment. The fees charged by the independent accountant in connection with any audit pursuant to this Section 7.5 shall be paid by the auditing Party; provided, however, that if a discrepancy in favor of the auditing Party of more than [***] of the payments due under this Agreement for the period being audited is established, then the audited Party shall pay [***].
(c)Confidential Financial Information; Other Matters. Each Party shall treat all financial information subject to review under this ARTICLE VII as the Confidential Information of the other Party in accordance with Section 8.1. Any auditor shall enter into a confidentiality agreement with the audited Party and shall not disclose or use the audited Party’s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by Eagle or the amount of payments due by a Party to the other Party under this Agreement. If Eagle – in breach of its obligation pursuant to Section 7.5(a)(i) – is unable to obtain from any Sublicensee a right for AOP to audit the books of account and records of such Sublicensee, Eagle shall obtain the right to inspect and audit such Sublicensee’s books and records for itself and shall exercise such audit rights on behalf of AOP – with the fees and expenses associated with such audit to be borne by the applicable Party according to Section 7.5(b), with AOP being considered the auditing Party – upon AOP’s written request and disclose the results of any such audit to AOP in accordance with Section 7.5(b).
Article VIII
CONFIDENTIALITY
VIII.1Confidential Information. Except to the extent expressly authorized by this Agreement, each Party agrees that, during the term of this Agreement[***] such Party (the “Receiving Party”) shall keep confidential, and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement, or the Supply Agreement or further agreements accompanying this Agreement, or in the exercise of rights granted to it thereunder, any information furnished to it by or on behalf of the other Party (the “Disclosing Party”) pursuant to this Agreement that [***] (collectively, “Confidential Information”). The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to prevent unauthorized access, use and disclosure of the Disclosing Party’s Confidential Information and to ensure that its, and its Affiliates’, employees, agents, consultants, other representatives (“Representatives”) do not disclose, except as otherwise expressly permitted under this
Page 17
259471241 v2



Agreement, or make any unauthorized use of, the Disclosing Party’s Confidential Information. The Receiving Party shall promptly notify the Disclosing Party upon discovery of any unauthorized use or unauthorized disclosure of the Disclosing Party’s Confidential Information. For purposes of this Agreement, the terms of this Agreement shall be deemed the Confidential Information of both Eagle and AOP. [***].
VIII.2Exceptions. Confidential Information of a Disclosing Party shall not include any information to the extent that such information (which the Receiving Party can prove by competent written evidence): (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement, generally known or available to the public; (b) is lawfully known by the Receiving Party or any of its Affiliates (to the extent such Receiving Party or Affiliate has the right to use and disclose such information) at the time of receiving such information from the Disclosing Party; (c) is hereafter furnished to the Receiving Party or any of its Affiliates by a Third Party who has a legal right to make such disclosure and who did not obtain such information directly or indirectly from the Receiving Party (to the extent such Receiving Party or Affiliate has the right to use and disclose such information); or (d) is independently discovered or developed by the Receiving Party or any of its Affiliates, without the use of or reference to Confidential Information of the Disclosing Party.
VIII.3Trade Secrets. Notwithstanding the above, any trade secrets according to Directive (EU) 2016/943 disclosed under this Agreement shall be treated confidential [***].
VIII.4Authorized Disclosure. Notwithstanding the provisions of Section 8.1, the Receiving Party may disclose Confidential Information of the Disclosing Party as expressly permitted by this Agreement, or if and to the extent such disclosure is reasonably necessary in the following instances:
(a)In the case of either Party as the Receiving Party:
(i)enforcing such Party’s rights or performing its obligations under this Agreement;
(ii)prosecuting or defending litigation as permitted by this Agreement;
(iii)such disclosure is reasonably necessary to its employees, agents, consultants, advisors (including financial advisors, attorneys and accountants), contractors, licensees or Sublicensees on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement; provided that in each case, the disclosees are bound by obligations of confidentiality and non-use consistent with those contained in this Agreement;
(iv)such disclosure is necessary to comply with Applicable Laws, including regulations promulgated by applicable security exchanges, court order, administrative subpoena or order; provided in the event the Receiving Party is required to make a disclosure of the Disclosing Party’s Confidential Information pursuant to this subparagraph 8.4(a)(iv), it will, except where legally prohibited, (i) give reasonable advance notice to the Disclosing Party of such disclosure, (ii) use efforts to secure confidential treatment of such information at least as diligent as the Receiving Party would use to protect its own confidential information, and (iii) cooperate with any efforts by the Disclosing Party, at the Disclosing Party’s request and expense, to prevent or limit disclosure of such Confidential Information; or
(v)disclosure to Third Parties in connection with due diligence or similar investigations, and disclosure to any bona fide potential or actual investor, acquiror or merger partner for the sole purpose of evaluating an actual or potential investment, acquisition or merger; provided that in connection with such disclosure, such Party shall inform each disclosee of the confidential nature of such
Page 18
259471241 v2



Confidential Information and ensure that any such Third Party agrees to be bound by obligations of confidentiality and non-use similar to those contained in this Agreement.
(b)In the case of either Party as the Receiving Party:
(i)filing for, prosecuting or enforcing Licensed Patent Rights in accordance with this Agreement;
(ii)in Regulatory Filings or otherwise in seeking, obtaining and maintaining Regulatory Approvals (including complying with the requirements of Regulatory Authorities with respect to filing for, obtaining and maintaining such Regulatory Approvals); and
(iii)disclosure to actual or potential Sublicensees or subcontractors, or other Third Parties in connection with the exercise of its rights under this Agreement, provided that Eagle uses Commercially Reasonable Efforts to secure confidential treatment of such information at least as diligent as it would use to protect its own confidential information of a similar nature.
(c)Each Party shall be responsible for any breaches of confidentiality by any of its Affiliates, Sublicensees, subcontractors, Representatives, advisors and Third Parties to whom it discloses Confidential Information.
VIII.5Confidential Disclosure of Terms. The Parties agree that the terms of this Agreement are the Confidential Information of both Parties that a Party may not disclose to any Third Party without the prior written consent of the other Party hereto, except as permitted under Section 8.2 or 8.4.
VIII.6Publications. Except for the joint press release pursuant to Section 8.7, either Party, its Affiliates, its or their Sublicensees, or its or their respective employees or consultants, wishing to make a publication or presentation relating to the terms hereof or activities hereunder, shall deliver to the other Party a (i) copy of any proposed written publication at least [***] prior to submission of such publication or, as the case may be, (ii) an outline or copy of a proposed oral disclosure or presentation at least [***] prior to such oral disclosure or presentation. The reviewing Party shall have the right (a) to propose reasonable modifications to the publication or presentation, or (b) to request a reasonable delay in publication or presentation. If the reviewing Party requests a delay, the publishing Party shall delay submission or presentation for a period of at least [***] or such period of time as agreed upon between the Parties. Upon expiration of such [***] period or such longer period as agreed upon between the Parties, the publishing Party shall be free to proceed with the publication or presentation. If the reviewing Party requests reasonable modifications to the publication or presentation, the publishing Party shall edit such publication prior to submission of the publication or presentation. Notwithstanding the foregoing, [***].
VIII.7Joint Press Release. The Parties have mutually approved a joint press release attached hereto as Exhibit 8.7 with respect to this Agreement to be published on the Execution Date or immediately thereafter. After release of this press release in accordance with this Section 8.7, AOP may disclose to Third Parties the information contained in such press release without further consent.
For clarity, subject to AOP’s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed, Eagle shall have the right to issue subsequent press releases or other written public statements pertaining to the activities conducted hereunder. For avoidance of doubt, Eagle shall have the right to disclose to its investment community without AOP’s prior written consent: [***].
VIII.8Prior Non-Disclosure Agreements. This Agreement supersedes [***].
Page 19
259471241 v2



Article IX
PATENT PROSECUTION AND ENFORCEMENT
IX.1United States Law. For the Eagle Territory, Collaboration Know-How, inventorship of Know-How, including inventions, conceived, discovered, developed, or otherwise made under this Agreement shall be determined in accordance with Applicable Laws of the United States as such law exists as of the Execution Date irrespective of where such conception, discovery, development, or making occurs.
IX.2AOP Ownership. AOP or an Affiliate of AOP shall own and retain all right, title, and interest in and to all Licensed Intellectual Property, including all Data, AOP Trademarks, and any other trademark (except Eagle trademarks) used exclusively for the Commercialization of the Licensed Product in the Eagle Territory.
IX.3Eagle Ownership and License to AOP. Eagle or an Affiliate of Eagle shall own and retain all right, title and interest in and to Eagle Background Know-How, Eagle Background Patents, Eagle Non-Product-Specific Collaboration Know-How, and Eagle Non-Product-Specific Collaboration Patents. Eagle hereby grants to AOP a non-exclusive, fully paid-up, royalty-free, sublicensable (through multiple tiers) worldwide license under the Know-How and Patents referred to in this Section 9.3 for all acts necessary or useful to perform the rights or fulfill the obligations under this Agreement or the Supply Agreement, as well as a related quality agreement or pharmacovigilance agreement between the Parties.
IX.4Disclosure. During the Term, each Party will disclose to the other Party all Collaboration Know-How that is invented, discovered, developed, or otherwise generated by or on behalf of such Party or any of its Affiliates, whether solely or jointly with the other Party or any of the other Party’s Affiliates or with any Third Party, in the conduct of activities under this Agreement and of which such Party becomes aware. Such disclosure shall (a) be made [***] prior to the filing of any patent application with respect to such Collaboration Know-How, but in the case of AOP in no event more than [***] thereafter, and (b) shall include all invention disclosures or other similar documents submitted to such Party by its or its Affiliates’ employees, agents, or independent contractors relating thereto.
IX.5Cooperation. Each Party agrees and shall cause its Affiliates and Sublicensees to execute all papers and otherwise agrees to assist the other Party as reasonably required, to perfect in the other Party the rights, title and other interests owned by such Party under this ARTICLE IX. Each Party hereby assigns and automatically and in full transfers to the respective other Party all (ownership) rights, title and other interests it holds or acquires during the Term, and which the respective other Party is entitled to own under this ARTICLE IX, and the respective other Party herewith accepts such transfer of rights.
IX.6Patent Prosecution and Maintenance.
(a)Patent Prosecution and Maintenance. As between the Parties, AOP shall, at its expense, have the first right, but not the obligation, to file, maintain and prosecute the Licensed Patent Rights throughout the Eagle Territory, including conducting any interferences, inter parte reviews, reexaminations, reissues, opposition, and other similar proceedings relating thereto. AOP shall keep Eagle reasonably informed of progress with regard to the prosecution and maintenance of Licensed Patent Rights as set forth in this Section 9.6(a). Eagle shall have the right to review all material Patent filings in advance of any deadline, submission to or action with any patent office. AOP shall furnish to Eagle copies of all relevant drafts and documents of such Licensed Patent Rights reasonably in advance of such consultation for Eagle’s review. AOP shall provide to Eagle copies of all patent office submissions and correspondence relevant to such Licensed Patent Rights within a reasonable amount of time following submission or receipt thereof by AOP. AOP shall consider in good faith any reasonable and timely
Page 20
259471241 v2



comments provided by Eagle in connection with the prosecution and maintenance of such Licensed Patent Rights. At AOP’s request, Eagle shall reasonably cooperate with AOP in the prosecution and maintenance of such Licensed Patent Rights. If AOP desires to abandon or cease prosecution or maintenance of any such Licensed Patent Right in the Eagle Territory, AOP shall provide written notice to Eagle of such intention promptly after AOP makes such determination, but in no event later than [***] prior to any deadline that must be met in order to avoid such abandonment, and Eagle shall have the right, but not the obligation, to assume responsibility for prosecution and maintenance of such Licensed Patent Right at its sole cost and expense. AOP shall provide Eagle with an updated Exhibit 1.67 [***].
(b)Patent Term Extensions. AOP shall have the sole right to obtain patent term extensions, and supplementary protection certificates, with respect to any Licensed Product in the Field in the Eagle Territory, and Eagle shall reasonably cooperate with AOP in connection therewith, provided that Eagle shall have the right to request that AOP seek to obtain any such patent term extensions and AOP shall consider any such request by Eagle in good faith.
IX.7Trademark Prosecution and Maintenance. As between the Parties, AOP shall[***] have the first right, but not the obligation, to file, maintain and prosecute the AOP Trademarks throughout the Eagle Territory, including conducting any proceedings relating thereto. AOP shall keep Eagle reasonably informed of progress with regard to the prosecution and maintenance of AOP Trademarks. Eagle shall have the right to consult and review all material AOP Trademark filings in advance of any deadline, submission to or action with any trademark office. AOP shall consider in good faith any reasonable and timely comments provided by Eagle in connection with the prosecution and maintenance of such AOP Trademarks. At AOP’s request, Eagle shall reasonably cooperate with AOP in the prosecution and maintenance of such AOP Trademarks. If AOP desires to abandon or cease prosecution or maintenance of any such AOP Trademarks, AOP shall provide written notice to Eagle of such intention promptly after AOP makes such determination, but in no event later than [***] prior to any deadline that must be met in order to avoid such abandonment, and Eagle shall have the right, but not the obligation, to assume responsibility for prosecution and maintenance of such AOP Trademarks [***].
IX.8Enforcement
(a)Enforcement Actions
(i)In the event that either Party becomes aware of any patent or AOP Trademark nullity, invalidity or unenforceability actions, any declaratory judgment actions, or any actual or threatened infringement of any Licensed Patent Right or AOP Trademark in the Eagle Territory, including any claims arising under the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417), as amended, that Party shall promptly notify the other Party in writing. [***].
(ii)The Party conducting such Enforcement Action under this Section 9.8(a) shall have full control over its conduct, including settlement of an Enforcement Action; provided, however, that the Party conducting such Enforcement Action may not settle any such Enforcement Action, or make any admissions or assert any position in such Enforcement Action, in a manner that would materially adversely affect the validity of a Licensed Patent Right or AOP Trademark, without the prior written consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed. If one Party initiates any suit, action or proceeding under this Section 9.8(a), the other Party agrees to be joined as party plaintiff if reasonably necessary to prosecute the suit, action or proceeding, and to give the initiating Party authority to file, prosecute and control the suit, action or proceeding; provided, however, that such other Party shall in any case have the right to be represented by its own counsel at its cost and expense. In any event, the Parties shall assist and cooperate with one another in any Enforcement Action, including at their mutual reasonable requests.
Page 21
259471241 v2



(iii)Each Party shall assume and pay all costs and expenses incurred by it with respect to such Enforcement Action, including fees and expenses of counsel selected by it.
(b)Recovery. AOP and Eagle shall each recover their respective actual out-of-pocket expenses (including attorneys’ fees), or equitable proportions thereof in case they cannot fully be recovered, associated with any Enforcement Action against infringers undertaken pursuant to Section 9.8(a) from any resulting monetary amount received by award of a court of competent jurisdiction. Any excess amount of such a recovery shall (i) be [***]. If Eagle is the Party initiating the Enforcement Action under Section 9.8(a) and AOP does not join in such enforcement action, [***].
IX.9Third Party Infringement Claims. If the Development, Manufacture, Commercialization, or other acts of exploitation of any Licensed Product in the Eagle Territory pursuant to this Agreement results in a claim, suit or proceeding alleging patent or other intellectual property infringement against a Party (or its Affiliates, or in the case of Eagle, its Sublicensees) (collectively, “Infringement Actions”), such Party shall [***] notify the other Party hereto in writing. Eagle shall have the right to direct and control the defense thereof, at its own expense (subject to AOP’s indemnification obligations set forth in Section 13.2) with counsel of its choice. Eagle shall keep AOP informed of all material developments in connection with any such Infringement Action and take into good faith consideration AOP’s views on the conduct of Infringement Actions. Eagle shall not enter into any settlement or consent decree that (i) requires any payment by or admits or imparts any other liability to AOP; or (ii) admits the invalidity or unenforceability of any Licensed Patent; or (iii) settle any Infringement Action in a manner that has a material adverse effect on the rights or interests of AOP or in a manner that imposes any costs or liability on, or involves any admission by, AOP, [***]. Eagle may treat any reasonable out-of-pocket costs, including reasonable attorneys’ fees, damages and other liabilities, incurred in connection with such Infringement Action and which are (i) part of a final judgment or (ii) paid by Eagle in a settlement of the Infringement Action to which AOP has given its prior written consent and as entered into in compliance with this Section 9.9 as “Third Party Payments.
IX.10AOP Territory. AOP shall [***].
Article X
TERM AND TERMINATION
X.1HSR and Other Government Filings.
(a)The Parties shall each, as promptly as practicable after the Execution Date, file or cause to be filed with the U.S. Federal Trade Commission (“FTC”) and the U.S. Department of Justice (“DOJ”) and any relevant foreign Governmental Authority any notifications required to be filed under the HSR Act (the “HSR Filing”) or any similar Applicable (foreign) Laws with respect to the transactions contemplated hereby; provided that the Parties shall each make the HSR Filing within [***] after the Execution Date and shall each file any notifications or filings required to be filed under similar Applicable (foreign) Laws and regulations as promptly as reasonably practicable. The Parties shall use their reasonable best efforts to respond promptly to any requests for additional information made by such agencies, and to cause the waiting period (and any extension thereof) under the HSR Act to terminate or expire at the earliest possible date or obtain any required authorization or clearance under any similar Applicable (foreign) Laws after the date of filing. Eagle will be responsible for one hundred percent (100%) of the filing fees and each Party will be responsible for internal and out-of-pocket costs and expenses (including its own legal and other advice) in connection with the preparation and conduct of the HSR Filing and any filing under similar Applicable (foreign) Laws, including responding to the relevant Governmental Authorities.
Page 22
259471241 v2



(b)In connection with obtaining clearance under the HSR Act, each of AOP and Eagle shall (i) cooperate with each other in connection with any investigation or other inquiry relating to an HSR Filing and the transactions contemplated hereby, (ii) keep the other Party or its counsel informed of any communication received from or given to the FTC or DOJ relating to the HSR Filing and the transactions contemplated hereby (and provide a copy to the other Party if such communication is in writing), (iii) reasonably consult with each other in advance of any meeting or conference with the FTC or DOJ, and, to the extent permitted by the FTC or DOJ, give the other Party or its counsel the opportunity to attend and participate in such meetings and conferences, and (iv) permit the other Party or its counsel to review in advance, and in good faith consider the views of the other Party or its counsel and incorporating where appropriate, concerning, any submission, filing or communication (and documents submitted therewith) intended to be given to the FTC or DOJ. This Section 10.1(b) applies, mutatis mutandis, to filings under similar Applicable (foreign) Laws
X.2Effective Date. Notwithstanding anything in this Agreement to the contrary, this Agreement (other than this ARTICLE X, which is binding and effective as of the Execution Date) shall not become effective until (i) the Parties’ execution of the Supply Agreement, and (ii) the expiration or earlier termination of the waiting period (or any extension thereof) under the HSR Act in the United States, provided that neither the FTC nor the DOJ have commenced or threatened litigation to enjoin the transactions contemplated by this Agreement nor have the parties agreed with the FTC or DOJ to postpone closing (the date on which (i) and (ii) are fulfilled, the “Effective Date”). If, on the [***] after the date of filing under the HSR Act, the waiting period required thereunder has not expired, either Party shall have the right, on written notice to the other Party, to terminate this Agreement, and upon receipt of such notice by the terminating Party, this Agreement shall be null and void and have no further force and effect; provided, however, that [***] shall survive, in particular with respect to any rights that accrued to the benefit of a Party prior to such termination.
X.3Term. On the Effective Date, the full Agreement and all its terms and provisions shall be automatically effective and binding on both Parties for [***] terminated in accordance with the termination provisions under this Agreement (“Term”).
X.4Termination for Material Breach. If either Party materially breaches this Agreement at any time, the non-breaching Party shall have the right to terminate this Agreement by written termination notice to the breaching Party, if such material breach is not cured within [***] after written breach notice is given by the non-breaching Party to the breaching Party specifying the breach, provided that in the event of a good faith dispute with respect to the existence of a material breach, this Agreement shall not be terminated unless it is finally determined under ARTICLE XIV that this Agreement was materially breached, and the breaching Party fails to cure such breach within [***] after such determination. For clarity, [***].
X.5Termination for Bankruptcy. Either Party shall have the right to terminate this Agreement upon written notice to the other Party: (a) if such other Party is declared insolvent or bankrupt by a court of competent jurisdiction; (b) if a voluntary or involuntary petition in bankruptcy is filed in any court of competent jurisdiction against such other Party and such petition is not dismissed within [***] after filing; (c) if such other Party shall make or execute an assignment of substantially all of its assets for the benefit of creditors; or (d) substantially all of the assets of such other Party are seized or attached and not released within [***] thereafter.
X.6Termination by Eagle. [***] Eagle shall have the right to terminate this Agreement, [***] prior written notice to AOP. Notwithstanding any other provision of this Agreement, during this [***], AOP shall have [***].
Page 23
259471241 v2



X.7Termination by AOP for Failure to Make Upfront Payment. If Eagle fails to timely make the upfront payment to AOP as set forth under Section 6.1, AOP may terminate this Agreement by written termination notice to Eagle, if full payment is not made within [***] after written notice of non-payment is given to Eagle, and AOP may collect from Eagle the amount of US Dollars [***] as its sole and exclusive remedy besides the termination right. Any other failure of Eagle to make a payment due to AOP under this Agreement shall be considered a material breach.
X.8Termination by AOP for Patent Challenge. AOP may terminate this Agreement in its entirety upon [***] written notice if Eagle or its Affiliates or Sublicensees, individually or in association with any other Third Party, commences a Patent Challenge. Notwithstanding the foregoing, [***].
X.9Notice to AOP for Competitive Change of Control Over Eagle. Eagle shall, unless prohibited by Applicable Laws, immediately notify AOP in writing of any Competitive Change of Control over Eagle, as soon as Eagle reasonably expects such Competitive Change of Control over Eagle to occur.
X.10Surviving Provisions. In case of a termination of this Agreement, [***] shall survive, in particular with respect to any rights that accrued to the benefit of a Party prior to such termination.
Article XI
EFFECT OF TERMINATION
XI.1Accrued Obligations. The expiration or termination of this Agreement for any reason shall not release either Party from any liability which, at the time of such expiration or termination, has already accrued to the other Party prior to such expiration or termination, nor will any termination of this Agreement preclude either Party from pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with respect to any breach of this Agreement that occurred prior to such expiration or termination.
XI.2Return of Confidential Information. Within [***] after the Effective Date of any such termination, each Party shall promptly return to the other Party, or delete or destroy, all Confidential Information of the other Party; provided that (i) each Party may retain copies of the Confidential Information of the other Party to the extent [***]; (ii) each Party may retain one copy of the Confidential Information of the other Party [***] and (iii) neither Party shall be required to [***]. Upon any termination of this Agreement, Confidential Information comprising Licensed Know-How shall cease to be Confidential Information of Eagle, and thereafter shall be Confidential Information solely of AOP.
XI.3Reversion of Rights. All rights and licenses granted to Eagle under this Agreement shall terminate and revert to AOP and Eagle shall no longer use the Licensed Intellectual Property, the AOP Trademarks, or any other trademark (except Eagle trademarks) used exclusively for the Commercialization of the Licensed Product in the Eagle Territory.
XI.4Wind-Down Period. If this Agreement is terminated after the First Commercial Sale in the Eagle Territory, Eagle and its Affiliates may continue to Commercialize the Licensed Product for use in the Field in the Eagle Territory, in accordance with the terms and conditions of this Agreement, for a period [***] from the effective date of such termination (the “Wind-Down Period”). Notwithstanding any other provision of this Agreement, during this Wind-Down Period, Eagle’s and its Affiliates’ rights with respect to the Licensed Product shall be non-exclusive and AOP shall have the right to engage one or more partners(s) or distributor(s) of the Licensed Product in the Eagle Territory. During the Wind-Down Period, Eagle shall continue to make any and all Profit Share Payments and related reports to AOP for the Licensed Product sold by Eagle, its Affiliates, or its Sublicensees. After the Wind-Down Period, Eagle
Page 24
259471241 v2



and its Affiliates and Sublicensees shall not sell the Licensed Product or make any representation regarding their status as a licensee of AOP, or as distributor of the Licensed Product. Within [***] of expiration of the Wind-Down Period, Eagle shall notify AOP of any quantity of the Licensed Product remaining in Eagle’s inventory and AOP shall have [***].
XI.5Regulatory Filings. Eagle shall promptly assign and transfer to AOP the Regulatory Approvals together with all Regulatory Filings for the Licensed Product that are held or controlled by or under authority of Eagle, and shall take such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights under the Regulatory Filings to AOP. Eagle shall cause each of its Affiliates or Sublicensees to transfer any such Regulatory Filings to AOP upon termination of this Agreement. If Applicable Laws prevent or delay the transfer of ownership of a Regulatory Filing to AOP, Eagle shall grant, and does hereby grant, to AOP an exclusive, royalty-free and irrevocable right of access and reference to such Regulatory Filing for the Licensed Product, and shall cooperate fully to make the benefits of such Regulatory Filings available to AOP and/or its designee(s). Within [***] after notice of termination, Eagle shall provide to AOP copies of all such Regulatory Filings, and of all Data Controlled by Eagle. AOP shall be free to use such Regulatory Filings and Data in the further Development and Commercialization of the Licensed Product in the Eagle Territory.
XI.6Transition Assistance. Eagle shall cooperate with AOP and its designee(s) to facilitate a smooth, orderly and prompt transition of the Development and Commercialization of the Licensed Product in the Eagle Territory to AOP and/or its designee(s). This includes, without limitation, Eagle’s obligation to cooperate (i) in the transition to AOP of the lead, or any other role Eagle or its Affiliates play, in any Clinical Studies or other clinical Development activities ongoing at the time of termination, if AOP chooses to take over such lead or other role in such Studies or such other activities, or (ii) in the winding-up and termination of such Clinical Studies or other activities if AOP so chooses.
XI.7Non-Compete. For a period of [***], Eagle shall not, and shall cause its Affiliates not to, develop, use, make, have made, sell, have sold, offer for sale, export, import or otherwise commercialize [***] Competing Product.
XI.8Costs and Expenses. [***].
Article XII
REPRESENTATIONS, WARRANTIES AND COVENANTS
XII.1Representations and Warranties of AOP. AOP represents, warrants and covenants to Eagle that, as of the Execution Date:
(a)AOP is a corporation duly organized, validly existing and is in good standing under the laws of Austria, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and failure to have such would prevent AOP from performing its obligations under this Agreement;
(b)this Agreement is a legal and valid obligation binding upon AOP and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by AOP have been duly authorized by all necessary corporate action and do not and will not: (i) violate any law, rule, regulation, order, writ, judgment, decree, determination or award of any court, governmental body or administrative or other agency having jurisdiction over AOP; nor (ii) conflict with, or constitute a default under, any agreement, instrument or understanding, oral or written, to which AOP is a party or by which it is bound;
Page 25
259471241 v2



(c)AOP is the sole owner or otherwise has sufficient legal title or beneficial title or ownership or license with respect to the Licensed Patent Rights and the Licensed Know-How and has the full right and authority to grant the rights and licenses with respect to the Licensed Patent Rights and Licensed Know-How, without limitation or restriction;
(d)Exhibit 1.67 sets forth a true and complete list of all Patents owned by AOP or its Affiliates as of the Execution Date that Cover the Licensed Products in the Eagle Territory, and AOP has the full right and authority to grant to Eagle the rights or licenses granted under this Agreement regarding the Patents described in Exhibit 1.67, and to prosecute and enforce such Patents in accordance with ARTICLE IX;
(e)AOP has not previously granted and will not grant any right, license or interest in or to a Licensed Product, Licensed Know-How, or Licensed Patent Rights, or any portion thereof, that is in conflict with, limits or derogates from the rights or licenses granted to Eagle under this Agreement;
(f)the Licensed Patent Rights and the Licensed Know-How are free and clear of all liens, claims, security interests or other encumbrances of any kind and during the term of this Agreement, AOP shall not permit the Licensed Patent Rights or the Licensed Know-How to become encumbered by any liens, claims, security interests or other encumbrances that diminish the rights or licenses granted to Eagle under this Agreement;
(g)[***];
(h)all necessary consents, approvals and authorizations of all Regulatory Authorities, other Governmental Authorities and other persons or entities required to be obtained by AOP in order to enter into this Agreement have been obtained;
(i)to AOP’s knowledge, [***];
(j)[***];
(k)AOP has not knowingly and intentionally withheld any Licensed Know-How that is reasonably material for Eagle’s conduct of activities under this Agreement and, to AOP’s knowledge, all Licensed Know-How provided to Eagle is free from any material inaccuracies;
(l)AOP has disclosed to Eagle all material information relating to the safety and efficacy of the Licensed Product known to it or its Affiliates;
(m)[***];
(n)to AOP’s knowledge, AOP has complied with all Applicable Laws in all material respects, including any disclosure requirements, in connection with the filing, prosecution and maintenance of the Licensed Patent Rights and, to AOP’s knowledge, none of the issued Licensed Patent Rights are invalid or unenforceable;
(o)the Licensed Patent Rights and Licensed Know-How are not subject to any funding agreement with any government or Governmental Authority; and
(p)to AOP’s knowledge, none of the materials and documents provided to Eagle in the course of Eagle’s due diligence preceding execution of this Agreement contained any untrue statement of material fact.
Page 26
259471241 v2



XII.2Representations and Warranties of Eagle. Eagle represents and warrants to AOP that, as of the Execution Date:
(a)Eagle is a corporation duly organized, validly existing and is in good standing under the laws of the State of Delaware, U.S.A., is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and failure to have such would prevent Eagle from performing its obligations under this Agreement;
(b)this Agreement is a legal and valid obligation binding upon Eagle and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by Eagle have been duly authorized by all necessary corporate action and do not and will not: (i) violate any law, rule, regulation, order, writ, judgment, decree, determination or award of any court, governmental body or administrative or other agency having jurisdiction over Eagle; nor (ii) conflict with, or constitute a default under, any agreement, instrument or understanding, oral or written, to which Eagle is a party or by which it is bound;
(c)all necessary consents, approvals and authorizations of all Regulatory Authorities, other Governmental Authorities and other persons or entities required to be obtained by Eagle in order to enter into this Agreement have been obtained;
(d)Eagle has not previously granted and will not grant any right, license or interest in or to Eagle Background Know-How, Eagle Background Patents, Eagle Non-Product-Specific Collaboration Know-How, and Eagle Non-Product-Specific Collaboration Patents, or any portion thereof, that is in conflict with, limits or derogates from the rights or licenses granted to AOP under this Agreement; and
(e)Eagle Background Know-How, Eagle Background Patents, and all portions thereof, are free and clear of all liens, claims, security interests or other encumbrances of any kind and during the term of this Agreement, Eagle shall not permit them, Eagle Non-Product-Specific Collaboration Know-How and Eagle Non-Product-Specific Collaboration Patents, to become encumbered by any liens, claims, security interests or other encumbrances that could diminish AOP’s rights under the Agreement;
(f)[***];
(g)to Eagle’s knowledge, [***];
(h)[***];
(i)to Eagle’s knowledge, none of the materials and documents provided to preceding execution of this Agreement contained any untrue statement of material fact.
XII.3Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OR VALIDITY OF INTELLECTUAL PROPERTY RIGHTS.
XII.4Effective Date. During the period from the Execution Date until the Effective Date, each Party shall promptly inform the other Party in writing if and when it or any of its Affiliates becomes aware that the representations and warranties made pursuant to Section 12.1 or 12.2 as of the Execution
Page 27
259471241 v2



Date are no longer true and correct in any material respects if made on and as of the date of such notice. Upon receipt of such notice, the notified Party shall have the right, on written notice to the notifying Party, to terminate this Agreement at any point prior to the Effective Date or within [***] thereafter, in the event that the notified Party determines in good faith that the applicable change to the status of the representations and warranties as of the Execution Date would be reasonably likely to have a material adverse effect, and upon receipt of such notice by the notifying Party, this Agreement shall be null and void and have no further force and effect; provided, however, [***] shall survive, in particular with respect to any rights that accrued to the benefit of a Party prior to such termination.
Article XIII
INDEMNIFICATION; RECALLS
XIII.1Indemnification of AOP. Eagle shall indemnify and hold harmless each of AOP, its Affiliates, and the directors, officers, shareholders and employees of such entities and the successors and assignees of any of the foregoing (the “AOP Indemnitees”), from and against any and all liabilities, damages, penalties, fines, costs, expenses [***] (“Liabilities”) incurred by any AOP Indemnitee as a result of any claims, actions, suits or proceedings brought by a Third Party (a “Third Party Claim”) against an AOP Indemnitee, arising from, or occurring as a result of: (a) the Development, Manufacture or Commercialization of any Licensed Product by Eagle, its Affiliates or Sublicensees; (b) any breach of any representations or warranties by Eagle; and (c) any breach by Eagle or failure by Eagle to perform an agreement assigned to Eagle, [***]; except to the extent such Third Party Claims fall within the scope of AOP’s indemnification obligations set forth in Section 13.2 below or result from the material fault of an AOP Indemnitee.
XIII.2Indemnification of Eagle. AOP shall indemnify and hold harmless each of Eagle, its Affiliates and Sublicensees and the directors, officers and employees of Eagle, its Affiliates and Sublicensees and the successors and assignees of any of the foregoing (the “Eagle Indemnitees”), from and against any and all Liabilities incurred by any Eagle Indemnitee as a result of any Third Party Claims against an Eagle Indemnitee, arising from, or occurring as a result of (a) the Development, Manufacture or Commercialization of any Licensed Product by AOP, its Affiliates or (sub)licensees prior to the Effective Date; (b) any breach of any representations, warranties or covenants by AOP; except to the extent such Third Party Claims fall within the scope of Eagle’s indemnification obligations set forth in Section 13.1 or result from the material fault of an Eagle Indemnitee.
XIII.3Procedure. A Party that intends to claim indemnification under this ARTICLE XIII (the “Indemnitee”) shall promptly notify the other Party (the “Indemnitor”) in writing of any Third Party Claim, in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense or settlement thereof, except as set forth in Section 9.9. The indemnity arrangement in this Section 13.3 shall not apply to amounts paid in settlement of any action with respect to a Third Party Claim, if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within [***], if prejudicial to its ability to defend such action, shall relieve such Indemnitor of any liability to the Indemnitee under this Section 13.3, but the omission to so deliver written notice to the Indemnitor shall not relieve the Indemnitor of any liability that it may have to any Indemnitee otherwise than under this Section 13.3. The Indemnitee under this Section 13.3 shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Third Party Claim covered by this indemnification.
XIII.4Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, OR INDIRECT DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT,
Page 28
259471241 v2



REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 13.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 13.1 OR 13.2, AND THE FOREGOING LIMITATIONS SHALL NOT APPLY WITH RESPECT TO DAMAGES RESULTING FROM A PARTY’S WILLFUL MISCONDUCT OR GROSS NEGLIGENCE OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE VIII.
Article XIV
DISPUTE RESOLUTION
XIV.1Referral to Senior Executives. The Parties recognize that disputes as to certain matters relating to or in connection with this Agreement may from time to time arise during the term of this Agreement (each, including any dispute arising with respect to the interpretation, enforcement, termination or invalidity of this Agreement, a “Dispute”). If any such Dispute cannot be resolved by good faith negotiations, [***].
XIV.2Arbitration. Any Dispute that is not resolved pursuant to Section 14.1 shall be finally settled by arbitration in accordance with [***]. The seat of the arbitration shall be [***]. The language of the proceedings shall be English. If so requested by the arbitrator, any evidence originally in a language other than English shall be submitted with a certified English translation accompanied by an original or true copy thereof. Any decision and/or award of the arbitrator may be entered in any court of competent jurisdiction for judicial recognition of the decision and an order of enforcement. The arbitration proceedings and the decision of the arbitrator shall be deemed the Confidential Information of both Parties subject to ARTICLE VIII. If a party asserted to be in breach under Section 10.4 disputes the asserted breach, this Agreement shall not be terminated and the license herein shall not be affected as a result of the disputed breach unless and until it has been determined in accordance with this Section 14.2 that this Agreement was materially breached, and such breach is not cured within [***] after such determination or such longer period as the arbitrator may establish. The Parties agree that they shall share equally the [***].
XIV.3Interim Relief. Notwithstanding anything in Sections 14.1 or 14.2 to the contrary, each Party shall have the right to apply, for a temporary restraining order, preliminary injunction or other similar interim or conservatory relief, as necessary to protect the rights or property of such Party, (i) to any court of competent jurisdiction pending the selection of the arbitrator or pending the arbitrator’s determination of the merits of any Dispute, or (ii) to an emergency arbitrator appointed [***] prior to the constitution of an arbitral tribunal. Nothing in the preceding sentence shall be interpreted as limiting the powers of the arbitrator(s) with respect to any Dispute subject to arbitration under this Agreement.
XIV.4Jury Waiver. EACH PARTY, TO THE EXTENT PERMITTED BY LAW, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES AND AGREES TO ARBITRATE AS SET FORTH IN SECTION 14.2 (ARBITRATION). THIS WAIVER APPLIES TO ANY ACTION OR LEGAL PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE.
Article XV
GENERAL PROVISIONS
Page 29
259471241 v2



XV.1Force Majeure. Except with regard to obligations to pay money, neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay (again: except for a failure or delay in making a money payment pursuant to this Agreement) is caused by or results from events beyond the reasonable control of the non-performing Party, including fire, flood, earthquake, hurricane, embargo, shortage, epidemic, pandemic, quarantine, war, act of war (whether war be declared or not), terrorist act, insurrection, riot, civil commotion, strike, lockout or other labor disturbance (whether involving the workforce of the non-performing Party or of any other Person) or act, omission or delay in acting by any Governmental Authority, including due to a clinical hold pursuant to 21 C.F.R. §312.42, as amended (and any equivalent in any jurisdiction outside the United States). The non-performing Party shall notify the other Party of such force majeure by giving written notice to the other Party stating the nature of the event, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than necessary to resolve such force majeure event and the non-performing Party shall use diligent efforts to remedy its inability to perform. If a condition constituting force majeure exists for more than [***], the parties shall meet to negotiate a mutually satisfactory solution to the problem. The Party not affected by the force majeure situation shall have the right to terminate this Agreement upon [***] written notice from the failure of reaching a mutually satisfactory solution to the force majeure situation.
XV.2Governing Law. This Agreement and all questions regarding its validity or interpretation, or the breach or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of [***], without reference to conflict of law provisions or principles. The Parties hereby agree that the provisions of the United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement and are strictly excluded.
XV.3Data Protection.
(a)The Parties are – and will make their employees – aware of, consent to, and acknowledge that (i) the respective other Party may collect, process, transmit and use (personal) data according to Regulation 2016/679 of the European Parliament and of the Council of 27 April 2016 (“GDPR”) and other Applicable Laws on data protection such as information on personal or material circumstances of an identified or an identifiable individual in the performance of this Agreement and the Supply Agreement and to comply with that other Party’s obligation to report to the responsible authorities and/or disclose mandatory details; and (ii) such data may be stored in the other Party’s database for the performance of this Agreement and the Supply Agreement, and that it may – if applicable and necessary – be transmitted to the other Party’s Affiliates. The Parties and, if applicable, their employees have been informed about their rights according to the GDPR and other Applicable Laws on data protection, including their right to revoke the above given consent at any time and to have their (personal) data deleted or rectified. The Parties acknowledge that the other Party’s obligation to report and/or disclose mandatory information remains irrespective of a revocation of such consent.
(b)With regard to personal data relating to other data subjects than the Parties and their employees (“Third Party Personal Data”) including, but not limited to, clinical trial data, each Party shall ensure that is permitted under the GDPR and other Applicable Laws on data protection to disclose such Third Party Personal Data to the other Party for the other Party’s processing of such Third Party Personal Data in the performance of this Agreement and the Supply Agreement. Given the sensitivity of such Third Party Personal Data, each Party will put the necessary technical and organizational measures in place to preserve its security at all times.
Page 30
259471241 v2



(c)Prior to any disclosure or transfer of personal data under this Agreement or the Supply Agreement, the Parties will enter into data processing and data transfer agreements, each as applicable and required by the GDPR and other Applicable Laws on data protection.
XV.4Waiver of Breach. The failure of either Party at any time or times to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another condition or term.
XV.5Modification. No amendment or modification of any provision of this Agreement shall be effective unless in writing signed by both Parties hereto. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by both Parties hereto.
XV.6Severability. In the event any provision of this Agreement should be held invalid, illegal, or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Agreement shall remain in full force and effect in such jurisdiction. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction.
XV.7Entire Agreement; Amendments. This Agreement (including the Exhibits attached hereto) constitutes the complete, final and entire agreement between the Parties relating to the subject matter hereof and supersede all prior and contemporaneous agreements, representations and/or understandings, including the Prior CDA. The foregoing shall not be interpreted as a waiver of any remedies available to either Party as a result of any breach, prior to the Effective Date, by the other Party of its obligations under the Prior CDA. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party.
XV.8Notices. Unless otherwise agreed by the Parties or specified in this Agreement, all communications between the Parties relating to, and all written documentation to be prepared and provided under, this Agreement shall be in the English language. Any notice between the Parties required or permitted under this Agreement shall be in writing in the English language, and (a) delivered personally, (b) sent by air mail or express courier service providing evidence of receipt, postage pre-paid where applicable, or (c) by electronic transmission (complete transmission confirmed and a copy promptly sent by another permissible method of providing notice described in paragraph (a) or (b) above), to the following addresses of the Parties (or such other address for a Party as may be specified by like notice):
Page 31
259471241 v2



To AOP:To Eagle:
AOP Orphan Pharmaceuticals GmbH
Leopold-Ungar-Platz 2
A-1190 Vienna
Attention: [***]
Electronic mail: [***]
Eagle Pharmaceuticals, Inc.
50 Tice Blvd, Suite 315
Woodcliff Lake, NJ 07677
Attention: [***]
Electronic mail: [***]
With a copy to:With a copy to:
AOP Orphan Pharmaceuticals GmbH
Leopold-Ungar-Platz 2
A-1190 Vienna
Attention: [***]
Electronic mail: [***]
Cooley LLP
One Freedom Square
Reston Town Center
11951 Freedom Drive
Reston, Virginia 20190-5656
Attn: [***]
Electronic mail: [***]

Any notice required or permitted to be given concerning this Agreement shall be effective upon receipt by the Party to whom it is addressed.
XV.9Assignment.
(a)Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment or transfer without the other Party’s consent to (i) its Affiliates or (ii) a Third Party successor to substantially all of the business of such Party to which this Agreement relates, whether in a merger, sale of stock, sale of assets or other transaction.
(b)Any permitted assignee shall assume all obligations of its assignor under this Agreement. Subject to the foregoing, this Agreement shall inure to the benefit of each Party, its successors and permitted assignees. Any purported assignment of this Agreement in contravention of this Section 15.9 shall be null and void.
XV.10No Partnership or Joint Venture. Nothing in this Agreement is intended, or shall be deemed, to establish a joint venture or partnership between Eagle and AOP. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, or to bind the other Party to any contract, agreement or undertaking with any Third Party.
XV.11Interpretation. The captions to the several Articles and Sections of this Agreement are not a part of this Agreement, but are included for convenience of reference and shall not affect its meaning or interpretation. In this Agreement: (a) the word “including” shall be deemed to be followed by the phrase “without limitation” or like expression; (b) the singular shall include the plural and vice versa; (c) masculine, feminine and neuter pronouns and expressions shall be interchangeable; and (d) the term “or” will be interpreted in the inclusive sense commonly associated with the term “and/or.”. Each accounting term used herein that is not specifically defined herein shall have the meaning given to it under generally accepted cost accounting principles, but only to the extent consistent with its usage and the other definitions in this Agreement. This Agreement has been prepared jointly by the Parties and shall not be strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.
Page 32
259471241 v2



XV.12Performance by Affiliates. Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party’s Affiliate.
XV.13Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.
XV.14Counterparts; Other Matters. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Each Party may execute this Agreement only by wet ink signature. In addition, wet ink signatures of authorized signatories of any Party will be deemed to be original signatures and will be valid and binding. Wet ink signature counterparts must be transmitted to the respective other Party by delivery in person or via internationally recognized overnight delivery, or by registered or certified mail (postage prepaid, return receipt requested). This Agreement is established in the English language. Any translation in another language shall be deemed for convenience only and shall never prevail over the original English version.
[Remainder of this page intentionally blank.]


Page 33
259471241 v2



IN WITNESS WHEREOF, the Parties have executed this License Agreement as of the date first set forth above.
AOP ORPHAN PHARMACEUTICALS GmbH
By:    [***]    
Name:    [***]
Title:    [***]
By:     [***]    
Name:    [***]
Title:    [***]


EAGLE PHARMACEUTICALS, INC.
By:     [***]    
Name:    [***]
Title:    [***]


259471241 v2



Exhibit 1.43 – [***]

259471241 v2



Exhibit 1.67 – [***]

259471241 v2



Exhibit 6.4 – [***]




259471241 v2



Exhibit 6.5 – [***]




259471241 v2



Exhibit 8.7. – Press Release
For Immediate Release
Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker
-- Eagle poised to facilitate regulatory pathway for approval in the U.S. based on existing data from Japanese and European studies, with no additional clinical work expected –
-- Anticipates filing new drug application (“NDA”) in Q1 2022, with expected ten-month review, based on well-defined feedback from U.S. Food and Drug Administration provided during AOP Orphan’s Type C meeting --
-- Landiolol, a leading hospital emergency use product, is approved in Europe for the treatment of non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias --
-- Eagle to support seeking the approval of Landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter in the U.S.
--
-- Studies of additional indications, including sepsis and other cardioprotective indications, have begun in Europe, with the potential to be pursued in the U.S. --
-- Enrollment of study of pediatric patients with supraventricular tachycardia is under way in Europe and will serve as the basis for initial pediatric study plans for a future FDA submission --
-- Company expects five years of new chemical entity exclusivity --

WOODCLIFF LAKE, NJ—August ___, 2021—Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH (“AOP Orphan”), a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, Landiolol in the United States. Landiolol, a leading hospital emergency use product, is currently approved in Europe for the treatment of non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias. The Company will support the submission of a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) seeking approval for Landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia (“SVT”), including atrial fibrillation and atrial flutter.
259471241 v2



Landiolol is a short-acting, ultra-high selective beta-1 adrenoceptor blocker developed by AOP Orphan that has a selective effect on heart rate over cardiac contractility. Landiolol is available in two forms (20 mg/2ml concentrate, 300 mg powder) and is designed for use in emergency, cardiac critical care, operating room, and intensive care settings. It is registered in several European countries for the treatment of non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias. The drug uses a proprietary dosing algorithm to facilitate the administration.
Under the terms of the agreement, Eagle will facilitate the U.S. regulatory pathway for the approval of Landiolol. In addition, Eagle will be responsible for the U.S. commercialization of the product upon approval. Landiolol, which has not previously been marketed in the U.S., is covered by several patents, and the Company anticipates five years of new chemical entity (“NCE”) exclusivity.
Landiolol is already commercially available in Japan (Onoact(®)) and several European markets as RAPIBLOC®. A review of multiple clinical studies suggests that Landiolol is a useful option for the rapid short-term control of tachyarrhythmias (Syed YY. Landiolol: A Review in Tachyarrhythmias. Drugs. 2018 Mar;78(3):377-388. doi: 10.1007/s40265-018-0883-9. PMID: 29470800.). A Type C meeting was held with FDA in July 2020, at which time AOP Orphan proposed a submission strategy in which it would provide summaries of pre-existing safety and efficacy data and a meta-analysis of published randomized controlled trials. FDA tentatively agreed with this methodological approach and deemed data sets adequate to support a proposed NDA.
“This is an exciting near-term opportunity for Eagle, with the potential to file an NDA in the first quarter of next year. The clinical advantages of Landiolol are well recognized within the medical community, and we look forward to advancing this asset for FDA approval in the United States. Our deep understanding of the U.S. regulatory landscape, along with our established research and development infrastructure, will be valuable in accelerating the program. Once approved, we plan to leverage our current sales force and relationships in the critical care setting to promote the product. There is broad potential to expand the portfolio of future indications for Landiolol’s use,” stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.
“With this license agreement, we are solidifying our hospital and critical care product portfolio, as we look to capitalize on multiple near- and longer-term opportunities. As we have stated, executing on our growth strategy for Eagle beyond 2021 has been a priority. With the anticipated launch of vasopressin, the February 2022 launch of PEMFEXY, the recent launch of bendamustine in Japan, our current pipeline, and now the future potential Landiolol launch, we believe we have a firm foundation for sustained future growth,” concluded Tarriff.
“The step into the American market forms the basis for further expansion of AOP Orphan. I am convinced that with an experienced partner like Eagle, we will succeed in making Landiolol available to patients in the U.S. as well,” stated Georg Fischer, Chief Executive Officer of AOP Orphan.
259471241 v2



The management of rapid heart rate (tachycardia) in critically ill patients can be quite complicated regardless of the underlying cause, which may include shock, arrhythmias, heart failure, and the postoperative setting. Beta blockers, also known as beta-adrenergic blocking agents, are a class of drugs that works by blocking the neurotransmitters norepinephrine and epinephrine from binding to receptors. These neurotransmitters contribute to the development of tachycardia. The β-1 receptor beta blockers are used frequently in critical care settings to manage tachycardia; however, the available β-1 beta blockers in the U.S. also can have the unwanted effects of decreasing the contractility, or muscle strength, of the heart, and of lowering blood pressure.
Landiolol has the potential to become a cornerstone therapy in the management of these patients. It is ultra short acting, with a rapid on and off effect that allows clinicians to balance heart rate control and blood pressure more precisely. In addition, it predominantly affects heart rate without much effect on cardiac contractility and blood pressure. The Company believes that clinicians will welcome Landiolol as a key therapeutic tool for the more precise management of tachycardia in the critical care setting.
There are additional clinical settings for which Landiolol has the potential to improve patient management. Enrollment is under way in Europe for a trial of Landiolol in patients with tachycardia and septic shock, and importantly, the product is also being studied in a pediatric population, for whom no beta-blocker drug products are approved in the U.S. for ventricular rate control. The U.S. FDA has tentatively agreed that this study could form the basis for initial pediatric study plan (“iPSP”) for a future submission to FDA.
“We believe that we can expedite and prepare a compelling submission for approval of this important cardioprotective therapeutic,” stated Judith Ng-Cashin, MD, Chief Medical Officer of Eagle Pharmaceuticals
Terms of the Agreement
The agreement is subject to regulatory clearance. Under the terms of the agreement, Eagle will make an upfront payment of $5 million, followed by additional payments upon regulatory approval(s) and based upon commercial sales.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.
259471241 v2



AOP Orphan Pharmaceuticals GmbH is an international pharmaceutical company with its registered office in Vienna and a focus on rare and special diseases. Over the past 25 years, the company has become an established provider of integrated therapy solutions from its headquarters in Vienna. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all our stakeholders on the other - especially the patients and their families but also the doctors and care professionals treating them. In the third quarter of 2020, AOP Orphan took over Amomed and SciPharm, two European health care companies, continuing its consistent path of growth into a pan-European health care group specializing in rare and special diseases.
Agreement is subject to regulatory clearance.



Investor Relations for Eagle Pharmaceuticals, Inc.:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com


259471241 v2

EX-31.1 4 exhibit311q32021.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
I, Scott Tarriff, certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q of Eagle Pharmaceuticals, Inc.;
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.     The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: November 9, 2021
/s/ Scott Tarriff
Scott Tarriff
Chief Executive Officer
(Principal Executive Officer)


EX-31.2 5 exhibit312q32021.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
I, Brian J. Cahill, certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q of Eagle Pharmaceuticals, Inc.;
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.     The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: November 9, 2021
/s/ Brian J. Cahill
Brian J. Cahill
Chief Financial Officer
(Principal Accounting and Financial Officer)


EX-32.1 6 exhibit321q32021.htm EX-32.1 Document

Exhibit 32.1
Certification Pursuant to
18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals, Inc. (the “Company”), and Brian J. Cahill, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:
1.The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2021, (the “Quarterly Report”), to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and
2.The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
In Witness Whereof, the undersigned have set their hands hereto as of the 9th day of November 2021.
By:
/s/ Scott Tarriff
 
 Scott Tarriff
 Chief Executive Officer
(Principal Executive Officer)
By:
/s/ Brian J. Cahill
 
 Brian J. Cahill
 Chief Financial Officer
(Principal Financial and Accounting Officer)
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Eagle Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.


EX-101.SCH 7 egrx-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Basis of Presentation and Other Company Information link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Basis of Presentation and Other Company Information (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Summary of Significant Accounting Policies - Revenue and Accounts Receivable By Major Customer (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Summary of Significant Accounting Policies - Anti-Dilutive Common Shares Equivalents Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net (Loss) Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 2111103 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 2312302 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 2114104 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2117105 - Disclosure - Balance Sheet Accounts link:presentationLink link:calculationLink link:definitionLink 2318304 - Disclosure - Balance Sheet Accounts (Tables) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Balance Sheet Accounts - Prepaid and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2421411 - Disclosure - Balance Sheet Accounts - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2422412 - Disclosure - Balance Sheet Accounts - Lease Related Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2423413 - Disclosure - Balance Sheet Accounts - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2124106 - Disclosure - Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 2325305 - Disclosure - Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2426414 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2427415 - Disclosure - Intangible Assets, Net - Schedule of Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2128107 - Disclosure - Common Stock and Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2329306 - Disclosure - Common Stock and Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2430416 - Disclosure - Common Stock and Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2431417 - Disclosure - Common Stock and Stock-Based Compensation - Summary of Stock Options, RSU and PSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2432418 - Disclosure - Common Stock and Stock-Based Compensation - Fair Value of Stock Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 2433419 - Disclosure - Common Stock and Stock-Based Compensation - Schedule of Share-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2134108 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 2335307 - Disclosure - Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 2436420 - Disclosure - Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 2436420 - Disclosure - Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 2137109 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2338308 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2439421 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2440422 - Disclosure - Debt - Schedule of Debt Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2141110 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2342309 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2443423 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2144111 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 2445424 - Disclosure - Legal Proceedings (Details) link:presentationLink link:calculationLink link:definitionLink 2146112 - Disclosure - License and Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 2447425 - Disclosure - License and Collaboration Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2148113 - Disclosure - Convertible Promissory Note link:presentationLink link:calculationLink link:definitionLink 2349310 - Disclosure - Convertible Promissory Note (Tables) link:presentationLink link:calculationLink link:definitionLink 2450426 - Disclosure - Convertible Promissory Note (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 egrx-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 egrx-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 egrx-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Customer [Domain] Customer [Domain] Legal Proceedings Legal Matters and Contingencies [Text Block] Changes in operating assets and liabilities which provided (used) cash: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Work in process Inventory, Work in Process, Gross Earnings Per Share Earnings Per Share, Policy [Policy Text Block] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Leasehold improvements Leasehold Improvements [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net (loss) income Net (loss) income Net income (loss) Net Income (Loss) Attributable to Parent Entity Emerging Growth Company Entity Emerging Growth Company Convertible promissory note, net Total in Other Current Assets, beginning balance Total in Other Current Assets, ending balance Debt Securities, Available-for-sale, Current Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Income Statement Location [Axis] Income Statement Location [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two 2023 Contractual Obligation, to be Paid, Year Two Schedule of debt maturities Schedule of Maturities of Long-term Debt [Table Text Block] Combioxin Combioxin [Member] Combioxin Number of tax jurisdictions currently auditing the company Number Of Tax Jurisdictions Currently Auditing The Company Number Of Tax Jurisdictions Currently Auditing The Company Entity Filer Category Entity Filer Category Weighted-average remaining lease term - operating leases Operating Lease, Weighted Average Remaining Lease Term Other assets Other Assets, Noncurrent 2021 Contractual Obligation, to be Paid, Remainder of Fiscal Year Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Thereafter Finite-Lived Intangible Assets, Expected Amortization, After Year Four Finite-Lived Intangible Assets, Expected Amortization, After Year Four Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 2023 Long-Term Debt, Maturity, Year Two Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Debt Securities, Available-for-sale Debt Securities, Available-for-sale [Table Text Block] 2021 2021 (remainder) Long-Term Debt, Maturity, Remainder of Fiscal Year Document Fiscal Year Focus Document Fiscal Year Focus Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization expense of intangible assets Amortization of Intangible Assets Weighted-average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Schedule of inventories Schedule of Inventory, Current [Table Text Block] Anti-dilutive common shares equivalents outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Research and development Research and Development Expense [Member] Prepaid FDA user fee and advances to clinical research organization Prepaid FDA User Fee Prepaid FDA User Fee Prepaid income taxes Prepaid Taxes Line of credit facility, commitment fee Line of Credit Facility, Commitment Fee Percentage Weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Award Type [Domain] Award Type [Domain] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Estimated Amortization Expense Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Credit Facility [Domain] Credit Facility [Domain] ASSETS Assets [Abstract] 2024 Long-Term Debt, Maturity, Year Three Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Percentage of concentration Concentration Risk, Percentage Preferred stock, 1,500,000 shares authorized and no shares issued or outstanding as of September 30, 2021 and December 31, 2020 Preferred Stock, Value, Issued Accretion of discount on convertible promissory note Accretion Income Accretion Income Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Entity Address, City or Town Entity Address, City or Town Retained Earnings Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Advertising and Marketing Advertising Cost [Policy Text Block] Advertising and marketing costs Marketing and Advertising Expense Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Accelerated share repurchases, shares received (in shares) Accelerated Share Repurchases, Shares Received Accelerated Share Repurchases, Shares Received Accounts receivable Increase (Decrease) in Accounts Receivable Right-of-use asset obtained in exchange for lease obligation - lease amendment Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Award vesting percentage of target number granted Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Entity Interactive Data Current Entity Interactive Data Current Prime Rate Prime Rate [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Basic (in dollars per share) Basic net (loss) earnings per share (in dollars per share) Earnings Per Share, Basic Operating lease, expense Operating Lease, Expense 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Receivable from commercial partner Receivables, Long-term Contracts or Programs Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Document Type Document Type Purchase of equity investment security Payments to Acquire Equity Securities, FV-NI 2022 Long-Term Debt, Maturity, Year One Balance Sheet Classification as of September 30: Balance Sheet Classification [Abstract] Balance Sheet Classification 2026 Long-Term Debt, Maturity, Year Five Raw materials Inventory, Raw Materials, Gross 2024 Purchase Obligation, to be Paid, Year Three Diluted net (loss) earnings per share Earnings Per Share, Diluted [Abstract] Accrued research & development Accrued Research and Development, Current Accrued Research and Development, Current Entity Current Reporting Status Entity Current Reporting Status Payment of employee withholding tax upon vesting of stock-based awards Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Operating cash flows for operating leases Operating Lease, Payments 2025 Contractual Obligation, to be Paid, Year Four Research and Development Expense Research and Development Expense, Policy [Policy Text Block] Convertible Promissory Note, net, beginning balance Convertible Promissory Note, net, ending balance Receivables, Net, Current Assets: Assets, Fair Value Disclosure [Abstract] Total Long-term Debt Total financial assets Assets, Fair Value Disclosure Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill impairment loss Goodwill, Impairment Loss Document Transition Report Document Transition Report Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] October 2018 Plan October 2018 Plan [Member] October 2018 Plan [Member] Operating lease Lessee, Operating Lease, Liability, Payment, Due [Abstract] Interest Income Interest Income, Debt Securities, Available-for-sale, Operating Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Supplemental disclosures of cash flow information: Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Total liabilities and stockholders' equity Liabilities and Equity Accrued other Other Accrued Liabilities, Current Investments, Debt and Equity Securities [Abstract] Pending Litigation Pending Litigation [Member] AOP Orphan Pharmaceuticals GmbH AOP Orphan Pharmaceuticals GmbH [Member] AOP Orphan Pharmaceuticals GmbH Milestone PSUs Milestone Performance-Based Stock Units [Member] Milestone Performance-Based Stock Units Commitments Commitments Disclosure [Text Block] Accrued sales reserves Contract with Customer, Liability, Current 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five Unamortized deferred debt issuance cost Debt Issuance Cost, Gross, Noncurrent Additional paid in capital Additional Paid in Capital Cash paid during the period for: Supplemental Cash Flow Elements [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Common stock repurchases Treasury Stock, Value, Acquired, Cost Method Operating expenses: Operating Expenses [Abstract] Beyond Long-Term Debt, Maturity, after Year Five 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Four Issuance of common stock upon exercise of stock option grants Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] Fair value adjustments related to derivative instrument Fair Value Adjustment On Accelerated Share Repurchases Fair Value Adjustment On Accelerated Share Repurchases 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Purchase Obligation, to be Paid, Year Five Selling, general and administrative Selling, General and Administrative Expense Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Unrecognized tax benefits Unrecognized Tax Benefits Trading Symbol Trading Symbol Deferred tax asset, net Deferred Income Tax Assets, Net Current liabilities: Liabilities, Current [Abstract] 2025 Long-Term Debt, Maturity, Year Four Debt Debt Disclosure [Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Line of credit Line of Credit [Member] Common Stock and Stock-Based Compensation Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Inventories Inventory Disclosure [Text Block] Accounting Policies [Abstract] Accounting Policies [Abstract] Total Contractual Obligation Accrued professional fees Accrued Professional Fees, Current Accretion of Discount Investment Income, Amortization of Discount Number of patents, claims dismissed Loss Contingency, Patents Found Not Infringed, Number Total lease liabilities Operating Lease, Liability Common stock, $0.001 par value; 50,000,000 shares authorized; 16,886,123 and 16,739,203 shares issued as of September 30, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total other expense, net Nonoperating Income (Expense) Purchase of convertible promissory note Payments to Acquire Notes Receivable Collaborative arrangement, rights and obligations, upfront payment Collaborative Arrangement, Rights And Obligations, Upfront Payment Collaborative Arrangement, Rights And Obligations, Upfront Payment Customer Concentration Risk Customer Concentration Risk [Member] PSUs Performance Shares [Member] Commitments and Contingencies Commitments and Contingencies Credit facility Long-term Debt, Fiscal Year Maturity [Abstract] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Schedule of financial assets and liabilities measured and recognized at fair value Fair Value, by Balance Sheet Grouping [Table Text Block] 2021 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Fair value of stock options Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of stock options, RSU and PSU activity Share-based Payment Arrangement, Activity [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Document Period End Date Document Period End Date Convertible Promissory Note Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Total operating expenses Costs and Expenses Cost of royalty revenue Royalty Expense Entity Registrant Name Entity Registrant Name Numerator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Treasury stock (in shares) Treasury Stock, Shares Total obligations Contractual Obligation, Fiscal Year Maturity [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Revised Credit Agreement Second Amended And Restated Credit Agreement [Member] Second Amended And Restated Credit Agreement [Member] Financial Instrument [Axis] Financial Instrument [Axis] Selling, general and administrative Selling, General and Administrative Expenses [Member] Accrued expenses and other liabilities Total accrued expenses Accrued Liabilities, Current Total revenue Revenue from Contract with Customer, Excluding Assessed Tax 2023 Purchase Obligation, to be Paid, Year Two Office equipment Office Equipment [Member] Stock options Share-based Payment Arrangement, Option [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Common Stock Common Stock [Member] Interest income Investment Income, Interest Variable Rate [Axis] Variable Rate [Axis] Ryanodex intangible Royalty Buy-Back Agreement [Member] Royalty Buy-Back Agreement [Member] (Loss) income from operations Operating Income (Loss) Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Current portion of lease liability Current lease liabilities (included with Accrued Expenses and other liabilities) Operating Lease, Liability, Current License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Two Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Variable Rate [Domain] Variable Rate [Domain] Additional Paid-In Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation expense Depreciation Treasury Stock Treasury Stock [Member] Beyond Purchase Obligation, to be Paid, after Year Five Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Convertible promissory note related credit losses Estimated Credit Loss Debt Securities, Available-for-sale, Change in Present Value, Expense (Reversal) Interest Receivable, beginning balance Interest Receivable, ending balance Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss Draw on line of credit Proceeds from Lines of Credit Number of milestones required to be met Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Milestones Required To Be Met Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Milestones Required To Be Met Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other expense Other Nonoperating Income (Expense) Discount on the note, beginning balance Discount on the note, ending balance Receivable with Imputed Interest, Discount Prepaid insurance Prepaid Insurance Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities S&P Biotechnology S&P Biotechnology [Member] S&P Biotechnology Schedule of accrued expenses Schedule of Accrued Liabilities [Table Text Block] Award Type [Axis] Award Type [Axis] 2022 Finite-Lived Intangible Asset, Expected Amortization, Year One Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Future minimum lease payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of revenues and accounts receivables by major customers Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Total stockholders' equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Purchase obligations Purchase Obligation, Fiscal Year Maturity [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets, Net Intangible Assets Disclosure [Text Block] Repurchases of common stock Payments to repurchase stock Payments for Repurchase of Common Stock Estimated Useful Life (years) Property, Plant and Equipment, Useful Life Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Risk-free interest minimum rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Par Pharmaceutical, Inc. et al. v. Eagle Pharmaceuticals, Inc. (Vasopressin) Par Pharmaceutical, Inc. Et Al. V. Eagle Pharmaceuticals, Inc. (Vasopressin) [Member] Par Pharmaceutical, Inc. Et Al. V. Eagle Pharmaceuticals, Inc. (Vasopressin) Long-term lease liabilities (included with Other long-term liabilities) Operating Lease, Liability, Noncurrent Interest expense Interest Expense City Area Code City Area Code Retained earnings Retained Earnings (Accumulated Deficit) Litigation Case [Domain] Litigation Case [Domain] Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Restricted stock units RSUs Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Co-promotion agreement, percentage of net revenue receivable due to collaborator Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Net Revenue Receivable Due To Collaborator Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Net Revenue Receivable Due To Collaborator Lessee, operating lease, remaining lease term Lessee, Operating Lease, Remaining Lease Term March 2020 Plan March 2020 Plan [Member] March 2020 Plan [Member] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share Repurchase Program [Axis] Share Repurchase Program [Axis] Advances to commercial manufacturers Advances to commercial manufacturers Advances to commercial manufacturers Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Concentration Risk [Table] Concentration Risk [Table] Collaborative arrangement, rights and obligations, maximum aggregate milestone payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Repayment of existing revolving credit facility Repayments of Lines of Credit Proceeds from common stock option exercises Proceeds from Stock Options Exercised Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Current Assets, Total Increase (Decrease) in Prepaid Expense and Other Current Assets, Total Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax benefit (provision) Income tax benefit (provision) Income Tax Expense (Benefit) Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Proceeds from existing revolving credit facility Proceeds from Issuance of Long-term Debt Equity Components [Axis] Equity Components [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Total current assets Assets, Current Total Lessee, Operating Lease, Liability, to be Paid Accounts receivable Accounts Receivable [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Expired (in shares) Forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Weighted average number of common shares outstanding: Denominator Weighted Average Number of Shares Outstanding Reconciliation [Abstract] 2021 Purchase Obligation, to be Paid, Remainder of Fiscal Year Inventories Total inventories Inventory, Net Investment in Tyme Other Assets, Fair Value Disclosure Entity File Number Entity File Number Stock-Based Compensation Share-based Payment Arrangement [Policy Text Block] 2025 Purchase Obligation, to be Paid, Year Four Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Beyond Lessee, Operating Lease, Liability, to be Paid, after Year Five Number of milestones Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Milestones Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Milestones Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Current portion of long-term debt Long-term Debt, Current Maturities Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Small Business Entity Small Business Basis of Presentation and Other Company Information Basis of Accounting [Text Block] Total revenues Revenue Benchmark [Member] Number of potential future product launches Number Of Potential Future Product Launches Number Of Potential Future Product Launches Equity Component [Domain] Equity Component [Domain] 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Fair Value Adjustment to Embedded Derivative Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Statement [Line Items] Statement [Line Items] Litigation Case [Axis] Litigation Case [Axis] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Period after quarter commercial partners report net product sales Royalty Revenue, Commercial Partners' Obligation of Sales Report, Term Royalty Revenue, Commercial Partners' Obligation of Sales Report, Term Issuance of common stock related to vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Debt securities, available-for-sale Debt Securities, Available-for-sale Share-based payment arrangement, cost by plan Share-based Payment Arrangement, Cost by Plan [Table Text Block] Counterparty Name [Domain] Counterparty Name [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Debt Disclosure [Abstract] Debt Disclosure [Abstract] 2022 Contractual Obligation, to be Paid, Year One Entity Address, State or Province Entity Address, State or Province (Loss) income before income tax benefit (provision) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Fair value of the note, beginning balance Fair value of the note, ending balance Notes Receivable, Fair Value Disclosure Level 2 Fair Value, Inputs, Level 2 [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Fair value adjustments related to derivative instrument Derivative, Gain (Loss) on Derivative, Net Useful Life (In Years) Finite-Lived Intangible Asset, Useful Life Customer [Axis] Customer [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Computation for basic and diluted net (loss) earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Entity Shell Company Entity Shell Company Local Phone Number Local Phone Number Total other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Co-promotion agreement, right to repurchase, amount Securities Purchase Agreement, Co-promotion Agreement, Right To Repurchase, Amount Securities Purchase Agreement, Co-promotion Agreement, Right To Repurchase, Amount Total assets Assets Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward] Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward] Deferred income taxes Deferred Income Taxes and Tax Credits Common stock, shares authorized (in shares) Common Stock, Shares Authorized Concentration of Major Customers and Vendors Major Customers, Policy [Policy Text Block] Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Numerator for basic and diluted (loss) earnings per share-net (loss) earnings Net Income (Loss) Available to Common Stockholders, Basic Research and development Research and Development Expense Product and Service [Domain] Product and Service [Domain] Share Repurchase Programs Accelerated Share Repurchase [Member] Accelerated Share Repurchase [Member] Balance Sheet Accounts Supplemental Balance Sheet Disclosures [Text Block] Bendeka Bendeka [Member] Bendeka [Member] Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving credit facility Revolving Credit Facility [Member] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Tyme Tyme [Member] Tyme [Member] Litigation Status [Axis] Litigation Status [Axis] 2024 Contractual Obligation, to be Paid, Year Three Furniture and fixtures Furniture and Fixtures [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Lease related disclosures Lease, Cost [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Basic net (loss) earnings per share Earnings Per Share, Basic [Abstract] Basic (in shares) Basic weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in dollars per share) Diluted net (loss) earnings per share (in dollars per share) Earnings Per Share, Diluted Noncash operating lease expense related to right-of-use assets Operating Lease, Right-of-Use Asset, Amortization Expense Diluted weighted average common shares outstanding (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Product sales, net Product [Member] Schedule of operating lease obligations and purchase obligations Contractual Obligation, Fiscal Year Maturity [Table Text Block] Income taxes, net Income Taxes Paid, Net Accelerated share repurchases, authorized amount Accelerated Share Repurchases, Authorized Amount Accelerated Share Repurchases, Authorized Amount Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Fair value adjustments on equity investment Fair value loss on equity investment Unrealized Gain (Loss) on Investments Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Treasury stock, at cost, 3,941,541 and 3,682,176 shares as of September 30, 2021 and December 31, 2020, respectively Treasury Stock, Value Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Adjusted London Interbank Offered Rate (LIBOR) Adjusted London Interbank Offered Rate (LIBOR) [Member] Adjusted London Interbank Offered Rate (LIBOR) [Member] Convertible promissory note Receivables, Fair Value Disclosure Schedule of effective income tax rate reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Accounts payable Accounts Payable, Current Concentration Risk Type [Axis] Concentration Risk Type [Axis] Depreciation expense Depreciation, Depletion and Amortization Accelerated share repurchases, initial price paid per share (in dollars per share) Accelerated Share Repurchases, Initial Price Paid Per Share Accrued salary and other compensation Accrued Salaries, Current 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Three Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] 2021 (remainder) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Inventories Increase (Decrease) in Inventories Royalties payable to commercial partners Accrued Royalties, Current Dilutive effect of stock awards (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Financial Instruments [Domain] Financial Instruments [Domain] Other Other Customers [Member] Other Customers [Member] Cost of product sales Cost of Goods and Services Sold Revenue: Revenues [Abstract] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Issuance of common stock related to vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Unrealized gain (loss) for convertible promissory note Fair Value Adjustments to the note OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Stock Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Schedule of property and equipment, net Property, Plant and Equipment [Table Text Block] Term Debt Instrument, Term Income Statement Location [Domain] Income Statement Location [Domain] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Expected achievement rate Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Expected Achievement Rate Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Expected Achievement Rate Loss Contingencies [Line Items] Loss Contingencies [Line Items] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Other long-term liabilities Other Liabilities, Noncurrent Embedded derivative asset in convertible promissory note Embedded Derivative, beginning balance Embedded Derivative, ending balance Embedded Derivative, Fair Value of Embedded Derivative Asset Shares of common stock repurchased (in shares) Treasury Stock, Shares, Acquired Schedule of future amortization expense of finite-lived intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Payment of debt Repayments of Long-term Debt (Loss) earnings per share attributable to common stockholders: Earnings Per Share [Abstract] Property, plant and equipment, gross Property, Plant and Equipment, Gross Document Quarterly Report Document Quarterly Report Beyond Contractual Obligation, to be Paid, after Year Five Equipment Equipment [Member] Cephalon, Inc. (Teva) Cephalon, Inc. [Member] Cephalon, Inc. [Member] Finished products Inventory, Finished Goods, Gross Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Long-term debt, less current portion Long-term Debt, Excluding Current Maturities Stock-based compensation expense Share-based Payment Arrangement, Expense Convertible Promissory Note Convertible Debt Securities [Member] Document Fiscal Period Focus Document Fiscal Period Focus Effective tax rate Effective Income Tax Rate Reconciliation, Percent Amortization of debt issuance costs Amortization of Debt Issuance Costs Accelerated share repurchases, payment Accelerated Share Repurchases, Settlement (Payment) or Receipt Counterparty Name [Axis] Counterparty Name [Axis] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Common stock, par value per share (in dollars per share) Common Stock, Par or Stated Value Per Share Estimated Credit Loss, beginning balance Estimated Credit Loss, ending balance Debt Securities, Available-for-sale, Allowance for Credit Loss Co-promotion agreement, percentage of promotional sales effort responsible for Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Promotional Sales Effort Responsible For Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Promotional Sales Effort Responsible For Risk-free interest maximum rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Statement of Comprehensive Income [Abstract] Current assets: Assets, Current [Abstract] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Co-promotion agreement, percentage of net revenue receivable Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Net Revenue Receivable Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Net Revenue Receivable Entity Central Index Key Entity Central Index Key Schedule of intangible asset Schedule of Finite-Lived Intangible Assets [Table Text Block] Income Taxes Income Tax, Policy [Policy Text Block] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Security Exchange Name Security Exchange Name Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] 2026 Contractual Obligation, to be Paid, Year Five Money market funds Cash and Cash Equivalents, Fair Value Disclosure Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Issuance of common stock upon exercise of stock option grants (in shares) Options Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 2022 Purchase Obligation, to be Paid, Year One Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Income Taxes Income Tax Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Variable interest rate spread Debt Instrument, Basis Spread on Variable Rate Other assets and other long-term liabilities, net Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net Schedule of dilutive and anti-dilutive common shares equivalents outstanding Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] New York Federal Reserve Bank (NYFRB) New York Federal Reserve Bank (NYFRB) [Member] New York Federal Reserve Bank (NYFRB) [Member] Credit Facility [Axis] Credit Facility [Axis] Total Purchase Obligation Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Number of products commercially launched Number Of Products Launched Number Of Products Launched Royalty revenue Royalty [Member] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Schedule of prepaid and other current assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Expected term Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Employee withholding taxes related to stock-based awards Payment, Tax Withholding, Share-based Payment Arrangement Cash paid for amounts included in the measurement of lease liabilities Cash Flow, Operating Activities, Lessee [Abstract] Litigation Status [Domain] Litigation Status [Domain] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Loss Contingencies [Table] Loss Contingencies [Table] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Title of 12(b) Security Title of 12(b) Security All other Other Assets, Current Statement [Table] Statement [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] RSUs and PSUs Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Cover [Abstract] Cover [Abstract] Net Book Value Finite-Lived Intangible Assets, Net Goodwill Goodwill License and other revenue License [Member] Forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Inventories Inventory, Policy [Policy Text Block] Adjustments to reconcile net (loss) income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Developed technology Developed Technology Rights [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] EX-101.PRE 11 egrx-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 egrx-20210930_htm.xml IDEA: XBRL DOCUMENT 0000827871 2021-01-01 2021-09-30 0000827871 2021-11-02 0000827871 2021-09-30 0000827871 2020-12-31 0000827871 us-gaap:ProductMember 2021-07-01 2021-09-30 0000827871 us-gaap:ProductMember 2020-07-01 2020-09-30 0000827871 us-gaap:ProductMember 2021-01-01 2021-09-30 0000827871 us-gaap:ProductMember 2020-01-01 2020-09-30 0000827871 us-gaap:RoyaltyMember 2021-07-01 2021-09-30 0000827871 us-gaap:RoyaltyMember 2020-07-01 2020-09-30 0000827871 us-gaap:RoyaltyMember 2021-01-01 2021-09-30 0000827871 us-gaap:RoyaltyMember 2020-01-01 2020-09-30 0000827871 us-gaap:LicenseMember 2021-07-01 2021-09-30 0000827871 us-gaap:LicenseMember 2020-07-01 2020-09-30 0000827871 us-gaap:LicenseMember 2021-01-01 2021-09-30 0000827871 us-gaap:LicenseMember 2020-01-01 2020-09-30 0000827871 2021-07-01 2021-09-30 0000827871 2020-07-01 2020-09-30 0000827871 2020-01-01 2020-09-30 0000827871 us-gaap:CommonStockMember 2021-06-30 0000827871 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000827871 us-gaap:TreasuryStockMember 2021-06-30 0000827871 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000827871 us-gaap:RetainedEarningsMember 2021-06-30 0000827871 2021-06-30 0000827871 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000827871 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000827871 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0000827871 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000827871 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000827871 us-gaap:CommonStockMember 2021-09-30 0000827871 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000827871 us-gaap:TreasuryStockMember 2021-09-30 0000827871 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000827871 us-gaap:RetainedEarningsMember 2021-09-30 0000827871 us-gaap:CommonStockMember 2020-12-31 0000827871 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000827871 us-gaap:TreasuryStockMember 2020-12-31 0000827871 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000827871 us-gaap:RetainedEarningsMember 2020-12-31 0000827871 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000827871 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000827871 us-gaap:TreasuryStockMember 2021-01-01 2021-09-30 0000827871 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000827871 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000827871 us-gaap:CommonStockMember 2020-06-30 0000827871 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000827871 us-gaap:TreasuryStockMember 2020-06-30 0000827871 us-gaap:RetainedEarningsMember 2020-06-30 0000827871 2020-06-30 0000827871 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000827871 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000827871 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000827871 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000827871 us-gaap:CommonStockMember 2020-09-30 0000827871 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000827871 us-gaap:TreasuryStockMember 2020-09-30 0000827871 us-gaap:RetainedEarningsMember 2020-09-30 0000827871 2020-09-30 0000827871 us-gaap:CommonStockMember 2019-12-31 0000827871 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000827871 us-gaap:TreasuryStockMember 2019-12-31 0000827871 us-gaap:RetainedEarningsMember 2019-12-31 0000827871 2019-12-31 0000827871 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000827871 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000827871 us-gaap:TreasuryStockMember 2020-01-01 2020-09-30 0000827871 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000827871 us-gaap:FairValueInputsLevel1Member 2021-09-30 0000827871 us-gaap:FairValueInputsLevel2Member 2021-09-30 0000827871 us-gaap:FairValueInputsLevel3Member 2021-09-30 0000827871 us-gaap:FairValueInputsLevel1Member 2020-12-31 0000827871 us-gaap:FairValueInputsLevel2Member 2020-12-31 0000827871 us-gaap:FairValueInputsLevel3Member 2020-12-31 0000827871 egrx:CephalonInc.Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000827871 egrx:CephalonInc.Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000827871 egrx:CephalonInc.Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000827871 egrx:CephalonInc.Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000827871 egrx:OtherCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000827871 egrx:OtherCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000827871 egrx:OtherCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000827871 egrx:OtherCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000827871 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000827871 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000827871 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000827871 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000827871 egrx:CephalonInc.Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000827871 egrx:CephalonInc.Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000827871 egrx:OtherCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000827871 egrx:OtherCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000827871 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000827871 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000827871 egrx:BendekaMember 2021-01-01 2021-09-30 0000827871 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0000827871 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0000827871 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0000827871 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000827871 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0000827871 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0000827871 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0000827871 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0000827871 us-gaap:FurnitureAndFixturesMember 2021-09-30 0000827871 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000827871 us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-09-30 0000827871 us-gaap:OfficeEquipmentMember 2021-09-30 0000827871 us-gaap:OfficeEquipmentMember 2020-12-31 0000827871 us-gaap:OfficeEquipmentMember 2021-01-01 2021-09-30 0000827871 us-gaap:EquipmentMember 2021-09-30 0000827871 us-gaap:EquipmentMember 2020-12-31 0000827871 us-gaap:EquipmentMember 2021-01-01 2021-09-30 0000827871 us-gaap:LeaseholdImprovementsMember 2021-09-30 0000827871 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000827871 us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-09-30 0000827871 2020-01-01 2020-12-31 0000827871 egrx:RoyaltyBuyBackAgreementMember 2021-01-01 2021-09-30 0000827871 egrx:RoyaltyBuyBackAgreementMember 2021-09-30 0000827871 us-gaap:DevelopedTechnologyRightsMember 2021-01-01 2021-09-30 0000827871 us-gaap:DevelopedTechnologyRightsMember 2021-09-30 0000827871 egrx:RoyaltyBuyBackAgreementMember 2020-01-01 2020-12-31 0000827871 egrx:RoyaltyBuyBackAgreementMember 2020-12-31 0000827871 us-gaap:DevelopedTechnologyRightsMember 2020-01-01 2020-12-31 0000827871 us-gaap:DevelopedTechnologyRightsMember 2020-12-31 0000827871 egrx:March2020PlanMember 2020-03-17 0000827871 egrx:October2018PlanMember 2018-10-31 2020-03-17 0000827871 egrx:March2020PlanMember 2020-09-23 0000827871 egrx:March2020PlanMember 2020-09-24 0000827871 egrx:March2020PlanMember 2020-09-24 2020-09-24 0000827871 egrx:March2020PlanMember 2020-01-01 2020-12-31 0000827871 egrx:AcceleratedShareRepurchaseMember 2016-08-01 2021-06-30 0000827871 us-gaap:PerformanceSharesMember 2021-01-01 2021-03-31 0000827871 egrx:SPBiotechnologyMember us-gaap:PerformanceSharesMember 2021-01-01 2021-03-31 0000827871 egrx:MilestonePerformanceBasedStockUnitsMember 2021-01-01 2021-03-31 0000827871 srt:MinimumMember egrx:MilestonePerformanceBasedStockUnitsMember 2021-01-01 2021-03-31 0000827871 srt:MaximumMember egrx:MilestonePerformanceBasedStockUnitsMember 2021-01-01 2021-03-31 0000827871 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000827871 us-gaap:PerformanceSharesMember 2019-12-31 0000827871 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0000827871 us-gaap:PerformanceSharesMember 2020-01-01 2020-09-30 0000827871 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0000827871 us-gaap:PerformanceSharesMember 2020-09-30 0000827871 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0000827871 us-gaap:PerformanceSharesMember 2020-12-31 0000827871 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0000827871 us-gaap:PerformanceSharesMember 2021-01-01 2021-09-30 0000827871 us-gaap:RestrictedStockUnitsRSUMember 2021-09-30 0000827871 us-gaap:PerformanceSharesMember 2021-09-30 0000827871 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0000827871 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0000827871 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0000827871 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000827871 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0000827871 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0000827871 us-gaap:PerformanceSharesMember 2021-07-01 2021-09-30 0000827871 us-gaap:PerformanceSharesMember 2020-07-01 2020-09-30 0000827871 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0000827871 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000827871 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0000827871 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000827871 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0000827871 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0000827871 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0000827871 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0000827871 us-gaap:LineOfCreditMember egrx:SecondAmendedAndRestatedCreditAgreementMember 2019-11-08 2019-11-08 0000827871 us-gaap:RevolvingCreditFacilityMember egrx:SecondAmendedAndRestatedCreditAgreementMember 2019-11-08 0000827871 srt:MinimumMember egrx:SecondAmendedAndRestatedCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-11-08 2019-11-08 0000827871 srt:MaximumMember egrx:SecondAmendedAndRestatedCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-11-08 2019-11-08 0000827871 egrx:SecondAmendedAndRestatedCreditAgreementMember egrx:AdjustedLondonInterbankOfferedRateLIBORMember 2019-11-08 2019-11-08 0000827871 srt:MinimumMember egrx:SecondAmendedAndRestatedCreditAgreementMember us-gaap:PrimeRateMember 2019-11-08 2019-11-08 0000827871 srt:MaximumMember egrx:SecondAmendedAndRestatedCreditAgreementMember us-gaap:PrimeRateMember 2019-11-08 2019-11-08 0000827871 srt:MinimumMember egrx:SecondAmendedAndRestatedCreditAgreementMember 2019-11-08 2019-11-08 0000827871 srt:MaximumMember egrx:SecondAmendedAndRestatedCreditAgreementMember 2019-11-08 2019-11-08 0000827871 egrx:SecondAmendedAndRestatedCreditAgreementMember egrx:NewYorkFederalReserveBankNYFRBMember 2019-11-08 2019-11-08 0000827871 egrx:ParPharmaceuticalIncEtAlVEaglePharmaceuticalsIncVasopressinMember us-gaap:PendingLitigationMember 2019-12-20 2019-12-20 0000827871 egrx:CombioxinMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-08-31 0000827871 egrx:AOPOrphanPharmaceuticalsGmbHMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-09-30 0000827871 egrx:AOPOrphanPharmaceuticalsGmbHMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-08-31 0000827871 egrx:TymeMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2020-01-07 0000827871 egrx:TymeMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-07-01 2021-09-30 0000827871 egrx:TymeMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2020-07-01 2020-09-30 0000827871 egrx:TymeMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-01-01 2021-09-30 0000827871 egrx:TymeMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2020-01-01 2020-09-30 0000827871 us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0000827871 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-03-31 0000827871 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-09-30 0000827871 us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0000827871 us-gaap:ConvertibleDebtSecuritiesMember 2021-06-30 0000827871 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2021-09-30 shares iso4217:USD iso4217:USD shares egrx:product pure egrx:milestone egrx:jurisdiction egrx:patent 0000827871 --12-31 2021 Q3 false http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent 0.005 10-Q true 2021-09-30 false 001-36306 Eagle Pharmaceuticals, Inc. DE 20-8179278 50 Tice Boulevard Suite 315 Woodcliff Lake NJ 07677 (201) 326-5300 Common stock, $0.001 par value per share EGRX NASDAQ Yes Yes Accelerated Filer false false false 12913879 99741000 103155000 45335000 50678000 9315000 8075000 17303000 4157000 171694000 166065000 1775000 2077000 10799000 12917000 39743000 39743000 17713000 15180000 14537000 17208000 256261000 253190000 12717000 6268000 27714000 23817000 8000000 8000000 48431000 38085000 3048000 3959000 19489000 25135000 70968000 67179000 1500000 1500000 0 0 0 0 0 0 0.001 0.001 50000000 50000000 16886123 16739203 17000 17000 320566000 305403000 -882000 0 82058000 84489000 3941541 3682176 216466000 203898000 185293000 186011000 256261000 253190000 12124000 17317000 48865000 49387000 27729000 27611000 80361000 83499000 0 5000000 0 5000000 39853000 49928000 129226000 137886000 5486000 8726000 21835000 23804000 2773000 3260000 8036000 9120000 23289000 4828000 47488000 21390000 18482000 17697000 54997000 60411000 50030000 34511000 132356000 114725000 -10177000 15417000 -3130000 23161000 197000 46000 395000 542000 396000 489000 1240000 2164000 -2284000 -6049000 -1797000 -10249000 -2483000 -6492000 -2642000 -11871000 -12660000 8925000 -5772000 11290000 -7038000 1866000 -3341000 7358000 -5622000 7059000 -2431000 3932000 -0.43 0.52 -0.19 0.29 -0.43 0.51 -0.19 0.28 13077298 13531372 13103203 13620981 13077298 13786803 13103203 13917800 -5622000 7059000 -2431000 3932000 22000 0 -882000 0 22000 0 -882000 0 -5600000 7059000 -3313000 3932000 16880000 17000 316249000 -208195000 -904000 87680000 194847000 4084000 4084000 6000 233000 233000 8271000 8271000 22000 22000 -5622000 -5622000 16886000 17000 320566000 -216466000 -882000 82058000 185293000 16739000 17000 305403000 -203898000 0 84489000 186011000 14873000 14873000 84000 1841000 1841000 63000 -1551000 -1551000 12568000 12568000 -882000 -882000 -2431000 -2431000 16886000 17000 320566000 -216466000 -882000 82058000 185293000 16622000 17000 291434000 -176860000 69373000 183964000 4722000 4722000 3000 42000 42000 23000000 23000000 7059000 7059000 16625000 17000 296198000 -199860000 76432000 172787000 16538000 17000 278518000 -171861000 72500000 179174000 18435000 18435000 42000 555000 555000 1310000 1310000 45000 27999000 27999000 3932000 3932000 16625000 17000 296198000 -199860000 76432000 172787000 -2431000 3932000 -2533000 -1671000 575000 656000 768000 980000 2118000 1999000 -1900000 -7700000 14873000 18435000 150000 0 354000 301000 254000 -2549000 102000 0 -5343000 4195000 1240000 20000 8821000 2774000 6449000 7606000 3897000 -3916000 908000 1845000 20138000 29737000 0 17500000 274000 577000 5000000 0 -5274000 -18077000 1841000 555000 1551000 1310000 0 110000000 0 110000000 6000000 3000000 12568000 27999000 -18278000 -31754000 -3414000 -20094000 103155000 109775000 99741000 89681000 6303000 3036000 917000 1878000 0 842000 Basis of Presentation and Other Company Information <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting quarterly information. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2020 was derived from audited financial statements, but certain information and footnote disclosures normally included in our annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results for the year ending December 31, 2021 or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 5, 2021. </span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an integrated pharmaceutical company focused on finding ways to help medicines do more for patients. We and our collaborators have the capabilities to take a molecule from preclinical research through regulatory approval and into the marketplace, including development, manufacturing and commercialization. Our business model applies our scientific expertise, proprietary research-based insights and marketplace proficiency to identify challenging-to-treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. By focusing on patients' unmet needs, we strive to provide healthcare professionals with urgently needed treatment solutions that are designed to improve patient care and outcomes and create near- and long-term value for our stakeholders, including patients and healthcare providers and our employees, marketing partners, collaborators and investors. Our science-based business model has a proven track record with U.S. Food and Drug Administration ("FDA") approval and commercial launches of three products: Ryanodex® (dantrolene sodium) ("Ryanodex"), bendamustine ready-to-dilute ("RTD") 500ml solution ("Belrapzo"), and rapidly infused bendamustine RTD ("Bendeka"). We market our products through marketing partners and/or our internal direct sales force. We market Ryanodex and Belrapzo, and Teva Pharmaceutical Industries Ltd. ("Teva") markets Bendeka through its subsidiary Cephalon, Inc. SymBio Pharmaceuticals Limited, or SymBio, marke</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ts Treakisym, a RTD product, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Japan. Reflecting further expansion of our oncology portfolio, in February 2020, we received final FDA approval for Pemfexy, a branded alternative to Alimta for metastatic non-squamous non-small cell lung cancer and malignant pleural mesothelioma. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With several pipeline projects underway and the potential for up to five product launches over the next several years, we believe we have many growth opportunities ahead. We believe that each of our pipeline projects currently has the potential to enter the market as a first-in-class, first-to-file, first-to-market or best-in-class product. In particular, we are applying our expertise to conduct novel research regarding the potential for Ryanodex to address conditions inclu</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ding Alzheimer’s disease, traumatic brain injury/concussion, nerve agent exposure and acute radiation syndrome. In ad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dition, our clinical development program includes a strategic partnership with Tyme Technologies, Inc., or Tyme, for Tyme’s product candidate for the treatment of patients with pancreatic or other advanced cancers, SM-88, as well as investigations of compounds such as EA-114 (our fulvestrant product candidate) for patients with HR-positive advanced breast cancer. Other products in development include Vasopressin, ou</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r first-to-file Abbreviated New Drug Application, or ANDA, that references Endo International plc’s Vasostrict indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines; and EA-111, a new chemical entity and next-generation ryanodine receptor antagonist, in an intramuscular formulation that that would allow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for easier and more rapid administration in emergency situations (military and civilian).</span></div> 3 5 Summary of Significant Accounting Policies<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 and the notes thereto filed with the SEC on March 5, 2021. Since the date </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of those consolidated financial statements, there have been no material changes to our significant accounting policies other than as listed below.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Risks and Uncertainties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In response to the ongoing COVID-19 pandemic, we have taken and continue to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on our business, such as remote working policies, facilitating management’s periodic communication to address employee and business concerns and providing frequent updates to our Board of Directors (“Board”). During t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">he second quar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ter of 2021, we implemented a plan to reopen our office to allow employees to return to the office, with a focus on employee safety and optimal work environment. Our management continues to monitor and evaluate such plans as the pandemic continues to evolve. We anticipate that the COVID-19 pandemic may also have an impact on the clinical development timelines for certain of our clinical programs. We also anticipate that the COVID-19 pandemic may have an impact on our supply chain. The COVID-19 pandemic and associated lockdowns have resulted in a decrease in healthcare utilization broadly and specifically lead to a continuing reduction in the utilization of physician-administered oncology products including Belrapzo and Bendeka. In addition, the COVID-19 pandemic has delayed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the timing of certain litigation, including the litigation with Par (as defined below) with respect to Vasopressin, and we anticipate that such delays will continue for the duration of the pandemic. The extent to which the COVID-19 pandemic will continue to impact our business, clinical development and regulatory efforts, supply chain and sales efforts, corporate development objectives and the value of, and market for, our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and other risks and uncertainties associated with the pandemic have impacted our operations and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we are subject to other challenges and risks specific to our business and our ability to execute on our business plan and strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with research and development operations, including, without limitation, risks and uncertainties associated with: delays or problems in obtaining clinical supply; obtaining regulatory approval of product candidates; loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing intellectual property rights; and the challenges of complying with applicable regulatory requirements. In addition, as the ongoing COVID-19 pandemic affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. Our critical accounting policies are those that are both most important to our financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. We anticipate that the COVID-19 pandemic will continue to disrupt our supply chain and marketing and sales efforts for certain of our products, including Bendeka, although it is not currently expected that any disruption would be significant. As of the date of issuance of these financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying value of our assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates, and any such differences may be material to our financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform with the current year presentation, including for amounts related to accounts receivable, net and prepaid expenses and other current assets. None of the amounts pertaining to the reclassifications were significant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, at times, maintain balances with financial institutions in excess of the Federal Deposit Insurance Corporation (“FDIC”) limit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of interest-bearing cash, cash equivalents, accounts receivable and accounts payable approximate fair value due to their life being short term in nature, and are classified as Level 1 for all periods presented.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured and recognized at fair value are as follows:</span></div><div style="margin-bottom:3pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible promissory note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative asset in convertible promissory note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Tyme</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,880 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,555 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.787%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,682 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,682 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Tyme</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,882 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,882 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We recognize transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months or nine months ended September 30, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our investment in the convertible promissory note and the embedded derivative are classified as Level 3. We analyzed and accessed the embedded derivative feature contained in the convertible promissory note agreement. We used a probability factor to value the embedded derivative asset based on management's best estimate, including the principal and estimated accrued interest among other contractual terms. The convertible promissory note is accounted for as available for sale. The convertible promissory note is reported at fair value with unrealized gains and losses included in Accumulated other comprehensive income (loss). Refer to Note 13, Convertible Promissory Note for further details. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our investment in restricted shares of common stock of Tyme Technologies, Inc.are classified as Level 1. Refer to Note 12, License and Collaboration Agreements for further details. </span></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of debt is classified as Level 2 for the periods presented and approximates its book value due to the variable interest rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We review the recoverability of our finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, we assess the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, we measure the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets. The Company determined that no indicators of impairment of finite-lived intangible assets or long-lived assets existed as of September 30, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:2pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of purchase price over the fair value of net assets acquired in the Eagle Biologics acquisition. Goodwill is not amortized, but is evaluated for impairment on an annual basis, in the fourth quarter, or more frequently if events or changes in circumstances indicate that the reporting unit’s goodwill is less than its carrying amount. We did not identify any impairment to goodwill during the periods presented.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Major Customers and Vendors</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our commercial partner, Teva, who markets and sells Bendeka. Our customer for Bendeka is our commercial and licensing partner; therefore, our future revenues are highly dependent on the related exclusive license and distribution arrangement.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total revenues and accounts receivables broken down by major customers as a percentage of the total are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:43.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.490%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teva - See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Recognition</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"/><td style="width:60.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.101%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teva - See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Recognition</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost and net realizable value, with cost determined on a first-in first-out basis. We periodically review the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, we will record a write-down to lower of cost and net realizable value in the period that the decline in value is first recognized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for research and development are charged to expense as incurred and include; employee-related expenses including salaries, benefits, travel and stock-based compensation expense for research and development personnel; expenses incurred under agreements with contract research organizations, contract manufacturing organizations and service providers that assist in conducting clinical and preclinical studies; costs associated with preclinical activities and development activities, costs associated with regulatory operations; and depreciation expense for assets used in research and development activities. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for certain development activities, such as in licensing intellectual property related to new projects, clinical studies, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid expenses or accrued expenses as deemed appropriate. Recoveries of previously recognized research and development expenses from third parties are recorded as a reduction to research and development expense in the period it becomes realizable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising and marketing costs are expensed as incurred. Advertising and marketing costs were $0.5 million and $0.3 million for the three months ended September 30, 2021 and 2020, respectively, and $1.3 million and $2.2 million for the nine months ended September 30, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes using the liability method in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), 740 - Income Taxes (“ASC 740”). Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax bases of assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income (loss) in the period that the rate changes. A valuation allowance is required when it is “more likely than not” that all or a portion of deferred tax assets will not be realized. ASC 740 also prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that a company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. We recognize any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">arrangements that an entity determines are within the scope of ASC 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">- Revenue from Contracts with Customers (“ASC 606”), we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determines those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Receivables from our product sales have payment terms ranging from 30 to 75 days with select extended terms to wholesalers on initial purchases of product launch quantities. Our receivables from royalty revenue are due 45 days from the end of the quarter.</span></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- We recognize net revenue on sales to our commercial partners and to end users. In each instance, revenue is generally recognized when the customer obtains control of our product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenue on sales to commercial partners relates to Bendeka and Treakisym. Sales to our commercial partners are presented gross because we are primarily responsible for fulfilling the promise to provide the product, and are responsible to ensure that the product is produced in accordance with the related supply agreement and we bear risk of loss while the inventory is in-transit to the commercial partner.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services to a customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing the expected value method to which we expect to be entitled. As such, revenue on sales to customers for Belrapzo and Ryanodex are recorded net of chargebacks, rebates, returns, prompt pay discounts, wholesaler fees and other deductions. Our products are contracted with a limited number of oncology distributors and hospital buying groups with narrow differences in ultimate realized contract prices used to estimate our chargeback and rebate reserves. We have a product return policy on some of our products that allows the customer to return pharmaceutical products within a specified period of time both prior to and subsequent to the product’s expiration date. Our estimate of the provision for returns is analyzed quarterly and is based upon many factors, including historical experience of actual returns and analysis of the level of inventory in the distribution channel, if any. We have terms on sales of Ryanodex by which we do not accept returns. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration are made using the expected value method and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available. We believe that the estimates we have established are reasonable based upon current facts and circumstances. Applying different judgments to the same facts and circumstances could result in the estimated amounts to vary.</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Components of Gross-to-Net (GTN) Estimates</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Chargebacks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Chargebacks are discounts that occur when certain contracted customers, including group purchasing organizations (“GPOs”), public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase from our distributors. Our distributors purchase product from us at invoice price, then resell the product to certain contracted customers on the basis of prices negotiated between us and the providers. The difference between the distributors’ purchase price and the typically lower certain contracted customers’ purchase price is refunded to the distributors through a chargeback credit. We record estimates for these chargebacks at the time of sale as deductions from gross revenues, with corresponding adjustments to our accounts receivable reserves and allowances.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for chargebacks is the most significant provision in the context of our gross-to-net adjustments in the determination of net revenue. Chargebacks are estimated based on payer mix and contracted price, adjusted for current period assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Commercial and Medicaid Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: We contract with government agencies or collectively, third-party payors, so that Belrapzo and Ryanodex will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. We estimate the rebates we will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reduction of product revenue and the establishment of a current liability. The current liability is included in accrued expenses and other current liabilities on the consolidated balance sheets. We estimate the rebates that we will provide to third-party payors based upon (i) our contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payer mix, and (iv) information obtained from our distributors. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information that we also consider when establishing our rebate reserves are purchases by customers, projected annual sales for customers, actual rebates payments made, processing time lags, and for indirect rebates, the level of inventory in the distribution channel that will be subject to indirect rebates. We do not provide incentives designed to increase shipments to our customers that we believe would result in out-of-the-ordinary course of business inventory for them. We regularly review and monitor estimated or actual customer inventory information at our largest distributors for our key products to ascertain whether customer inventories are in excess of ordinary course of business levels.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Product Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our distributors have the right to return unopened unprescribed Belrapzo during certain time periods around the period beginning prior to the labeled expiration date and ending after the labeled expiration date. We estimate future product returns on sales of Belrapzo based on: (i) data provided to us by our distributors (including weekly reporting of distributors’ sales and inventory held by distributors that provided us with visibility into the distribution channel in order to determine what quantities were sold to retail pharmacies and other providers), (ii) information provided to us from retail pharmacies, (iii) data provided to us by a third-party data provider which collects and publishes prescription data, and other third parties, (iv) historical industry information regarding return rates for similar pharmaceutical products, (v) the estimated remaining shelf life of Belrapzo previously shipped and currently being shipped to distributors and (vi) contractual agreements intended to limit the amount of inventory maintained by our distributors. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for product returns based on the factors noted above generally encompass a time range from 12 to 48 months after revenue is recognized. Additionally, we consider other factors when estimating our current period return provision, including levels of inventory in the distribution channel, significant market changes that may impact future expected returns, and actual product returns, and may record additional provisions for specific returns that it believes are not covered by the historical rates. Our commercial returns policy and terms with certain customers also states that certain products are sold as non-returnable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Wholesaler fees and other incentives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: We generally provide invoice discounts on Belrapzo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ryanodex sales to our distributors for prompt payment and fees for distribution services, such as fees for certain data that distributors provide to us. The payment terms for sales to distributors generally include a 2% discount for prompt payment which is generally defined in invoice terms as a range from 30 to 70 days, while the fees for distribution services are based on contractual rates agreed with the respective distributors. Based on historical data, we expect our distributors to earn these discounts and fees, and deducts the full amount of these discounts and fees from our gross product revenues and accounts receivable at the time such revenues are recognized. </span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other GTN considerations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may at our discretion provide price adjustments due to various competitive factors. There are circumstances under which we may not provide price adjustments to certain customers as a matter of business strategy, and consequently may lose future sales volume to competitors and risk a greater level of product returns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed above, we have the experience and access to relevant information that we believe are necessary to reasonably estimate the amounts of such deductions from gross revenues. Some of the assumptions we use for certain of these estimates are based on information received from third parties, such as wholesale customer inventories and market data, or other market factors beyond our control. The estimates that are most critical to the establishment of these reserves, and therefore, would have the largest impact if these estimates were not accurate, are estimates related to contract sales volumes, average contract pricing, customer inventories and return volumes. We regularly review the information related to these estimates and adjust our reserves accordingly, if and when actual experience differs from previous estimates. With the exception of the product returns allowance, the ending balances of accounts receivable reserves and allowances generally are processed during a two-month to four-month period.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — We recognize revenue from license arrangements with our commercial partners' net sales of products. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner’s products occurs. Our commercial partners are obligated to report their net product sales and the resulting royalty due to us within 25 days for Bendeka. Based on historical product sales, royalty receipts and other relevant information, we accrue royalty revenue each quarter and subsequently determine a true-up when we receive royalty reports from our commercial partners. Historically, these true-up adjustments have been immaterial.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and other revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— We analyze each element of our licensing agreements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. We determine standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, we estimate the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, we determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, we assess each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of these future events, we will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, we do not assess whether a significant financing component exists if the period between when we perform our obligations under the contract and when the customer pays is one year or less. None of our contracts contained a significant financing component as of September 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation using the fair value provisions of ASC 718, Compensation - Stock Compensation that requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock-based payments including stock options and restricted stock. This topic requires companies to estimate the fair value of the stock-based awards on the date of grant for options issued to employees and directors and record expense over the employees' service periods, which are generally the vesting period of the equity awards. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation by measuring and recognizing compensation expense for all stock-based payments made to employees and directors based on estimated grant date fair values. The straight-line method is used to allocate compensation cost to reporting periods over each optionee's requisite service period, which is generally the vesting period. The fair value of our stock option awards to employees and directors is estimated using the Black-Scholes valuation model and a Monte Carlo simulation model is used to estimate the fair value for market condition share units. These models require the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, historical forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate is determined with the implied yield currently available for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options. The fair value of restricted stock units ("RSUs") granted are estimated based on the trading price of our common stock on the date of grant. The fair value of performance condition performance-based stock units ("PSUs") granted are also estimated based on the trading price of our common stock on the date of grant and adjusted for the probability of achievement of the performance conditions. Forfeitures are estimated for all stock-based awards. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per common share is computed using the weighted average number of shares outstanding during the period. Diluted earnings per share is computed in a manner similar to the basic earnings per share, except that the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of warrants, options, convertible debt and other such convertible instruments. Diluted earnings per share contemplate a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The anti-dilutive common share equivalents outstanding for the three and nine months ended September 30, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:42.856%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.830%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.557%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,446,657 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,156,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,777,995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905,021 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,446,657 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,362,057 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,901,595 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,130,198 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation for basic and diluted net (loss) earnings per share for the three and nine months ended September 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:44.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for basic and diluted (loss) earnings per share-net (loss) earnings </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,622)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,059 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,431)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,932 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,077,298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,531,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,103,203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,620,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock awards </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding </span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,077,298 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,786,803 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,103,203 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,917,800 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net (loss) earnings per share </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) earnings per share </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net (loss) earnings per share </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) earnings per share </span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All potentially dilutive items were excluded from the diluted share calculation for the three months and nine months ended September 30, 2021 because their effect would have been anti-dilutive, as the Company was in a loss position.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Update 2020-04 Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting to provide temporary optional guidance to ease the potential burden in accounting for </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reference rate reform. The amendments in Update 2020-04 are elective and apply to all entities that have contracts, hedging relationships, and other transactions that reference LIBOR, formerly known as the London Interbank Offered Rate,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or another reference rate expected to be discontinued due to reference rate reform. The new guidance provides optional expedients, including; (1) Simplify accounting analyses under current GAAP for contract modifications, such as modifications of contracts within the scope of Topic 470, Debt, that will be accounted for by prospectively adjusting the effective interest rate, as if any modification was not substantial. That is, the original contract and the new contract shall be accounted for as if they were not substantially different from one another; (2) Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue; (3) Allow a one-time election to sell or transfer debt securities classified as held to maturity before January 1, 2020 that reference a rate affected by reference rate reform. The amendments are effective for all entities from the beginning of an interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The adoption of ASU 2020-4 is not expected to have a material impact on our financial position or results of operations.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. Our critical accounting policies are those that are both most important to our financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. We anticipate that the COVID-19 pandemic will continue to disrupt our supply chain and marketing and sales efforts for certain of our products, including Bendeka, although it is not currently expected that any disruption would be significant. As of the date of issuance of these financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying value of our assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates, and any such differences may be material to our financial statements.</span></div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform with the current year presentation, including for amounts related to accounts receivable, net and prepaid expenses and other current assets. None of the amounts pertaining to the reclassifications were significant.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, at times, maintain balances with financial institutions in excess of the Federal Deposit Insurance Corporation (“FDIC”) limit.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of interest-bearing cash, cash equivalents, accounts receivable and accounts payable approximate fair value due to their life being short term in nature, and are classified as Level 1 for all periods presented.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We recognize transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months or nine months ended September 30, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our investment in the convertible promissory note and the embedded derivative are classified as Level 3. We analyzed and accessed the embedded derivative feature contained in the convertible promissory note agreement. We used a probability factor to value the embedded derivative asset based on management's best estimate, including the principal and estimated accrued interest among other contractual terms. The convertible promissory note is accounted for as available for sale. The convertible promissory note is reported at fair value with unrealized gains and losses included in Accumulated other comprehensive income (loss). Refer to Note 13, Convertible Promissory Note for further details. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our investment in restricted shares of common stock of Tyme Technologies, Inc.are classified as Level 1. Refer to Note 12, License and Collaboration Agreements for further details. </span></div>The fair value of debt is classified as Level 2 for the periods presented and approximates its book value due to the variable interest rate. <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured and recognized at fair value are as follows:</span></div><div style="margin-bottom:3pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible promissory note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative asset in convertible promissory note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Tyme</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,880 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,555 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.787%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,682 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,682 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Tyme</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,882 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,882 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 95255000 95255000 0 0 3795000 0 0 3795000 530000 0 0 530000 10300000 10300000 0 0 109880000 105555000 0 4325000 79682000 79682000 0 0 12200000 12200000 0 0 91882000 91882000 0 0 Intangible Assets We review the recoverability of our finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, we assess the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, we measure the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets. The Company determined that no indicators of impairment of finite-lived intangible assets or long-lived assets existed as of September 30, 2021. GoodwillGoodwill represents the excess of purchase price over the fair value of net assets acquired in the Eagle Biologics acquisition. Goodwill is not amortized, but is evaluated for impairment on an annual basis, in the fourth quarter, or more frequently if events or changes in circumstances indicate that the reporting unit’s goodwill is less than its carrying amount. 0 0 0 0 <div style="margin-bottom:8pt;margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Major Customers and Vendors</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our commercial partner, Teva, who markets and sells Bendeka. Our customer for Bendeka is our commercial and licensing partner; therefore, our future revenues are highly dependent on the related exclusive license and distribution arrangement.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total revenues and accounts receivables broken down by major customers as a percentage of the total are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:43.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.490%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teva - See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Recognition</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"/><td style="width:60.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.101%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teva - See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Recognition</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table> 0.69 0.74 0.66 0.72 0.31 0.26 0.34 0.28 1 1 1 1 0.63 0.58 0.37 0.42 1 1 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost and net realizable value, with cost determined on a first-in first-out basis. We periodically review the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, we will record a write-down to lower of cost and net realizable value in the period that the decline in value is first recognized.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for research and development are charged to expense as incurred and include; employee-related expenses including salaries, benefits, travel and stock-based compensation expense for research and development personnel; expenses incurred under agreements with contract research organizations, contract manufacturing organizations and service providers that assist in conducting clinical and preclinical studies; costs associated with preclinical activities and development activities, costs associated with regulatory operations; and depreciation expense for assets used in research and development activities. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for certain development activities, such as in licensing intellectual property related to new projects, clinical studies, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid expenses or accrued expenses as deemed appropriate. Recoveries of previously recognized research and development expenses from third parties are recorded as a reduction to research and development expense in the period it becomes realizable.</span></div> Advertising and MarketingAdvertising and marketing costs are expensed as incurred. 500000 300000 1300000 2200000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes using the liability method in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), 740 - Income Taxes (“ASC 740”). Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax bases of assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income (loss) in the period that the rate changes. A valuation allowance is required when it is “more likely than not” that all or a portion of deferred tax assets will not be realized. ASC 740 also prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that a company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. We recognize any interest and penalties accrued related to unrecognized tax benefits as income tax expense.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">arrangements that an entity determines are within the scope of ASC 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">- Revenue from Contracts with Customers (“ASC 606”), we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determines those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Receivables from our product sales have payment terms ranging from 30 to 75 days with select extended terms to wholesalers on initial purchases of product launch quantities. Our receivables from royalty revenue are due 45 days from the end of the quarter.</span></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- We recognize net revenue on sales to our commercial partners and to end users. In each instance, revenue is generally recognized when the customer obtains control of our product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenue on sales to commercial partners relates to Bendeka and Treakisym. Sales to our commercial partners are presented gross because we are primarily responsible for fulfilling the promise to provide the product, and are responsible to ensure that the product is produced in accordance with the related supply agreement and we bear risk of loss while the inventory is in-transit to the commercial partner.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services to a customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing the expected value method to which we expect to be entitled. As such, revenue on sales to customers for Belrapzo and Ryanodex are recorded net of chargebacks, rebates, returns, prompt pay discounts, wholesaler fees and other deductions. Our products are contracted with a limited number of oncology distributors and hospital buying groups with narrow differences in ultimate realized contract prices used to estimate our chargeback and rebate reserves. We have a product return policy on some of our products that allows the customer to return pharmaceutical products within a specified period of time both prior to and subsequent to the product’s expiration date. Our estimate of the provision for returns is analyzed quarterly and is based upon many factors, including historical experience of actual returns and analysis of the level of inventory in the distribution channel, if any. We have terms on sales of Ryanodex by which we do not accept returns. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration are made using the expected value method and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available. We believe that the estimates we have established are reasonable based upon current facts and circumstances. Applying different judgments to the same facts and circumstances could result in the estimated amounts to vary.</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Components of Gross-to-Net (GTN) Estimates</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Chargebacks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Chargebacks are discounts that occur when certain contracted customers, including group purchasing organizations (“GPOs”), public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase from our distributors. Our distributors purchase product from us at invoice price, then resell the product to certain contracted customers on the basis of prices negotiated between us and the providers. The difference between the distributors’ purchase price and the typically lower certain contracted customers’ purchase price is refunded to the distributors through a chargeback credit. We record estimates for these chargebacks at the time of sale as deductions from gross revenues, with corresponding adjustments to our accounts receivable reserves and allowances.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for chargebacks is the most significant provision in the context of our gross-to-net adjustments in the determination of net revenue. Chargebacks are estimated based on payer mix and contracted price, adjusted for current period assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Commercial and Medicaid Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: We contract with government agencies or collectively, third-party payors, so that Belrapzo and Ryanodex will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. We estimate the rebates we will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reduction of product revenue and the establishment of a current liability. The current liability is included in accrued expenses and other current liabilities on the consolidated balance sheets. We estimate the rebates that we will provide to third-party payors based upon (i) our contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payer mix, and (iv) information obtained from our distributors. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information that we also consider when establishing our rebate reserves are purchases by customers, projected annual sales for customers, actual rebates payments made, processing time lags, and for indirect rebates, the level of inventory in the distribution channel that will be subject to indirect rebates. We do not provide incentives designed to increase shipments to our customers that we believe would result in out-of-the-ordinary course of business inventory for them. We regularly review and monitor estimated or actual customer inventory information at our largest distributors for our key products to ascertain whether customer inventories are in excess of ordinary course of business levels.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Product Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our distributors have the right to return unopened unprescribed Belrapzo during certain time periods around the period beginning prior to the labeled expiration date and ending after the labeled expiration date. We estimate future product returns on sales of Belrapzo based on: (i) data provided to us by our distributors (including weekly reporting of distributors’ sales and inventory held by distributors that provided us with visibility into the distribution channel in order to determine what quantities were sold to retail pharmacies and other providers), (ii) information provided to us from retail pharmacies, (iii) data provided to us by a third-party data provider which collects and publishes prescription data, and other third parties, (iv) historical industry information regarding return rates for similar pharmaceutical products, (v) the estimated remaining shelf life of Belrapzo previously shipped and currently being shipped to distributors and (vi) contractual agreements intended to limit the amount of inventory maintained by our distributors. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for product returns based on the factors noted above generally encompass a time range from 12 to 48 months after revenue is recognized. Additionally, we consider other factors when estimating our current period return provision, including levels of inventory in the distribution channel, significant market changes that may impact future expected returns, and actual product returns, and may record additional provisions for specific returns that it believes are not covered by the historical rates. Our commercial returns policy and terms with certain customers also states that certain products are sold as non-returnable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Wholesaler fees and other incentives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: We generally provide invoice discounts on Belrapzo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ryanodex sales to our distributors for prompt payment and fees for distribution services, such as fees for certain data that distributors provide to us. The payment terms for sales to distributors generally include a 2% discount for prompt payment which is generally defined in invoice terms as a range from 30 to 70 days, while the fees for distribution services are based on contractual rates agreed with the respective distributors. Based on historical data, we expect our distributors to earn these discounts and fees, and deducts the full amount of these discounts and fees from our gross product revenues and accounts receivable at the time such revenues are recognized. </span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other GTN considerations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may at our discretion provide price adjustments due to various competitive factors. There are circumstances under which we may not provide price adjustments to certain customers as a matter of business strategy, and consequently may lose future sales volume to competitors and risk a greater level of product returns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed above, we have the experience and access to relevant information that we believe are necessary to reasonably estimate the amounts of such deductions from gross revenues. Some of the assumptions we use for certain of these estimates are based on information received from third parties, such as wholesale customer inventories and market data, or other market factors beyond our control. The estimates that are most critical to the establishment of these reserves, and therefore, would have the largest impact if these estimates were not accurate, are estimates related to contract sales volumes, average contract pricing, customer inventories and return volumes. We regularly review the information related to these estimates and adjust our reserves accordingly, if and when actual experience differs from previous estimates. With the exception of the product returns allowance, the ending balances of accounts receivable reserves and allowances generally are processed during a two-month to four-month period.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — We recognize revenue from license arrangements with our commercial partners' net sales of products. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner’s products occurs. Our commercial partners are obligated to report their net product sales and the resulting royalty due to us within 25 days for Bendeka. Based on historical product sales, royalty receipts and other relevant information, we accrue royalty revenue each quarter and subsequently determine a true-up when we receive royalty reports from our commercial partners. Historically, these true-up adjustments have been immaterial.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and other revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— We analyze each element of our licensing agreements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. We determine standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, we estimate the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, we determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, we assess each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of these future events, we will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, we do not assess whether a significant financing component exists if the period between when we perform our obligations under the contract and when the customer pays is one year or less. None of our contracts contained a significant financing component as of September 30, 2021.</span></div> P25D <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation using the fair value provisions of ASC 718, Compensation - Stock Compensation that requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock-based payments including stock options and restricted stock. This topic requires companies to estimate the fair value of the stock-based awards on the date of grant for options issued to employees and directors and record expense over the employees' service periods, which are generally the vesting period of the equity awards. </span></div>We account for stock-based compensation by measuring and recognizing compensation expense for all stock-based payments made to employees and directors based on estimated grant date fair values. The straight-line method is used to allocate compensation cost to reporting periods over each optionee's requisite service period, which is generally the vesting period. The fair value of our stock option awards to employees and directors is estimated using the Black-Scholes valuation model and a Monte Carlo simulation model is used to estimate the fair value for market condition share units. These models require the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, historical forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate is determined with the implied yield currently available for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options. The fair value of restricted stock units ("RSUs") granted are estimated based on the trading price of our common stock on the date of grant. The fair value of performance condition performance-based stock units ("PSUs") granted are also estimated based on the trading price of our common stock on the date of grant and adjusted for the probability of achievement of the performance conditions. Forfeitures are estimated for all stock-based awards. Earnings Per Share Basic earnings per common share is computed using the weighted average number of shares outstanding during the period. Diluted earnings per share is computed in a manner similar to the basic earnings per share, except that the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of warrants, options, convertible debt and other such convertible instruments. Diluted earnings per share contemplate a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The anti-dilutive common share equivalents outstanding for the three and nine months ended September 30, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:42.856%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.830%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.557%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,446,657 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,156,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,777,995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905,021 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,446,657 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,362,057 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,901,595 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,130,198 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2446657 3156166 2777995 2905021 0 205891 123600 225177 2446657 3362057 2901595 3130198 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation for basic and diluted net (loss) earnings per share for the three and nine months ended September 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:44.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for basic and diluted (loss) earnings per share-net (loss) earnings </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,622)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,059 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,431)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,932 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,077,298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,531,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,103,203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,620,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock awards </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding </span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,077,298 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,786,803 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,103,203 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,917,800 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net (loss) earnings per share </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) earnings per share </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net (loss) earnings per share </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) earnings per share </span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28 </span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -5622000 7059000 -2431000 3932000 13077298 13531372 13103203 13620981 255431 296819 13077298 13786803 13103203 13917800 -0.43 0.52 -0.19 0.29 -0.43 0.51 -0.19 0.28 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Update 2020-04 Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting to provide temporary optional guidance to ease the potential burden in accounting for </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reference rate reform. The amendments in Update 2020-04 are elective and apply to all entities that have contracts, hedging relationships, and other transactions that reference LIBOR, formerly known as the London Interbank Offered Rate,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or another reference rate expected to be discontinued due to reference rate reform. The new guidance provides optional expedients, including; (1) Simplify accounting analyses under current GAAP for contract modifications, such as modifications of contracts within the scope of Topic 470, Debt, that will be accounted for by prospectively adjusting the effective interest rate, as if any modification was not substantial. That is, the original contract and the new contract shall be accounted for as if they were not substantially different from one another; (2) Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue; (3) Allow a one-time election to sell or transfer debt securities classified as held to maturity before January 1, 2020 that reference a rate affected by reference rate reform. The amendments are effective for all entities from the beginning of an interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The adoption of ASU 2020-4 is not expected to have a material impact on our financial position or results of operations.</span></div> Property and Equipment, net <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#3b5a6f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,191)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,077 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment amounted to $197 and $196 for the three months ended September 30, 2021 and 2020, respectively, and $575 and $656 for the nine months ended September 30, 2021 and 2020, respectively.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#3b5a6f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,191)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,077 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div> 1476000 1476000 P7Y 1077000 1152000 P3Y 3834000 3485000 P7Y 1155000 1155000 P2Y 7542000 7268000 5767000 5191000 1775000 2077000 197000 196000 575000 656000 Inventories<div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:3pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"/><td style="width:58.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.586%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,315 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,075 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:3pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"/><td style="width:58.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.586%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,315 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,075 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6006000 3515000 1309000 2589000 2000000 1971000 9315000 8075000 Balance Sheet Accounts<div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"/><td style="width:61.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,898 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid FDA user fee and advances to clinical research organization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances to commercial manufacturers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Receivable from commercial partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible promissory note, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,303 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,157 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"/><td style="width:58.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.586%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties payable to commercial partners</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,879 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued salary and other compensation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,552 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research &amp; development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,714 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,817 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We lease office space in Woodcliff Lake, New Jersey for our principal office under an amended lease agreement through June 2025. We also lease a lab space in Cambridge, Massachusetts under a lease agreement through April 2024. Both of our leases are classified as operating leases and have remaining lease terms of approximately 3.3 years. The principal office and the lab space leases include renewal options to extend the lease for up to 5 years. Furthermore, we have not elected the practical expedient to separate lease and non-lease components for all classes of underlying assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The table below summarizes our total lease costs included in the condensed consolidated financial statements, as well as other required quantitative disclosures (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:61.323%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.153%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating cash flows for operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.701%"><tr><td style="width:1.0%"/><td style="width:78.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.372%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification as of September 30:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEyYjEzYzU5YTQzNjRiNmE5ZDM1YjMyOWRlZWY0OTY0L3NlYzphMmIxM2M1OWE0MzY0YjZhOWQzNWIzMjlkZWVmNDk2NF80Ni9mcmFnOjBhYmMzNDQwODk2MjQ1MGRhMDc2MGVjMjM5ZWRkYTlmL3RhYmxlOjVjZmEyYzM4ZjQ3ZjQ3OGU4NmQ5YjM3ZTI2MjFmMDFiL3RhYmxlcmFuZ2U6NWNmYTJjMzhmNDdmNDc4ZTg2ZDliMzdlMjYyMWYwMWJfMTItMC0xLTEtNjU0Nw_4fdfcc10-9d1d-4b62-a6e8-0d1ae33eba74">Current lease liabilities (included with Accrued Expenses and other liabilities)</span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEyYjEzYzU5YTQzNjRiNmE5ZDM1YjMyOWRlZWY0OTY0L3NlYzphMmIxM2M1OWE0MzY0YjZhOWQzNWIzMjlkZWVmNDk2NF80Ni9mcmFnOjBhYmMzNDQwODk2MjQ1MGRhMDc2MGVjMjM5ZWRkYTlmL3RhYmxlOjVjZmEyYzM4ZjQ3ZjQ3OGU4NmQ5YjM3ZTI2MjFmMDFiL3RhYmxlcmFuZ2U6NWNmYTJjMzhmNDdmNDc4ZTg2ZDliMzdlMjYyMWYwMWJfMTMtMC0xLTEtNjU0Nw_baa9ba33-33b7-4ec5-bc47-de8965ce1d24">Long-term lease liabilities (included with Other long-term liabilities)</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"/><td style="width:61.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,898 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid FDA user fee and advances to clinical research organization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances to commercial manufacturers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Receivable from commercial partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible promissory note, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,303 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,157 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5898000 0 1478000 1262000 468000 191000 734000 660000 1746000 439000 4551000 0 2428000 1605000 17303000 4157000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"/><td style="width:58.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.586%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties payable to commercial partners</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,879 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued salary and other compensation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,552 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research &amp; development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,714 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,817 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3046000 4966000 4879000 5996000 5255000 4686000 2552000 2370000 8528000 2724000 1199000 1123000 2255000 1952000 27714000 23817000 P3Y3M18D P5Y <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The table below summarizes our total lease costs included in the condensed consolidated financial statements, as well as other required quantitative disclosures (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:61.323%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.153%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating cash flows for operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1040000 1323000 0 855000 P3Y3M18D P4Y1M6D 0.060 0.060 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.701%"><tr><td style="width:1.0%"/><td style="width:78.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.372%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification as of September 30:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEyYjEzYzU5YTQzNjRiNmE5ZDM1YjMyOWRlZWY0OTY0L3NlYzphMmIxM2M1OWE0MzY0YjZhOWQzNWIzMjlkZWVmNDk2NF80Ni9mcmFnOjBhYmMzNDQwODk2MjQ1MGRhMDc2MGVjMjM5ZWRkYTlmL3RhYmxlOjVjZmEyYzM4ZjQ3ZjQ3OGU4NmQ5YjM3ZTI2MjFmMDFiL3RhYmxlcmFuZ2U6NWNmYTJjMzhmNDdmNDc4ZTg2ZDliMzdlMjYyMWYwMWJfMTItMC0xLTEtNjU0Nw_4fdfcc10-9d1d-4b62-a6e8-0d1ae33eba74">Current lease liabilities (included with Accrued Expenses and other liabilities)</span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEyYjEzYzU5YTQzNjRiNmE5ZDM1YjMyOWRlZWY0OTY0L3NlYzphMmIxM2M1OWE0MzY0YjZhOWQzNWIzMjlkZWVmNDk2NF80Ni9mcmFnOjBhYmMzNDQwODk2MjQ1MGRhMDc2MGVjMjM5ZWRkYTlmL3RhYmxlOjVjZmEyYzM4ZjQ3ZjQ3OGU4NmQ5YjM3ZTI2MjFmMDFiL3RhYmxlcmFuZ2U6NWNmYTJjMzhmNDdmNDc4ZTg2ZDliMzdlMjYyMWYwMWJfMTMtMC0xLTEtNjU0Nw_baa9ba33-33b7-4ec5-bc47-de8965ce1d24">Long-term lease liabilities (included with Other long-term liabilities)</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table> 1199000 3048000 4247000 Intangible Assets, Net<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amounts and net book value of our intangible assets are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.730%"><tr><td style="width:1.0%"/><td style="width:30.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life (In Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ryanodex intangible </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(i)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,897)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,301)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,799 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.730%"><tr><td style="width:1.0%"/><td style="width:30.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life (In Years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ryanodex intangible </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(i)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,183)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,917 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents a one-time payment made to reduce the royalties payable to a third party on Ryanodex net sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $706 and $667 for the three months ended September 30, 2021 and 2020, respectively and $2,118 and $1,999 for the nine months ended September 30, 2021 and 2020, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Amortization Expense for Intangible Assets </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on definite-lived intangible assets recorded as of September 30, 2021, and assuming that the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses are estimated as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.918%"><tr><td style="width:1.0%"/><td style="width:74.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.714%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Amortization Expense </span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total estimated amortization expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amounts and net book value of our intangible assets are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.730%"><tr><td style="width:1.0%"/><td style="width:30.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life (In Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ryanodex intangible </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(i)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,897)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,301)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,799 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.730%"><tr><td style="width:1.0%"/><td style="width:30.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life (In Years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ryanodex intangible </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(i)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,183)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,917 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents a one-time payment made to reduce the royalties payable to a third party on Ryanodex net sales.</span></div> P20Y 15000000 4404000 10596000 P5Y 8100000 7897000 203000 23100000 12301000 10799000 P20Y 15000000 3500000 11500000 P5Y 8100000 6683000 1417000 23100000 10183000 12917000 706000 667000 2118000 1999000 Based on definite-lived intangible assets recorded as of September 30, 2021, and assuming that the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses are estimated as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.918%"><tr><td style="width:1.0%"/><td style="width:74.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.714%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Amortization Expense </span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total estimated amortization expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 504000 1369000 1570000 1898000 1520000 3938000 10799000 Common Stock and Stock-Based Compensation<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2020, we announced that our Board approved a new share repurchase program, or the Share Repurchase Program, providing for the repurchase of up to an aggregate of $160 million of our outstanding common stock. The Share Repurchase Program replaced our then existing share repurchase program, or the Previous Share Repurchase Program, which was announced on October 30, 2018 and was terminated in connection with the Board’s approval of the Share Repurchase Program. At termination, we had repurchased approximately $68 million of our outstanding common stock under the Previous Share Repurchase Program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Share Repurchase Program, we are authorized to repurchase shares through open market purchases, privately-negotiated transactions, accelerated share repurchases or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans and under Rule 10b-18 of the Exchange Act. The repurchases have no time limit and may be suspended or discontinued completely at any time. The specific timing and amount of repurchases will vary based on available capital resources and other financial and operational performance, market conditions, securities law limitations, and other factors. The repurchases will be made using our cash resources. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 23, 2020, our Board of Directors approved a $25 million accelerated share repurchase (“ASR”) transaction with JPMorgan Chase Bank, National Association (“JP Morgan”) as part of our existing $160 million share repurchase program. The specific number of shares to be repurchased pursuant to the ASR is based on the average of the daily volume weighted average share prices of our common stock, less a discount, during the term of the ASR program. Under the terms of our agreement with JP Morgan, we paid $25 million to JP Morgan on September 24, 2020, and received 550,623 shares, representing the notional amount of the ASR, based on the average of the daily volume weighted average share prices of our common stock, less a discount, during the term of the ASR, which was $45.40. The ASR was completed in the fourth quarter of 2020. We determined the ASR contained a forward contract and therefore we recorded fair value adjustments on the accelerated share repurchase agreement in the amount of $3 million which was a loss recorded in Other expense on our consolidated statements of operations in the year ended December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2021, we had repurchased an aggregate of 3,941,541 shares of common stock for an aggregate of $219.5 million pursuant to our share repurchase programs in effect since August 2016. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2013, our Board of Directors approved the 2014 Equity Incentive Plan (the "2014 Plan") which became effective on February 11, 2014. The 2014 Plan provides for the awards of incentive stock options, non-qualified stock options, restricted stock, restricted stock units and other stock-based awards. Awards generally vest equally over a period of four years from grant </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date. Vesting may be accelerated under a change in control of the Company or in the event of death or disability to the recipient. In the event of termination, any unvested shares or options are forfeited.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2018, we introduced a new long-term incentive program with the objective to better align the stock-based awards granted to management with our focus on improving total shareholder return over the long-term. The stock-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and PSUs. PSUs are comprised of awards: i) that would have vested upon achievement of certain share price appreciation conditions or ii) that would have vested upon achievement of certain milestone events. These PSUs expired in the first quarter of 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, 97,750 market condition PSUs expired. We also granted 99,500 market condition PSUs based on our total shareholder return ("TSR") relative to the TSR of each member of the S&amp;P Biotechnology Select Industry Index (the defined peer group) with a weighted-average grant date fair value of $71.09 per respective PSU. The fair value of PSUs granted to employees was estimated using a Monte Carlo simulation model. Inputs used in the calculation include a risk-free interest rate of 0.18%, an expected volatility of 44%, contractual term of 3 years, and no expected dividend yield.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, we also granted 59,500 performance based (milestones) PSUs with grant date fair value of $49.32 using our closing stock price on the date of the grant. These PSUs will vest (if earned) from 0% to 200% of target number granted based on the achievement of one or more of three milestones related to i) regulatory approval of Fulvestrant ("EA-114"), ii) sales of Pemfexy and; iii) sales of Vasopressin, respectively. The contractual term of these awards is 3 years. We estimated 0% probability of achievement for the year-to-date period of 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option, RSU and PSU activity under the 2014 Plan during the nine months ended September 30, 2021 and 2020 is presented below:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"/><td style="width:53.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3b5a6f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,096,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662,700 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,450 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised/RSUs vested/PSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,951)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185,615)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,824)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,431)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,331,890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,600 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised/RSUs vested/PSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,477)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308,815)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,941)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,750)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,031,598 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,782 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to employees, directors, and consultants were estimated using the following assumptions:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:27.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/> September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82% - 0.93%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37% - 0.41%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51% - 1.12%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37% - 1.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.92%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.42%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.07%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.98%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested time-based RSU represents the right of a holder to receive one share of our common stock. The fair value of each RSU granted was estimated based on the trading price of our common stock on the date of grant.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PSUs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of market condition PSUs granted to employees was estimated using a Monte Carlo simulation model. Inputs used in the calculation are described above.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of performance condition PSUs granted to employees was estimated based on the trading price of our common stock on the date of grant adjusted for probability of achievement of the performance conditions as described above.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not recognize any expense for performance based PSUs granted to employees based on our estimated probability of achievement as described above. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized stock-based compensation in our condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"/><td style="width:41.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.368%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,685 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,084 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,722 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,873 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,435 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,084 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,722 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,873 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,435 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 160000000 68000000 25000000 160000000 -25000000 550623 45.40 3000000 3941541 219500000 P4Y 97750 99500000 71.09 0.0018 0.44 P3Y 0 59500 49.32 0 2 1 3 P3Y 0 <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option, RSU and PSU activity under the 2014 Plan during the nine months ended September 30, 2021 and 2020 is presented below:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"/><td style="width:53.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3b5a6f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,096,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662,700 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,450 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised/RSUs vested/PSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,951)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185,615)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,824)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,431)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,331,890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,600 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised/RSUs vested/PSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,477)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308,815)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,941)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,750)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,031,598 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,782 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3096161 251215 116181 662700 231450 0 41951 67970 0 185615 53824 11431 3531295 360871 104750 3331890 328396 97750 109000 106600 159000 100477 94273 0 308815 46941 97750 3031598 293782 159000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to employees, directors, and consultants were estimated using the following assumptions:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:27.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/> September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82% - 0.93%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37% - 0.41%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51% - 1.12%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37% - 1.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.92%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.42%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.07%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.98%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr></table></div> 0.0082 0.0093 0.0037 0.0041 0.0051 0.0112 0.0037 0.0165 0.5492 0.5542 0.5607 0.5498 P6Y29D P6Y25D P5Y8M4D P6Y10D 0.000 0.000 0.000 0.000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized stock-based compensation in our condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"/><td style="width:41.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.368%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,685 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,084 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,722 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,873 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,435 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,084 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,722 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,873 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,435 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2515000 3685000 8393000 12831000 1046000 928000 4051000 4115000 523000 109000 2429000 1489000 4084000 4722000 14873000 18435000 3443000 5236000 12696000 16365000 641000 -514000 2177000 2070000 4084000 4722000 14873000 18435000 Commitments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future material contractual obligations as of September 30, 2021, included the following: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"/><td style="width:22.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beyond</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,680 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit facility (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total obligations </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,856 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,527 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,423 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,455 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1) We lease our corporate office location. The term of our existing lease expires on June 30, 2025. We also lease our lab space under a lease agreement that expires on October 31, 2023. Rental expense for the operating leases was $325 and $276, for the three months ended September 30, 2021 and 2020, respectively. Rental expense for the operating leases was $976 and $910 for the nine months ended September 30, 2021 and 2020. The remaining future lease payments under the operating leases are $4.7 million as of September 30, 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2) Refer to Note 9, “Debt” for further information regarding our Credit Agreement.</span></div>(3) As of September 30, 2021, we had purchase obligations in the amount of $53.2 million which represents the contractual commitments under contract manufacturing and supply agreements with suppliers. The obligations under the supply agreements are primarily for finished product, inventory, and research and development. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future material contractual obligations as of September 30, 2021, included the following: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"/><td style="width:22.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beyond</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,680 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit facility (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total obligations </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,856 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,527 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,423 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,455 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1) We lease our corporate office location. The term of our existing lease expires on June 30, 2025. We also lease our lab space under a lease agreement that expires on October 31, 2023. Rental expense for the operating leases was $325 and $276, for the three months ended September 30, 2021 and 2020, respectively. Rental expense for the operating leases was $976 and $910 for the nine months ended September 30, 2021 and 2020. The remaining future lease payments under the operating leases are $4.7 million as of September 30, 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2) Refer to Note 9, “Debt” for further information regarding our Credit Agreement.</span></div>(3) As of September 30, 2021, we had purchase obligations in the amount of $53.2 million which represents the contractual commitments under contract manufacturing and supply agreements with suppliers. The obligations under the supply agreements are primarily for finished product, inventory, and research and development. 4680000 351000 1423000 1455000 1038000 413000 0 0 28000000 2000000 26000000 0 0 0 0 0 53176000 53176000 0 0 0 0 0 0 85856000 55527000 27423000 1455000 1038000 413000 0 0 325000 276000 976000 910000 4700000 53200000 Debt <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2019, we entered into the Second Amended and Restated Credit Agreement (the “Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”) and the lenders party thereto. The terms and amounts borrowed under the Credit Agreement includes a drawn term loan of $40 million and an undrawn revolving credit facility of $110 million. The schedule of principal payments for the new term loan facility was extended to November 8, 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We classified the current portion of long-term debt of $8 million on the condensed consolidated balance sheet as of September 30, 2021. Per the terms of the Credit Agreement, the Company is limited in its ability to pay dividends. As of September 30 2021, we were in compliance with each of the senior secured net leverage ratio; total net leverage ratio; and fixed charge coverage ratio covenants. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term loan facility bears interest at the Adjusted LIBOR (equal to (a) the LIBOR for such Interest Period multiplied by (b) the Statutory Reserve Rate as established by Board of Governors of the Federal Reserve System of the United States of America) for the interest period in effect for such borrowing plus the applicable rate as described below. The Agent and us may amend the Credit Agreement to replace the LIBOR with a Benchmark Replacement, described below.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans under the Credit Agreement bear interest at a rate equal to either (a) the LIBOR rate, plus an applicable margin ranging from 2.25% to 3.0% per annum, based upon the total net leverage ratio (as defined in the Credit Agreement), or (b) the Benchmark Replacement which is defined as the greatest of the prime lending rate, or the NYFRB Rate (the rate for a federal funds transaction) in effect on such day plus ½ of 1% or the Adjusted LIBO Rate for a one month Interest Period on such day plus 1% plus an applicable margin ranging from 1.25% to 2.0% per annum, based upon the total net leverage ratio.  </span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay a commitment fee on the unused portion of the new revolving credit facility in the Credit Agreement at a rate ranging from 0.35% to 0.45% per annum based upon the total net leverage ratio. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we had $0.5 million of unamortized deferred debt issuance costs as part of long-term debt in its condensed consolidated balance sheets.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"><tr><td style="width:1.0%"/><td style="width:34.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.148%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Maturities </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     2021 (remainder)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,000 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 40000000 110000000 8000000 0.0225 0.030 0.01 0.0125 0.020 0.0035 0.0045 500000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"><tr><td style="width:1.0%"/><td style="width:34.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.148%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Maturities </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     2021 (remainder)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,000 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2000000 26000000 28000000 Income Taxes <div style="margin-top:5pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:37.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.279%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (provision)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,038 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,866)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,341 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,358)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim periods, we recognize an income tax provision based on our estimated annual effective tax rate expected for the entire year plus the effects of certain discrete items occurring in the quarter. The interim annual estimated effective tax rate is based on the statutory tax rates then in effect, as adjusted for changes in estimated permanent differences, and certain discrete items whose tax effect, when material, is recognized in the interim period in which they occur.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The effective tax rate for the three and nine months ended September 30, 2021, reflects an interim tax benefit resulting from our research and development expense of acquired licenses and credits for research and development activity, partially offset by impact of certain non-deductible executive compensation and expired stock compensation. We review the realizability of our deferred tax assets on a quarterly basis, or whenever events or changes in circumstances indicate that a review is required. In determining the requirement for a valuation allowance, the historical and projected financial results of the legal entity or consolidated group recording the net deferred tax asset are considered, along with any other positive or negative evidence. Since future financial results, including the fair value adjustment on our investment in Tyme may differ from previous estimates, periodic adjustments to our valuation allowances may be necessary.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax assets as of September 30, 2021 consisted of temporary differences primarily related to stock-based compensation and research and development tax credit carryforwards, partially offset by temporary differences related to intangible assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We file income tax returns in the U.S. federal jurisdiction and several states. Given that we have incurred tax losses in most years since our inception, all of our tax years are effectively open to examination. We are currently under audit by three State tax jurisdictions. We had no amount recorded for any unrecognized tax benefits as of September 30, 2021. We regularly evaluate our tax positions for additional unrecognized tax benefits and associated interest and penalties, if applicable. There are many factors that are considered when evaluating these tax positions including: interpretation of tax laws, recent tax litigation on a position, past audit or examination history, and subjective estimates and assumptions. We reflect interest and penalties attributable to income taxes, to the extent they arise, as a component of income tax provision or benefit.</span></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:37.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.279%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (provision)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,038 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,866)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,341 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,358)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> -7038000 1866000 -3341000 7358000 0.56 0.21 0.58 0.65 3 0 Legal Proceedings<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the below legal proceedings, from time to time, we may be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters, or matters discussed below, will not have a material adverse effect on our business nor have we recorded any loss in connection with these matters because we believe that loss is neither probable nor estimable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Litigation</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cipla v. Eagle</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2020, Cipla Limited (“Cipla”) filed a request for arbitration against Eagle with the London Court of International Arbitration. The request alleges that Eagle’s refusal to take delivery of several batches of Argatroban finished drug product </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">constitutes a breach of the parties’ December 14, 2012 supply agreement. Eagle believes that the allegations against it are without merit and is vigorously defending itself in the Arbitration, which was scheduled for June 2021, has been rescheduled for April 2022. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Eagle Pharmaceuticals, Inc., et al. v. Slayback Pharma Limited Liability Company; Eagle Pharmaceuticals, Inc., et al. v. Apotex Inc. and Apotex Corp.; Eagle Pharmaceuticals, Inc., et al. v. Fresenius Kabi USA, LLC; Eagle Pharmaceuticals, Inc., et al. v. Mylan Laboratories Limited; Eagle Pharmaceuticals, Inc. et al. v. Hospira, Inc; Eagle Pharmaceuticals, Inc. et al. v. Lupin, Ltd. and Lupin Pharmaceuticals, Inc.; Teva Pharmaceuticals Int’l GmbH et al v. Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., and Eugia Pharma Specialities Ltd.; Teva Pharmaceuticals Int’l GmbH et al v. Accord Healthcare Inc., Accord Healthcare Ltd., and Intas Pharmaceuticals Ltd.; Teva Pharmaceuticals Int’l GmbH et al v. Dr. Reddy’s Laboratories, Ltd., and Dr. Reddy’s Laboratories, Inc. - (Bendeka</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bendeka, which contains bendamustine hydrochloride, is an alkylating drug that is indicated for the treatment of patients with chronic lymphocytic leukemia, as well as for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Slayback Pharma Limited Liability Company (“Slayback”), Apotex Inc. and Apotex Corp. (“Apotex”), Fresenius Kabi USA, LLC (“Fresenius”), Mylan Laboratories Limited (“Mylan”), Lupin, Ltd. and Lupin Pharmaceuticals, Inc. (“Lupin”), and Aurobindo Pharma, Ltd, Aurobindo Pharma USA, Inc., and Eugia Pharma Specialities Ltd (“Aurobindo”) have filed Abbreviated New Drug Applications (“ANDA’s”) referencing Bendeka</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that include challenges to one or more of the Bendeka</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Orange Book-listed patents. Hospira, Inc. (“Hospira”) filed a 505(b)(2) NDA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We, Cephalon, Inc. and/or Teva Pharmaceuticals International GMBH (together the “Patentees”), filed separate suits against Slayback, Apotex, Fresenius, Mylan, Hospira, Lupin, and Aurobindo in the United States District Court for the District of Delaware on August 16, 2017 (Slayback (“Slayback I”)), August 18, 2017 (Apotex), August 24, 2017 (Fresenius), December 12, 2017 (Mylan), January 19, 2018 (Slayback (“Slayback II”)), July 19, 2018 (Hospira), and July 2, 2019 (Lupin) and May 11, 2020 (Aurobindo). In these Complaints, the Patentees allege infringement of the challenged patents, namely U.S. Patent Nos. 8,791,270 and 9,572,887 against Slayback (Slayback I and Slayback II), and of U.S. Patent Nos. 8,609,707, 8,791,270, 9,000,021, 9,034,908, 9,144,568, 9,265,831, 9,572,796, 9,572,797, 9,572,887, 9,579,384, 9,597,397, 9,597,398, 9,597,399 against Fresenius, Apotex, and Mylan, and of U.S. Patent Nos. 9,572,887, 10,010,533, 9,034,908, 9,144,568, 9,597,397, 9,597,398, 9,597,399, 9,000,021, 9,579,384 against Hospira, and of U.S. Patent Nos. 8,609,707, 9,000,021, 9,034,908, 9,144,568, 9,265,831, 9,572,796, 9,572,797, 9,572,887, 9,579,384, 9,597,397, 9,597,398, 9,597,399, 10,010,533, and 10,052,385 against Lupin and of U.S. Patent Nos. 8,609,707, 9,265,831, 9,572,796, 9,572,797, 9,034,908, 9,144,568, 9,572,887, 9,597,397, 9,597,398, 9,597,399, 9,000,021, 9,579,384, 10,010,533, and 10,052,385 against Aurobindo. The parties stipulated to dismiss without prejudice U.S. Patent No. 8,791,270 as to Apotex, Fresenius and Mylan on July 24, 2018, August 2, 2018, and August 3, 2018, respectively. Slayback, Apotex, Fresenius, and Mylan answered their Complaints and some filed various counterclaims on September 29, 2017 (Slayback I), February 12, 2018 (Slayback II), November 27, 2017, September 15, 2017, and February 14, 2018, respectively. The Patentees answered the Slayback I, Slayback II, Fresenius, and Apotex counterclaims on October 20, 2017, March 5, 2018, October 6, 2017, and December 18, 2017, respectively. On October 15, 2018, the Patentees filed a suit against Fresenius and Mylan in the United States District Court for the District of Delaware, alleging patent infringement of U.S. Patent Nos. 10,010,533 and 10,052,385. The Slayback I, Slayback II, Apotex, Fresenius and Mylan cases have been consolidated for all purposes (the “Consolidated Bendeka Litigation”), and a bench trial in these cases was held September 9-19, 2019. On April 27, 2020, the district court held that the asserted patents are valid and infringed by Slayback, Apotex, Fresenius and Mylan. On July 6, 2020, the district court entered a final judgment reflecting this decision, stating that pursuant to 35 U.S.C. § 271(e)(4)(A), the FDA shall not approve Apotex’s, Fresenius’s, Mylan’s, or Slayback’s ANDA products on a date which is earlier than January 28, 2031, and enjoining Apotex, Fresenius, Mylan, and Slayback from commercially manufacturing, using, offering to sell, or selling within the US or importing into the US, their ANDA products before that date. On August 4, 2020, Apotex, Fresenius, and Mylan appealed this final judgment, and filed their opening briefs on November 4, 2020. Plaintiffs’ responsive appeal brief was filed on February 12, 2021. Defendants’ reply briefs were filed April 5, 2021. On August 2, 2021, Fresenius’s appeal was dismissed pursuant to a settlement agreement reached with Patentees. Oral argument for the remaining defendants occurred on August 3, 2021. On August 13, 2021, the appeals court affirmed the trial court’s decision. The mandate was issued on October 22, 2021. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Hospira filed a motion to dismiss, which was fully briefed on November 16, 2018. On December 16, 2019, the United States District Court for the District of Delaware denied Hospira’s motion to dismiss with respect to U.S. Patent No. 9,572,887 and granted that motion with respect to the remaining patents. On December 15, 2020, the Court held a claim construction hearing, ruling in our favor on all claim terms. Fact discovery closed on April 1, 2021. Expert discovery is ongoing. Trial has been rescheduled for April 25, 2022. The case remains pending.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2020, the parties filed a stipulation and order of dismissal without prejudice as to Lupin, which the Court entered March 11, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Aurobindo answered the Complaint on July 20, 2020. The parties exchanged initial disclosures on December 11, 2020. Plaintiffs provided their infringement contentions on March 12, 2021. On October 20, 2021 the Court entered a stipulation of dismissal based on a settlement between the parties. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patentees filed suit against Dr. Reddy’s Laboratories on May 13, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patentees have asserted U.S. Patent Nos. 8,609,707, 9,265,831, 9,572,796, 9,572,797, 9,034,908, 9,144,568, 9,572,887, 9,597,397, 9,597,398, 9,597,399, 9,000,021, 9,579,384, 10,010,533, and 10,052,385.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Reddy’s answer was filed August 16, 2021. Scheduling for the case is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patentees filed suit against Accord Healthcare on June 29, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patentees have asserted U.S. Patent Nos. 8,609,707, 9,265,831, 9,572,796, 9,572,797, 9,034,908, 9,144,568, 9,572,887, 9,597,397, 9,597,398, 9,597,399, 9,000,021, 9,579,384, 10,010,533, and 10,052,385. Accord has answered the complaint. </span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eagle Pharmaceuticals, Inc. v. Slayback Pharma Limited Liability Company</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Slayback filed an ANDA referencing Eagle's Belrapzo NDA. Slayback’s ANDA includes challenges to one or more of the Belrapzo Orange Book-listed patents. On September 20, 2018, the Company filed a suit against Slayback in the United States District Court for the District of Delaware, alleging patent infringement of U.S. Patent Nos. 8,609,707, 9,265,831, 9,572,796, 9,572,797 and 10,010,533. On October 10, 2018, Slayback answered the Complaint and filed various counterclaims. On October 31, 2018, the Company answered Slayback’s counterclaims. Pursuant to a stipulation between the parties, Slayback is bound by any final judgment entered in the Consolidated Bendeka Litigation. This case is currently stayed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eagle Pharmaceuticals, Inc. v. Slayback Pharma Limited Liability Company, Apotex, Inc. and Apotex Corp.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both Slayback and Apotex filed NDAs referencing Eagle’s Belrapzo NDA. On August 31, 2021, the Company filed suit against Slayback and Apotex in the United States District Court for the District of Delaware, alleging infringement of U.S. Patent No. 11,103,483. On September 22, 2021, both Slayback and Apotex filed their Answers. Scheduling for the case is ongoing.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Par Pharmaceutical, Inc. et al. v. Eagle Pharmaceuticals, Inc. (Vasopressin)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 31, 2018, Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC (together, “Par”) filed suit against the Company in the United States District Court for the District of Delaware. Par alleged patent infringement based on the filing of the Company’s ANDA seeking approval to manufacture and sell the Company’s vasopressin product. The Company’s vasopressin product, if approved by FDA, will be an alternative to Vasostrict, which is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. The Company answered the complaint on August 6, 2018, and filed an amended answer and counterclaims on October 30, 2019. The court issued a Markman ruling on July 1, 2019. On December 20, 2019, Par dismissed with prejudice claims of three of the patents asserted against Eagle, and the Court entered an Order reflecting that dismissal on December 27, 2019. Mediation took place on March 3, 2020. On April 17, 2020, we submitted a letter requesting leave to file a motion for summary judgment of non-infringement. Par’s responsive letter was submitted on May 8, 2020. On May 18, 2020, the court said it would hear non-infringement arguments at trial and not through summary judgment. Fact discovery ended in October 2019, and expert discovery ended in February 2020. Due to the COVID-19 pandemic, the trial, which was scheduled to begin May 18, 2020, was rescheduled to and occurred on July 7-9, 2021. Post-trial briefing was submitted on July 28, 2021. The Court issued an opinion on August 31, 2021 and entered a final judgment of non-infringement in favor of Eagle on September 16, 2021. Par filed a Notice of Appeal of the final judgment on September 22, 2021, and the appeal was docketed with the United States Court of Appeals for the Federal Circuit on September 23, 2021. The 30-month stay of FDA approval expired on October 17, 2020. This suit is pending.</span></div>On December 7, 2020, Par filed a separate suit against us in the United States District Court for the District of New Jersey, asserting patent infringement of U.S. Patent No. 10,844,435, based on the filing of our ANDA seeking approval to manufacture and sell our vasopressin product. Eagle moved to dismiss Par’s complaint on March 2, 2021. On March 22, 2021, Par amended its complaint to additionally assert U.S. Patent No. 10,920,278, and on April 5, 2021, Eagle moved to dismiss Par’s amended complaint. This suit is pending. 3 License and Collaboration Agreements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License agreement with Combioxin</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into a license agreement with Combioxin, SA under which the Company was granted exclusive, worldwide development and commercialization rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. The Company will be solely responsible for the development, regulatory, manufacturing and commercialization activities of CAL02. Combioxin will assist the Company in transitioning the manufacturing and supply of CAL02 to the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we paid $10 million as upfront license consideration that was expensed immediately as research and development and is reflected within the operating activities of the condensed consolidated statements of cash flows. The Company may pay to Combioxin up to $105 million upon achievement of certain development, regulatory and sales based milestone payments plus royalty payments at royalty rates ranging in low double digit percentages on the net sales of all products sold, subject to certain adjustments as provided in the agreement. The Company is also obligated to make certain payments based upon amounts received by sublicensees under the agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License agreement with AOP Orphan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2021, we entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH (“AOP Orphan”), a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, landiolol in the United States. Landiolol, a leading hospital emergency use product, is currently approved in Europe for the treatment of non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias. We will support the submission of a new drug application (“NDA”) by AOP Orphan to the FDA seeking approval for landiolol for the short term reduction of ventricular rate in patients with supraventricular tachycardia </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(“SVT”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, including atrial fibrillation and atrial flutter. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the agreement, we accrued a $5 million upfront license consideration that was expensed immediately as research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and is reflected within the operating activities of the condensed consolidated statements of cash flows</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The Company may pay to AOP Orphan up to $25 million upon achievement of certain regulatory milestone payments plus profit share payments, subject to certain adjustments as provided in the agreement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also entered into a supply agreement at the same time as the licensing agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration with Tyme</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2020, Tyme and we announced a strategic collaboration to advance SM-88, an oral product candidate for the treatment of patients with cancer. SM-88 is an investigational agent in two Phase II studies, one for pancreatic cancer and another for prostate cancer. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of a related co-promotion agreement, we would be responsible for 25% of the promotional sales effort of SM-88 and would receive 15% royalty on the net revenues of SM-88 in the United States. Tyme is responsible for clinical development, regulatory approval, commercial strategy, marketing, reimbursement and manufacturing of SM-88. Tyme retains the remaining 85% of net U.S. revenues and reserves the right to repurchase our U.S. co-promotion right for $200.0 million. </span></div>Our equity investment in Tyme is included in Other assets on our condensed consolidated balance sheet. For the three months ended September 30, 2021 and 2020, the fair value adjustments for the equity investment was a loss of $2.3 million and $3.5 million, respectively. For the nine months ended September 30, 2021 and 2020, the fair value adjustments for the equity investment was a loss of $1.9 million and a loss of $7.7 million, respectively. These adjustments were recorded in Other (expense) income on our condensed consolidated statements of operations. 10000000 105000000 5000000 25000000 0.25 0.15 0.85 200000000 -2300000 -3500000 1900000 -7700000 Convertible Promissory Note<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, we invested $5 million in a convertible promissory note ("the note") of a privately held clinical-stage biotechnology company (the "issuer"). The note bears an 8% annual interest rate and has an 18-month term. The issuer is not required to make any principal or interest payments until the end of the term. The note, along with any accrued interest, may automatically convert into equity securities of the issuer under either a financing event or a change in control event as defined in the convertible promissory note agreement. The issuer's product development efforts could encounter technical or other difficulties that could increase their development costs more than expected. The issuer will likely require additional capital prior to obtaining certain regulatory approval or to be able to repay the convertible promissory note with accrued interest at the end of the term. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recorded and activity during the nine months ended September 30, 2021;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.919%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Adjustments to the note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accretion of Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Credit Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Adjustment to Embedded Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of the note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(882)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discount on the note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Credit Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Convertible Promissory Note, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,724 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(882)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Embedded Derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total in Other Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(882)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,551 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity during the three months ended September 30, 2021;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:16.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Adjustments to the note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accretion of Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Credit Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Adjustment to Embedded Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of the note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discount on the note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Credit Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Convertible Promissory Note, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Embedded Derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total in Other Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,365 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,551 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5000000 0.08 P18M <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recorded and activity during the nine months ended September 30, 2021;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.919%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Adjustments to the note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accretion of Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Credit Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Adjustment to Embedded Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of the note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(882)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discount on the note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Credit Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Convertible Promissory Note, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,724 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(882)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Embedded Derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total in Other Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(882)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,551 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity during the three months ended September 30, 2021;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:16.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Adjustments to the note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accretion of Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Credit Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Adjustment to Embedded Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of the note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discount on the note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Credit Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Convertible Promissory Note, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Embedded Derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total in Other Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,365 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,551 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5000000 -882000 4118000 276000 102000 174000 0 150000 150000 4724000 -882000 102000 150000 3794000 276000 254000 530000 0 227000 227000 5000000 -882000 102000 150000 227000 254000 4551000 4096000 22000 4118000 220000 46000 174000 100000 50000 150000 3776000 22000 46000 50000 3794000 464000 66000 530000 125000 102000 227000 4365000 22000 46000 50000 102000 66000 4551000 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
9 Months Ended
Sep. 30, 2021
Nov. 02, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Document Transition Report false  
Entity File Number 001-36306  
Entity Registrant Name Eagle Pharmaceuticals, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 20-8179278  
Entity Address, Address Line One 50 Tice Boulevard  
Entity Address, Address Line Two Suite 315  
Entity Address, City or Town Woodcliff Lake  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07677  
City Area Code (201)  
Local Phone Number 326-5300  
Title of 12(b) Security Common stock, $0.001 par value per share  
Trading Symbol EGRX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   12,913,879
Entity Central Index Key 0000827871  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 99,741 $ 103,155
Accounts receivable, net 45,335 50,678
Inventories 9,315 8,075
Prepaid expenses and other current assets 17,303 4,157
Total current assets 171,694 166,065
Property and equipment, net 1,775 2,077
Intangible assets, net 10,799 12,917
Goodwill 39,743 39,743
Deferred tax asset, net 17,713 15,180
Other assets 14,537 17,208
Total assets 256,261 253,190
Current liabilities:    
Accounts payable 12,717 6,268
Accrued expenses and other liabilities 27,714 23,817
Current portion of long-term debt 8,000 8,000
Total current liabilities 48,431 38,085
Other long-term liabilities 3,048 3,959
Long-term debt, less current portion 19,489 25,135
Total liabilities 70,968 67,179
Commitments and Contingencies
Stockholders' equity:    
Preferred stock, 1,500,000 shares authorized and no shares issued or outstanding as of September 30, 2021 and December 31, 2020 0 0
Common stock, $0.001 par value; 50,000,000 shares authorized; 16,886,123 and 16,739,203 shares issued as of September 30, 2021 and December 31, 2020, respectively 17 17
Additional paid in capital 320,566 305,403
Accumulated other comprehensive loss (882) 0
Retained earnings 82,058 84,489
Treasury stock, at cost, 3,941,541 and 3,682,176 shares as of September 30, 2021 and December 31, 2020, respectively (216,466) (203,898)
Total stockholders' equity 185,293 186,011
Total liabilities and stockholders' equity $ 256,261 $ 253,190
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, shares authorized (in shares) 1,500,000 1,500,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 50,000,000 50,000,000
Common stock, shares issued (in shares) 16,886,123 16,739,203
Treasury stock (in shares) 3,941,541 3,682,176
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue:        
Total revenue $ 39,853 $ 49,928 $ 129,226 $ 137,886
Operating expenses:        
Cost of product sales 5,486 8,726 21,835 23,804
Cost of royalty revenue 2,773 3,260 8,036 9,120
Research and development 23,289 4,828 47,488 21,390
Selling, general and administrative 18,482 17,697 54,997 60,411
Total operating expenses 50,030 34,511 132,356 114,725
(Loss) income from operations (10,177) 15,417 (3,130) 23,161
Interest income 197 46 395 542
Interest expense (396) (489) (1,240) (2,164)
Other expense (2,284) (6,049) (1,797) (10,249)
Total other expense, net (2,483) (6,492) (2,642) (11,871)
(Loss) income before income tax benefit (provision) (12,660) 8,925 (5,772) 11,290
Income tax benefit (provision) 7,038 (1,866) 3,341 (7,358)
Net (loss) income $ (5,622) $ 7,059 $ (2,431) $ 3,932
(Loss) earnings per share attributable to common stockholders:        
Basic (in dollars per share) $ (0.43) $ 0.52 $ (0.19) $ 0.29
Diluted (in dollars per share) $ (0.43) $ 0.51 $ (0.19) $ 0.28
Weighted average number of common shares outstanding:        
Basic (in shares) 13,077,298 13,531,372 13,103,203 13,620,981
Diluted (in shares)   13,786,803   13,917,800
Product sales, net        
Revenue:        
Total revenue $ 12,124 $ 17,317 $ 48,865 $ 49,387
Royalty revenue        
Revenue:        
Total revenue 27,729 27,611 80,361 83,499
License and other revenue        
Revenue:        
Total revenue $ 0 $ 5,000 $ 0 $ 5,000
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]        
Net (loss) income $ (5,622) $ 7,059 $ (2,431) $ 3,932
Other comprehensive income (loss), net of tax:        
Unrealized gain (loss) for convertible promissory note 22 0 (882) 0
Total other comprehensive income (loss) 22 0 (882) 0
Comprehensive (loss) income $ (5,600) $ 7,059 $ (3,313) $ 3,932
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Treasury Stock
Accumulated Other Comprehensive (Loss) Income
Retained Earnings
Beginning balance (in shares) at Dec. 31, 2019   16,538,000        
Beginning balance at Dec. 31, 2019 $ 179,174 $ 17 $ 278,518 $ (171,861)   $ 72,500
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation expense $ 18,435   18,435      
Issuance of common stock upon exercise of stock option grants (in shares) 41,951 42,000        
Issuance of common stock upon exercise of stock option grants $ 555   555      
Payment of employee withholding tax upon vesting of stock-based awards (1,310)   (1,310)      
Issuance of common stock related to vesting of restricted stock units (in shares)   45,000        
Common stock repurchases (27,999)     (27,999)    
Other comprehensive income (loss) 0          
Net income (loss) 3,932         3,932
Ending balance (in shares) at Sep. 30, 2020   16,625,000        
Ending balance at Sep. 30, 2020 172,787 $ 17 296,198 (199,860)   76,432
Beginning balance (in shares) at Jun. 30, 2020   16,622,000        
Beginning balance at Jun. 30, 2020 183,964 $ 17 291,434 (176,860)   69,373
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation expense 4,722   4,722      
Issuance of common stock upon exercise of stock option grants (in shares)   3,000        
Issuance of common stock upon exercise of stock option grants 42   42      
Common stock repurchases (23,000)     (23,000)    
Other comprehensive income (loss) 0          
Net income (loss) 7,059         7,059
Ending balance (in shares) at Sep. 30, 2020   16,625,000        
Ending balance at Sep. 30, 2020 172,787 $ 17 296,198 (199,860)   76,432
Beginning balance (in shares) at Dec. 31, 2020   16,739,000        
Beginning balance at Dec. 31, 2020 186,011 $ 17 305,403 (203,898) $ 0 84,489
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation expense $ 14,873   14,873      
Issuance of common stock upon exercise of stock option grants (in shares) 100,477 84,000        
Issuance of common stock upon exercise of stock option grants $ 1,841   1,841      
Issuance of common stock related to vesting of restricted stock units (in shares)   63,000        
Issuance of common stock related to vesting of restricted stock units (1,551)   (1,551)      
Common stock repurchases (12,568)     (12,568)    
Other comprehensive income (loss) (882)       (882)  
Net income (loss) (2,431)         (2,431)
Ending balance (in shares) at Sep. 30, 2021   16,886,000        
Ending balance at Sep. 30, 2021 185,293 $ 17 320,566 (216,466) (882) 82,058
Beginning balance (in shares) at Jun. 30, 2021   16,880,000        
Beginning balance at Jun. 30, 2021 194,847 $ 17 316,249 (208,195) (904) 87,680
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation expense 4,084   4,084      
Issuance of common stock upon exercise of stock option grants (in shares)   6,000        
Issuance of common stock upon exercise of stock option grants 233   233      
Common stock repurchases (8,271)     (8,271)    
Other comprehensive income (loss) 22       22  
Net income (loss) (5,622)         (5,622)
Ending balance (in shares) at Sep. 30, 2021   16,886,000        
Ending balance at Sep. 30, 2021 $ 185,293 $ 17 $ 320,566 $ (216,466) $ (882) $ 82,058
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Cash flows from operating activities:          
Net (loss) income $ (5,622) $ 7,059 $ (2,431) $ 3,932  
Adjustments to reconcile net (loss) income to net cash provided by operating activities:          
Deferred income taxes     (2,533) (1,671)  
Depreciation expense     575 656  
Noncash operating lease expense related to right-of-use assets     768 980  
Amortization expense of intangible assets 706 667 2,118 1,999  
Fair value adjustments on equity investment     1,900 7,700  
Stock-based compensation expense     14,873 18,435  
Convertible promissory note related credit losses     150 0  
Amortization of debt issuance costs     354 301  
Fair value adjustments related to derivative instrument     (254) 2,549  
Accretion of discount on convertible promissory note     (102) 0  
Changes in operating assets and liabilities which provided (used) cash:          
Accounts receivable     5,343 (4,195)  
Inventories     (1,240) (20)  
Prepaid expenses and other current assets     (8,821) (2,774)  
Accounts payable     6,449 7,606  
Accrued expenses and other liabilities     3,897 (3,916)  
Other assets and other long-term liabilities, net     (908) (1,845)  
Net cash provided by operating activities     20,138 29,737  
Cash flows from investing activities:          
Purchase of equity investment security     0 (17,500)  
Purchase of property and equipment     (274) (577)  
Purchase of convertible promissory note     (5,000) 0  
Net cash used in investing activities     (5,274) (18,077)  
Cash flows from financing activities:          
Proceeds from common stock option exercises     1,841 555  
Employee withholding taxes related to stock-based awards     (1,551) (1,310)  
Proceeds from existing revolving credit facility     0 110,000  
Repayment of existing revolving credit facility     0 (110,000)  
Payment of debt     (6,000) (3,000)  
Repurchases of common stock     (12,568) (27,999)  
Net cash used in financing activities     (18,278) (31,754)  
Net decrease in cash and cash equivalents     (3,414) (20,094)  
Cash and cash equivalents at beginning of period     103,155 109,775 $ 109,775
Cash and cash equivalents at end of period $ 99,741 $ 89,681 99,741 89,681 103,155
Cash paid during the period for:          
Income taxes, net     6,303 3,036  
Interest     917 1,878  
Right-of-use asset obtained in exchange for lease obligation - lease amendment     $ 0 $ 842 $ 855
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Other Company Information
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Other Company Information Basis of Presentation and Other Company Information
The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting quarterly information. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2020 was derived from audited financial statements, but certain information and footnote disclosures normally included in our annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results for the year ending December 31, 2021 or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 5, 2021.
We are an integrated pharmaceutical company focused on finding ways to help medicines do more for patients. We and our collaborators have the capabilities to take a molecule from preclinical research through regulatory approval and into the marketplace, including development, manufacturing and commercialization. Our business model applies our scientific expertise, proprietary research-based insights and marketplace proficiency to identify challenging-to-treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. By focusing on patients' unmet needs, we strive to provide healthcare professionals with urgently needed treatment solutions that are designed to improve patient care and outcomes and create near- and long-term value for our stakeholders, including patients and healthcare providers and our employees, marketing partners, collaborators and investors. Our science-based business model has a proven track record with U.S. Food and Drug Administration ("FDA") approval and commercial launches of three products: Ryanodex® (dantrolene sodium) ("Ryanodex"), bendamustine ready-to-dilute ("RTD") 500ml solution ("Belrapzo"), and rapidly infused bendamustine RTD ("Bendeka"). We market our products through marketing partners and/or our internal direct sales force. We market Ryanodex and Belrapzo, and Teva Pharmaceutical Industries Ltd. ("Teva") markets Bendeka through its subsidiary Cephalon, Inc. SymBio Pharmaceuticals Limited, or SymBio, markets Treakisym, a RTD product, in Japan. Reflecting further expansion of our oncology portfolio, in February 2020, we received final FDA approval for Pemfexy, a branded alternative to Alimta for metastatic non-squamous non-small cell lung cancer and malignant pleural mesothelioma.
With several pipeline projects underway and the potential for up to five product launches over the next several years, we believe we have many growth opportunities ahead. We believe that each of our pipeline projects currently has the potential to enter the market as a first-in-class, first-to-file, first-to-market or best-in-class product. In particular, we are applying our expertise to conduct novel research regarding the potential for Ryanodex to address conditions including Alzheimer’s disease, traumatic brain injury/concussion, nerve agent exposure and acute radiation syndrome. In addition, our clinical development program includes a strategic partnership with Tyme Technologies, Inc., or Tyme, for Tyme’s product candidate for the treatment of patients with pancreatic or other advanced cancers, SM-88, as well as investigations of compounds such as EA-114 (our fulvestrant product candidate) for patients with HR-positive advanced breast cancer. Other products in development include Vasopressin, our first-to-file Abbreviated New Drug Application, or ANDA, that references Endo International plc’s Vasostrict indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines; and EA-111, a new chemical entity and next-generation ryanodine receptor antagonist, in an intramuscular formulation that that would allow for easier and more rapid administration in emergency situations (military and civilian).
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Significant Accounting Policies
Our significant accounting policies are described in the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 and the notes thereto filed with the SEC on March 5, 2021. Since the date
of those consolidated financial statements, there have been no material changes to our significant accounting policies other than as listed below.
Significant Risks and Uncertainties
In response to the ongoing COVID-19 pandemic, we have taken and continue to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on our business, such as remote working policies, facilitating management’s periodic communication to address employee and business concerns and providing frequent updates to our Board of Directors (“Board”). During the second quarter of 2021, we implemented a plan to reopen our office to allow employees to return to the office, with a focus on employee safety and optimal work environment. Our management continues to monitor and evaluate such plans as the pandemic continues to evolve. We anticipate that the COVID-19 pandemic may also have an impact on the clinical development timelines for certain of our clinical programs. We also anticipate that the COVID-19 pandemic may have an impact on our supply chain. The COVID-19 pandemic and associated lockdowns have resulted in a decrease in healthcare utilization broadly and specifically lead to a continuing reduction in the utilization of physician-administered oncology products including Belrapzo and Bendeka. In addition, the COVID-19 pandemic has delayed the timing of certain litigation, including the litigation with Par (as defined below) with respect to Vasopressin, and we anticipate that such delays will continue for the duration of the pandemic. The extent to which the COVID-19 pandemic will continue to impact our business, clinical development and regulatory efforts, supply chain and sales efforts, corporate development objectives and the value of, and market for, our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and other risks and uncertainties associated with the pandemic have impacted our operations and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

In addition, we are subject to other challenges and risks specific to our business and our ability to execute on our business plan and strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with research and development operations, including, without limitation, risks and uncertainties associated with: delays or problems in obtaining clinical supply; obtaining regulatory approval of product candidates; loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing intellectual property rights; and the challenges of complying with applicable regulatory requirements. In addition, as the ongoing COVID-19 pandemic affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.
Use of Estimates
These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. Our critical accounting policies are those that are both most important to our financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. We anticipate that the COVID-19 pandemic will continue to disrupt our supply chain and marketing and sales efforts for certain of our products, including Bendeka, although it is not currently expected that any disruption would be significant. As of the date of issuance of these financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying value of our assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates, and any such differences may be material to our financial statements.
Reclassifications
Certain reclassifications have been made to prior year amounts to conform with the current year presentation, including for amounts related to accounts receivable, net and prepaid expenses and other current assets. None of the amounts pertaining to the reclassifications were significant.
Cash and Cash Equivalents
We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.
We, at times, maintain balances with financial institutions in excess of the Federal Deposit Insurance Corporation (“FDIC”) limit.
Fair Value Measurements

U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
Level 1: Quoted prices in active markets for identical assets or liabilities.
Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The fair value of interest-bearing cash, cash equivalents, accounts receivable and accounts payable approximate fair value due to their life being short term in nature, and are classified as Level 1 for all periods presented.
Financial assets and liabilities measured and recognized at fair value are as follows:
September 30, 2021
TotalLevel 1Level 2Level 3
Assets:
Money market funds$95,255 $95,255 $— $— 
Convertible promissory note3,795 — — 3,795 
Embedded derivative asset in convertible promissory note530 — — 530 
Investment in Tyme10,300 10,300 — — 
Total financial assets$109,880 $105,555 $— $4,325 
December 31, 2020
TotalLevel 1Level 2Level 3
Assets:
Money market funds$79,682 $79,682 $— $— 
Investment in Tyme12,200 12,200 — — 
Total financial assets$91,882 $91,882 $— $— 
We recognize transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months or nine months ended September 30, 2021 and 2020, respectively.

Our investment in the convertible promissory note and the embedded derivative are classified as Level 3. We analyzed and accessed the embedded derivative feature contained in the convertible promissory note agreement. We used a probability factor to value the embedded derivative asset based on management's best estimate, including the principal and estimated accrued interest among other contractual terms. The convertible promissory note is accounted for as available for sale. The convertible promissory note is reported at fair value with unrealized gains and losses included in Accumulated other comprehensive income (loss). Refer to Note 13, Convertible Promissory Note for further details.

Our investment in restricted shares of common stock of Tyme Technologies, Inc.are classified as Level 1. Refer to Note 12, License and Collaboration Agreements for further details.

The fair value of debt is classified as Level 2 for the periods presented and approximates its book value due to the variable interest rate.
Intangible Assets
We review the recoverability of our finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, we assess the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, we measure the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets. The Company determined that no indicators of impairment of finite-lived intangible assets or long-lived assets existed as of September 30, 2021.
Goodwill
Goodwill represents the excess of purchase price over the fair value of net assets acquired in the Eagle Biologics acquisition. Goodwill is not amortized, but is evaluated for impairment on an annual basis, in the fourth quarter, or more frequently if events or changes in circumstances indicate that the reporting unit’s goodwill is less than its carrying amount. We did not identify any impairment to goodwill during the periods presented.
Concentration of Major Customers and Vendors
We are dependent on our commercial partner, Teva, who markets and sells Bendeka. Our customer for Bendeka is our commercial and licensing partner; therefore, our future revenues are highly dependent on the related exclusive license and distribution arrangement.
The total revenues and accounts receivables broken down by major customers as a percentage of the total are as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2021202020212020
Total revenues
Teva - See Revenue Recognition
69 %74 %66 %72 %
Other31 %26 %34 %28 %
100 %100 %100 %100 %
September 30, December 31,
20212020
Accounts receivable
Teva - See Revenue Recognition
63 %58 %
Other37 %42 %
100 %100 %

Inventories
Inventories are recorded at the lower of cost and net realizable value, with cost determined on a first-in first-out basis. We periodically review the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, we will record a write-down to lower of cost and net realizable value in the period that the decline in value is first recognized.
Research and Development Expense
Costs for research and development are charged to expense as incurred and include; employee-related expenses including salaries, benefits, travel and stock-based compensation expense for research and development personnel; expenses incurred under agreements with contract research organizations, contract manufacturing organizations and service providers that assist in conducting clinical and preclinical studies; costs associated with preclinical activities and development activities, costs associated with regulatory operations; and depreciation expense for assets used in research and development activities.
Costs for certain development activities, such as in licensing intellectual property related to new projects, clinical studies, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid expenses or accrued expenses as deemed appropriate. Recoveries of previously recognized research and development expenses from third parties are recorded as a reduction to research and development expense in the period it becomes realizable.
Advertising and Marketing
Advertising and marketing costs are expensed as incurred. Advertising and marketing costs were $0.5 million and $0.3 million for the three months ended September 30, 2021 and 2020, respectively, and $1.3 million and $2.2 million for the nine months ended September 30, 2021 and 2020, respectively.
Income Taxes
We account for income taxes using the liability method in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), 740 - Income Taxes (“ASC 740”). Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax bases of assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income (loss) in the period that the rate changes. A valuation allowance is required when it is “more likely than not” that all or a portion of deferred tax assets will not be realized. ASC 740 also prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that a company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. We recognize any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
Revenue Recognition
Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for
arrangements that an entity determines are within the scope of ASC 606 - Revenue from Contracts with Customers (“ASC 606”), we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determines those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Receivables from our product sales have payment terms ranging from 30 to 75 days with select extended terms to wholesalers on initial purchases of product launch quantities. Our receivables from royalty revenue are due 45 days from the end of the quarter.
Product revenue - We recognize net revenue on sales to our commercial partners and to end users. In each instance, revenue is generally recognized when the customer obtains control of our product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.
Revenue on sales to commercial partners relates to Bendeka and Treakisym. Sales to our commercial partners are presented gross because we are primarily responsible for fulfilling the promise to provide the product, and are responsible to ensure that the product is produced in accordance with the related supply agreement and we bear risk of loss while the inventory is in-transit to the commercial partner.
Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services to a customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing the expected value method to which we expect to be entitled. As such, revenue on sales to customers for Belrapzo and Ryanodex are recorded net of chargebacks, rebates, returns, prompt pay discounts, wholesaler fees and other deductions. Our products are contracted with a limited number of oncology distributors and hospital buying groups with narrow differences in ultimate realized contract prices used to estimate our chargeback and rebate reserves. We have a product return policy on some of our products that allows the customer to return pharmaceutical products within a specified period of time both prior to and subsequent to the product’s expiration date. Our estimate of the provision for returns is analyzed quarterly and is based upon many factors, including historical experience of actual returns and analysis of the level of inventory in the distribution channel, if any. We have terms on sales of Ryanodex by which we do not accept returns. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration are made using the expected value method and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available. We believe that the estimates we have established are reasonable based upon current facts and circumstances. Applying different judgments to the same facts and circumstances could result in the estimated amounts to vary.
Components of Gross-to-Net (GTN) Estimates
Chargebacks: Chargebacks are discounts that occur when certain contracted customers, including group purchasing organizations (“GPOs”), public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase from our distributors. Our distributors purchase product from us at invoice price, then resell the product to certain contracted customers on the basis of prices negotiated between us and the providers. The difference between the distributors’ purchase price and the typically lower certain contracted customers’ purchase price is refunded to the distributors through a chargeback credit. We record estimates for these chargebacks at the time of sale as deductions from gross revenues, with corresponding adjustments to our accounts receivable reserves and allowances.
The provision for chargebacks is the most significant provision in the context of our gross-to-net adjustments in the determination of net revenue. Chargebacks are estimated based on payer mix and contracted price, adjusted for current period assumptions.

Commercial and Medicaid Rebates: We contract with government agencies or collectively, third-party payors, so that Belrapzo and Ryanodex will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. We estimate the rebates we will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a
reduction of product revenue and the establishment of a current liability. The current liability is included in accrued expenses and other current liabilities on the consolidated balance sheets. We estimate the rebates that we will provide to third-party payors based upon (i) our contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payer mix, and (iv) information obtained from our distributors.
The information that we also consider when establishing our rebate reserves are purchases by customers, projected annual sales for customers, actual rebates payments made, processing time lags, and for indirect rebates, the level of inventory in the distribution channel that will be subject to indirect rebates. We do not provide incentives designed to increase shipments to our customers that we believe would result in out-of-the-ordinary course of business inventory for them. We regularly review and monitor estimated or actual customer inventory information at our largest distributors for our key products to ascertain whether customer inventories are in excess of ordinary course of business levels.

Product Returns: Our distributors have the right to return unopened unprescribed Belrapzo during certain time periods around the period beginning prior to the labeled expiration date and ending after the labeled expiration date. We estimate future product returns on sales of Belrapzo based on: (i) data provided to us by our distributors (including weekly reporting of distributors’ sales and inventory held by distributors that provided us with visibility into the distribution channel in order to determine what quantities were sold to retail pharmacies and other providers), (ii) information provided to us from retail pharmacies, (iii) data provided to us by a third-party data provider which collects and publishes prescription data, and other third parties, (iv) historical industry information regarding return rates for similar pharmaceutical products, (v) the estimated remaining shelf life of Belrapzo previously shipped and currently being shipped to distributors and (vi) contractual agreements intended to limit the amount of inventory maintained by our distributors. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Our provision for product returns based on the factors noted above generally encompass a time range from 12 to 48 months after revenue is recognized. Additionally, we consider other factors when estimating our current period return provision, including levels of inventory in the distribution channel, significant market changes that may impact future expected returns, and actual product returns, and may record additional provisions for specific returns that it believes are not covered by the historical rates. Our commercial returns policy and terms with certain customers also states that certain products are sold as non-returnable.

Wholesaler fees and other incentives: We generally provide invoice discounts on Belrapzo and Ryanodex sales to our distributors for prompt payment and fees for distribution services, such as fees for certain data that distributors provide to us. The payment terms for sales to distributors generally include a 2% discount for prompt payment which is generally defined in invoice terms as a range from 30 to 70 days, while the fees for distribution services are based on contractual rates agreed with the respective distributors. Based on historical data, we expect our distributors to earn these discounts and fees, and deducts the full amount of these discounts and fees from our gross product revenues and accounts receivable at the time such revenues are recognized.

Other GTN considerations
We may at our discretion provide price adjustments due to various competitive factors. There are circumstances under which we may not provide price adjustments to certain customers as a matter of business strategy, and consequently may lose future sales volume to competitors and risk a greater level of product returns.

As detailed above, we have the experience and access to relevant information that we believe are necessary to reasonably estimate the amounts of such deductions from gross revenues. Some of the assumptions we use for certain of these estimates are based on information received from third parties, such as wholesale customer inventories and market data, or other market factors beyond our control. The estimates that are most critical to the establishment of these reserves, and therefore, would have the largest impact if these estimates were not accurate, are estimates related to contract sales volumes, average contract pricing, customer inventories and return volumes. We regularly review the information related to these estimates and adjust our reserves accordingly, if and when actual experience differs from previous estimates. With the exception of the product returns allowance, the ending balances of accounts receivable reserves and allowances generally are processed during a two-month to four-month period.
Royalty Revenue — We recognize revenue from license arrangements with our commercial partners' net sales of products. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner’s products occurs. Our commercial partners are obligated to report their net product sales and the resulting royalty due to us within 25 days for Bendeka. Based on historical product sales, royalty receipts and other relevant information, we accrue royalty revenue each quarter and subsequently determine a true-up when we receive royalty reports from our commercial partners. Historically, these true-up adjustments have been immaterial.
License and other revenue — We analyze each element of our licensing agreements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer.
If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. We determine standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, we estimate the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.
We recognize sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, we determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, we assess each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of these future events, we will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event.
When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, we do not assess whether a significant financing component exists if the period between when we perform our obligations under the contract and when the customer pays is one year or less. None of our contracts contained a significant financing component as of September 30, 2021.
Stock-Based Compensation
We account for stock-based compensation using the fair value provisions of ASC 718, Compensation - Stock Compensation that requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock-based payments including stock options and restricted stock. This topic requires companies to estimate the fair value of the stock-based awards on the date of grant for options issued to employees and directors and record expense over the employees' service periods, which are generally the vesting period of the equity awards.
We account for stock-based compensation by measuring and recognizing compensation expense for all stock-based payments made to employees and directors based on estimated grant date fair values. The straight-line method is used to allocate compensation cost to reporting periods over each optionee's requisite service period, which is generally the vesting period. The fair value of our stock option awards to employees and directors is estimated using the Black-Scholes valuation model and a Monte Carlo simulation model is used to estimate the fair value for market condition share units. These models require the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, historical forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate is determined with the implied yield currently available for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options. The fair value of restricted stock units ("RSUs") granted are estimated based on the trading price of our common stock on the date of grant. The fair value of performance condition performance-based stock units ("PSUs") granted are also estimated based on the trading price of our common stock on the date of grant and adjusted for the probability of achievement of the performance conditions. Forfeitures are estimated for all stock-based awards.
Earnings Per Share
Basic earnings per common share is computed using the weighted average number of shares outstanding during the period. Diluted earnings per share is computed in a manner similar to the basic earnings per share, except that the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of warrants, options, convertible debt and other such convertible instruments. Diluted earnings per share contemplate a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share.
The anti-dilutive common share equivalents outstanding for the three and nine months ended September 30, 2021 and 2020 were as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2021202020212020
Stock options2,446,657 3,156,166 2,777,995 2,905,021 
Restricted stock units
— 205,891 123,600 225,177 
Total2,446,657 3,362,057 2,901,595 3,130,198 

The following table sets forth the computation for basic and diluted net (loss) earnings per share for the three and nine months ended September 30, 2021 and 2020:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2021202020212020
Numerator
Numerator for basic and diluted (loss) earnings per share-net (loss) earnings $(5,622)$7,059 $(2,431)$3,932 
Denominator
Basic weighted average common shares outstanding 13,077,298 13,531,372 13,103,203 13,620,981 
Dilutive effect of stock awards — 255,431 — 296,819 
Diluted weighted average common shares outstanding 13,077,298 13,786,803 13,103,203 13,917,800 
Basic net (loss) earnings per share
Basic net (loss) earnings per share $(0.43)$0.52 $(0.19)$0.29 
Diluted net (loss) earnings per share
Diluted net (loss) earnings per share $(0.43)$0.51 $(0.19)$0.28 

All potentially dilutive items were excluded from the diluted share calculation for the three months and nine months ended September 30, 2021 because their effect would have been anti-dilutive, as the Company was in a loss position.

Recent Accounting Pronouncements
Recent Accounting Pronouncements - Not Yet Adopted
In March 2020, the FASB issued Update 2020-04 Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting to provide temporary optional guidance to ease the potential burden in accounting for
reference rate reform. The amendments in Update 2020-04 are elective and apply to all entities that have contracts, hedging relationships, and other transactions that reference LIBOR, formerly known as the London Interbank Offered Rate,
or another reference rate expected to be discontinued due to reference rate reform. The new guidance provides optional expedients, including; (1) Simplify accounting analyses under current GAAP for contract modifications, such as modifications of contracts within the scope of Topic 470, Debt, that will be accounted for by prospectively adjusting the effective interest rate, as if any modification was not substantial. That is, the original contract and the new contract shall be accounted for as if they were not substantially different from one another; (2) Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue; (3) Allow a one-time election to sell or transfer debt securities classified as held to maturity before January 1, 2020 that reference a rate affected by reference rate reform. The amendments are effective for all entities from the beginning of an interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The adoption of ASU 2020-4 is not expected to have a material impact on our financial position or results of operations.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment, net
9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment, net Property and Equipment, net
Property and equipment consisted of the following:
 September 30, 2021December 31, 2020Estimated Useful Life (years)
Furniture and fixtures$1,476 $1,476 7
Office equipment1,077 1,152 3
Equipment3,834 3,485 7
Leasehold improvements1,155 1,155 2
 7,542 7,268  
Less accumulated depreciation(5,767)(5,191)
Property and equipment, net$1,775 $2,077  

Depreciation expense related to property and equipment amounted to $197 and $196 for the three months ended September 30, 2021 and 2020, respectively, and $575 and $656 for the nine months ended September 30, 2021 and 2020, respectively.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories
9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consist of the following:
September 30, December 31,
20212020
Raw materials$6,006 $3,515 
Work in process 1,309 2,589 
Finished products2,000 1,971 
Total inventories$9,315 $8,075 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Accounts
9 Months Ended
Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Accounts Balance Sheet Accounts
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
September 30, December 31,
20212020
Prepaid income taxes$5,898 $— 
Prepaid FDA user fee and advances to clinical research organization1,478 1,262 
Prepaid insurance468 191 
Advances to commercial manufacturers734 660 
Receivable from commercial partner
1,746 439 
Convertible promissory note, net4,551 — 
All other2,428 1,605 
Total prepaid expenses and other current assets$17,303 $4,157 

Accrued Expenses
Accrued expenses consist of the following:
September 30, December 31,
20212020
Accrued sales reserves$3,046 $4,966 
Royalties payable to commercial partners4,879 5,996 
Accrued salary and other compensation 5,255 4,686 
Accrued professional fees2,552 2,370 
Accrued research & development8,528 2,724 
Current portion of lease liability1,199 1,123 
Accrued other 2,255 1,952 
Total accrued expenses$27,714 $23,817 

Leases
We lease office space in Woodcliff Lake, New Jersey for our principal office under an amended lease agreement through June 2025. We also lease a lab space in Cambridge, Massachusetts under a lease agreement through April 2024. Both of our leases are classified as operating leases and have remaining lease terms of approximately 3.3 years. The principal office and the lab space leases include renewal options to extend the lease for up to 5 years. Furthermore, we have not elected the practical expedient to separate lease and non-lease components for all classes of underlying assets.
The table below summarizes our total lease costs included in the condensed consolidated financial statements, as well as other required quantitative disclosures (in thousands):

September 30, 2021December 31, 2020
Cash paid for amounts included in the measurement of lease liabilities
     Operating cash flows for operating leases$1,040 $1,323 
Right-of-use assets obtained in exchange for new operating lease liabilities$— $855 
Weighted-average remaining lease term - operating leases 3.3 years4.1 years
Weighted-average discount rate - operating leases 6.0 %6.0 %

Balance Sheet Classification as of September 30:
Current lease liabilities (included with Accrued Expenses and other liabilities)$1,199 
Long-term lease liabilities (included with Other long-term liabilities)3,048 
Total lease liabilities$4,247 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets, Net
9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets, Net Intangible Assets, Net
The gross carrying amounts and net book value of our intangible assets are as follows:
September 30, 2021
Useful Life (In Years)Gross Carrying AmountAccumulated AmortizationNet Book Value
Ryanodex intangible (i)
20$15,000 $(4,404)$10,596 
Developed technology58,100 (7,897)203 
Total$23,100 $(12,301)$10,799 
December 31, 2020
Useful Life (In Years)Gross Carrying AmountAccumulated AmortizationNet Book Value
Ryanodex intangible (i)
2015,000 (3,500)11,500 
Developed technology58,100 (6,683)1,417 
Total$23,100 $(10,183)$12,917 
(i) Represents a one-time payment made to reduce the royalties payable to a third party on Ryanodex net sales.
Amortization expense was $706 and $667 for the three months ended September 30, 2021 and 2020, respectively and $2,118 and $1,999 for the nine months ended September 30, 2021 and 2020, respectively.
Estimated Amortization Expense for Intangible Assets
Based on definite-lived intangible assets recorded as of September 30, 2021, and assuming that the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses are estimated as follows:
Estimated Amortization Expense
Year Ending December 31,
2021 (remainder)504 
20221,369 
20231,570 
20241,898 
20251,520 
Thereafter3,938 
Total estimated amortization expense$10,799 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Common Stock and Stock-Based Compensation
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Common Stock and Stock-Based Compensation Common Stock and Stock-Based Compensation
Common Stock
Share Repurchase Program

On March 17, 2020, we announced that our Board approved a new share repurchase program, or the Share Repurchase Program, providing for the repurchase of up to an aggregate of $160 million of our outstanding common stock. The Share Repurchase Program replaced our then existing share repurchase program, or the Previous Share Repurchase Program, which was announced on October 30, 2018 and was terminated in connection with the Board’s approval of the Share Repurchase Program. At termination, we had repurchased approximately $68 million of our outstanding common stock under the Previous Share Repurchase Program.

Under the Share Repurchase Program, we are authorized to repurchase shares through open market purchases, privately-negotiated transactions, accelerated share repurchases or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans and under Rule 10b-18 of the Exchange Act. The repurchases have no time limit and may be suspended or discontinued completely at any time. The specific timing and amount of repurchases will vary based on available capital resources and other financial and operational performance, market conditions, securities law limitations, and other factors. The repurchases will be made using our cash resources.

On September 23, 2020, our Board of Directors approved a $25 million accelerated share repurchase (“ASR”) transaction with JPMorgan Chase Bank, National Association (“JP Morgan”) as part of our existing $160 million share repurchase program. The specific number of shares to be repurchased pursuant to the ASR is based on the average of the daily volume weighted average share prices of our common stock, less a discount, during the term of the ASR program. Under the terms of our agreement with JP Morgan, we paid $25 million to JP Morgan on September 24, 2020, and received 550,623 shares, representing the notional amount of the ASR, based on the average of the daily volume weighted average share prices of our common stock, less a discount, during the term of the ASR, which was $45.40. The ASR was completed in the fourth quarter of 2020. We determined the ASR contained a forward contract and therefore we recorded fair value adjustments on the accelerated share repurchase agreement in the amount of $3 million which was a loss recorded in Other expense on our consolidated statements of operations in the year ended December 31, 2020.

As of September 30, 2021, we had repurchased an aggregate of 3,941,541 shares of common stock for an aggregate of $219.5 million pursuant to our share repurchase programs in effect since August 2016.

Stock-Based Compensation
In November 2013, our Board of Directors approved the 2014 Equity Incentive Plan (the "2014 Plan") which became effective on February 11, 2014. The 2014 Plan provides for the awards of incentive stock options, non-qualified stock options, restricted stock, restricted stock units and other stock-based awards. Awards generally vest equally over a period of four years from grant
date. Vesting may be accelerated under a change in control of the Company or in the event of death or disability to the recipient. In the event of termination, any unvested shares or options are forfeited.

During the first quarter of 2018, we introduced a new long-term incentive program with the objective to better align the stock-based awards granted to management with our focus on improving total shareholder return over the long-term. The stock-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and PSUs. PSUs are comprised of awards: i) that would have vested upon achievement of certain share price appreciation conditions or ii) that would have vested upon achievement of certain milestone events. These PSUs expired in the first quarter of 2021.

During the first quarter of 2021, 97,750 market condition PSUs expired. We also granted 99,500 market condition PSUs based on our total shareholder return ("TSR") relative to the TSR of each member of the S&P Biotechnology Select Industry Index (the defined peer group) with a weighted-average grant date fair value of $71.09 per respective PSU. The fair value of PSUs granted to employees was estimated using a Monte Carlo simulation model. Inputs used in the calculation include a risk-free interest rate of 0.18%, an expected volatility of 44%, contractual term of 3 years, and no expected dividend yield.

During the first quarter of 2021, we also granted 59,500 performance based (milestones) PSUs with grant date fair value of $49.32 using our closing stock price on the date of the grant. These PSUs will vest (if earned) from 0% to 200% of target number granted based on the achievement of one or more of three milestones related to i) regulatory approval of Fulvestrant ("EA-114"), ii) sales of Pemfexy and; iii) sales of Vasopressin, respectively. The contractual term of these awards is 3 years. We estimated 0% probability of achievement for the year-to-date period of 2021.

A summary of stock option, RSU and PSU activity under the 2014 Plan during the nine months ended September 30, 2021 and 2020 is presented below:
 Stock OptionsRSUsPSUs
Outstanding at December 31, 20193,096,161 251,215 116,181 
Granted662,700 231,450 — 
Options exercised/RSUs vested/PSUs vested(41,951)(67,970)— 
Forfeited or expired(185,615)(53,824)(11,431)
Outstanding at September 30, 20203,531,295 360,871 104,750 
Outstanding at December 31, 20203,331,890 328,396 97,750 
Granted109,000 106,600 159,000 
Options exercised/RSUs vested/PSUs vested(100,477)(94,273)— 
Forfeited or expired(308,815)(46,941)(97,750)
Outstanding at September 30, 20213,031,598 293,782 159,000 
Stock Options
The fair value of stock options granted to employees, directors, and consultants were estimated using the following assumptions:
Three Months Ended
September 30,
Nine Months Ended 
 September 30,
2021202020212020
Risk-free interest rate
0.82% - 0.93%
0.37% - 0.41%
0.51% - 1.12%
0.37% - 1.65%
Volatility54.92%55.42%56.07%54.98%
Expected term (in years)6.08 years6.07 years5.68 years6.03 years
Expected dividend yield0.0%0.0%0.0%0.0%

RSUs
Each vested time-based RSU represents the right of a holder to receive one share of our common stock. The fair value of each RSU granted was estimated based on the trading price of our common stock on the date of grant.
PSUs
The fair value of market condition PSUs granted to employees was estimated using a Monte Carlo simulation model. Inputs used in the calculation are described above.

The fair value of performance condition PSUs granted to employees was estimated based on the trading price of our common stock on the date of grant adjusted for probability of achievement of the performance conditions as described above.

We did not recognize any expense for performance based PSUs granted to employees based on our estimated probability of achievement as described above.

We recognized stock-based compensation in our condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 as follows:
Three Months Ended September 30, Nine Months Ended September 30,
2021202020212020
Stock options $2,515 $3,685 $8,393 $12,831 
RSUs1,046 928 4,051 4,115 
PSUs523 109 2,429 1,489 
Stock-based compensation expense $4,084 $4,722 $14,873 $18,435 
Selling, general and administrative$3,443 $5,236 $12,696 $16,365 
Research and development641 (514)2,177 2,070 
Stock-based compensation expense$4,084 $4,722 $14,873 $18,435 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments
9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments Commitments
Our future material contractual obligations as of September 30, 2021, included the following:
ObligationsTotal202120222023202420252026Beyond
Operating leases (1)$4,680 $351 $1,423 $1,455 $1,038 $413 $— $— 
Credit facility (2)28,000 2,000 26,000 — — — — — 
Purchase obligations (3)53,176 53,176 — — — — — — 
Total obligations $85,856 $55,527 $27,423 $1,455 $1,038 $413 $— $— 

(1) We lease our corporate office location. The term of our existing lease expires on June 30, 2025. We also lease our lab space under a lease agreement that expires on October 31, 2023. Rental expense for the operating leases was $325 and $276, for the three months ended September 30, 2021 and 2020, respectively. Rental expense for the operating leases was $976 and $910 for the nine months ended September 30, 2021 and 2020. The remaining future lease payments under the operating leases are $4.7 million as of September 30, 2021.
(2) Refer to Note 9, “Debt” for further information regarding our Credit Agreement.
(3) As of September 30, 2021, we had purchase obligations in the amount of $53.2 million which represents the contractual commitments under contract manufacturing and supply agreements with suppliers. The obligations under the supply agreements are primarily for finished product, inventory, and research and development.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Debt
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Debt Debt
On November 8, 2019, we entered into the Second Amended and Restated Credit Agreement (the “Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”) and the lenders party thereto. The terms and amounts borrowed under the Credit Agreement includes a drawn term loan of $40 million and an undrawn revolving credit facility of $110 million. The schedule of principal payments for the new term loan facility was extended to November 8, 2022.
We classified the current portion of long-term debt of $8 million on the condensed consolidated balance sheet as of September 30, 2021. Per the terms of the Credit Agreement, the Company is limited in its ability to pay dividends. As of September 30 2021, we were in compliance with each of the senior secured net leverage ratio; total net leverage ratio; and fixed charge coverage ratio covenants.
The term loan facility bears interest at the Adjusted LIBOR (equal to (a) the LIBOR for such Interest Period multiplied by (b) the Statutory Reserve Rate as established by Board of Governors of the Federal Reserve System of the United States of America) for the interest period in effect for such borrowing plus the applicable rate as described below. The Agent and us may amend the Credit Agreement to replace the LIBOR with a Benchmark Replacement, described below.

Loans under the Credit Agreement bear interest at a rate equal to either (a) the LIBOR rate, plus an applicable margin ranging from 2.25% to 3.0% per annum, based upon the total net leverage ratio (as defined in the Credit Agreement), or (b) the Benchmark Replacement which is defined as the greatest of the prime lending rate, or the NYFRB Rate (the rate for a federal funds transaction) in effect on such day plus ½ of 1% or the Adjusted LIBO Rate for a one month Interest Period on such day plus 1% plus an applicable margin ranging from 1.25% to 2.0% per annum, based upon the total net leverage ratio. 
We are required to pay a commitment fee on the unused portion of the new revolving credit facility in the Credit Agreement at a rate ranging from 0.35% to 0.45% per annum based upon the total net leverage ratio.

As of September 30, 2021, we had $0.5 million of unamortized deferred debt issuance costs as part of long-term debt in its condensed consolidated balance sheets.
Debt Maturities As of September 30, 2021
     2021 (remainder)$2,000 
     202226,000 
Total$28,000 
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
Three Months Ended September 30, Nine Months Ended September 30,
2021202020212020
Income tax benefit (provision)$7,038 $(1,866)$3,341 $(7,358)
Effective tax rate 56 %21 %58 %65 %

For interim periods, we recognize an income tax provision based on our estimated annual effective tax rate expected for the entire year plus the effects of certain discrete items occurring in the quarter. The interim annual estimated effective tax rate is based on the statutory tax rates then in effect, as adjusted for changes in estimated permanent differences, and certain discrete items whose tax effect, when material, is recognized in the interim period in which they occur.
The effective tax rate for the three and nine months ended September 30, 2021, reflects an interim tax benefit resulting from our research and development expense of acquired licenses and credits for research and development activity, partially offset by impact of certain non-deductible executive compensation and expired stock compensation. We review the realizability of our deferred tax assets on a quarterly basis, or whenever events or changes in circumstances indicate that a review is required. In determining the requirement for a valuation allowance, the historical and projected financial results of the legal entity or consolidated group recording the net deferred tax asset are considered, along with any other positive or negative evidence. Since future financial results, including the fair value adjustment on our investment in Tyme may differ from previous estimates, periodic adjustments to our valuation allowances may be necessary.
Deferred income tax assets as of September 30, 2021 consisted of temporary differences primarily related to stock-based compensation and research and development tax credit carryforwards, partially offset by temporary differences related to intangible assets.
We file income tax returns in the U.S. federal jurisdiction and several states. Given that we have incurred tax losses in most years since our inception, all of our tax years are effectively open to examination. We are currently under audit by three State tax jurisdictions. We had no amount recorded for any unrecognized tax benefits as of September 30, 2021. We regularly evaluate our tax positions for additional unrecognized tax benefits and associated interest and penalties, if applicable. There are many factors that are considered when evaluating these tax positions including: interpretation of tax laws, recent tax litigation on a position, past audit or examination history, and subjective estimates and assumptions. We reflect interest and penalties attributable to income taxes, to the extent they arise, as a component of income tax provision or benefit.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Legal Proceedings
9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Legal Proceedings Legal Proceedings
In addition to the below legal proceedings, from time to time, we may be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters, or matters discussed below, will not have a material adverse effect on our business nor have we recorded any loss in connection with these matters because we believe that loss is neither probable nor estimable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Commercial Litigation
Cipla v. Eagle
On April 16, 2020, Cipla Limited (“Cipla”) filed a request for arbitration against Eagle with the London Court of International Arbitration. The request alleges that Eagle’s refusal to take delivery of several batches of Argatroban finished drug product
constitutes a breach of the parties’ December 14, 2012 supply agreement. Eagle believes that the allegations against it are without merit and is vigorously defending itself in the Arbitration, which was scheduled for June 2021, has been rescheduled for April 2022.

Patent Litigation
Eagle Pharmaceuticals, Inc., et al. v. Slayback Pharma Limited Liability Company; Eagle Pharmaceuticals, Inc., et al. v. Apotex Inc. and Apotex Corp.; Eagle Pharmaceuticals, Inc., et al. v. Fresenius Kabi USA, LLC; Eagle Pharmaceuticals, Inc., et al. v. Mylan Laboratories Limited; Eagle Pharmaceuticals, Inc. et al. v. Hospira, Inc; Eagle Pharmaceuticals, Inc. et al. v. Lupin, Ltd. and Lupin Pharmaceuticals, Inc.; Teva Pharmaceuticals Int’l GmbH et al v. Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., and Eugia Pharma Specialities Ltd.; Teva Pharmaceuticals Int’l GmbH et al v. Accord Healthcare Inc., Accord Healthcare Ltd., and Intas Pharmaceuticals Ltd.; Teva Pharmaceuticals Int’l GmbH et al v. Dr. Reddy’s Laboratories, Ltd., and Dr. Reddy’s Laboratories, Inc. - (Bendeka®)

Bendeka, which contains bendamustine hydrochloride, is an alkylating drug that is indicated for the treatment of patients with chronic lymphocytic leukemia, as well as for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Slayback Pharma Limited Liability Company (“Slayback”), Apotex Inc. and Apotex Corp. (“Apotex”), Fresenius Kabi USA, LLC (“Fresenius”), Mylan Laboratories Limited (“Mylan”), Lupin, Ltd. and Lupin Pharmaceuticals, Inc. (“Lupin”), and Aurobindo Pharma, Ltd, Aurobindo Pharma USA, Inc., and Eugia Pharma Specialities Ltd (“Aurobindo”) have filed Abbreviated New Drug Applications (“ANDA’s”) referencing Bendeka® that include challenges to one or more of the Bendeka® Orange Book-listed patents. Hospira, Inc. (“Hospira”) filed a 505(b)(2) NDA.

We, Cephalon, Inc. and/or Teva Pharmaceuticals International GMBH (together the “Patentees”), filed separate suits against Slayback, Apotex, Fresenius, Mylan, Hospira, Lupin, and Aurobindo in the United States District Court for the District of Delaware on August 16, 2017 (Slayback (“Slayback I”)), August 18, 2017 (Apotex), August 24, 2017 (Fresenius), December 12, 2017 (Mylan), January 19, 2018 (Slayback (“Slayback II”)), July 19, 2018 (Hospira), and July 2, 2019 (Lupin) and May 11, 2020 (Aurobindo). In these Complaints, the Patentees allege infringement of the challenged patents, namely U.S. Patent Nos. 8,791,270 and 9,572,887 against Slayback (Slayback I and Slayback II), and of U.S. Patent Nos. 8,609,707, 8,791,270, 9,000,021, 9,034,908, 9,144,568, 9,265,831, 9,572,796, 9,572,797, 9,572,887, 9,579,384, 9,597,397, 9,597,398, 9,597,399 against Fresenius, Apotex, and Mylan, and of U.S. Patent Nos. 9,572,887, 10,010,533, 9,034,908, 9,144,568, 9,597,397, 9,597,398, 9,597,399, 9,000,021, 9,579,384 against Hospira, and of U.S. Patent Nos. 8,609,707, 9,000,021, 9,034,908, 9,144,568, 9,265,831, 9,572,796, 9,572,797, 9,572,887, 9,579,384, 9,597,397, 9,597,398, 9,597,399, 10,010,533, and 10,052,385 against Lupin and of U.S. Patent Nos. 8,609,707, 9,265,831, 9,572,796, 9,572,797, 9,034,908, 9,144,568, 9,572,887, 9,597,397, 9,597,398, 9,597,399, 9,000,021, 9,579,384, 10,010,533, and 10,052,385 against Aurobindo. The parties stipulated to dismiss without prejudice U.S. Patent No. 8,791,270 as to Apotex, Fresenius and Mylan on July 24, 2018, August 2, 2018, and August 3, 2018, respectively. Slayback, Apotex, Fresenius, and Mylan answered their Complaints and some filed various counterclaims on September 29, 2017 (Slayback I), February 12, 2018 (Slayback II), November 27, 2017, September 15, 2017, and February 14, 2018, respectively. The Patentees answered the Slayback I, Slayback II, Fresenius, and Apotex counterclaims on October 20, 2017, March 5, 2018, October 6, 2017, and December 18, 2017, respectively. On October 15, 2018, the Patentees filed a suit against Fresenius and Mylan in the United States District Court for the District of Delaware, alleging patent infringement of U.S. Patent Nos. 10,010,533 and 10,052,385. The Slayback I, Slayback II, Apotex, Fresenius and Mylan cases have been consolidated for all purposes (the “Consolidated Bendeka Litigation”), and a bench trial in these cases was held September 9-19, 2019. On April 27, 2020, the district court held that the asserted patents are valid and infringed by Slayback, Apotex, Fresenius and Mylan. On July 6, 2020, the district court entered a final judgment reflecting this decision, stating that pursuant to 35 U.S.C. § 271(e)(4)(A), the FDA shall not approve Apotex’s, Fresenius’s, Mylan’s, or Slayback’s ANDA products on a date which is earlier than January 28, 2031, and enjoining Apotex, Fresenius, Mylan, and Slayback from commercially manufacturing, using, offering to sell, or selling within the US or importing into the US, their ANDA products before that date. On August 4, 2020, Apotex, Fresenius, and Mylan appealed this final judgment, and filed their opening briefs on November 4, 2020. Plaintiffs’ responsive appeal brief was filed on February 12, 2021. Defendants’ reply briefs were filed April 5, 2021. On August 2, 2021, Fresenius’s appeal was dismissed pursuant to a settlement agreement reached with Patentees. Oral argument for the remaining defendants occurred on August 3, 2021. On August 13, 2021, the appeals court affirmed the trial court’s decision. The mandate was issued on October 22, 2021.
Hospira filed a motion to dismiss, which was fully briefed on November 16, 2018. On December 16, 2019, the United States District Court for the District of Delaware denied Hospira’s motion to dismiss with respect to U.S. Patent No. 9,572,887 and granted that motion with respect to the remaining patents. On December 15, 2020, the Court held a claim construction hearing, ruling in our favor on all claim terms. Fact discovery closed on April 1, 2021. Expert discovery is ongoing. Trial has been rescheduled for April 25, 2022. The case remains pending.

On March 10, 2020, the parties filed a stipulation and order of dismissal without prejudice as to Lupin, which the Court entered March 11, 2020.

Aurobindo answered the Complaint on July 20, 2020. The parties exchanged initial disclosures on December 11, 2020. Plaintiffs provided their infringement contentions on March 12, 2021. On October 20, 2021 the Court entered a stipulation of dismissal based on a settlement between the parties.

Patentees filed suit against Dr. Reddy’s Laboratories on May 13, 2021. Patentees have asserted U.S. Patent Nos. 8,609,707, 9,265,831, 9,572,796, 9,572,797, 9,034,908, 9,144,568, 9,572,887, 9,597,397, 9,597,398, 9,597,399, 9,000,021, 9,579,384, 10,010,533, and 10,052,385. Dr. Reddy’s answer was filed August 16, 2021. Scheduling for the case is ongoing.

Patentees filed suit against Accord Healthcare on June 29, 2021. Patentees have asserted U.S. Patent Nos. 8,609,707, 9,265,831, 9,572,796, 9,572,797, 9,034,908, 9,144,568, 9,572,887, 9,597,397, 9,597,398, 9,597,399, 9,000,021, 9,579,384, 10,010,533, and 10,052,385. Accord has answered the complaint.

Eagle Pharmaceuticals, Inc. v. Slayback Pharma Limited Liability Company
Slayback filed an ANDA referencing Eagle's Belrapzo NDA. Slayback’s ANDA includes challenges to one or more of the Belrapzo Orange Book-listed patents. On September 20, 2018, the Company filed a suit against Slayback in the United States District Court for the District of Delaware, alleging patent infringement of U.S. Patent Nos. 8,609,707, 9,265,831, 9,572,796, 9,572,797 and 10,010,533. On October 10, 2018, Slayback answered the Complaint and filed various counterclaims. On October 31, 2018, the Company answered Slayback’s counterclaims. Pursuant to a stipulation between the parties, Slayback is bound by any final judgment entered in the Consolidated Bendeka Litigation. This case is currently stayed.

Eagle Pharmaceuticals, Inc. v. Slayback Pharma Limited Liability Company, Apotex, Inc. and Apotex Corp.
Both Slayback and Apotex filed NDAs referencing Eagle’s Belrapzo NDA. On August 31, 2021, the Company filed suit against Slayback and Apotex in the United States District Court for the District of Delaware, alleging infringement of U.S. Patent No. 11,103,483. On September 22, 2021, both Slayback and Apotex filed their Answers. Scheduling for the case is ongoing.

Par Pharmaceutical, Inc. et al. v. Eagle Pharmaceuticals, Inc. (Vasopressin)
On May 31, 2018, Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC (together, “Par”) filed suit against the Company in the United States District Court for the District of Delaware. Par alleged patent infringement based on the filing of the Company’s ANDA seeking approval to manufacture and sell the Company’s vasopressin product. The Company’s vasopressin product, if approved by FDA, will be an alternative to Vasostrict, which is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. The Company answered the complaint on August 6, 2018, and filed an amended answer and counterclaims on October 30, 2019. The court issued a Markman ruling on July 1, 2019. On December 20, 2019, Par dismissed with prejudice claims of three of the patents asserted against Eagle, and the Court entered an Order reflecting that dismissal on December 27, 2019. Mediation took place on March 3, 2020. On April 17, 2020, we submitted a letter requesting leave to file a motion for summary judgment of non-infringement. Par’s responsive letter was submitted on May 8, 2020. On May 18, 2020, the court said it would hear non-infringement arguments at trial and not through summary judgment. Fact discovery ended in October 2019, and expert discovery ended in February 2020. Due to the COVID-19 pandemic, the trial, which was scheduled to begin May 18, 2020, was rescheduled to and occurred on July 7-9, 2021. Post-trial briefing was submitted on July 28, 2021. The Court issued an opinion on August 31, 2021 and entered a final judgment of non-infringement in favor of Eagle on September 16, 2021. Par filed a Notice of Appeal of the final judgment on September 22, 2021, and the appeal was docketed with the United States Court of Appeals for the Federal Circuit on September 23, 2021. The 30-month stay of FDA approval expired on October 17, 2020. This suit is pending.
On December 7, 2020, Par filed a separate suit against us in the United States District Court for the District of New Jersey, asserting patent infringement of U.S. Patent No. 10,844,435, based on the filing of our ANDA seeking approval to manufacture and sell our vasopressin product. Eagle moved to dismiss Par’s complaint on March 2, 2021. On March 22, 2021, Par amended its complaint to additionally assert U.S. Patent No. 10,920,278, and on April 5, 2021, Eagle moved to dismiss Par’s amended complaint. This suit is pending.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.2
License and Collaboration Agreements
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
License and Collaboration Agreements License and Collaboration Agreements
License agreement with Combioxin

In August 2021, we entered into a license agreement with Combioxin, SA under which the Company was granted exclusive, worldwide development and commercialization rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. The Company will be solely responsible for the development, regulatory, manufacturing and commercialization activities of CAL02. Combioxin will assist the Company in transitioning the manufacturing and supply of CAL02 to the Company.

Under the terms of the agreement, we paid $10 million as upfront license consideration that was expensed immediately as research and development and is reflected within the operating activities of the condensed consolidated statements of cash flows. The Company may pay to Combioxin up to $105 million upon achievement of certain development, regulatory and sales based milestone payments plus royalty payments at royalty rates ranging in low double digit percentages on the net sales of all products sold, subject to certain adjustments as provided in the agreement. The Company is also obligated to make certain payments based upon amounts received by sublicensees under the agreement.

License agreement with AOP Orphan

In August 2021, we entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH (“AOP Orphan”), a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, landiolol in the United States. Landiolol, a leading hospital emergency use product, is currently approved in Europe for the treatment of non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias. We will support the submission of a new drug application (“NDA”) by AOP Orphan to the FDA seeking approval for landiolol for the short term reduction of ventricular rate in patients with supraventricular tachycardia (“SVT”), including atrial fibrillation and atrial flutter.

Under the terms of the agreement, we accrued a $5 million upfront license consideration that was expensed immediately as research and development and is reflected within the operating activities of the condensed consolidated statements of cash flows. The Company may pay to AOP Orphan up to $25 million upon achievement of certain regulatory milestone payments plus profit share payments, subject to certain adjustments as provided in the agreement. We also entered into a supply agreement at the same time as the licensing agreement.

Collaboration with Tyme
On January 7, 2020, Tyme and we announced a strategic collaboration to advance SM-88, an oral product candidate for the treatment of patients with cancer. SM-88 is an investigational agent in two Phase II studies, one for pancreatic cancer and another for prostate cancer.
Under the terms of a related co-promotion agreement, we would be responsible for 25% of the promotional sales effort of SM-88 and would receive 15% royalty on the net revenues of SM-88 in the United States. Tyme is responsible for clinical development, regulatory approval, commercial strategy, marketing, reimbursement and manufacturing of SM-88. Tyme retains the remaining 85% of net U.S. revenues and reserves the right to repurchase our U.S. co-promotion right for $200.0 million.
Our equity investment in Tyme is included in Other assets on our condensed consolidated balance sheet. For the three months ended September 30, 2021 and 2020, the fair value adjustments for the equity investment was a loss of $2.3 million and $3.5 million, respectively. For the nine months ended September 30, 2021 and 2020, the fair value adjustments for the equity investment was a loss of $1.9 million and a loss of $7.7 million, respectively. These adjustments were recorded in Other (expense) income on our condensed consolidated statements of operations.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Convertible Promissory Note
9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Convertible Promissory Note Convertible Promissory Note
During the first quarter of 2021, we invested $5 million in a convertible promissory note ("the note") of a privately held clinical-stage biotechnology company (the "issuer"). The note bears an 8% annual interest rate and has an 18-month term. The issuer is not required to make any principal or interest payments until the end of the term. The note, along with any accrued interest, may automatically convert into equity securities of the issuer under either a financing event or a change in control event as defined in the convertible promissory note agreement. The issuer's product development efforts could encounter technical or other difficulties that could increase their development costs more than expected. The issuer will likely require additional capital prior to obtaining certain regulatory approval or to be able to repay the convertible promissory note with accrued interest at the end of the term.

The following table summarizes the amounts recorded and activity during the nine months ended September 30, 2021;
InitialFair Value Adjustments to the noteAccretion of DiscountEstimated Credit LossInterest IncomeFair Value Adjustment to Embedded DerivativeSeptember 30, 2021
Fair value of the note$5,000 $(882)$— $— $— $— $4,118 
Discount on the note(276)— 102 — — — (174)
Estimated Credit Loss— — — (150)— — (150)
Convertible Promissory Note, net$4,724 $(882)$102 $(150)$— $— $3,794 
Embedded Derivative$276 $— $— $— $— $254 $530 
Interest Receivable$— $— $— $— $227 $— $227 
Total in Other Current Assets$5,000 $(882)$102 $(150)$227 $254 $4,551 
The following table summarizes the activity during the three months ended September 30, 2021;
June 30, 2021Fair Value Adjustments to the noteAccretion of DiscountEstimated Credit LossInterest IncomeFair Value Adjustment to Embedded DerivativeSeptember 30, 2021
Fair value of the note$4,096 $22 $— $— $— $— $4,118 
Discount on the note(220)— 46 — — — (174)
Estimated Credit Loss(100)— — (50)— — (150)
Convertible Promissory Note, net$3,776 $22 $46 $(50)$— $— $3,794 
Embedded Derivative$464 $— $— $— $— $66 $530 
Interest Receivable$125 $— $— $— $102 $— $227 
Total in Other Current Assets$4,365 $22 $46 $(50)$102 $66 $4,551 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Use of Estimates
Use of Estimates
These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. Our critical accounting policies are those that are both most important to our financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. We anticipate that the COVID-19 pandemic will continue to disrupt our supply chain and marketing and sales efforts for certain of our products, including Bendeka, although it is not currently expected that any disruption would be significant. As of the date of issuance of these financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying value of our assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates, and any such differences may be material to our financial statements.
Reclassifications
Reclassifications
Certain reclassifications have been made to prior year amounts to conform with the current year presentation, including for amounts related to accounts receivable, net and prepaid expenses and other current assets. None of the amounts pertaining to the reclassifications were significant.
Cash and Cash Equivalents
Cash and Cash Equivalents
We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.
We, at times, maintain balances with financial institutions in excess of the Federal Deposit Insurance Corporation (“FDIC”) limit.
Fair Value Measurements
Fair Value Measurements

U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
Level 1: Quoted prices in active markets for identical assets or liabilities.
Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The fair value of interest-bearing cash, cash equivalents, accounts receivable and accounts payable approximate fair value due to their life being short term in nature, and are classified as Level 1 for all periods presented.
We recognize transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months or nine months ended September 30, 2021 and 2020, respectively.

Our investment in the convertible promissory note and the embedded derivative are classified as Level 3. We analyzed and accessed the embedded derivative feature contained in the convertible promissory note agreement. We used a probability factor to value the embedded derivative asset based on management's best estimate, including the principal and estimated accrued interest among other contractual terms. The convertible promissory note is accounted for as available for sale. The convertible promissory note is reported at fair value with unrealized gains and losses included in Accumulated other comprehensive income (loss). Refer to Note 13, Convertible Promissory Note for further details.

Our investment in restricted shares of common stock of Tyme Technologies, Inc.are classified as Level 1. Refer to Note 12, License and Collaboration Agreements for further details.
The fair value of debt is classified as Level 2 for the periods presented and approximates its book value due to the variable interest rate.
Intangible Assets Intangible Assets We review the recoverability of our finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, we assess the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, we measure the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets. The Company determined that no indicators of impairment of finite-lived intangible assets or long-lived assets existed as of September 30, 2021.
Goodwill GoodwillGoodwill represents the excess of purchase price over the fair value of net assets acquired in the Eagle Biologics acquisition. Goodwill is not amortized, but is evaluated for impairment on an annual basis, in the fourth quarter, or more frequently if events or changes in circumstances indicate that the reporting unit’s goodwill is less than its carrying amount.
Concentration of Major Customers and Vendors
Concentration of Major Customers and Vendors
We are dependent on our commercial partner, Teva, who markets and sells Bendeka. Our customer for Bendeka is our commercial and licensing partner; therefore, our future revenues are highly dependent on the related exclusive license and distribution arrangement.
Inventories
Inventories
Inventories are recorded at the lower of cost and net realizable value, with cost determined on a first-in first-out basis. We periodically review the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, we will record a write-down to lower of cost and net realizable value in the period that the decline in value is first recognized.
Research and Development Expense
Research and Development Expense
Costs for research and development are charged to expense as incurred and include; employee-related expenses including salaries, benefits, travel and stock-based compensation expense for research and development personnel; expenses incurred under agreements with contract research organizations, contract manufacturing organizations and service providers that assist in conducting clinical and preclinical studies; costs associated with preclinical activities and development activities, costs associated with regulatory operations; and depreciation expense for assets used in research and development activities.
Costs for certain development activities, such as in licensing intellectual property related to new projects, clinical studies, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid expenses or accrued expenses as deemed appropriate. Recoveries of previously recognized research and development expenses from third parties are recorded as a reduction to research and development expense in the period it becomes realizable.
Advertising and Marketing Advertising and MarketingAdvertising and marketing costs are expensed as incurred.
Income Taxes
Income Taxes
We account for income taxes using the liability method in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), 740 - Income Taxes (“ASC 740”). Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax bases of assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income (loss) in the period that the rate changes. A valuation allowance is required when it is “more likely than not” that all or a portion of deferred tax assets will not be realized. ASC 740 also prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that a company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. We recognize any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
Revenue Recognition
Revenue Recognition
Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for
arrangements that an entity determines are within the scope of ASC 606 - Revenue from Contracts with Customers (“ASC 606”), we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determines those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Receivables from our product sales have payment terms ranging from 30 to 75 days with select extended terms to wholesalers on initial purchases of product launch quantities. Our receivables from royalty revenue are due 45 days from the end of the quarter.
Product revenue - We recognize net revenue on sales to our commercial partners and to end users. In each instance, revenue is generally recognized when the customer obtains control of our product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.
Revenue on sales to commercial partners relates to Bendeka and Treakisym. Sales to our commercial partners are presented gross because we are primarily responsible for fulfilling the promise to provide the product, and are responsible to ensure that the product is produced in accordance with the related supply agreement and we bear risk of loss while the inventory is in-transit to the commercial partner.
Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services to a customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing the expected value method to which we expect to be entitled. As such, revenue on sales to customers for Belrapzo and Ryanodex are recorded net of chargebacks, rebates, returns, prompt pay discounts, wholesaler fees and other deductions. Our products are contracted with a limited number of oncology distributors and hospital buying groups with narrow differences in ultimate realized contract prices used to estimate our chargeback and rebate reserves. We have a product return policy on some of our products that allows the customer to return pharmaceutical products within a specified period of time both prior to and subsequent to the product’s expiration date. Our estimate of the provision for returns is analyzed quarterly and is based upon many factors, including historical experience of actual returns and analysis of the level of inventory in the distribution channel, if any. We have terms on sales of Ryanodex by which we do not accept returns. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration are made using the expected value method and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available. We believe that the estimates we have established are reasonable based upon current facts and circumstances. Applying different judgments to the same facts and circumstances could result in the estimated amounts to vary.
Components of Gross-to-Net (GTN) Estimates
Chargebacks: Chargebacks are discounts that occur when certain contracted customers, including group purchasing organizations (“GPOs”), public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase from our distributors. Our distributors purchase product from us at invoice price, then resell the product to certain contracted customers on the basis of prices negotiated between us and the providers. The difference between the distributors’ purchase price and the typically lower certain contracted customers’ purchase price is refunded to the distributors through a chargeback credit. We record estimates for these chargebacks at the time of sale as deductions from gross revenues, with corresponding adjustments to our accounts receivable reserves and allowances.
The provision for chargebacks is the most significant provision in the context of our gross-to-net adjustments in the determination of net revenue. Chargebacks are estimated based on payer mix and contracted price, adjusted for current period assumptions.

Commercial and Medicaid Rebates: We contract with government agencies or collectively, third-party payors, so that Belrapzo and Ryanodex will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. We estimate the rebates we will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a
reduction of product revenue and the establishment of a current liability. The current liability is included in accrued expenses and other current liabilities on the consolidated balance sheets. We estimate the rebates that we will provide to third-party payors based upon (i) our contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payer mix, and (iv) information obtained from our distributors.
The information that we also consider when establishing our rebate reserves are purchases by customers, projected annual sales for customers, actual rebates payments made, processing time lags, and for indirect rebates, the level of inventory in the distribution channel that will be subject to indirect rebates. We do not provide incentives designed to increase shipments to our customers that we believe would result in out-of-the-ordinary course of business inventory for them. We regularly review and monitor estimated or actual customer inventory information at our largest distributors for our key products to ascertain whether customer inventories are in excess of ordinary course of business levels.

Product Returns: Our distributors have the right to return unopened unprescribed Belrapzo during certain time periods around the period beginning prior to the labeled expiration date and ending after the labeled expiration date. We estimate future product returns on sales of Belrapzo based on: (i) data provided to us by our distributors (including weekly reporting of distributors’ sales and inventory held by distributors that provided us with visibility into the distribution channel in order to determine what quantities were sold to retail pharmacies and other providers), (ii) information provided to us from retail pharmacies, (iii) data provided to us by a third-party data provider which collects and publishes prescription data, and other third parties, (iv) historical industry information regarding return rates for similar pharmaceutical products, (v) the estimated remaining shelf life of Belrapzo previously shipped and currently being shipped to distributors and (vi) contractual agreements intended to limit the amount of inventory maintained by our distributors. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Our provision for product returns based on the factors noted above generally encompass a time range from 12 to 48 months after revenue is recognized. Additionally, we consider other factors when estimating our current period return provision, including levels of inventory in the distribution channel, significant market changes that may impact future expected returns, and actual product returns, and may record additional provisions for specific returns that it believes are not covered by the historical rates. Our commercial returns policy and terms with certain customers also states that certain products are sold as non-returnable.

Wholesaler fees and other incentives: We generally provide invoice discounts on Belrapzo and Ryanodex sales to our distributors for prompt payment and fees for distribution services, such as fees for certain data that distributors provide to us. The payment terms for sales to distributors generally include a 2% discount for prompt payment which is generally defined in invoice terms as a range from 30 to 70 days, while the fees for distribution services are based on contractual rates agreed with the respective distributors. Based on historical data, we expect our distributors to earn these discounts and fees, and deducts the full amount of these discounts and fees from our gross product revenues and accounts receivable at the time such revenues are recognized.

Other GTN considerations
We may at our discretion provide price adjustments due to various competitive factors. There are circumstances under which we may not provide price adjustments to certain customers as a matter of business strategy, and consequently may lose future sales volume to competitors and risk a greater level of product returns.

As detailed above, we have the experience and access to relevant information that we believe are necessary to reasonably estimate the amounts of such deductions from gross revenues. Some of the assumptions we use for certain of these estimates are based on information received from third parties, such as wholesale customer inventories and market data, or other market factors beyond our control. The estimates that are most critical to the establishment of these reserves, and therefore, would have the largest impact if these estimates were not accurate, are estimates related to contract sales volumes, average contract pricing, customer inventories and return volumes. We regularly review the information related to these estimates and adjust our reserves accordingly, if and when actual experience differs from previous estimates. With the exception of the product returns allowance, the ending balances of accounts receivable reserves and allowances generally are processed during a two-month to four-month period.
Royalty Revenue — We recognize revenue from license arrangements with our commercial partners' net sales of products. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner’s products occurs. Our commercial partners are obligated to report their net product sales and the resulting royalty due to us within 25 days for Bendeka. Based on historical product sales, royalty receipts and other relevant information, we accrue royalty revenue each quarter and subsequently determine a true-up when we receive royalty reports from our commercial partners. Historically, these true-up adjustments have been immaterial.
License and other revenue — We analyze each element of our licensing agreements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer.
If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. We determine standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, we estimate the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.
We recognize sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, we determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, we assess each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of these future events, we will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event.
When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, we do not assess whether a significant financing component exists if the period between when we perform our obligations under the contract and when the customer pays is one year or less. None of our contracts contained a significant financing component as of September 30, 2021.
Stock-Based Compensation
Stock-Based Compensation
We account for stock-based compensation using the fair value provisions of ASC 718, Compensation - Stock Compensation that requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock-based payments including stock options and restricted stock. This topic requires companies to estimate the fair value of the stock-based awards on the date of grant for options issued to employees and directors and record expense over the employees' service periods, which are generally the vesting period of the equity awards.
We account for stock-based compensation by measuring and recognizing compensation expense for all stock-based payments made to employees and directors based on estimated grant date fair values. The straight-line method is used to allocate compensation cost to reporting periods over each optionee's requisite service period, which is generally the vesting period. The fair value of our stock option awards to employees and directors is estimated using the Black-Scholes valuation model and a Monte Carlo simulation model is used to estimate the fair value for market condition share units. These models require the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, historical forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate is determined with the implied yield currently available for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options. The fair value of restricted stock units ("RSUs") granted are estimated based on the trading price of our common stock on the date of grant. The fair value of performance condition performance-based stock units ("PSUs") granted are also estimated based on the trading price of our common stock on the date of grant and adjusted for the probability of achievement of the performance conditions. Forfeitures are estimated for all stock-based awards.
Earnings Per Share Earnings Per Share Basic earnings per common share is computed using the weighted average number of shares outstanding during the period. Diluted earnings per share is computed in a manner similar to the basic earnings per share, except that the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of warrants, options, convertible debt and other such convertible instruments. Diluted earnings per share contemplate a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Recent Accounting Pronouncements - Not Yet Adopted
In March 2020, the FASB issued Update 2020-04 Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting to provide temporary optional guidance to ease the potential burden in accounting for
reference rate reform. The amendments in Update 2020-04 are elective and apply to all entities that have contracts, hedging relationships, and other transactions that reference LIBOR, formerly known as the London Interbank Offered Rate,
or another reference rate expected to be discontinued due to reference rate reform. The new guidance provides optional expedients, including; (1) Simplify accounting analyses under current GAAP for contract modifications, such as modifications of contracts within the scope of Topic 470, Debt, that will be accounted for by prospectively adjusting the effective interest rate, as if any modification was not substantial. That is, the original contract and the new contract shall be accounted for as if they were not substantially different from one another; (2) Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue; (3) Allow a one-time election to sell or transfer debt securities classified as held to maturity before January 1, 2020 that reference a rate affected by reference rate reform. The amendments are effective for all entities from the beginning of an interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The adoption of ASU 2020-4 is not expected to have a material impact on our financial position or results of operations.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Schedule of financial assets and liabilities measured and recognized at fair value
Financial assets and liabilities measured and recognized at fair value are as follows:
September 30, 2021
TotalLevel 1Level 2Level 3
Assets:
Money market funds$95,255 $95,255 $— $— 
Convertible promissory note3,795 — — 3,795 
Embedded derivative asset in convertible promissory note530 — — 530 
Investment in Tyme10,300 10,300 — — 
Total financial assets$109,880 $105,555 $— $4,325 
December 31, 2020
TotalLevel 1Level 2Level 3
Assets:
Money market funds$79,682 $79,682 $— $— 
Investment in Tyme12,200 12,200 — — 
Total financial assets$91,882 $91,882 $— $— 
Schedule of revenues and accounts receivables by major customers
The total revenues and accounts receivables broken down by major customers as a percentage of the total are as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2021202020212020
Total revenues
Teva - See Revenue Recognition
69 %74 %66 %72 %
Other31 %26 %34 %28 %
100 %100 %100 %100 %
September 30, December 31,
20212020
Accounts receivable
Teva - See Revenue Recognition
63 %58 %
Other37 %42 %
100 %100 %
Schedule of dilutive and anti-dilutive common shares equivalents outstanding
The anti-dilutive common share equivalents outstanding for the three and nine months ended September 30, 2021 and 2020 were as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2021202020212020
Stock options2,446,657 3,156,166 2,777,995 2,905,021 
Restricted stock units
— 205,891 123,600 225,177 
Total2,446,657 3,362,057 2,901,595 3,130,198 
Computation for basic and diluted net (loss) earnings per share
The following table sets forth the computation for basic and diluted net (loss) earnings per share for the three and nine months ended September 30, 2021 and 2020:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2021202020212020
Numerator
Numerator for basic and diluted (loss) earnings per share-net (loss) earnings $(5,622)$7,059 $(2,431)$3,932 
Denominator
Basic weighted average common shares outstanding 13,077,298 13,531,372 13,103,203 13,620,981 
Dilutive effect of stock awards — 255,431 — 296,819 
Diluted weighted average common shares outstanding 13,077,298 13,786,803 13,103,203 13,917,800 
Basic net (loss) earnings per share
Basic net (loss) earnings per share $(0.43)$0.52 $(0.19)$0.29 
Diluted net (loss) earnings per share
Diluted net (loss) earnings per share $(0.43)$0.51 $(0.19)$0.28 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment, net (Tables)
9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment, net
Property and equipment consisted of the following:
 September 30, 2021December 31, 2020Estimated Useful Life (years)
Furniture and fixtures$1,476 $1,476 7
Office equipment1,077 1,152 3
Equipment3,834 3,485 7
Leasehold improvements1,155 1,155 2
 7,542 7,268  
Less accumulated depreciation(5,767)(5,191)
Property and equipment, net$1,775 $2,077  
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories (Tables)
9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Schedule of inventories
Inventories consist of the following:
September 30, December 31,
20212020
Raw materials$6,006 $3,515 
Work in process 1,309 2,589 
Finished products2,000 1,971 
Total inventories$9,315 $8,075 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Accounts (Tables)
9 Months Ended
Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]  
Schedule of prepaid and other current assets
Prepaid expenses and other current assets consist of the following:
September 30, December 31,
20212020
Prepaid income taxes$5,898 $— 
Prepaid FDA user fee and advances to clinical research organization1,478 1,262 
Prepaid insurance468 191 
Advances to commercial manufacturers734 660 
Receivable from commercial partner
1,746 439 
Convertible promissory note, net4,551 — 
All other2,428 1,605 
Total prepaid expenses and other current assets$17,303 $4,157 
Schedule of accrued expenses
Accrued expenses consist of the following:
September 30, December 31,
20212020
Accrued sales reserves$3,046 $4,966 
Royalties payable to commercial partners4,879 5,996 
Accrued salary and other compensation 5,255 4,686 
Accrued professional fees2,552 2,370 
Accrued research & development8,528 2,724 
Current portion of lease liability1,199 1,123 
Accrued other 2,255 1,952 
Total accrued expenses$27,714 $23,817 
Lease related disclosures
The table below summarizes our total lease costs included in the condensed consolidated financial statements, as well as other required quantitative disclosures (in thousands):

September 30, 2021December 31, 2020
Cash paid for amounts included in the measurement of lease liabilities
     Operating cash flows for operating leases$1,040 $1,323 
Right-of-use assets obtained in exchange for new operating lease liabilities$— $855 
Weighted-average remaining lease term - operating leases 3.3 years4.1 years
Weighted-average discount rate - operating leases 6.0 %6.0 %
Future minimum lease payments
Balance Sheet Classification as of September 30:
Current lease liabilities (included with Accrued Expenses and other liabilities)$1,199 
Long-term lease liabilities (included with Other long-term liabilities)3,048 
Total lease liabilities$4,247 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets, Net (Tables)
9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible asset
The gross carrying amounts and net book value of our intangible assets are as follows:
September 30, 2021
Useful Life (In Years)Gross Carrying AmountAccumulated AmortizationNet Book Value
Ryanodex intangible (i)
20$15,000 $(4,404)$10,596 
Developed technology58,100 (7,897)203 
Total$23,100 $(12,301)$10,799 
December 31, 2020
Useful Life (In Years)Gross Carrying AmountAccumulated AmortizationNet Book Value
Ryanodex intangible (i)
2015,000 (3,500)11,500 
Developed technology58,100 (6,683)1,417 
Total$23,100 $(10,183)$12,917 
(i) Represents a one-time payment made to reduce the royalties payable to a third party on Ryanodex net sales.
Schedule of future amortization expense of finite-lived intangible assets Based on definite-lived intangible assets recorded as of September 30, 2021, and assuming that the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses are estimated as follows:
Estimated Amortization Expense
Year Ending December 31,
2021 (remainder)504 
20221,369 
20231,570 
20241,898 
20251,520 
Thereafter3,938 
Total estimated amortization expense$10,799 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Common Stock and Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Summary of stock options, RSU and PSU activity
A summary of stock option, RSU and PSU activity under the 2014 Plan during the nine months ended September 30, 2021 and 2020 is presented below:
 Stock OptionsRSUsPSUs
Outstanding at December 31, 20193,096,161 251,215 116,181 
Granted662,700 231,450 — 
Options exercised/RSUs vested/PSUs vested(41,951)(67,970)— 
Forfeited or expired(185,615)(53,824)(11,431)
Outstanding at September 30, 20203,531,295 360,871 104,750 
Outstanding at December 31, 20203,331,890 328,396 97,750 
Granted109,000 106,600 159,000 
Options exercised/RSUs vested/PSUs vested(100,477)(94,273)— 
Forfeited or expired(308,815)(46,941)(97,750)
Outstanding at September 30, 20213,031,598 293,782 159,000 
Fair value of stock options
The fair value of stock options granted to employees, directors, and consultants were estimated using the following assumptions:
Three Months Ended
September 30,
Nine Months Ended 
 September 30,
2021202020212020
Risk-free interest rate
0.82% - 0.93%
0.37% - 0.41%
0.51% - 1.12%
0.37% - 1.65%
Volatility54.92%55.42%56.07%54.98%
Expected term (in years)6.08 years6.07 years5.68 years6.03 years
Expected dividend yield0.0%0.0%0.0%0.0%
Share-based payment arrangement, cost by plan
We recognized stock-based compensation in our condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 as follows:
Three Months Ended September 30, Nine Months Ended September 30,
2021202020212020
Stock options $2,515 $3,685 $8,393 $12,831 
RSUs1,046 928 4,051 4,115 
PSUs523 109 2,429 1,489 
Stock-based compensation expense $4,084 $4,722 $14,873 $18,435 
Selling, general and administrative$3,443 $5,236 $12,696 $16,365 
Research and development641 (514)2,177 2,070 
Stock-based compensation expense$4,084 $4,722 $14,873 $18,435 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments (Tables)
9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Schedule of operating lease obligations and purchase obligations
Our future material contractual obligations as of September 30, 2021, included the following:
ObligationsTotal202120222023202420252026Beyond
Operating leases (1)$4,680 $351 $1,423 $1,455 $1,038 $413 $— $— 
Credit facility (2)28,000 2,000 26,000 — — — — — 
Purchase obligations (3)53,176 53,176 — — — — — — 
Total obligations $85,856 $55,527 $27,423 $1,455 $1,038 $413 $— $— 

(1) We lease our corporate office location. The term of our existing lease expires on June 30, 2025. We also lease our lab space under a lease agreement that expires on October 31, 2023. Rental expense for the operating leases was $325 and $276, for the three months ended September 30, 2021 and 2020, respectively. Rental expense for the operating leases was $976 and $910 for the nine months ended September 30, 2021 and 2020. The remaining future lease payments under the operating leases are $4.7 million as of September 30, 2021.
(2) Refer to Note 9, “Debt” for further information regarding our Credit Agreement.
(3) As of September 30, 2021, we had purchase obligations in the amount of $53.2 million which represents the contractual commitments under contract manufacturing and supply agreements with suppliers. The obligations under the supply agreements are primarily for finished product, inventory, and research and development.
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Debt (Tables)
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Schedule of debt maturities
Debt Maturities As of September 30, 2021
     2021 (remainder)$2,000 
     202226,000 
Total$28,000 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes (Tables)
9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
Schedule of effective income tax rate reconciliation
Three Months Ended September 30, Nine Months Ended September 30,
2021202020212020
Income tax benefit (provision)$7,038 $(1,866)$3,341 $(7,358)
Effective tax rate 56 %21 %58 %65 %
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Convertible Promissory Note (Tables)
9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Debt Securities, Available-for-sale
The following table summarizes the amounts recorded and activity during the nine months ended September 30, 2021;
InitialFair Value Adjustments to the noteAccretion of DiscountEstimated Credit LossInterest IncomeFair Value Adjustment to Embedded DerivativeSeptember 30, 2021
Fair value of the note$5,000 $(882)$— $— $— $— $4,118 
Discount on the note(276)— 102 — — — (174)
Estimated Credit Loss— — — (150)— — (150)
Convertible Promissory Note, net$4,724 $(882)$102 $(150)$— $— $3,794 
Embedded Derivative$276 $— $— $— $— $254 $530 
Interest Receivable$— $— $— $— $227 $— $227 
Total in Other Current Assets$5,000 $(882)$102 $(150)$227 $254 $4,551 
The following table summarizes the activity during the three months ended September 30, 2021;
June 30, 2021Fair Value Adjustments to the noteAccretion of DiscountEstimated Credit LossInterest IncomeFair Value Adjustment to Embedded DerivativeSeptember 30, 2021
Fair value of the note$4,096 $22 $— $— $— $— $4,118 
Discount on the note(220)— 46 — — — (174)
Estimated Credit Loss(100)— — (50)— — (150)
Convertible Promissory Note, net$3,776 $22 $46 $(50)$— $— $3,794 
Embedded Derivative$464 $— $— $— $— $66 $530 
Interest Receivable$125 $— $— $— $102 $— $227 
Total in Other Current Assets$4,365 $22 $46 $(50)$102 $66 $4,551 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Other Company Information (Details)
9 Months Ended
Sep. 30, 2021
product
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of products commercially launched 3
Number of potential future product launches 5
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Schedule of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Assets:    
Money market funds $ 95,255 $ 79,682
Convertible promissory note 3,795  
Embedded derivative asset in convertible promissory note 530  
Investment in Tyme 10,300 12,200
Total financial assets 109,880 91,882
Level 1    
Assets:    
Money market funds 95,255 79,682
Convertible promissory note 0  
Embedded derivative asset in convertible promissory note 0  
Investment in Tyme 10,300 12,200
Total financial assets 105,555 91,882
Level 2    
Assets:    
Money market funds 0 0
Convertible promissory note 0  
Embedded derivative asset in convertible promissory note 0  
Investment in Tyme 0 0
Total financial assets 0 0
Level 3    
Assets:    
Money market funds 0 0
Convertible promissory note 3,795  
Embedded derivative asset in convertible promissory note 530  
Investment in Tyme 0 0
Total financial assets $ 4,325 $ 0
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Disaggregation of Revenue [Line Items]        
Goodwill impairment loss $ 0 $ 0 $ 0 $ 0
Advertising and marketing costs $ 500,000 $ 300,000 $ 1,300,000 $ 2,200,000
Bendeka        
Disaggregation of Revenue [Line Items]        
Period after quarter commercial partners report net product sales     25 days  
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Revenue and Accounts Receivable By Major Customer (Details) - Customer Concentration Risk
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Total revenues          
Concentration Risk [Line Items]          
Percentage of concentration 100.00% 100.00% 100.00% 100.00%  
Total revenues | Cephalon, Inc. (Teva)          
Concentration Risk [Line Items]          
Percentage of concentration 69.00% 74.00% 66.00% 72.00%  
Total revenues | Other          
Concentration Risk [Line Items]          
Percentage of concentration 31.00% 26.00% 34.00% 28.00%  
Accounts receivable          
Concentration Risk [Line Items]          
Percentage of concentration     100.00%   100.00%
Accounts receivable | Cephalon, Inc. (Teva)          
Concentration Risk [Line Items]          
Percentage of concentration     63.00%   58.00%
Accounts receivable | Other          
Concentration Risk [Line Items]          
Percentage of concentration     37.00%   42.00%
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Anti-Dilutive Common Shares Equivalents Outstanding (Details) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive common shares equivalents outstanding (in shares) 2,446,657 3,362,057 2,901,595 3,130,198
Stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive common shares equivalents outstanding (in shares) 2,446,657 3,156,166 2,777,995 2,905,021
Restricted stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive common shares equivalents outstanding (in shares) 0 205,891 123,600 225,177
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net (Loss) Earnings (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Numerator        
Numerator for basic and diluted (loss) earnings per share-net (loss) earnings $ (5,622) $ 7,059 $ (2,431) $ 3,932
Denominator        
Basic weighted average common shares outstanding (in shares) 13,077,298 13,531,372 13,103,203 13,620,981
Dilutive effect of stock awards (in shares)   255,431   296,819
Diluted weighted average common shares outstanding (in shares) 13,077,298 13,786,803 13,103,203 13,917,800
Basic net (loss) earnings per share        
Basic net (loss) earnings per share (in dollars per share) $ (0.43) $ 0.52 $ (0.19) $ 0.29
Diluted net (loss) earnings per share        
Diluted net (loss) earnings per share (in dollars per share) $ (0.43) $ 0.51 $ (0.19) $ 0.28
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment, net (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, gross $ 7,542   $ 7,542   $ 7,268
Less accumulated depreciation (5,767)   (5,767)   (5,191)
Property and equipment, net 1,775   1,775   2,077
Depreciation expense 197 $ 196 575 $ 656  
Furniture and fixtures          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, gross 1,476   $ 1,476   1,476
Estimated Useful Life (years)     7 years    
Office equipment          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, gross 1,077   $ 1,077   1,152
Estimated Useful Life (years)     3 years    
Equipment          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, gross 3,834   $ 3,834   3,485
Estimated Useful Life (years)     7 years    
Leasehold improvements          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, gross $ 1,155   $ 1,155   $ 1,155
Estimated Useful Life (years)     2 years    
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Raw materials $ 6,006 $ 3,515
Work in process 1,309 2,589
Finished products 2,000 1,971
Total inventories $ 9,315 $ 8,075
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Accounts - Prepaid and Other Current Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]    
Prepaid income taxes $ 5,898 $ 0
Prepaid FDA user fee and advances to clinical research organization 1,478 1,262
Prepaid insurance 468 191
Advances to commercial manufacturers 734 660
Receivable from commercial partner 1,746 439
Convertible promissory note, net 4,551 0
All other 2,428 1,605
Total prepaid expenses and other current assets $ 17,303 $ 4,157
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Accounts - Accrued Expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]    
Accrued sales reserves $ 3,046 $ 4,966
Royalties payable to commercial partners 4,879 5,996
Accrued salary and other compensation 5,255 4,686
Accrued professional fees 2,552 2,370
Accrued research & development 8,528 2,724
Current portion of lease liability 1,199 1,123
Accrued other 2,255 1,952
Total accrued expenses $ 27,714 $ 23,817
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Accounts - Narrative (Details)
Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]  
Lessee, operating lease, remaining lease term 3 years 3 months 18 days
Lessee, operating lease, renewal term 5 years
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Accounts - Lease Related Disclosures (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities      
Operating cash flows for operating leases $ 1,040   $ 1,323
Right-of-use assets obtained in exchange for new operating lease liabilities $ 0 $ 842 $ 855
Weighted-average remaining lease term - operating leases 3 years 3 months 18 days   4 years 1 month 6 days
Weighted-average discount rate - operating leases 6.00%   6.00%
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Accounts - Future Minimum Lease Payments (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Balance Sheet Classification as of September 30:    
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accrued Liabilities, Current  
Current lease liabilities (included with Accrued Expenses and other liabilities) $ 1,199 $ 1,123
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other long-term liabilities  
Long-term lease liabilities (included with Other long-term liabilities) $ 3,048  
Total lease liabilities $ 4,247  
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]          
Gross Carrying Amount $ 23,100   $ 23,100   $ 23,100
Accumulated Amortization (12,301)   (12,301)   (10,183)
Net Book Value 10,799   10,799   $ 12,917
Amortization expense of intangible assets 706 $ 667 $ 2,118 $ 1,999  
Ryanodex intangible          
Finite-Lived Intangible Assets [Line Items]          
Useful Life (In Years)     20 years   20 years
Gross Carrying Amount 15,000   $ 15,000   $ 15,000
Accumulated Amortization (4,404)   (4,404)   (3,500)
Net Book Value 10,596   $ 10,596   $ 11,500
Developed technology          
Finite-Lived Intangible Assets [Line Items]          
Useful Life (In Years)     5 years   5 years
Gross Carrying Amount 8,100   $ 8,100   $ 8,100
Accumulated Amortization (7,897)   (7,897)   (6,683)
Net Book Value $ 203   $ 203   $ 1,417
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets, Net - Schedule of Future Amortization Expense (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Estimated Amortization Expense    
2021 (remainder) $ 504  
2022 1,369  
2023 1,570  
2024 1,898  
2025 1,520  
Thereafter 3,938  
Net Book Value $ 10,799 $ 12,917
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Common Stock and Stock-Based Compensation - Narrative (Details)
3 Months Ended 9 Months Ended 12 Months Ended 17 Months Ended 59 Months Ended
Sep. 24, 2020
USD ($)
$ / shares
shares
Mar. 31, 2021
milestone
$ / shares
shares
Sep. 30, 2021
USD ($)
shares
Sep. 30, 2020
USD ($)
shares
Dec. 31, 2020
USD ($)
Mar. 17, 2020
USD ($)
Jun. 30, 2021
USD ($)
shares
Sep. 23, 2020
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Payments to repurchase stock     $ 12,568,000 $ 27,999,000        
Award vesting period     4 years          
Volatility     56.07% 54.98%        
Expected term     5 years 8 months 4 days 6 years 10 days        
Expected dividend yield     0.00% 0.00%        
PSUs                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Expired (in shares) | shares   97,750 97,750 11,431        
Granted (in shares) | shares     159,000 0        
Risk-free interest rate   0.18%            
Volatility   44.00%            
Expected term   3 years            
Expected dividend yield   0.00%            
PSUs | S&P Biotechnology                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Granted (in shares) | shares   99,500,000            
Weighted average grant date fair value (in dollars per share) | $ / shares   $ 71.09            
Milestone PSUs                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Granted (in shares) | shares   59,500            
Weighted average grant date fair value (in dollars per share) | $ / shares   $ 49.32            
Number of milestones | milestone   3            
Number of milestones required to be met | milestone   1            
Expiration period   3 years            
Expected achievement rate   0.00%            
Milestone PSUs | Minimum                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Award vesting percentage of target number granted   0.00%            
Milestone PSUs | Maximum                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Award vesting percentage of target number granted   200.00%            
Share Repurchase Programs                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Payments to repurchase stock             $ 219,500,000  
Shares of common stock repurchased (in shares) | shares             3,941,541  
March 2020 Plan                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock repurchase program, authorized amount           $ 160,000,000    
Accelerated share repurchases, authorized amount               $ 25,000,000
Accelerated share repurchases, payment $ 25,000,000              
Accelerated share repurchases, shares received (in shares) | shares 550,623              
Accelerated share repurchases, initial price paid per share (in dollars per share) | $ / shares $ 45.40              
Fair value adjustments related to derivative instrument         $ 3,000,000      
October 2018 Plan                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Payments to repurchase stock           $ 68,000,000    
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Common Stock and Stock-Based Compensation - Summary of Stock Options, RSU and PSU Activity (Details) - shares
3 Months Ended 9 Months Ended
Mar. 31, 2021
Sep. 30, 2021
Sep. 30, 2020
Stock Options      
Outstanding beginning balance (in shares) 3,331,890 3,331,890 3,096,161
Granted (in shares)   109,000 662,700
Options Exercised (in shares)   (100,477) (41,951)
Forfeited or expired (in shares)   (308,815) (185,615)
Outstanding ending balance (in shares)   3,031,598 3,531,295
RSUs      
RSUs and PSUs      
Outstanding beginning balance (in shares) 328,396 328,396 251,215
Granted (in shares)   106,600 231,450
Vested (in shares)   (94,273) (67,970)
Forfeited or expired (in shares)   (46,941) (53,824)
Outstanding ending balance (in shares)   293,782 360,871
PSUs      
RSUs and PSUs      
Outstanding beginning balance (in shares) 97,750 97,750 116,181
Granted (in shares)   159,000 0
Vested (in shares)   0 0
Forfeited or expired (in shares) (97,750) (97,750) (11,431)
Outstanding ending balance (in shares)   159,000 104,750
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Common Stock and Stock-Based Compensation - Fair Value of Stock Options Granted (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Risk-free interest minimum rate     0.51% 0.37%
Risk-free interest maximum rate     1.12% 1.65%
Volatility     56.07% 54.98%
Expected term (in years)     5 years 8 months 4 days 6 years 10 days
Expected dividend yield     0.00% 0.00%
Stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Risk-free interest minimum rate 0.82% 0.37%    
Risk-free interest maximum rate 0.93% 0.41%    
Volatility 54.92% 55.42%    
Expected term (in years) 6 years 29 days 6 years 25 days    
Expected dividend yield 0.00% 0.00%    
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Common Stock and Stock-Based Compensation - Schedule of Share-based Compensation (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Stock-based compensation expense $ 4,084 $ 4,722 $ 14,873 $ 18,435
Selling, general and administrative        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Stock-based compensation expense 3,443 5,236 12,696 16,365
Research and development        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Stock-based compensation expense 641 (514) 2,177 2,070
Stock options        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Stock-based compensation expense 2,515 3,685 8,393 12,831
RSUs        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Stock-based compensation expense 1,046 928 4,051 4,115
PSUs        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Stock-based compensation expense $ 523 $ 109 $ 2,429 $ 1,489
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating lease        
Total $ 4,680   $ 4,680  
2021 351   351  
2022 1,423   1,423  
2023 1,455   1,455  
2024 1,038   1,038  
2025 413   413  
2026 0   0  
Beyond 0   0  
Credit facility        
Total 28,000   28,000  
2021 2,000   2,000  
2022 26,000   26,000  
2023 0   0  
2024 0   0  
2025 0   0  
2026 0   0  
Beyond 0   0  
Purchase obligations        
Total 53,176   53,176  
2021 53,176   53,176  
2022 0   0  
2023 0   0  
2024 0   0  
2025 0   0  
2026 0   0  
Beyond 0   0  
Total obligations        
Total 85,856   85,856  
2021 55,527   55,527  
2022 27,423   27,423  
2023 1,455   1,455  
2024 1,038   1,038  
2025 413   413  
2026 0   0  
Beyond 0   0  
Operating lease, expense $ 325 $ 276 $ 976 $ 910
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.21.2
Debt - Narrative (Details) - USD ($)
Nov. 08, 2019
Sep. 30, 2021
Dec. 31, 2020
Debt Instrument [Line Items]      
Current portion of long-term debt   $ 8,000,000 $ 8,000,000
Unamortized deferred debt issuance cost   $ 500,000  
Revised Credit Agreement | Minimum      
Debt Instrument [Line Items]      
Line of credit facility, commitment fee 0.35%    
Revised Credit Agreement | Maximum      
Debt Instrument [Line Items]      
Line of credit facility, commitment fee 0.45%    
Revised Credit Agreement | London Interbank Offered Rate (LIBOR) | Minimum      
Debt Instrument [Line Items]      
Variable interest rate spread 2.25%    
Revised Credit Agreement | London Interbank Offered Rate (LIBOR) | Maximum      
Debt Instrument [Line Items]      
Variable interest rate spread 3.00%    
Revised Credit Agreement | New York Federal Reserve Bank (NYFRB)      
Debt Instrument [Line Items]      
Variable interest rate spread 0.50%    
Revised Credit Agreement | Adjusted London Interbank Offered Rate (LIBOR)      
Debt Instrument [Line Items]      
Variable interest rate spread 1.00%    
Revised Credit Agreement | Prime Rate | Minimum      
Debt Instrument [Line Items]      
Variable interest rate spread 1.25%    
Revised Credit Agreement | Prime Rate | Maximum      
Debt Instrument [Line Items]      
Variable interest rate spread 2.00%    
Line of credit | Revised Credit Agreement      
Debt Instrument [Line Items]      
Draw on line of credit $ 40,000,000    
Revolving credit facility | Revised Credit Agreement      
Debt Instrument [Line Items]      
Maximum borrowing capacity $ 110,000,000    
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.21.2
Debt - Schedule of Debt Maturities (Details)
$ in Thousands
Sep. 30, 2021
USD ($)
Credit facility  
2021 (remainder) $ 2,000
2022 26,000
Total $ 28,000
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
jurisdiction
Sep. 30, 2020
USD ($)
Income Tax Disclosure [Abstract]        
Income tax benefit (provision) $ 7,038,000 $ (1,866,000) $ 3,341,000 $ (7,358,000)
Effective tax rate 56.00% 21.00% 58.00% 65.00%
Number of tax jurisdictions currently auditing the company | jurisdiction     3  
Unrecognized tax benefits $ 0   $ 0  
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Legal Proceedings (Details)
Dec. 20, 2019
patent
Par Pharmaceutical, Inc. et al. v. Eagle Pharmaceuticals, Inc. (Vasopressin) | Pending Litigation  
Loss Contingencies [Line Items]  
Number of patents, claims dismissed 3
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.21.2
License and Collaboration Agreements (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Aug. 31, 2021
Jan. 07, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Fair value loss on equity investment     $ 1,900,000 $ 7,700,000    
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Combioxin            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaborative arrangement, rights and obligations, upfront payment         $ 10,000,000  
Collaborative arrangement, rights and obligations, maximum aggregate milestone payments         105,000,000  
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | AOP Orphan Pharmaceuticals GmbH            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaborative arrangement, rights and obligations, upfront payment $ 5,000,000   5,000,000      
Collaborative arrangement, rights and obligations, maximum aggregate milestone payments         $ 25,000,000  
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Tyme            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Co-promotion agreement, percentage of promotional sales effort responsible for           25.00%
Co-promotion agreement, percentage of net revenue receivable           15.00%
Co-promotion agreement, percentage of net revenue receivable due to collaborator           85.00%
Co-promotion agreement, right to repurchase, amount           $ 200,000,000
Fair value loss on equity investment $ 2,300,000 $ 3,500,000 $ (1,900,000) $ 7,700,000    
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Convertible Promissory Note (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]          
Total in Other Current Assets, beginning balance   $ 0   $ 0  
Fair Value Adjustments to the note $ 22,000   $ 0 (882,000) $ 0
Estimated Credit Loss       (150,000) $ 0
Embedded Derivative, ending balance 530,000     530,000  
Total in Other Current Assets, ending balance 4,551,000     4,551,000  
Convertible Promissory Note          
Debt Securities, Available-for-sale [Line Items]          
Debt securities, available-for-sale   $ 5,000,000      
Stated interest rate   8.00%      
Term   18 months      
Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]          
Fair value of the note, beginning balance 4,096,000        
Discount on the note, beginning balance 220,000        
Estimated Credit Loss, beginning balance 100,000        
Convertible Promissory Note, net, beginning balance 3,776,000        
Embedded Derivative, beginning balance 464,000        
Interest Receivable, beginning balance 125,000        
Total in Other Current Assets, beginning balance 4,365,000        
Fair Value Adjustments to the note 22,000     (882,000)  
Accretion of Discount 46,000     102,000  
Estimated Credit Loss (50,000)     (150,000)  
Interest Income 102,000     227,000  
Fair Value Adjustment to Embedded Derivative 66,000     254,000  
Fair value of the note, ending balance 4,118,000 $ 5,000,000   4,118,000  
Discount on the note, ending balance 174,000 276,000   174,000  
Estimated Credit Loss, ending balance 150,000 0   150,000  
Convertible Promissory Note, net, ending balance 3,794,000 4,724,000   3,794,000  
Embedded Derivative, ending balance 530,000 276,000   530,000  
Interest Receivable, ending balance 227,000 0   227,000  
Total in Other Current Assets, ending balance $ 4,551,000 $ 5,000,000   $ 4,551,000  
EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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� &0 @(%$B0 >&PO=V]R:W-H965T&UL4$L! A0#% M @ PX)I4R[7R,AT$ WS( !D ("!WI4 'AL+W=O&PO=V]R:W-H965TNM !X M;"]W;W)K&UL4$L! A0#% @ PX)I4_O8IR3. M)@ .GD !D ("!7;, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ PX)I4]1(E=!Q @ )04 !D M ("!]>( 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ PX)I4WCNI$!&!0 I@P !D ("!8N\ M 'AL+W=O&PO=V]R:W-H965T+X !X;"]W;W)K&UL4$L! A0#% @ MPX)I4YAZP_Y< @ * 4 !D ("!0_L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ PX)I4T&0HD@!! M Q( !D ("!2@0! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ PX)I4R"D7A]% P 3@L !D M ("!A0\! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ PX)I4U3TQ7!H @ +P8 !D ("!7!L! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ PX)I M4_'G&PO=V]R:W-H965T&UL4$L! A0#% @ PX)I4T9ENQPP! U!$ M !D ("!EBT! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ PX)I4Y=!6;P@! =Q$ !D M ("!HCL! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ PX)I4^$2!\;*! P!D !D ("![4&PO=V]R:W-H965T&UL4$L! A0#% @ PX)I4]!A M1U'T @ , D !D ("!E5,! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ PX)I4R9+C 2"!0 V1H !D M ("!F5T! 'AL+W=O&PO M>D! 2(@ &@ @ $:; $ >&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " ##@FE3LFA)V-4! "_ M(0 $P @ $[;@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 00!! +X1 !!< $ ! end XML 71 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 187 381 1 false 51 0 false 8 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.eagleus.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) Sheet http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) Sheet http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) Statements 6 false false R7.htm 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 7 false false R8.htm 2101101 - Disclosure - Basis of Presentation and Other Company Information Sheet http://www.eagleus.com/role/BasisofPresentationandOtherCompanyInformation Basis of Presentation and Other Company Information Notes 8 false false R9.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.eagleus.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2111103 - Disclosure - Property and Equipment, net Sheet http://www.eagleus.com/role/PropertyandEquipmentnet Property and Equipment, net Notes 10 false false R11.htm 2114104 - Disclosure - Inventories Sheet http://www.eagleus.com/role/Inventories Inventories Notes 11 false false R12.htm 2117105 - Disclosure - Balance Sheet Accounts Sheet http://www.eagleus.com/role/BalanceSheetAccounts Balance Sheet Accounts Notes 12 false false R13.htm 2124106 - Disclosure - Intangible Assets, Net Sheet http://www.eagleus.com/role/IntangibleAssetsNet Intangible Assets, Net Notes 13 false false R14.htm 2128107 - Disclosure - Common Stock and Stock-Based Compensation Sheet http://www.eagleus.com/role/CommonStockandStockBasedCompensation Common Stock and Stock-Based Compensation Notes 14 false false R15.htm 2134108 - Disclosure - Commitments Sheet http://www.eagleus.com/role/Commitments Commitments Notes 15 false false R16.htm 2137109 - Disclosure - Debt Sheet http://www.eagleus.com/role/Debt Debt Notes 16 false false R17.htm 2141110 - Disclosure - Income Taxes Sheet http://www.eagleus.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 2144111 - Disclosure - Legal Proceedings Sheet http://www.eagleus.com/role/LegalProceedings Legal Proceedings Notes 18 false false R19.htm 2146112 - Disclosure - License and Collaboration Agreements Sheet http://www.eagleus.com/role/LicenseandCollaborationAgreements License and Collaboration Agreements Notes 19 false false R20.htm 2148113 - Disclosure - Convertible Promissory Note Sheet http://www.eagleus.com/role/ConvertiblePromissoryNote Convertible Promissory Note Notes 20 false false R21.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.eagleus.com/role/SummaryofSignificantAccountingPolicies 21 false false R22.htm 2305301 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.eagleus.com/role/SummaryofSignificantAccountingPolicies 22 false false R23.htm 2312302 - Disclosure - Property and Equipment, net (Tables) Sheet http://www.eagleus.com/role/PropertyandEquipmentnetTables Property and Equipment, net (Tables) Tables http://www.eagleus.com/role/PropertyandEquipmentnet 23 false false R24.htm 2315303 - Disclosure - Inventories (Tables) Sheet http://www.eagleus.com/role/InventoriesTables Inventories (Tables) Tables http://www.eagleus.com/role/Inventories 24 false false R25.htm 2318304 - Disclosure - Balance Sheet Accounts (Tables) Sheet http://www.eagleus.com/role/BalanceSheetAccountsTables Balance Sheet Accounts (Tables) Tables http://www.eagleus.com/role/BalanceSheetAccounts 25 false false R26.htm 2325305 - Disclosure - Intangible Assets, Net (Tables) Sheet http://www.eagleus.com/role/IntangibleAssetsNetTables Intangible Assets, Net (Tables) Tables http://www.eagleus.com/role/IntangibleAssetsNet 26 false false R27.htm 2329306 - Disclosure - Common Stock and Stock-Based Compensation (Tables) Sheet http://www.eagleus.com/role/CommonStockandStockBasedCompensationTables Common Stock and Stock-Based Compensation (Tables) Tables http://www.eagleus.com/role/CommonStockandStockBasedCompensation 27 false false R28.htm 2335307 - Disclosure - Commitments (Tables) Sheet http://www.eagleus.com/role/CommitmentsTables Commitments (Tables) Tables http://www.eagleus.com/role/Commitments 28 false false R29.htm 2338308 - Disclosure - Debt (Tables) Sheet http://www.eagleus.com/role/DebtTables Debt (Tables) Tables http://www.eagleus.com/role/Debt 29 false false R30.htm 2342309 - Disclosure - Income Taxes (Tables) Sheet http://www.eagleus.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.eagleus.com/role/IncomeTaxes 30 false false R31.htm 2349310 - Disclosure - Convertible Promissory Note (Tables) Sheet http://www.eagleus.com/role/ConvertiblePromissoryNoteTables Convertible Promissory Note (Tables) Tables http://www.eagleus.com/role/ConvertiblePromissoryNote 31 false false R32.htm 2402401 - Disclosure - Basis of Presentation and Other Company Information (Details) Sheet http://www.eagleus.com/role/BasisofPresentationandOtherCompanyInformationDetails Basis of Presentation and Other Company Information (Details) Details http://www.eagleus.com/role/BasisofPresentationandOtherCompanyInformation 32 false false R33.htm 2406402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details) Sheet http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails Summary of Significant Accounting Policies - Schedule of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details) Details 33 false false R34.htm 2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 34 false false R35.htm 2408404 - Disclosure - Summary of Significant Accounting Policies - Revenue and Accounts Receivable By Major Customer (Details) Sheet http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails Summary of Significant Accounting Policies - Revenue and Accounts Receivable By Major Customer (Details) Details 35 false false R36.htm 2409405 - Disclosure - Summary of Significant Accounting Policies - Anti-Dilutive Common Shares Equivalents Outstanding (Details) Sheet http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesAntiDilutiveCommonSharesEquivalentsOutstandingDetails Summary of Significant Accounting Policies - Anti-Dilutive Common Shares Equivalents Outstanding (Details) Details 36 false false R37.htm 2410406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net (Loss) Earnings (Details) Sheet http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net (Loss) Earnings (Details) Details 37 false false R38.htm 2413407 - Disclosure - Property and Equipment, net (Details) Sheet http://www.eagleus.com/role/PropertyandEquipmentnetDetails Property and Equipment, net (Details) Details http://www.eagleus.com/role/PropertyandEquipmentnetTables 38 false false R39.htm 2416408 - Disclosure - Inventories (Details) Sheet http://www.eagleus.com/role/InventoriesDetails Inventories (Details) Details http://www.eagleus.com/role/InventoriesTables 39 false false R40.htm 2419409 - Disclosure - Balance Sheet Accounts - Prepaid and Other Current Assets (Details) Sheet http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails Balance Sheet Accounts - Prepaid and Other Current Assets (Details) Details 40 false false R41.htm 2420410 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details) Sheet http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails Balance Sheet Accounts - Accrued Expenses (Details) Details 41 false false R42.htm 2421411 - Disclosure - Balance Sheet Accounts - Narrative (Details) Sheet http://www.eagleus.com/role/BalanceSheetAccountsNarrativeDetails Balance Sheet Accounts - Narrative (Details) Details 42 false false R43.htm 2422412 - Disclosure - Balance Sheet Accounts - Lease Related Disclosures (Details) Sheet http://www.eagleus.com/role/BalanceSheetAccountsLeaseRelatedDisclosuresDetails Balance Sheet Accounts - Lease Related Disclosures (Details) Details 43 false false R44.htm 2423413 - Disclosure - Balance Sheet Accounts - Future Minimum Lease Payments (Details) Sheet http://www.eagleus.com/role/BalanceSheetAccountsFutureMinimumLeasePaymentsDetails Balance Sheet Accounts - Future Minimum Lease Payments (Details) Details 44 false false R45.htm 2426414 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details) Sheet http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails Intangible Assets, Net - Schedule of Intangible Assets (Details) Details 45 false false R46.htm 2427415 - Disclosure - Intangible Assets, Net - Schedule of Future Amortization Expense (Details) Sheet http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails Intangible Assets, Net - Schedule of Future Amortization Expense (Details) Details 46 false false R47.htm 2430416 - Disclosure - Common Stock and Stock-Based Compensation - Narrative (Details) Sheet http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails Common Stock and Stock-Based Compensation - Narrative (Details) Details 47 false false R48.htm 2431417 - Disclosure - Common Stock and Stock-Based Compensation - Summary of Stock Options, RSU and PSU Activity (Details) Sheet http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails Common Stock and Stock-Based Compensation - Summary of Stock Options, RSU and PSU Activity (Details) Details 48 false false R49.htm 2432418 - Disclosure - Common Stock and Stock-Based Compensation - Fair Value of Stock Options Granted (Details) Sheet http://www.eagleus.com/role/CommonStockandStockBasedCompensationFairValueofStockOptionsGrantedDetails Common Stock and Stock-Based Compensation - Fair Value of Stock Options Granted (Details) Details 49 false false R50.htm 2433419 - Disclosure - Common Stock and Stock-Based Compensation - Schedule of Share-based Compensation (Details) Sheet http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails Common Stock and Stock-Based Compensation - Schedule of Share-based Compensation (Details) Details 50 false false R51.htm 2436420 - Disclosure - Commitments (Details) Sheet http://www.eagleus.com/role/CommitmentsDetails Commitments (Details) Details http://www.eagleus.com/role/CommitmentsTables 51 false false R52.htm 2439421 - Disclosure - Debt - Narrative (Details) Sheet http://www.eagleus.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 52 false false R53.htm 2440422 - Disclosure - Debt - Schedule of Debt Maturities (Details) Sheet http://www.eagleus.com/role/DebtScheduleofDebtMaturitiesDetails Debt - Schedule of Debt Maturities (Details) Details 53 false false R54.htm 2443423 - Disclosure - Income Taxes (Details) Sheet http://www.eagleus.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.eagleus.com/role/IncomeTaxesTables 54 false false R55.htm 2445424 - Disclosure - Legal Proceedings (Details) Sheet http://www.eagleus.com/role/LegalProceedingsDetails Legal Proceedings (Details) Details http://www.eagleus.com/role/LegalProceedings 55 false false R56.htm 2447425 - Disclosure - License and Collaboration Agreements (Details) Sheet http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails License and Collaboration Agreements (Details) Details http://www.eagleus.com/role/LicenseandCollaborationAgreements 56 false false R57.htm 2450426 - Disclosure - Convertible Promissory Note (Details) Sheet http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails Convertible Promissory Note (Details) Details http://www.eagleus.com/role/ConvertiblePromissoryNoteTables 57 false false All Reports Book All Reports egrx-20210930.htm egrx-20210930.xsd egrx-20210930_cal.xml egrx-20210930_def.xml egrx-20210930_lab.xml egrx-20210930_pre.xml ex102eagle-aoplicenseagree.htm exhibit101redacted.htm exhibit311q32021.htm exhibit312q32021.htm exhibit321q32021.htm http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "egrx-20210930.htm": { "axisCustom": 0, "axisStandard": 21, "contextCount": 187, "dts": { "calculationLink": { "local": [ "egrx-20210930_cal.xml" ] }, "definitionLink": { "local": [ "egrx-20210930_def.xml" ] }, "inline": { "local": [ "egrx-20210930.htm" ] }, "labelLink": { "local": [ "egrx-20210930_lab.xml" ] }, "presentationLink": { "local": [ "egrx-20210930_pre.xml" ] }, "schema": { "local": [ "egrx-20210930.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 481, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 3, "http://xbrl.sec.gov/dei/2021": 5, "total": 8 }, "keyCustom": 22, "keyStandard": 359, "memberCustom": 16, "memberStandard": 33, "nsprefix": "egrx", "nsuri": "http://www.eagleus.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.eagleus.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111103 - Disclosure - Property and Equipment, net", "role": "http://www.eagleus.com/role/PropertyandEquipmentnet", "shortName": "Property and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114104 - Disclosure - Inventories", "role": "http://www.eagleus.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - Balance Sheet Accounts", "role": "http://www.eagleus.com/role/BalanceSheetAccounts", "shortName": "Balance Sheet Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124106 - Disclosure - Intangible Assets, Net", "role": "http://www.eagleus.com/role/IntangibleAssetsNet", "shortName": "Intangible Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128107 - Disclosure - Common Stock and Stock-Based Compensation", "role": "http://www.eagleus.com/role/CommonStockandStockBasedCompensation", "shortName": "Common Stock and Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134108 - Disclosure - Commitments", "role": "http://www.eagleus.com/role/Commitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137109 - Disclosure - Debt", "role": "http://www.eagleus.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141110 - Disclosure - Income Taxes", "role": "http://www.eagleus.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144111 - Disclosure - Legal Proceedings", "role": "http://www.eagleus.com/role/LegalProceedings", "shortName": "Legal Proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146112 - Disclosure - License and Collaboration Agreements", "role": "http://www.eagleus.com/role/LicenseandCollaborationAgreements", "shortName": "License and Collaboration Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "role": "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2148113 - Disclosure - Convertible Promissory Note", "role": "http://www.eagleus.com/role/ConvertiblePromissoryNote", "shortName": "Convertible Promissory Note", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312302 - Disclosure - Property and Equipment, net (Tables)", "role": "http://www.eagleus.com/role/PropertyandEquipmentnetTables", "shortName": "Property and Equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - Inventories (Tables)", "role": "http://www.eagleus.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318304 - Disclosure - Balance Sheet Accounts (Tables)", "role": "http://www.eagleus.com/role/BalanceSheetAccountsTables", "shortName": "Balance Sheet Accounts (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325305 - Disclosure - Intangible Assets, Net (Tables)", "role": "http://www.eagleus.com/role/IntangibleAssetsNetTables", "shortName": "Intangible Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2329306 - Disclosure - Common Stock and Stock-Based Compensation (Tables)", "role": "http://www.eagleus.com/role/CommonStockandStockBasedCompensationTables", "shortName": "Common Stock and Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335307 - Disclosure - Commitments (Tables)", "role": "http://www.eagleus.com/role/CommitmentsTables", "shortName": "Commitments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338308 - Disclosure - Debt (Tables)", "role": "http://www.eagleus.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "role": "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2342309 - Disclosure - Income Taxes (Tables)", "role": "http://www.eagleus.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2349310 - Disclosure - Convertible Promissory Note (Tables)", "role": "http://www.eagleus.com/role/ConvertiblePromissoryNoteTables", "shortName": "Convertible Promissory Note (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "egrx:NumberOfProductsLaunched", "reportCount": 1, "unique": true, "unitRef": "product", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Basis of Presentation and Other Company Information (Details)", "role": "http://www.eagleus.com/role/BasisofPresentationandOtherCompanyInformationDetails", "shortName": "Basis of Presentation and Other Company Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "egrx:NumberOfProductsLaunched", "reportCount": 1, "unique": true, "unitRef": "product", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details)", "role": "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails", "shortName": "Summary of Significant Accounting Policies - Schedule of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillImpairmentLoss", "us-gaap:GoodwillImpairmentLoss", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "role": "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillImpairmentLoss", "us-gaap:GoodwillImpairmentLoss", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i8c20b484c7b4472ebc34d3e0be57addc_D20210701-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Revenue and Accounts Receivable By Major Customer (Details)", "role": "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails", "shortName": "Summary of Significant Accounting Policies - Revenue and Accounts Receivable By Major Customer (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i8c20b484c7b4472ebc34d3e0be57addc_D20210701-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Anti-Dilutive Common Shares Equivalents Outstanding (Details)", "role": "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesAntiDilutiveCommonSharesEquivalentsOutstandingDetails", "shortName": "Summary of Significant Accounting Policies - Anti-Dilutive Common Shares Equivalents Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net (Loss) Earnings (Details)", "role": "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails", "shortName": "Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net (Loss) Earnings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413407 - Disclosure - Property and Equipment, net (Details)", "role": "http://www.eagleus.com/role/PropertyandEquipmentnetDetails", "shortName": "Property and Equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i28dfc0d9e7974e93920bb743540a6137_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - Inventories (Details)", "role": "http://www.eagleus.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "role": "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidTaxes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - Balance Sheet Accounts - Prepaid and Other Current Assets (Details)", "role": "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails", "shortName": "Balance Sheet Accounts - Prepaid and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidTaxes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details)", "role": "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails", "shortName": "Balance Sheet Accounts - Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - Balance Sheet Accounts - Narrative (Details)", "role": "http://www.eagleus.com/role/BalanceSheetAccountsNarrativeDetails", "shortName": "Balance Sheet Accounts - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422412 - Disclosure - Balance Sheet Accounts - Lease Related Disclosures (Details)", "role": "http://www.eagleus.com/role/BalanceSheetAccountsLeaseRelatedDisclosuresDetails", "shortName": "Balance Sheet Accounts - Lease Related Disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423413 - Disclosure - Balance Sheet Accounts - Future Minimum Lease Payments (Details)", "role": "http://www.eagleus.com/role/BalanceSheetAccountsFutureMinimumLeasePaymentsDetails", "shortName": "Balance Sheet Accounts - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)", "role": "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails", "shortName": "Intangible Assets, Net - Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i28dfc0d9e7974e93920bb743540a6137_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427415 - Disclosure - Intangible Assets, Net - Schedule of Future Amortization Expense (Details)", "role": "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails", "shortName": "Intangible Assets, Net - Schedule of Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430416 - Disclosure - Common Stock and Stock-Based Compensation - Narrative (Details)", "role": "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "shortName": "Common Stock and Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i28dfc0d9e7974e93920bb743540a6137_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431417 - Disclosure - Common Stock and Stock-Based Compensation - Summary of Stock Options, RSU and PSU Activity (Details)", "role": "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails", "shortName": "Common Stock and Stock-Based Compensation - Summary of Stock Options, RSU and PSU Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i33d99037b1804348a23d52a716480ff7_I20191231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432418 - Disclosure - Common Stock and Stock-Based Compensation - Fair Value of Stock Options Granted (Details)", "role": "http://www.eagleus.com/role/CommonStockandStockBasedCompensationFairValueofStockOptionsGrantedDetails", "shortName": "Common Stock and Stock-Based Compensation - Fair Value of Stock Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)", "role": "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433419 - Disclosure - Common Stock and Stock-Based Compensation - Schedule of Share-based Compensation (Details)", "role": "http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails", "shortName": "Common Stock and Stock-Based Compensation - Schedule of Share-based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436420 - Disclosure - Commitments (Details)", "role": "http://www.eagleus.com/role/CommitmentsDetails", "shortName": "Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439421 - Disclosure - Debt - Narrative (Details)", "role": "http://www.eagleus.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNoncurrentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ib43962e0e73840b4849df7d562bb0599_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440422 - Disclosure - Debt - Schedule of Debt Maturities (Details)", "role": "http://www.eagleus.com/role/DebtScheduleofDebtMaturitiesDetails", "shortName": "Debt - Schedule of Debt Maturities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443423 - Disclosure - Income Taxes (Details)", "role": "http://www.eagleus.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "2", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ibf077301dca54693853273d2eaed9620_D20191220-20191220", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyPatentsFoundNotInfringedNumber", "reportCount": 1, "unique": true, "unitRef": "patent", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445424 - Disclosure - Legal Proceedings (Details)", "role": "http://www.eagleus.com/role/LegalProceedingsDetails", "shortName": "Legal Proceedings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ibf077301dca54693853273d2eaed9620_D20191220-20191220", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyPatentsFoundNotInfringedNumber", "reportCount": 1, "unique": true, "unitRef": "patent", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447425 - Disclosure - License and Collaboration Agreements (Details)", "role": "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails", "shortName": "License and Collaboration Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ia546b558037c4a6fa3f6e8eb74246d0b_I20210831", "decimals": "-6", "lang": "en-US", "name": "egrx:CollaborativeArrangementRightsAndObligationsUpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i28dfc0d9e7974e93920bb743540a6137_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450426 - Disclosure - Convertible Promissory Note (Details)", "role": "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails", "shortName": "Convertible Promissory Note (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ibde85756be4b41a7ad97d8589f57bc0b_I20210331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ifb7ab08a65be4b329ed3eb69fbdae161_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)", "role": "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "ifb7ab08a65be4b329ed3eb69fbdae161_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i0d079683ec3e491293fbe5fc75408bc5_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxesAndTaxCredits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Basis of Presentation and Other Company Information", "role": "http://www.eagleus.com/role/BasisofPresentationandOtherCompanyInformation", "shortName": "Basis of Presentation and Other Company Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.eagleus.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "egrx-20210930.htm", "contextRef": "i6e6de13da27a4480bedb09499214032a_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 51, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.eagleus.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "egrx_AOPOrphanPharmaceuticalsGmbHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AOP Orphan Pharmaceuticals GmbH", "label": "AOP Orphan Pharmaceuticals GmbH [Member]", "terseLabel": "AOP Orphan Pharmaceuticals GmbH" } } }, "localname": "AOPOrphanPharmaceuticalsGmbHMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "domainItemType" }, "egrx_AcceleratedShareRepurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchase [Member]", "label": "Accelerated Share Repurchase [Member]", "terseLabel": "Share Repurchase Programs" } } }, "localname": "AcceleratedShareRepurchaseMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "egrx_AcceleratedShareRepurchasesAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchases, Authorized Amount", "label": "Accelerated Share Repurchases, Authorized Amount", "terseLabel": "Accelerated share repurchases, authorized amount" } } }, "localname": "AcceleratedShareRepurchasesAuthorizedAmount", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "egrx_AcceleratedShareRepurchasesSharesReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchases, Shares Received", "label": "Accelerated Share Repurchases, Shares Received", "terseLabel": "Accelerated share repurchases, shares received (in shares)" } } }, "localname": "AcceleratedShareRepurchasesSharesReceived", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "egrx_AccretionIncome": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accretion Income", "label": "Accretion Income", "negatedTerseLabel": "Accretion of discount on convertible promissory note" } } }, "localname": "AccretionIncome", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "egrx_AccruedResearchandDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Research and Development, Current", "label": "Accrued Research and Development, Current", "terseLabel": "Accrued research & development" } } }, "localname": "AccruedResearchandDevelopmentCurrent", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "egrx_AdjustedLondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjusted London Interbank Offered Rate (LIBOR) [Member]", "label": "Adjusted London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "Adjusted London Interbank Offered Rate (LIBOR)" } } }, "localname": "AdjustedLondonInterbankOfferedRateLIBORMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "egrx_AdvancesToCommercialManufacturers": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails": { "order": 7.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Advances to commercial manufacturers", "label": "Advances to commercial manufacturers", "terseLabel": "Advances to commercial manufacturers" } } }, "localname": "AdvancesToCommercialManufacturers", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "egrx_BalanceSheetClassificationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Balance Sheet Classification", "label": "Balance Sheet Classification [Abstract]", "terseLabel": "Balance Sheet Classification as of September 30:" } } }, "localname": "BalanceSheetClassificationAbstract", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "egrx_BendekaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bendeka [Member]", "label": "Bendeka [Member]", "terseLabel": "Bendeka" } } }, "localname": "BendekaMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "egrx_CephalonInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cephalon, Inc. [Member]", "label": "Cephalon, Inc. [Member]", "terseLabel": "Cephalon, Inc. (Teva)" } } }, "localname": "CephalonInc.Member", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "domainItemType" }, "egrx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments", "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments", "terseLabel": "Collaborative arrangement, rights and obligations, maximum aggregate milestone payments" } } }, "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "egrx_CollaborativeArrangementRightsAndObligationsUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment", "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment", "terseLabel": "Collaborative arrangement, rights and obligations, upfront payment" } } }, "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "egrx_CombioxinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Combioxin", "label": "Combioxin [Member]", "terseLabel": "Combioxin" } } }, "localname": "CombioxinMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "domainItemType" }, "egrx_FairValueAdjustmentOnAcceleratedShareRepurchases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair Value Adjustment On Accelerated Share Repurchases", "label": "Fair Value Adjustment On Accelerated Share Repurchases", "terseLabel": "Fair value adjustments related to derivative instrument" } } }, "localname": "FairValueAdjustmentOnAcceleratedShareRepurchases", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "egrx_FiniteLivedIntangibleAssetsExpectedAmortizationAfterYearFour": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Assets, Expected Amortization, After Year Four", "label": "Finite-Lived Intangible Assets, Expected Amortization, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsExpectedAmortizationAfterYearFour", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "egrx_IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Prepaid Expense and Other Current Assets, Total", "label": "Increase (Decrease) in Prepaid Expense and Other Current Assets, Total", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "egrx_March2020PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2020 Plan [Member]", "label": "March 2020 Plan [Member]", "terseLabel": "March 2020 Plan" } } }, "localname": "March2020PlanMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "egrx_MilestonePerformanceBasedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Performance-Based Stock Units", "label": "Milestone Performance-Based Stock Units [Member]", "terseLabel": "Milestone PSUs" } } }, "localname": "MilestonePerformanceBasedStockUnitsMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "egrx_NewYorkFederalReserveBankNYFRBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New York Federal Reserve Bank (NYFRB) [Member]", "label": "New York Federal Reserve Bank (NYFRB) [Member]", "terseLabel": "New York Federal Reserve Bank (NYFRB)" } } }, "localname": "NewYorkFederalReserveBankNYFRBMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "egrx_NumberOfPotentialFutureProductLaunches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Potential Future Product Launches", "label": "Number Of Potential Future Product Launches", "terseLabel": "Number of potential future product launches" } } }, "localname": "NumberOfPotentialFutureProductLaunches", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/BasisofPresentationandOtherCompanyInformationDetails" ], "xbrltype": "integerItemType" }, "egrx_NumberOfProductsLaunched": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Products Launched", "label": "Number Of Products Launched", "terseLabel": "Number of products commercially launched" } } }, "localname": "NumberOfProductsLaunched", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/BasisofPresentationandOtherCompanyInformationDetails" ], "xbrltype": "integerItemType" }, "egrx_NumberOfTaxJurisdictionsCurrentlyAuditingTheCompany": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Tax Jurisdictions Currently Auditing The Company", "label": "Number Of Tax Jurisdictions Currently Auditing The Company", "terseLabel": "Number of tax jurisdictions currently auditing the company" } } }, "localname": "NumberOfTaxJurisdictionsCurrentlyAuditingTheCompany", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/IncomeTaxesDetails" ], "xbrltype": "integerItemType" }, "egrx_October2018PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "October 2018 Plan [Member]", "label": "October 2018 Plan [Member]", "terseLabel": "October 2018 Plan" } } }, "localname": "October2018PlanMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "egrx_OtherCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Customers [Member]", "label": "Other Customers [Member]", "terseLabel": "Other" } } }, "localname": "OtherCustomersMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "domainItemType" }, "egrx_ParPharmaceuticalIncEtAlVEaglePharmaceuticalsIncVasopressinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Par Pharmaceutical, Inc. Et Al. V. Eagle Pharmaceuticals, Inc. (Vasopressin)", "label": "Par Pharmaceutical, Inc. Et Al. V. Eagle Pharmaceuticals, Inc. (Vasopressin) [Member]", "terseLabel": "Par Pharmaceutical, Inc. et al. v. Eagle Pharmaceuticals, Inc. (Vasopressin)" } } }, "localname": "ParPharmaceuticalIncEtAlVEaglePharmaceuticalsIncVasopressinMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/LegalProceedingsDetails" ], "xbrltype": "domainItemType" }, "egrx_PrepaidFDAUserFee": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid FDA User Fee", "label": "Prepaid FDA User Fee", "terseLabel": "Prepaid FDA user fee and advances to clinical research organization" } } }, "localname": "PrepaidFDAUserFee", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "egrx_RoyaltyBuyBackAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Buy-Back Agreement [Member]", "label": "Royalty Buy-Back Agreement [Member]", "terseLabel": "Ryanodex intangible" } } }, "localname": "RoyaltyBuyBackAgreementMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "egrx_RoyaltyRevenueCommercialPartnersObligationofSalesReportTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Revenue, Commercial Partners' Obligation of Sales Report, Term", "label": "Royalty Revenue, Commercial Partners' Obligation of Sales Report, Term", "terseLabel": "Period after quarter commercial partners report net product sales" } } }, "localname": "RoyaltyRevenueCommercialPartnersObligationofSalesReportTerm", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "egrx_SPBiotechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "S&P Biotechnology", "label": "S&P Biotechnology [Member]", "terseLabel": "S&P Biotechnology" } } }, "localname": "SPBiotechnologyMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "egrx_SecondAmendedAndRestatedCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Amended And Restated Credit Agreement [Member]", "label": "Second Amended And Restated Credit Agreement [Member]", "terseLabel": "Revised Credit Agreement" } } }, "localname": "SecondAmendedAndRestatedCreditAgreementMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "egrx_SecuritiesPurchaseAgreementCopromotionAgreementPercentageOfNetRevenueReceivable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Net Revenue Receivable", "label": "Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Net Revenue Receivable", "terseLabel": "Co-promotion agreement, percentage of net revenue receivable" } } }, "localname": "SecuritiesPurchaseAgreementCopromotionAgreementPercentageOfNetRevenueReceivable", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "percentItemType" }, "egrx_SecuritiesPurchaseAgreementCopromotionAgreementPercentageOfNetRevenueReceivableDueToCollaborator": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Net Revenue Receivable Due To Collaborator", "label": "Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Net Revenue Receivable Due To Collaborator", "terseLabel": "Co-promotion agreement, percentage of net revenue receivable due to collaborator" } } }, "localname": "SecuritiesPurchaseAgreementCopromotionAgreementPercentageOfNetRevenueReceivableDueToCollaborator", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "percentItemType" }, "egrx_SecuritiesPurchaseAgreementCopromotionAgreementPercentageOfPromotionalSalesEffortResponsibleFor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Promotional Sales Effort Responsible For", "label": "Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Promotional Sales Effort Responsible For", "terseLabel": "Co-promotion agreement, percentage of promotional sales effort responsible for" } } }, "localname": "SecuritiesPurchaseAgreementCopromotionAgreementPercentageOfPromotionalSalesEffortResponsibleFor", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "percentItemType" }, "egrx_SecuritiesPurchaseAgreementCopromotionAgreementRightToRepurchaseAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement, Co-promotion Agreement, Right To Repurchase, Amount", "label": "Securities Purchase Agreement, Co-promotion Agreement, Right To Repurchase, Amount", "terseLabel": "Co-promotion agreement, right to repurchase, amount" } } }, "localname": "SecuritiesPurchaseAgreementCopromotionAgreementRightToRepurchaseAmount", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "egrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMilestones": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Milestones", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Milestones", "terseLabel": "Number of milestones" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMilestones", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "egrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMilestonesRequiredToBeMet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Milestones Required To Be Met", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Milestones Required To Be Met", "terseLabel": "Number of milestones required to be met" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfMilestonesRequiredToBeMet", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "egrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAchievementRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Expected Achievement Rate", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Expected Achievement Rate", "terseLabel": "Expected achievement rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAchievementRate", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "egrx_TymeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tyme [Member]", "label": "Tyme [Member]", "terseLabel": "Tyme" } } }, "localname": "TymeMember", "nsuri": "http://www.eagleus.com/20210930", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of operating lease obligations and purchase obligations" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsTables" ], "xbrltype": "textBlockItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r62", "r64", "r122", "r123", "r280", "r312", "r578" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LegalProceedingsDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LegalProceedingsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r188", "r334", "r338", "r545" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r279", "r311", "r353", "r354", "r479", "r480", "r481", "r482", "r483", "r484", "r503", "r543", "r546", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r279", "r311", "r353", "r354", "r479", "r480", "r481", "r482", "r483", "r484", "r503", "r543", "r546", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r188", "r334", "r338", "r545" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r186", "r334", "r336", "r506", "r542", "r544" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r186", "r334", "r336", "r506", "r542", "r544" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r279", "r311", "r344", "r353", "r354", "r479", "r480", "r481", "r482", "r483", "r484", "r503", "r543", "r546", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r279", "r311", "r344", "r353", "r354", "r479", "r480", "r481", "r482", "r483", "r484", "r503", "r543", "r546", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r63", "r64", "r122", "r123", "r280", "r312" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.", "label": "Accelerated Share Repurchases, Initial Price Paid Per Share", "terseLabel": "Accelerated share repurchases, initial price paid per share (in dollars per share)" } } }, "localname": "AcceleratedShareRepurchasesInitialPricePaidPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": { "auth_ref": [ "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.", "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt", "negatedTerseLabel": "Accelerated share repurchases, payment" } } }, "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r40", "r472" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r23", "r189", "r190" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Total accrued expenses", "verboseLabel": "Accrued expenses and other liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails", "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r11", "r12", "r44" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r11", "r12", "r44" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "verboseLabel": "Royalties payable to commercial partners" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r11", "r12", "r44" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Accrued salary and other compensation" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r38", "r248" ], "calculation": { "http://www.eagleus.com/role/PropertyandEquipmentnetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r69", "r70", "r71", "r531", "r551", "r552" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r68", "r71", "r79", "r80", "r81", "r126", "r127", "r128", "r426", "r547", "r548", "r579" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r24", "r385", "r472" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r126", "r127", "r128", "r382", "r383", "r384", "r433" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Payment of employee withholding tax upon vesting of stock-based awards" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r355", "r357", "r388", "r389" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net (loss) income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising and Marketing" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r357", "r379", "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r87", "r108", "r299", "r454" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r108", "r235", "r242" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive common shares equivalents outstanding (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesAntiDilutiveCommonSharesEquivalentsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesAntiDilutiveCommonSharesEquivalentsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesAntiDilutiveCommonSharesEquivalentsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesAntiDilutiveCommonSharesEquivalentsOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r119", "r175", "r178", "r184", "r204", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r423", "r427", "r443", "r470", "r472", "r512", "r529" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r10", "r60", "r119", "r204", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r423", "r427", "r443", "r470", "r472" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r436" ], "calculation": { "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r192", "r194", "r211", "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt securities, available-for-sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r193", "r211" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 }, "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "periodEndLabel": "Total in Other Current Assets, ending balance", "periodStartLabel": "Total in Other Current Assets, beginning balance", "verboseLabel": "Convertible promissory note, net" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails", "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r358", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationFairValueofStockOptionsGrantedDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation and Other Company Information" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BasisofPresentationandOtherCompanyInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r36", "r110" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r15", "r111" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r104", "r110", "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r104", "r444" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsLeaseRelatedDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r417", "r418", "r420" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "License and Collaboration Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r49", "r254", "r518", "r536" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Commitments" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/Commitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r126", "r127", "r433" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value per share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22", "r472" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 50,000,000 shares authorized; 16,886,123 and 16,739,203 shares issued as of September 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r74", "r76", "r77", "r85", "r521", "r538" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive (loss) income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r163", "r164", "r188", "r440", "r441", "r556" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r163", "r164", "r188", "r440", "r441", "r553", "r556" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r163", "r164", "r188", "r440", "r441", "r553", "r556" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r163", "r164", "r188", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Percentage of concentration" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r161", "r163", "r164", "r165", "r440", "r442", "r556" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r163", "r164", "r188", "r440", "r441", "r556" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r323", "r324", "r335" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Accrued sales reserves" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.eagleus.com/role/CommitmentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "totalLabel": "Total" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueAfterFifthYear": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 7.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, after Year Five", "totalLabel": "Beyond" } } }, "localname": "ContractualObligationDueAfterFifthYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInFifthYear": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 6.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Five", "totalLabel": "2026" } } }, "localname": "ContractualObligationDueInFifthYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInFourthYear": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 5.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Four", "totalLabel": "2025" } } }, "localname": "ContractualObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 2.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year One", "totalLabel": "2022" } } }, "localname": "ContractualObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInSecondYear": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 3.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Two", "totalLabel": "2023" } } }, "localname": "ContractualObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInThirdYear": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 4.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Three", "totalLabel": "2024" } } }, "localname": "ContractualObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contractual Obligation, Fiscal Year Maturity [Abstract]", "terseLabel": "Total obligations" } } }, "localname": "ContractualObligationFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 1.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in remainder of current fiscal year.", "label": "Contractual Obligation, to be Paid, Remainder of Fiscal Year", "totalLabel": "2021" } } }, "localname": "ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]", "terseLabel": "Convertible Promissory Note" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r89", "r506" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r88" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r162", "r188" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r117", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r293", "r300", "r301", "r303", "r309" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r18", "r19", "r20", "r118", "r124", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r289", "r290", "r291", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r305", "r306", "r307", "r308", "r455", "r513", "r514", "r528" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable interest rate spread" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r46", "r277" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r47", "r118", "r124", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r289", "r290", "r291", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r305", "r306", "r307", "r308", "r455" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r47", "r118", "r124", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r289", "r290", "r291", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r302", "r305", "r306", "r307", "r308", "r315", "r316", "r317", "r318", "r452", "r453", "r455", "r456", "r527" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": { "auth_ref": [ "r196", "r211", "r213", "r214" ], "calculation": { "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss", "periodEndLabel": "Interest Receivable, ending balance", "periodStartLabel": "Interest Receivable, beginning balance" } } }, "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r195", "r211", "r218", "r219" ], "calculation": { "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails": { "order": 3.0, "parentTag": "us-gaap_ReceivablesNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss", "periodEndLabel": "Estimated Credit Loss, ending balance", "periodStartLabel": "Estimated Credit Loss, beginning balance" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleChangeInPresentValueExpenseReversal": { "auth_ref": [ "r212", "r217" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), from change in present value of expected cash flows.", "label": "Debt Securities, Available-for-sale, Change in Present Value, Expense (Reversal)", "negatedLabel": "Estimated Credit Loss", "terseLabel": "Convertible promissory note related credit losses" } } }, "localname": "DebtSecuritiesAvailableForSaleChangeInPresentValueExpenseReversal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Debt Securities, Available-for-sale" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of prepaid and other current assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentGross": { "auth_ref": [ "r39", "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Cost, Gross, Noncurrent", "terseLabel": "Unamortized deferred debt issuance cost" } } }, "localname": "DeferredFinanceCostsNoncurrentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r396", "r397" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset, net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r109" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r108", "r246" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r108", "r173" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r429" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedTerseLabel": "Fair value adjustments related to derivative instrument" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r334", "r336", "r337", "r338", "r339", "r340", "r341", "r342" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Common Stock and Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "(Loss) earnings per share attributable to common stockholders:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r86", "r131", "r132", "r133", "r134", "r135", "r139", "r142", "r148", "r149", "r150", "r153", "r154", "r434", "r435", "r522", "r539" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic net (loss) earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic net (loss) earnings per share" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r86", "r131", "r132", "r133", "r134", "r135", "r142", "r148", "r149", "r150", "r153", "r154", "r434", "r435", "r522", "r539" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted net (loss) earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted net (loss) earnings per share" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r151", "r152" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset": { "auth_ref": [ "r430" ], "calculation": { "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent", "weight": 1.0 }, "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as an asset.", "label": "Embedded Derivative, Fair Value of Embedded Derivative Asset", "periodEndLabel": "Embedded Derivative, ending balance", "periodStartLabel": "Embedded Derivative, beginning balance", "terseLabel": "Embedded derivative asset in convertible promissory note" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails", "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": { "auth_ref": [ "r431" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.", "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net", "terseLabel": "Fair Value Adjustment to Embedded Derivative" } } }, "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationFairValueofStockOptionsGrantedDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails", "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesAntiDilutiveCommonSharesEquivalentsOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r79", "r80", "r81", "r126", "r127", "r128", "r130", "r136", "r138", "r156", "r205", "r314", "r319", "r382", "r383", "r384", "r407", "r408", "r433", "r445", "r446", "r447", "r448", "r449", "r450", "r547", "r548", "r549", "r579" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r436", "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r436", "r438" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities measured and recognized at fair value" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r291", "r305", "r306", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r437", "r476", "r477", "r478" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r291", "r345", "r346", "r351", "r352", "r437", "r476" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r291", "r305", "r306", "r345", "r346", "r351", "r352", "r437", "r477" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r291", "r305", "r306", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r437", "r478" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r291", "r305", "r306", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r476", "r477", "r478" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r197", "r198", "r201", "r202", "r203", "r206", "r207", "r208", "r209", "r210", "r215", "r216", "r220", "r221", "r302", "r313", "r432", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r568", "r569", "r570", "r571", "r572", "r573", "r574" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful Life (In Years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r241" ], "calculation": { "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r243" ], "calculation": { "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "2021 (remainder)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r243" ], "calculation": { "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r243" ], "calculation": { "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r243" ], "calculation": { "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r236", "r237", "r241", "r244", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Estimated Amortization Expense" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r241", "r508" ], "calculation": { "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r236", "r240" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r241", "r507" ], "calculation": { "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Book Value" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails", "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r228", "r230", "r472", "r511" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r108", "r229", "r231", "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r83", "r175", "r177", "r180", "r183", "r185", "r509", "r519", "r524", "r540" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "(Loss) income before income tax benefit (provision)" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r250", "r252" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r120", "r400", "r402", "r405", "r409", "r411", "r413", "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r137", "r138", "r174", "r398", "r410", "r412", "r541" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit (provision)", "negatedTerseLabel": "Income tax benefit (provision)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.eagleus.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r78", "r394", "r395", "r402", "r403", "r404", "r406" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r112" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r107" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r107" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r107" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r107" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net", "negatedTerseLabel": "Other assets and other long-term liabilities, net" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]", "terseLabel": "Changes in operating assets and liabilities which provided (used) cash:" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r143", "r144", "r145", "r150" ], "calculation": { "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Dilutive effect of stock awards (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets, Net" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r234", "r239" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r82", "r172", "r451", "r454", "r523" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income, amortization of premium and accretion of discount on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale); classified as operating.", "label": "Interest Income, Debt Securities, Available-for-sale, Operating", "terseLabel": "Interest Income" } } }, "localname": "InterestIncomeDebtSecuritiesAvailableForSaleOperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r102", "r105", "r112" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r54" ], "calculation": { "http://www.eagleus.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished products" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r57", "r472" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.eagleus.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.eagleus.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r14", "r58", "r115", "r155", "r222", "r223", "r224", "r504" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r56" ], "calculation": { "http://www.eagleus.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r55" ], "calculation": { "http://www.eagleus.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeAmortizationOfDiscount": { "auth_ref": [ "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion of purchase discount on nonoperating securities.", "label": "Investment Income, Amortization of Discount", "terseLabel": "Accretion of Discount" } } }, "localname": "InvestmentIncomeAmortizationOfDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r92", "r171" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r199", "r510", "r525", "r555", "r575" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Convertible Promissory Note" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNote" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease related disclosures" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Proceedings" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r468" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.eagleus.com/role/CommitmentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r468" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "verboseLabel": "Beyond" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r468" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r468" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "verboseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r468" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 2.0, "parentTag": "us-gaap_ContractualObligationDueInFourthYear", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r468" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r468" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r468" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 3.0, "parentTag": "us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "verboseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Lessee, operating lease, remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lessee, operating lease, renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r43", "r119", "r179", "r204", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r424", "r427", "r428", "r443", "r470", "r471" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r119", "r204", "r443", "r472", "r515", "r533" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r45", "r119", "r204", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r424", "r427", "r428", "r443", "r470", "r471", "r472" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License and other revenue" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Line of credit facility, commitment fee" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LegalProceedingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LegalProceedingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r20", "r290", "r304", "r305", "r306", "r514", "r530" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.eagleus.com/role/CommitmentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 }, "http://www.eagleus.com/role/DebtScheduleofDebtMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails", "http://www.eagleus.com/role/DebtScheduleofDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Credit facility" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails", "http://www.eagleus.com/role/DebtScheduleofDebtMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r124", "r264", "r295" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 6.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Beyond" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r124", "r264", "r295" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 7.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.eagleus.com/role/DebtScheduleofDebtMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails", "http://www.eagleus.com/role/DebtScheduleofDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r124", "r264", "r295" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r124", "r264", "r295" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r124", "r264", "r295" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r124", "r264", "r295" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r124" ], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.eagleus.com/role/DebtScheduleofDebtMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2021 (remainder)", "verboseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails", "http://www.eagleus.com/role/DebtScheduleofDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, less current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LegalProceedingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LegalProceedingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyPatentsFoundNotInfringedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of another entity's patents that the entity was found not to have infringed.", "label": "Loss Contingency, Patents Found Not Infringed, Number", "terseLabel": "Number of patents, claims dismissed" } } }, "localname": "LossContingencyPatentsFoundNotInfringedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LegalProceedingsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MajorCustomersPolicyPolicyTextBlock": { "auth_ref": [ "r161", "r163", "r164", "r188" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.", "label": "Major Customers, Policy [Policy Text Block]", "terseLabel": "Concentration of Major Customers and Vendors" } } }, "localname": "MajorCustomersPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketingAndAdvertisingExpense": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Marketing and Advertising Expense", "terseLabel": "Advertising and marketing costs" } } }, "localname": "MarketingAndAdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r104" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r104" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r104", "r106", "r109" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r72", "r75", "r81", "r84", "r109", "r119", "r129", "r131", "r132", "r133", "r134", "r137", "r138", "r146", "r175", "r177", "r180", "r183", "r185", "r204", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r435", "r443", "r520", "r537" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net (loss) income", "totalLabel": "Net (loss) income", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED", "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r131", "r132", "r133", "r134", "r139", "r140", "r147", "r150", "r175", "r177", "r180", "r183", "r185" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "verboseLabel": "Numerator for basic and diluted (loss) earnings per share-net (loss) earnings" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableFairValueDisclosure": { "auth_ref": [ "r52" ], "calculation": { "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails": { "order": 2.0, "parentTag": "us-gaap_ReceivablesNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date.", "label": "Notes Receivable, Fair Value Disclosure", "periodEndLabel": "Fair value of the note, ending balance", "periodStartLabel": "Fair value of the note, beginning balance" } } }, "localname": "NotesReceivableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r175", "r177", "r180", "r183", "r185" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "(Loss) income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r459" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease, expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating lease" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r457" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r457" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 }, "http://www.eagleus.com/role/BalanceSheetAccountsFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of lease liability", "verboseLabel": "Current lease liabilities (included with Accrued Expenses and other liabilities)" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails", "http://www.eagleus.com/role/BalanceSheetAccountsFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsFutureMinimumLeasePaymentsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r457" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term lease liabilities (included with Other long-term liabilities)" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsFutureMinimumLeasePaymentsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r460", "r463" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsLeaseRelatedDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r108" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Noncash operating lease expense related to right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r466", "r469" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsLeaseRelatedDisclosuresDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r465", "r469" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsLeaseRelatedDisclosuresDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r13", "r44" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r59", "r472" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "All other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of other assets.", "label": "Other Assets, Fair Value Disclosure", "terseLabel": "Investment in Tyme" } } }, "localname": "OtherAssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r66", "r67", "r69" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Unrealized gain (loss) for convertible promissory note", "verboseLabel": "Fair Value Adjustments to the note" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED", "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r73", "r76", "r421", "r422", "r425" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r95" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r100" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchases of common stock", "terseLabel": "Payments to repurchase stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r100" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Employee withholding taxes related to stock-based awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": { "auth_ref": [ "r103", "r200" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.", "label": "Payments to Acquire Equity Securities, FV-NI", "negatedTerseLabel": "Purchase of equity investment security" } } }, "localname": "PaymentsToAcquireEquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireNotesReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Payments to Acquire Notes Receivable", "negatedLabel": "Purchase of convertible promissory note" } } }, "localname": "PaymentsToAcquireNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r97" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LegalProceedingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "PSUs" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21", "r310" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21", "r472" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, 1,500,000 shares authorized and no shares issued or outstanding as of September 30, 2021 and December 31, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r8", "r34", "r35" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails", "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r6", "r9", "r225", "r227" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r7", "r9", "r226", "r227" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r99" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from existing revolving credit facility" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r99", "r118" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Draw on line of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r98", "r381" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from common stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product sales, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r38", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r251", "r557", "r558", "r559" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r37", "r247" ], "calculation": { "http://www.eagleus.com/role/PropertyandEquipmentnetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r16", "r17", "r249", "r472", "r526", "r535" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.eagleus.com/role/PropertyandEquipmentnetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.eagleus.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r16", "r249" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r16", "r247" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated Useful Life (years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.eagleus.com/role/CommitmentsDetails_1": { "order": 3.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "totalLabel": "Total" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueAfterFifthYear": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 7.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid after fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, after Year Five", "terseLabel": "Beyond" } } }, "localname": "PurchaseObligationDueAfterFifthYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInFifthYear": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 6.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "PurchaseObligationDueInFifthYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInFourthYear": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 5.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "PurchaseObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 3.0, "parentTag": "us-gaap_ContractualObligationDueInNextTwelveMonths", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "PurchaseObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInSecondYear": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 3.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "PurchaseObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInThirdYear": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 4.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "PurchaseObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase Obligation, Fiscal Year Maturity [Abstract]", "terseLabel": "Purchase obligations" } } }, "localname": "PurchaseObligationFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.eagleus.com/role/CommitmentsDetails": { "order": 2.0, "parentTag": "us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.", "label": "Purchase Obligation, to be Paid, Remainder of Fiscal Year", "terseLabel": "2021" } } }, "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableWithImputedInterestDiscount": { "auth_ref": [ "r452" ], "calculation": { "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails": { "order": 1.0, "parentTag": "us-gaap_ReceivablesNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disclosure of the unamortized amount of the discount on the note or receivable which is deducted from the face amount of the receivable or loan. The discount or premium is the difference between the present value and the face amount.", "label": "Receivable with Imputed Interest, Discount", "periodEndLabel": "Discount on the note, ending balance", "periodStartLabel": "Discount on the note, beginning balance" } } }, "localname": "ReceivableWithImputedInterestDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesFairValueDisclosure": { "auth_ref": [ "r30", "r61", "r517", "r534" ], "calculation": { "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables.", "label": "Receivables, Fair Value Disclosure", "terseLabel": "Convertible promissory note" } } }, "localname": "ReceivablesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesLongTermContractsOrPrograms": { "auth_ref": [ "r53" ], "calculation": { "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date.", "label": "Receivables, Long-term Contracts or Programs", "terseLabel": "Receivable from commercial partner" } } }, "localname": "ReceivablesLongTermContractsOrPrograms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsPrepaidandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r23", "r30", "r472", "r534", "r554" ], "calculation": { "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "periodEndLabel": "Convertible Promissory Note, net, ending balance", "periodStartLabel": "Convertible Promissory Note, net, beginning balance" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r101", "r118" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedTerseLabel": "Repayment of existing revolving credit facility" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r101" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payment of debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r392", "r505", "r562" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research\u00a0and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs", "verboseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails", "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesAntiDilutiveCommonSharesEquivalentsOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r319", "r385", "r472", "r532", "r550", "r552" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r126", "r127", "r128", "r130", "r136", "r138", "r205", "r382", "r383", "r384", "r407", "r408", "r433", "r547", "r549" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r169", "r170", "r176", "r181", "r182", "r186", "r187", "r188", "r333", "r334", "r506" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r116", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r343" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r464", "r469" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use asset obtained in exchange for lease obligation - lease amendment", "verboseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsLeaseRelatedDisclosuresDetails", "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r90" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Cost of royalty revenue" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty revenue" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r163", "r188" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Total revenues" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesRevenueandAccountsReceivableByMajorCustomerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesAntiDilutiveCommonSharesEquivalentsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of dilutive and anti-dilutive common shares equivalents outstanding" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Share-based payment arrangement, cost by plan" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Computation for basic and diluted net (loss) earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of effective income tax rate reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r357", "r378", "r387" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r236", "r240", "r507" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r236", "r240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible asset" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r14", "r31", "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of debt maturities" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r38", "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "terseLabel": "Schedule of revenues and accounts receivables by major customers" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r366", "r370", "r371" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Activity [Table Text Block]", "terseLabel": "Summary of stock options, RSU and PSU activity" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r358", "r380" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationFairValueofStockOptionsGrantedDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Fair value of stock options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of future amortization expense of finite-lived intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r91" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r107" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited or expired (in shares)", "verboseLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding ending balance (in shares)", "periodStartLabel": "Outstanding beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationFairValueofStockOptionsGrantedDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationFairValueofStockOptionsGrantedDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest maximum rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationFairValueofStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest minimum rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationFairValueofStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationFairValueofStockOptionsGrantedDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "terseLabel": "RSUs and PSUs" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r363", "r380" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding ending balance (in shares)", "periodStartLabel": "Outstanding beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r356", "r361" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationFairValueofStockOptionsGrantedDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationScheduleofSharebasedCompensationDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r358", "r362" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting percentage of target number granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r373", "r386" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)", "verboseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationFairValueofStockOptionsGrantedDetails", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "negatedTerseLabel": "Forfeited or expired (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r114", "r125" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r51", "r79", "r80", "r81", "r126", "r127", "r128", "r130", "r136", "r138", "r156", "r205", "r314", "r319", "r382", "r383", "r384", "r407", "r408", "r433", "r445", "r446", "r447", "r448", "r449", "r450", "r547", "r548", "r549", "r579" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r126", "r127", "r128", "r156", "r506" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r21", "r22", "r314", "r319" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of common stock related to vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r21", "r22", "r314", "r319", "r364" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Options Exercised (in shares)", "terseLabel": "Issuance of common stock upon exercise of stock option grants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.eagleus.com/role/CommonStockandStockBasedCompensationSummaryofStockOptionsRSUandPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r314", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of common stock related to vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r51", "r314", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock option grants" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r27", "r28", "r119", "r191", "r204", "r443", "r472" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Accounts" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/BalanceSheetAccounts" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Cash paid during the period for:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r197", "r198", "r201", "r202", "r203", "r302", "r313", "r432", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r568", "r569", "r570", "r571", "r572", "r573", "r574" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/ConvertiblePromissoryNoteDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r50", "r321" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r50", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r22", "r314", "r319" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Shares of common stock repurchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CommonStockandStockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r50", "r321", "r322" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost, 3,941,541 and 3,682,176 shares as of September 30, 2021 and December 31, 2020, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r314", "r319", "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Common stock repurchases" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r108" ], "calculation": { "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Fair value loss on equity investment", "negatedTerseLabel": "Fair value adjustments on equity investment" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.eagleus.com/role/LicenseandCollaborationAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r393", "r401" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r157", "r158", "r159", "r160", "r166", "r167", "r168" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r150" ], "calculation": { "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "totalLabel": "Diluted weighted average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r141", "r150" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r139", "r150" ], "calculation": { "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted average number of common shares outstanding:", "verboseLabel": "Denominator" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.eagleus.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.eagleus.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossEarningsDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1828-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL121698322-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82922868-210454" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267856-210455" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922897-210455" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r309": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r343": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r415": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r431": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "15", "Topic": "815", "URI": "http://asc.fasb.org/subtopic&trid=2229187" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r525": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r555": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r563": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r564": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r565": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r566": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r567": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r568": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r569": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r571": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r572": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r573": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r574": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r575": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r576": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)" }, "r577": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r578": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13728-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" } }, "version": "2.1" } ZIP 77 0000827871-21-000029-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000827871-21-000029-xbrl.zip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�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柼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�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